Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome: a systematic review and economic analysis

C McDaid, S Griffin, H Weatherly, K Durée, M van der Burgt, S van Hout, J Akers, RJO Davies, M Sculpher and M Westwood

January 2009
DOI: 10.3310/hta13040
How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

- fax (with credit card or official purchase order)
- post (with credit card or official purchase order or cheque)
- phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch

Email: orders@hta.ac.uk

c/o Direct Mail Works Ltd

Tel: 02392 492 000

4 Oakwood Business Centre

Fax: 02392 478 555

Downley, HAVANT PO9 2NP, UK

Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.
Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome: a systematic review and economic analysis

C McDaid,1* S Griffin,2 H Weatherly,2 K Durée,1 M van der Burgt,2 S van Hout,2 J Akers,1 RJO Davies,3 M Sculpher2 and M Westwood1

1Centre for Reviews and Dissemination, University of York
2Centre for Health Economics, University of York
3Oxford Centre for Respiratory Medicine, Oxford Radcliffe Hospital

*Corresponding author

Declaration of competing interests of authors: Dr Robert JO Davies, ResMed (CPAP machine manufacturer), donated US$100,000 to the Oxford Centre for Respiratory Medicine to support the running costs of a randomised trial looking at blood pressure response to CPAP treatment in sleep apnoea between 1999 and 2003. The study finished in 2003. ResMed are also supplying 400 therapeutic and subtherapeutic CPAP machines to Oxford Centre for Respiratory Medicine for use in a currently recruiting multicentre, British Heart Foundation-funded, randomised trial looking at changes in cardiovascular function in patients with mild/moderate sleep apnoea.

Published January 2009
DOI: 10.3310/hta13040

This report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
The Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Second, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA Programme on behalf of NICE as project number 06/57/01. The protocol was agreed in November 2006. The assessment report began editorial review in June 2007 and was accepted for publication in February 2008. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.
Abstract

Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome: a systematic review and economic analysis

C McDaid,1* S Griffin,2 H Weatherly,2 K Durée,1 M van der Burgt,2 S van Hout,2 J Akers,1 RJO Davies,3 M Sculpher2 and M Westwood1

1Centre for Reviews and Dissemination, University of York
2Centre for Health Economics, University of York
3Oxford Centre for Respiratory Medicine, Oxford Radcliffe Hospital
*Corresponding author

Objectives: To determine the clinical effectiveness, safety and cost-effectiveness of continuous positive airway pressure (CPAP) devices for the treatment of obstructive apnoea–hypopnoea syndrome (OSAHS), compared with the best supportive care, placebo and dental devices.

Data sources: The main search was of fifteen electronic databases, including MEDLINE, EMBASE and the Cochrane Library, up to November 2006.

Review methods: Randomised controlled trials (RCTs) comparing CPAP with best supportive/usual care, placebo, and dental devices in adults with a diagnosis of OSAHS were included. The primary outcomes of interest were subjective daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS) and objective sleepiness assessed by the Maintenance of Wakefulness Test (MWT) and the Multiple Sleep Latency Test (MSLT). A new economic model was developed to assess incremental cost per quality-adjusted life-year (QALY). The cost-effectiveness of CPAP was compared with that of the use of dental devices and conservative management. The costs and QALYs were compared over a lifetime time horizon. Effectiveness was based on the RCT evidence on sleepiness symptoms (ESS), which was ‘mapped’ to utilities using individual patient data from a subset of studies. Utilities were expressed on the basis of generic HRQoL instruments [the EQ-5D (EuroQol-5 Dimensions) in the base-case analysis]. The base-case analysis focused on a male aged 50. A series of subgroup and scenario analyses were also undertaken.

Results: The searches yielded 6325 citations, from which 48 relevant clinical effectiveness studies were identified, 29 of these providing data on daytime sleepiness. The majority of the included RCTs did not report using an adequate method of allocation concealment or use an intention-to-treat analysis. Only the studies using a sham CPAP comparator were double blinded. There was a statistically significant benefit with CPAP compared with control (placebo and conservative treatment/usual care) on the ESS [mean difference (MD) –2.7 points, 95% CI –3.45 to –1.96]. However, there was statistical heterogeneity, which was reduced when trials were subgrouped by severity of disease. There was also a significant benefit with CPAP compared with usual care on the MWT. There was a non-statistically significant difference between CPAP and dental devices (six trials) in the impact on daytime sleepiness (ESS) among a population with moderate symptom severity at baseline (MD –0.9, 95% CI –2.1 to 0.4). A review of five studies evaluating the cost-effectiveness of CPAP was undertaken. All existing cost-effectiveness studies had limitations; therefore a new economic model was developed, based on which it was found that, on average, CPAP was associated with higher costs and benefits than dental devices or conservative management. The incremental cost per QALY gained of CPAP was below £20,000 in the base-case analysis and most alternative scenarios. There was a high probability of CPAP being more cost-effective than dental devices and conservative management for a cost-effectiveness threshold of £20,000 per QALY gained.

Conclusions: CPAP is an effective and cost-effective treatment for OSAHS compared with conservative/usual care and placebo in populations with moderate
Abstract

to severe daytime sleepiness, and there may be benefits when the disease is mild. Dental devices may be a treatment option in moderate disease but some uncertainty remains. Further research would be potentially valuable, particularly investigation of the effectiveness of CPAP for populations with mild sleepiness and further trials comparing CPAP with dental devices.
Contents

Glossary and list of abbreviations .......... vii

Executive summary ................................. xi

1 Background ........................................ 1
   Description of health problem ............ 1
   Current service provision ................. 4
   Description of technology under assessment ........ 4
   Previous systematic reviews ............. 5

2 Definition of decision problem .......... 7
   Decision problem ............................ 7
   Overall aims and objectives of assessment ........ 7

3 Assessment of clinical effectiveness .... 9
   Methods for reviewing clinical effectiveness ........ 9
   Results of review of clinical effectiveness .... 12

4 Assessment of cost-effectiveness evidence ........................................ 53
   Systematic review of existing cost-effectiveness evidence ........ 53
   York economic model ....................... 68

5 Assessment of factors relevant to the NHS and other parties .... 89

6 Discussion ........................................ 91
   Statement of principal findings .......... 91
   Strengths and limitations of the assessment ........ 96

7 Conclusions .................................... 99
   Implications for service provision .......... 99
   Suggested research priorities .............. 99

Acknowledgements ............................... 101

References ........................................... 103

Health Technology Assessment reports published to date ......................... 121
Health Technology Assessment Programme ........................................... 139

Appendix 1 Literature search strategies*

Appendix 2 Excluded studies*

Appendix 3 Quality assessment*

Appendix 4 Clinical effectiveness*

Appendix 5 Data extraction for clinical effectiveness trials*

Appendix 6 Economic evaluation data extraction*

Appendix 7 Review of utility data*

Appendix 8 Bivariate random-effects meta-analysis in WinBUGS*

*Due to the extensive nature of the appendices, these are available only in electronic format. The PDF file of the full report is available at www.ncchta.org/project/1592.asp. It will also be available on HTA on CD (see the inside front cover for full details).
Glossary

**Apnoea** The cessation of airflow during sleep as the result of an obstruction, preventing air from entering the lungs. Arbitrarily defined in adults as a 10-second breathing pause.

**Auto-positive airway pressure** A type of continuous positive airway pressure (CPAP) machine that monitors changes in breathing and compensates automatically by making appropriate adjustments in pressure.

**Continuous positive airway pressure (CPAP)** Device used to treat sleep apnoea that delivers a stream of compressed air at a prescribed pressure via a nose or full-face mask and hose, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible.

**Cost–benefit analysis** An attempt to give a monetary value to the consequences of the alternative interventions. In this way, the consequences can be more easily weighed against the costs of the intervention. This involves measuring individuals’ ‘willingness to pay’ for given outcomes and can present difficulties.

**Cost–consequence analysis** Costs and health effects are reported separately.

**Cost-effectiveness acceptability curve (CEAC)** A graphical representation of the probability of an intervention being cost-effective over a range of monetary values against society’s willingness to pay for an additional unit of health gain.

**Cost-effectiveness analysis** The consequences of the alternatives are measured in natural units, such as years of life gained. These consequences are not given a monetary value.

**Cost-minimisation** When two alternatives are found to have equal efficacy or outcomes (consequences), i.e. the only difference between the two is cost. This is sometimes considered to be a subtype of cost-effectiveness analysis.

**Cost–utility analysis** The consequences of alternatives are measured in ‘health state preferences’, which are given a weighting score. In this type of analysis, different consequences are valued in comparison with each other, and the outcomes (e.g. life-years gained) are adjusted by the weighting assigned. In this way, an attempt is made to value the quality of life associated with the outcome so that life-years gained become quality-adjusted life-years gained.

**Disutility** The reduction in utility in comparison with a healthy population.

**Hypopnoea** Reduction of airflow during sleep. Arbitrarily defined in adults as a 10-second breathing event where there is continuous breathing but ventilation is reduced by at least 50%.

**Mandibular advancement device** Dental device that holds the lower jaw and tongue forward to allow more space to breathe and to prevent snoring.

**Markov chain Monte Carlo (MCMC)** A mathematical model containing a finite number of mutually exclusive and exhaustive health states, with uniform time periods, in which the probability of movement from one state to another depends on the current state and remains constant over time.

**Mixed treatment comparison** A form of meta-analysis used to strengthen inference concerning the relative efficacy of two treatments. It uses data based on direct comparisons (A versus B and B versus C trials) and indirect comparisons (A versus C trials), and also facilitates simultaneous inference.
regarding all treatments in order to select those most appropriate.

**Odds ratio** A way of comparing whether the probability of a certain event is the same for two groups; refers to the ratio of the number of people having an event to the number not having an event.

**Oxygen desaturation** Less than the normal amount of oxygen carried by haemoglobin in the blood. Values below 90% are considered abnormal.

**Polysomnography** Procedure involved in the evaluation of sleep disorders, often conducted overnight, that consists of a simultaneous recording of multiple physiological parameters related to sleep and wakefulness.

**Quality of life (health-related quality of life)** A concept incorporating all the factors that might impact on an individual’s life, including factors such as the absence of disease or infirmity as well as other factors that might affect their physical, mental and social well-being.

**Quality-adjusted life-year (QALY)** An index of health gain whereby survival duration is weighted or adjusted by the patient’s quality of life during the survival period. QALYs have the advantage of incorporating changes in both quantity (mortality) and quality (morbidity) of life.

**Random-effects model** A statistical model sometimes used in meta-analysis in which both within-study sampling error (variance) and between-study variation are included in the assessment of the uncertainty (confidence interval) of the results of a meta-analysis.

**Sensitivity analysis** A mathematical method that examines uncertainty associated with parameters estimated into the analysis to test the robustness of the analysis findings. In one-way sensitivity analysis each parameter is varied individually, and in multi-way analysis two or more parameters are varied at the same time. Threshold analysis identifies the critical values above or below which the results of a study vary and analysis of extremes is used to examine the most pessimistic and the most optimistic scenarios. Finally, probabilistic sensitivity analysis attributes distributions of probabilities to uncertain variables that are incorporated within a model.

**Standard gamble** Measuring a health-state utility by comparing life in a particular given health state to a gamble with a probability that perfect health is the outcome or that immediate death is the outcome. The probability is varied until a point of indifference between the two choices (i.e. until the preference for the given health state is equal to the preference for the gamble).

**Time trade-off** Measuring a health state by trading off life-years in a state of less than perfect health for a shorter lifespan in a state of perfect health.

**Utility** A measure of the strength of an individual’s preference for a given health state or outcome. Utilities assign numerical values on a scale from 0 (death) to 1 (optimal or ‘perfect’ health), and provide a single number that summarises health-related quality of life.

**Weighted mean difference (in meta-analysis)** A method of meta-analysis used to combine measures on a continuous scale, where the mean, standard deviation and sample size in each group are known. The weight given to each study is determined by the precision of its estimate of effect and is equal to the inverse of the variance. This method assumes that all the trials have measured the outcome on the same scale.
## List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPM</td>
<td>ambulatory blood pressure monitoring</td>
</tr>
<tr>
<td>AHI</td>
<td>apnoea–hypopnoea index</td>
</tr>
<tr>
<td>APAP</td>
<td>autotitrating positive airway pressure</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BRMA</td>
<td>bivariate random-effects meta-analysis</td>
</tr>
<tr>
<td>BSJ</td>
<td>Brief Symptom Inventory</td>
</tr>
<tr>
<td>CEAC</td>
<td>cost-effectiveness acceptability curve</td>
</tr>
<tr>
<td>CHD</td>
<td>coronary heart disease</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COWAT</td>
<td>Controlled Oral Word Association Test</td>
</tr>
<tr>
<td>CPAP</td>
<td>continuous positive airway pressure</td>
</tr>
<tr>
<td>CRD</td>
<td>Centre for Reviews and Dissemination</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>CVE</td>
<td>cardiovascular event</td>
</tr>
<tr>
<td>DBP</td>
<td>diastolic blood pressure</td>
</tr>
<tr>
<td>DSST</td>
<td>Digit Symbol Substitution Test</td>
</tr>
<tr>
<td>DVT</td>
<td>Digit Vigilance Test</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>EuroQoL-5 Dimensions</td>
</tr>
<tr>
<td>ESS</td>
<td>Epworth Sleepiness Scale</td>
</tr>
<tr>
<td>EVPI</td>
<td>expected value of perfect information</td>
</tr>
<tr>
<td>FCI</td>
<td>Functional Capacity Index</td>
</tr>
<tr>
<td>FLP</td>
<td>Functional Limitations Profile</td>
</tr>
<tr>
<td>FOSQ</td>
<td>Functional Outcomes of Sleep Questionnaire</td>
</tr>
<tr>
<td>GHQ</td>
<td>General Health Questionnaire</td>
</tr>
<tr>
<td>GRISS</td>
<td>Golombok Rust Inventory of Sexual Satisfaction</td>
</tr>
<tr>
<td>HADS</td>
<td>Hospital Anxiety and Depression Scale</td>
</tr>
<tr>
<td>HCHS</td>
<td>Hospital and Community Health Services</td>
</tr>
<tr>
<td>HODaR</td>
<td>Health Outcomes Data Repository</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>ICER</td>
<td>incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>IHD</td>
<td>ischaemic heart disease</td>
</tr>
<tr>
<td>IQR</td>
<td>interquartile range</td>
</tr>
<tr>
<td>ITT</td>
<td>intention-to-treat</td>
</tr>
<tr>
<td>MAIS</td>
<td>Maximum Abbreviated Injury Scale</td>
</tr>
<tr>
<td>MAP</td>
<td>mean arterial pressure</td>
</tr>
<tr>
<td>MCAR</td>
<td>missing completely at random</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>MD</td>
<td>mean difference</td>
</tr>
<tr>
<td>MeSH</td>
<td>medical subject heading</td>
</tr>
<tr>
<td>MSLT</td>
<td>Multiple Sleep Latency Test</td>
</tr>
<tr>
<td>MWT</td>
<td>Maintenance of Wakefulness Test</td>
</tr>
<tr>
<td>NA</td>
<td>not applicable</td>
</tr>
<tr>
<td>nCPAP</td>
<td>nasal continuous positive airway pressure</td>
</tr>
<tr>
<td>NHP</td>
<td>Nottingham Health Profile</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Clinical Excellence</td>
</tr>
<tr>
<td>NR</td>
<td>not reported</td>
</tr>
<tr>
<td>OA</td>
<td>oral appliance</td>
</tr>
<tr>
<td>OLS</td>
<td>ordinary least squares</td>
</tr>
<tr>
<td>OP</td>
<td>oral placebo</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>OSAHS</td>
<td>obstructive sleep apnoea–hypopnoea syndrome</td>
</tr>
<tr>
<td>OSAS</td>
<td>obstructive sleep apnoea syndrome</td>
</tr>
<tr>
<td>PASAT</td>
<td>Paced Auditory Serial Addition Task</td>
</tr>
<tr>
<td>POMS</td>
<td>Profile of Mood State</td>
</tr>
<tr>
<td>PSG</td>
<td>polysomnography</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life-year</td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>RDI</td>
<td>respiratory disturbance index</td>
</tr>
<tr>
<td>RTA</td>
<td>road traffic accident</td>
</tr>
<tr>
<td>SAQLI</td>
<td>sleep apnoea quality of life index</td>
</tr>
<tr>
<td>SBP</td>
<td>systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SE</td>
<td>standard error</td>
</tr>
<tr>
<td>SF-36</td>
<td>Medical Outcomes Study 36-item Short Form Health Survey</td>
</tr>
<tr>
<td>TAP</td>
<td>Thornton Adjustable Positioner</td>
</tr>
<tr>
<td>TMT</td>
<td>Trail Making Task</td>
</tr>
<tr>
<td>UDA</td>
<td>unit of dental activity</td>
</tr>
<tr>
<td>UMAACL</td>
<td>University of Wales Institute of Science and Technology Mood Adjective Checklist</td>
</tr>
<tr>
<td>WAIS</td>
<td>Wechsler Adult Intelligence Scale</td>
</tr>
<tr>
<td>WMD</td>
<td>weighted mean difference</td>
</tr>
</tbody>
</table>

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it is has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the notes at the end of the table.
Executive summary

Background

Obstructive sleep apnoea–hypopnoea syndrome (OSAHS) is characterised by repeated, intermittent collapse and obstruction of the pharyngeal airway during sleep. This may result in brief awakening from sleep caused by increased respiratory effort. Recurrent arousal to restore airway functioning leads to a reduction in sleep quality. Untreated OSAHS is associated with increased daytime sleepiness, impairment of cognitive function and a reduction in health-related quality of life (HRQoL). As a result of increased daytime sleepiness and impaired concentration, there may be consequences for how effectively people can engage in work, home and leisure daytime activities. OSAHS has been associated with serious consequences such as increased risk of accidents and, if left untreated, it is a lifelong condition which may be a risk factor for hypertension, myocardial infarction and stroke. Owing to the association between OSAHS and obesity, the prevalence of OSAHS is expected to increase with increasing prevalence of obesity. The mainstay of medical treatment of OSAHS is administration of continuous positive airway pressure (CPAP) during sleep, although there are thought to be wide variations in the provision of CPAP treatment across the UK. CPAP devices are small, electric pumps that deliver air to the mouth and nose via a hose and soft plastic mask during sleep. The air pressure, which can be fixed or autotitrated, opens up the airway, particularly at pharyngeal level, preventing the soft tissue from collapsing. Excluding add-on expenses the cost of a CPAP machine is estimated at £280 and that of an autotitrating machine at £420.

Objectives

To determine the clinical effectiveness, safety and cost-effectiveness of CPAP devices for the treatment of OSAHS compared with the best supportive care, placebo and dental devices.

Methods

We conducted a systematic review of the clinical and cost-effectiveness literature. Fifteen electronic databases, including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials, were searched up to November 2006 to identify primary studies. The contents pages of nine journals were searched from the beginning of 2005 to May 2007 as well as the conference proceedings for the 2005 and 2006 American, British and Australia and New Zealand Thoracic Society meetings. Industry submissions were searched for additional unpublished data. Randomised controlled trials (RCTs) comparing CPAP with best supportive/usual care (e.g. lifestyle advice and other conservative management), placebo, and dental devices in adults with a diagnosis of OSAHS of any severity were included. Different forms of CPAP were treated as a single technology.

The primary outcomes of interest were subjective daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS) and objective sleepiness assessed by the Maintenance of Wakefulness Test (MWT) and the Multiple Sleep Latency Test (MSLT). Other outcomes of interest were blood pressure, cardiovascular events (CVEs), HRQoL, cognitive function and adverse events. The primary measure of cost-effectiveness was incremental cost per quality-adjusted life-year (QALY). Where sufficient clinical effectiveness data were available, they were pooled in a meta-analysis using a random-effects model. Studies in which the comparator was placebo or best supportive care were pooled separately from studies in which the comparator was dental devices. Where data sets included parallel and crossover trials these were pooled.

A new economic model was developed to make use of the available evidence on therapies for the treatment of OSAHS and to conform to the National Institute for Health and Clinical Excellence (NICE) scope. The cost-effectiveness of CPAP was compared with that of the use of dental...
devices and conservative management. The costs and QALYs associated with the three treatments were compared over a lifetime time horizon. Costs and resource use were estimated from the National Health Service (NHS) and Personal Social Services (PSS) perspective for England and Wales and reported for the financial year 2005. Effectiveness was based on the RCT evidence on sleepiness symptoms (ESS), which was ‘mapped’ to utilities using individual patient data from a subset of studies; trial evidence on changes in blood pressure following intervention to estimate differences in the rates of CVEs over time; and non-randomised evidence assessing the difference in risk of road traffic accidents (RTAs) across treatments. Utilities were expressed on the basis of generic HRQoL instruments [the EQ-5D (EuroQoL-5 Dimensions) in the base-case analysis] valued using the public preferences associated with those instruments. The base-case analysis focused on a male aged 50. A series of subgroup and scenario analyses were also undertaken.

Results

The searches yielded 6325 citations, from which 48 relevant clinical effectiveness studies were identified, and 29 of these provided data on daytime sleepiness. The majority of studies included overweight or obese men with severe disease as measured by the apnoea–hypopnoea index (AHI) during sleep and had moderate to severe daytime sleepiness. The majority of the included RCTs did not report using an adequate method of allocation concealment or use an intention-to-treat analysis. Only the studies using a sham CPAP comparator were double-blinded. There was a statistically significant benefit with CPAP compared with control (placebo and conservative treatment/usual care) on the ESS [mean difference (MD) –2.7 points, 95% confidence interval (CI) –3.45 to –1.96]. However, there was high inconsistency in the treatment effect (statistical heterogeneity); this was reduced when trials were subgrouped based on mean symptom severity at baseline. The benefit with CPAP was greatest in the group of trials of severe symptom severity (MD –5.0, 95% CI –6.5 to –3.5), and was progressively smaller with moderate (MD –2.3, 95% CI –3.0 to –1.6) and mild symptoms (MD –1.1, 95% CI –1.8 to –0.3). The treatment effect in all symptom severity groups was statistically significant. The benefit with CPAP on daytime sleepiness was robust across all the methodological subgroup analyses and sensitivity analyses. There was also a significant benefit with CPAP compared with usual care on the MWT, which measures capacity to stay awake, but not on the MSLT, which measures capacity to fall asleep. The evidence for any benefit with CPAP compared with control was less clear on the secondary outcome measures, although there was some evidence of a beneficial impact on HRQoL and daytime mean arterial pressure (MAP). There was a lack of evidence on long-term outcomes such as number of strokes and cardiac events and a lack of direct evidence of an effect on RTAs.

There was no statistically significant difference between CPAP and dental devices (six trials) on the impact on daytime sleepiness (ESS) amongst a population with moderate symptom severity at baseline, although there was a small decrease in favour of CPAP (MD –0.9, 95% CI –2.1 to 0.4). There was moderate inconsistency in the treatment effect but the small number of trials limited exploration of this. There was no statistically significant difference between CPAP and dental devices on the other outcomes of interest, although again the number of trials available was very small.

A review of five studies evaluating the cost-effectiveness of CPAP was undertaken. ResMed (manufacturer’s submission) estimated that, at year 1, the cost per QALY for CPAP compared with no CPAP is expected to exceed £20,000. Over the full 14-year time horizon CPAP was associated with lower costs and higher effects than no treatment and the cost-effectiveness–acceptability curve (CEAC) showed that, above a willingness to pay threshold of £2000 per QALY, CPAP was the optimal treatment strategy in all simulations. In the UK, Chilcott et al.14 estimated that at 5 years the cost per QALY for CPAP compared with no CPAP is £3200. The three remaining studies examined the cost-effectiveness of CPAP in settings outside the UK and all found that CPAP appeared cost-effective for conventional thresholds.

All existing cost-effectiveness studies had several limitations which needed to be addressed in order to assess the value for money of these technologies. None used the full range of RCT evidence for estimating the impact of treatment on daytime sleepiness, blood pressure, HRQoL and other relevant outcomes. There was a lack of trial-based evidence to compare the utility associated with different treatments for OSAHS and limited data on the long-term impact of OSAHS on HRQoL, CVEs, RTAs and other outcomes. None of the evaluations examined all the comparators relevant to the review. Therefore a new economic model was developed.
Based on the new economic model, it was found that, on average, CPAP was associated with higher costs and benefits than were dental devices or conservative management. In the base-case analysis the incremental cost-effectiveness ratio (ICER) for CPAP compared with dental devices was £3899 for men and £4335 for women. The probability of CPAP being more cost-effective than dental devices or conservative management at a threshold of £20,000 per QALY was 0.78 and 0.80 for men and women respectively. Subgroup and scenario analyses found that the (ICER) of CPAP was consistently below £20,000 per QALY gained, with one exception: the ICER in a subgroup with mild disease in terms of baseline ESS score was estimated to be £20,585.

**Discussion**

There was clear evidence of a benefit with CPAP compared with placebo and conservative management/usual care on two of the three primary outcomes, one assessing subjective sleepiness and one objective measure of sleepiness. There was also some evidence of benefit on MAP and quality of life although this was less robust. On the basis of the York model, the available evidence suggests that, overall, CPAP is cost-effective compared with dental devices and conservative management assuming a cost-effectiveness threshold of £20,000 per QALY gained.

A number of uncertainties and caveats need to be borne in mind. These include:

- The relative treatment benefits with CPAP according to symptom severity are based on summary data and cannot be regarded as definitive. The estimates of cost-effectiveness by disease severity should consequently also be treated with caution. Furthermore, because it was not possible to estimate treatment effects on blood pressure or RTAs by baseline OSAHS severity, these effects have been removed entirely from the cost-effectiveness analysis by severity.
- The treatment effect for daytime sleepiness in mild symptomatic disease is based on only two studies and needs to be interpreted with some caution.
- Some of the analyses may have been underpowered and this was particularly true in relation to blood pressure.
- Dental devices may be a treatment option in moderate disease. However, there was inconsistency in the treatment effect of CPAP compared with dental devices, possibly due to the variety of dental devices investigated. It remains unclear precisely what type of dental devices may be effective and in which populations with OSAHS. The effectiveness of dental devices compared with CPAP in mild and severe disease populations is unclear.
- Only two outcome measures from the clinical trial data [effect of treatment on ESS and systolic blood pressure (SBP)] were incorporated in the economic model. Potentially, other measures reported in the trials could impact on HRQoL independently of ESS, and this is not reflected in the current model. The model does not differentiate between conservative management, dental devices and CPAP in terms of the disutility associated with any undesirable side effects.
- The translation of health benefits in terms of ESS to utility scores was based on simple regression models. The effect of CPAP treatment on reducing RTAs was derived from observational studies. While some trials report the impact of CPAP on blood pressure, this outcome is infrequently reported, and the trials are too short in length to directly measure impact on CVEs, and so estimated changes in CVE rates are inferred from other published risk equations.

**Conclusions**

**Implications for service provision**

- CPAP is an effective treatment for OSAHS compared with conservative/usual care and placebo in populations with moderate to severe daytime sleepiness, and there may be benefits where the disease is mild.
- Dental devices may be a treatment option in moderate disease but some uncertainty remains.
- On average, CPAP was associated with higher costs and higher benefits than was conservative management. The incremental cost per QALY gained of CPAP was below £20,000 in the base-case analysis and most alternative scenarios. There was a high probability of CPAP being more cost-effective than dental devices and conservative management for a cost-effectiveness threshold of £20,000 per QALY gained.
Executive summary

Recommendations for research

- The expected value of further information calculated in the York economic model indicates that further research to reduce the uncertainty in the current evidence base would be potentially valuable.
- Further investigation of the effectiveness of CPAP for populations with mild sleepiness is required.
- Further trials comparing CPAP with dental devices may be useful.
- Further investigation of the effect of CPAP on hypertension would be beneficial, particularly with respect to what populations might be expected to benefit, as would trials adequately powered to identify changes in CVEs.
Chapter 1

Background

Description of health problem

Definition of obstructive sleep apnoea–hypopnoea syndrome

Obstructive sleep apnoea–hypopnoea is characterised by repeated, intermittent collapse and obstruction of the pharyngeal airway during sleep. Airway collapse can be complete, with total obstruction of the airway lumen and no respiratory airflow (apnoea), or partial with reduced respiratory airflow, arbitrarily often defined as at least a 50% reduction (hypopnoea). Pharyngeal patency (keeping the airway opened) depends on dilator muscles which contract during each inspiration to prevent the upper airway being closed by suction. The upper airway collapses due to falling muscle tone in the dilating muscles with sleep, leading to narrowing or total obstruction. This may result in brief awakenings from sleep caused by increased respiratory effort. Recurrent arousal required to restore airway patency results in fragmentation of normal sleep architecture (structure) and a reduction in sleep quality. When obstructive sleep-disordered breathing is accompanied by clinical symptoms such as excessive daytime sleepiness, this is known as obstructive sleep apnoea–hypopnoea syndrome (OSAHS).1–3

The most commonly reported symptoms of OSAHS are excessive daytime sleepiness, loud snoring and unrefreshing sleep.4 Other frequent symptoms are nocturnal choking, nocturia, witnessed apopnoeas and morning headaches. Less commonly reported symptoms include reduced libido and enuresis.4

Classification of disease severity

Diagnosis of OSHAS is usually based on recordings of multiple physiological signals during sleep polysomnography (PSG). These include the apnoea–hypopnoea index (AHI), and repetitive oxygen desaturation indices. The AHI is the frequency of apnoeas and hypopnoeas per hour of sleep; a typical cut-off for positive diagnosis is between 5 and 10 events per hour. The AHI is also used to categorise severity. Whilst definitions regarding the severity of OSAHS vary between sleep centres, recommendations for cut-offs suggest the following severity classification:2 mild OSAHS (AHI 5–15 events per hour of sleep); moderate OSAHS (AHI 15–30 events per hour of sleep); and severe OSAHS (AHI > 30 events per hour of sleep). Oxygen desaturation is calculated as the number of events causing a drop in arterial oxygen saturation per hour. Typically a diagnostic cut-off of > 4% drop is used to define an oxygen desaturation event, with thresholds approximating hypoxic dips per hour of 5–10 (mild), 10–30 (moderate) and greater than 30 (severe). The number of events can vary from night to night for individuals and these cut-off points for disease severity are considered arbitrary.1,4 None of these measures takes into account the severity of other symptoms such as daytime sleepiness. This is considered important as the daytime consequences of OSAHS are often of more concern to the patient than are nocturnal events.

Daytime sleepiness

Several tools are available for measuring sleepiness, both subjectively and objectively. The Epworth Sleepiness Scale (ESS) is the most frequently used assessment of daytime sleepiness. This short questionnaire measures the general level of daytime sleepiness based on the subjective probability of falling asleep in a variety of situations.6 The participant rates his or her likelihood of falling asleep in eight different daily situations, such as while sitting reading or while sitting inactive in a public place. The score range is from 0 to 24 and the higher the score the greater the sleepiness. A score of seven or less is regarded as normal sleepiness; a score of 16 or more indicates substantial daytime sleepiness.

The most commonly used objective measures of daytime sleepiness are the Maintenance of Wakefulness Test (MWT), which measures the
capacity to stay awake, and the Multiple Sleep Latency Test (MSLT), which measures the propensity to fall asleep in favourable conditions. The MWT is a 40-minute test that measures the capacity to remain awake in conditions supposedly ideal for falling sleep. If participants do not fall asleep during the test, they achieve the maximum score. The MSLT assesses the tendency to fall asleep during four or five tests at 2-hourly intervals throughout the day in conditions conducive to sleep. Both tests use a polysomnogram to establish when the participant has fallen asleep. An additional measure is the Osler test, a simplified version of the MWT, which uses a behavioural test rather than electroencephalograph recordings to define sleep onset. The score derived from all these tests is the time taken to fall asleep in minutes (sleep latency). Precise normative data on time taken to fall asleep have been difficult to establish for the MWT and MSLT as many factors may affect sleep latency, such as age, prior total sleep time and variations in the testing protocol. The 'normal' sleep latency for MSLT is around 10 minutes with an SD range of 2–19 minutes. The MWT, the mean time taken to fall asleep in a population without sleep disorder was estimated at 35.24 minutes [standard error (SE) 0.98], though this varied with age. Both the MSLT and MWT are relatively poor at discriminating between sleepy and non-sleepy populations as a result of the overlap of sleep latency time in these populations. However, they are sensitive to conditions expected to increase or decrease sleepiness. Performance on both tests can be affected by physiological factors such as age and circadian rhythms; psychological factors such as anxiety and depression; and test protocol factors such as the extent of activity prior to testing and the specific instructions given. The correlation between the MSLT and MWT is weak, probably because they measure different aspects of sleepiness. The MWT can have limited ability to discriminate the most alert individuals due to a ceiling effect; the MSLT can have limited ability to discriminate the most sleepy individuals due to a floor effect.

Epidemiology

The severity of sleeping upper airway collapse is a continuous variable in the community and ranges from normality, through postural and continuous snoring, postural and continuous repetitive obstructive apnoeas associated with excessive sleepiness (i.e. OSAHS) and ultimately, in the most severe cases, to daytime hypercapnic ventilatory failure, cor pulmonale and death. The major daytime symptom of the disease (excessive daytime sleepiness) also ranges from normality to very severe, disabling excessive somnolence. The severity of daytime sleepiness is moderately correlated with the objective severity of disease quantified from the number of episodes of airway obstruction per hour during sleep. The treatment of obstructive sleep apnoea is targeted mainly at controlling its symptoms (particularly excessive daytime sleepiness) and consequences (such as hypertension/vascular risk), through correction of the breathing disturbance. It is therefore appropriate that disease severity should primarily be stratified using symptom severity rather than the number of episodes of airway obstruction at night.

At least 1% of men in the UK have severe obstructive sleep apnoea with both marked objective respiratory abnormality at night and substantial excessive daytime somnolence, and about 6% of men have objectively detectable disease of lesser severity. The prevalence of the disease in the normal community depends on the exact definition of an episode of airway obstruction. The standard definitions of an obstructive apnoea, hypopnoea or > 4% oxygen desaturation episode, used to define disease severity for this analysis, are the most frequently used disease definitions. Using these indices, it is possible to define broad disease severity subgroups, such as the mild, moderate and severe definitions used in this report. However, the variation in the absolute number of identified respiratory events produced by modest alterations in sleep study scoring definitions means that the boundaries of these groups are necessarily arbitrary and they need to be applied to clinical practice with a degree of pragmatic common sense.

The main aetiological factor for adult obstructive sleep apnoea is obesity, particularly upper body and neck obesity. Fat deposition in these areas causes airway narrowing and ultimately collapse, although the severity of obesity required to cause airway collapse depends on associated features such as facial shape and jaw structure. Therefore, the prevalence of disease varies markedly with population obesity levels and minimising the prevalence of OSAHS is an important potential benefit of population weight reduction strategies. Other common risk factors are enlarged tonsils and adenoids, and craniofacial abnormalities. OSAHS has also been associated with endocrine conditions such as hypothyroidism and acromegaly.
Outcomes associated with OSAHS

The major treatment goal in OSAHS is improvement in daytime sleepiness. As well as being symptomatically unpleasant, excessive sleepiness impairs function on tasks requiring vigilance such as driving, and can result in loss of employment when it causes recurrent unwanted sleep in the work environment. OSAHS is also associated with other negative consequences: deterioration in cognitive function (especially in those tasks requiring concentration, such as driving), changes in mood or personality, and impaired quality of life. Such impairments may be mediated by the severity of daytime sleepiness. A key limitation of the evidence was a causal link with other adverse health outcomes (RTAs) but that the epidemiological evidence for sleepiness and possibly road traffic accidents (RTAs) that participants with OSAHS perform as poorly as alcohol-impaired participants. A recent systematic review found an increased risk of motor vehicle collisions in drivers with OSAHS compared with those without OSAHS although the size of the estimated increased risk varied among studies. The UK Driver and Vehicle Licensing Authority (DVLA) does not allow people who are prone to sleepiness that may impair vigilance while driving to hold a driving licence.

Health-related quality of life

Given the known effects of sleep apnoea on daytime sleepiness and cognitive function, an effect on measures of quality of life would be expected; a systematic review found that OSAHS significantly contributes to impairment of health-related quality of life (HRQoL). It is therefore desirable to assess the impact of treatments of sleep apnoea, such as CPAP, upon quality of life. The concept of HRQoL typically refers to an individual’s perception of function in at least one of four domains: somatic sensation, physical function, emotional state and social interaction. The consequences of sleep apnoea for HRQoL include the detrimental effects on physical, mental and social function, including excessive tiredness and decreased energy, decreased concentration and memory, depressive symptoms and relationship difficulties.

A number of generic instruments have been developed to measure HRQoL. These include the Medical Outcomes Study 36-item Short Form Health Survey (SF-36), the Nottingham Health Profile (NHP) and the EuroQol-5 Dimensions (EQ-5D). Such instruments measure HRQoL in a standardised way that allows for comparisons across studies and conditions. However, these instruments have not been designed to specifically address the aspects of life affected by OSAHS, and as a consequence the criticism has been made that they may be less sensitive to important improvements experienced with treatment than would be a condition-specific instrument. For instance, most generic instruments do not include sleep as a specific dimension; only the NHP (Part 1) includes a sleep-specific dimension.

The two condition-specific instruments most commonly used to assess the HRQoL of people with sleep apnoea are the Functional Outcomes of Sleep Questionnaire (FOSQ) and the sleep apnoea quality of life index (SAQLI). These are considered to have high acceptability and relevance for both patients and clinicians, and because they are disorder specific they are thought to be highly sensitive to change. The FOSQ, designed to detect
the impact of disorders of excessive sleepiness on physical, mental and social functioning on everyday activities, contains 30 items grouped into five subscales: activity level, vigilance, intimacy and sexual relationships, general productivity and social outcome. Respondents are able to indicate whether lack of engagement with any of the items was a consequence of something other than sleepiness. One weakness of this instrument is that it does not measure experience of symptoms or overall well-being. In addition to a total score, the FOSQ generates a mean score for each subscale; low scores indicate poorer HRQoL. The SAQLI, designed specifically for use in clinical trials with patients experiencing sleep apnoea, contains 35 items grouped into four dimensions: daily function, social interactions, emotional functioning and symptoms. An additional domain, treatment-related symptoms, can also be added to capture the impact of treatment side effects. The SAQLI generates a total score; a low score indicates poor HRQoL. A drawback of this instrument is that it was designed to be interviewer led, although it has been used as a self-completed measure.

Cardiovascular disease

Based on three recent overviews of the evidence establishing a link between OSAHS and cardiovascular disease, the evidence seems strongest in respect of OSAHS as a risk factor for hypertension.27–29 There is also evidence linking OSAHS with stroke and cardiac disease, although considerable uncertainties about whether it is an independent risk factor remain.4,27,28

Current service provision

The mainstay of medical treatment of OSAHS is administration of continuous positive airway pressure (CPAP) during sleep. There are thought to be wide variations in the provision of CPAP treatment across the United Kingdom. Dental devices (also known as oral appliances) represent the main alternative group of treatments, although these are generally used only in individuals with mild to moderate OSAHS. Evidence for lifestyle modification as an efficacious treatment is weak;30 however, lifestyle management is often recommended as an adjunct to other treatments, including conservative options such as weight loss, avoidance of alcohol or sedative medication, improved sleep hygiene and use of a lateral sleeping position. In the severely obese, bariatric surgery has sometimes been used to achieve weight loss.4 Other treatment options, such as surgery or drugs, are rarely used, and recent Cochrane reviews do not support their use for treatment of OSAHS.31,32

Description of technology under assessment

CPAP devices

CPAP devices are small, electric pumps that deliver air to the nose or mouth via a hose and soft plastic mask during sleep. The air pressure, which can be fixed or autotitrated, opens up the airway, particularly at pharyngeal level, preventing the soft tissue from collapsing. Fixed CPAP devices deliver air at a fixed optimal pressure, usually identified by earlier observation and titration during sleep, while autotitrating CPAP devices increase pressure, as needed, to maintain airway patency, or decrease pressure if no events are detected, over a set period of time. As the minimum effective pressure delivered is automatically adjusted in autotitrating CPAP devices, the mean pressure is often lower than that from optimal fixed pressure in CPAP units. Originally developed for patients with OSAHS, CPAP is increasingly being investigated for use in populations with serious co-morbidities such as Alzheimer’s disease33 and heart failure.34–36

It is difficult to obtain a precise estimate from the literature on rates of patient adherence to CPAP treatment. There are variations in how long-term adherence or compliance is defined, as well as in the methods used in epidemiological studies, and the influence of patient awareness that their compliance is being assessed also requires consideration.57 There are two aspects that are of relevance when considering adherence: initial acceptance of treatment and long-term adherence (frequency of use as well as number of hours of use per night). Adherences among those accepting treatment of over 70%,38 and 80%39,40 after 1 year, have been reported, although lower rates have also been reported. Reasons for discontinuation relate primarily to physical discomfort, nasal dryness and congestion, difficulty in adapting to the pressure, dislodgement during sleep, and the social consequences of using the unit. Some patients may discontinue because they achieve an improvement in symptoms through, for example, weight loss or tonsillectomy. Serious side effects from CPAP are thought to be very rare.

A number of variations of the technology have been developed, mainly with the aim of improving adherence. The primary variations have involved
the use of humidifiers, which have been shown to prevent upper airway dryness associated with CPAP use; and autotitrating and bi-level CPAP, which aim to vary the pressure depending on need during the night and therefore reduce both the pressure required and associated side effects. Lower treatment pressures have been reported with autotitrating than with fixed CPAP but no clinically important changes in adherence or other outcomes have been found, although one systematic review concluded that auto-CPAP may be of benefit in certain subgroups, as yet undefined. Similarly, there is no evidence of increased adherence with humidified CPAP, although a need for further research has been noted. Variations in the CPAP delivery interface, such as type of mask, have also been developed. A recent systematic review found a paucity of research on the impact of different masks, making it difficult to determine the best interface, but suggested that nasal pillows or the Oracle oral interface are potentially useful alternatives when patients are unable to tolerate the nasal mask. For the purposes of this technology assessment report all types of CPAP device are treated as a single intervention.

**Current usage in the UK**

There are no routine data available on current use. Expert opinion estimates that approximately 20,000 of the probable 180,000 patients with OSAHS are using CPAP devices. Chilcott et al. highlighted concerns about (1) the haphazard and sporadic provision of CPAP devices throughout the UK and (2) the potential scale of long-term costs related to provision of new devices and maintenance of an expanding pool of CPAP devices. Focusing on the Trent Region, the authors suggested that there is a great deal of variation in the pattern and range of services that are available in Trent for diagnosing and treating OSAHS. They gave the example that if 60 new CPAP devices are provided each year, as estimated in clinics in Leicester and Nottingham, the discounted cost of new investigations and maintenance of the existing pool of CPAP devices would increase exponentially. They reported the cost of a new, standard CPAP machine as £250 (no price year given) and estimated that, at that time, the annual maintenance and patient follow-up costs amount to an additional £250 per year. The cost of an initial investigation ranges from £370 to £790 per person investigated. They estimated that initial year 1 costs of about £60,000 in the Trent Region may rise to annual costs of £95,000 in year 5 and £115,000 in year 10.

**Dental devices**

Dental devices, also known as oral appliances, are designed to maintain the patency of the pharyngeal airway and prevent the lumen from collapsing during sleep by holding the tongue or mandible forward, thereby enlarging the posterior airspace. There are two main types – tongue repositioning devices and mandibular repositioning devices – although the latter is most commonly used for OSAHS. Mandibular repositioning dental devices are either one-piece, holding the mandible in a fixed anterior position, or two-piece, allowing some movement of the mandible. They can be custom-made or pre-fabricated; variations in design are available. Most side effects of treatment are reported to be minor and temporary, e.g. excessive salivation, although some are more significant, e.g. bite changes. Owing to the perception that the increases in pharyngeal patency achievable with mandibular devices are modest and the lack of high-quality evidence available on their effectiveness, dental devices are currently considered appropriate for use only in mild to moderate OSAHS (where airway collapse is more easily reversed), or in patients who do not wish to use CPAP.

**Previous systematic reviews**

A number of recent systematic reviews have evaluated the effectiveness of CPAP as a treatment for OSAHS. In addition, there have been systematic reviews underpinning guidelines in a number of countries, which are not discussed here. The earliest review, published ten years ago, concluded that there was a paucity of robust evidence for a clinical benefit and the cost-effectiveness of CPAP. A key deficit identified was the lack of trials using a placebo that was indistinguishable from CPAP as, at that time, a pill placebo was being used. A considerable number of trials have been published subsequently. A systematic review in 2005 identified 12 trials; CPAP was compared with oral placebo, conservative therapy such as lifestyle changes and sham CPAP (a device identical to CPAP set at a non-therapeutic pressure). The review investigated subjective sleepiness (ESS) and objective sleepiness (MSLT and MWT). When estimates from individual studies were pooled, there was a statistically significant improvement in the ESS score of 2.94 points (95% CI 1.61–4.26) with CPAP compared with control. There was evidence of variation in the treatment...
effect which remained unexplained by age, sex, body mass index (BMI), location of study or mean hours of CPAP use. Variations by study baseline disease severity and methodological quality were not investigated. The MSLT and MWT were pooled, which would seem inappropriate in view of the poor correlation between these measures. A more recent review identified a smaller number of relevant trials ($n = 7$) due to tighter inclusion criteria; again the comparators were oral placebo, conservative treatment and sham CPAP.\textsuperscript{48} When estimates from individual studies were pooled, there was a statistically significant improvement on the ESS of 1.2 points (95% CI 0.5–1.9) with CPAP compared with control in patients with mild to moderate OSAHS. There was also a statistically significant improvement in sleep latency on the MWT of 2.1 minutes (95% CI 0.5–3.7) with CPAP compared with control, but no statistically significant difference on the MSLT.

The most recent and comprehensive systematic review (a Cochrane review) concluded that CPAP was effective in reducing objective and subjective symptoms of sleepiness, and improving quality of life in individuals with moderate and severe OSAHS.\textsuperscript{50} Evidence was available from 36 trials and substantially more evidence was available from trials using sham CPAP as a comparator than had been the case in the earlier reviews. Compared with placebo (sham CPAP, oral placebo and conservative treatment), there was a statistically significant improvement in favour of CPAP of 3.83 points on the ESS (95% CI 3.09–4.57) from parallel trials and 1.92 points (95% CI 1.25–2.59) from crossover trials, although there was evidence of statistical heterogeneity (variation in the treatment effect) across the trials. There was a statistically significant benefit with CPAP compared with control in sleep latency on the MSLT (1.25 minutes, 95% CI 0.18–2.32) and on the MWT (2.36 minutes, 95% CI 0.31–4.40) from crossover trials.

Although this was a good-quality review, the current review provides an update, which includes additional studies, as well as an alternative approach to the meta-analyses; the Cochrane review analysed the data from crossover trials and parallel trials separately. While this is an appropriate approach, it does reduce the power of any subgroup analyses to investigate the influence of factors such as disease severity on treatment outcomes.\textsuperscript{50} Such an approach also results in two treatment effects (one for parallel trials and one for crossover trials) for each outcome for use in the economic modelling. The current review uses an established method to combine the results of parallel and crossover trials for which sufficient data are available.\textsuperscript{51,52}

Systematic reviews have also been conducted on the efficacy of dental devices. The Cochrane review discussed above found that CPAP was more effective than dental devices in reducing respiratory disturbances during sleep, although no difference was shown between the treatment groups in daytime symptoms such as sleepiness.\textsuperscript{50} A second Cochrane review, which was last updated in June 2005, compared dental devices with placebo devices that were similar devices placed in the mouth but which did not cause the mandible to protrude.\textsuperscript{53} When parallel studies were pooled, there was a statistically significant improvement with dental devices compared with control devices on the ESS (MD $–2.09$, 95% CI $–3.8$ to $–0.37$), although there was high statistical heterogeneity. Crossover trials also showed a statistically significant benefit on the ESS (MD $–1.81$, 95% CI $–2.72$ to $–0.90$). An earlier systematic review reported a statistically significant improvement on the AHI but reported contradictory results from trials on subjective sleepiness (ESS).\textsuperscript{45}
Chapter 2

Definition of decision problem

Decision problem

Untreated OSAHS is associated with increased daytime sleepiness, impairment of cognitive function and a reduction in quality of life. Owing to increased sleepiness and impaired concentration it may have consequences for how effectively people can engage in work, home and leisure daytime activities. It has been associated with serious consequences such as increased risk of accidents and, if left untreated, it is a lifelong condition that may be a risk factor for hypertension, myocardial infarction and stroke. As a result of the association between OSAHS and obesity, the prevalence of OSAHS is expected to increase with increasing prevalence of obesity.

There is evidence from previous systematic reviews that CPAP is an effective treatment for some of the outcomes associated with OSAHS. It is the recommended first choice of treatment for moderate or severe OSAHS. Surgery and drug therapy are generally not recommended. Treatment options for mild OSAHS include conservative options such as weight loss, avoidance of alcohol or sedative medication, improved sleep hygiene and use of a lateral sleeping position. Dental devices are also considered to be a treatment option for mild to moderate disease.

However, provision of CPAP for OSAHS is variable across the UK. This is thought to be due to a combination of lack of facilities for diagnosis and treatment and a lack of recognition of the significant morbidity associated with OSAHS. An evaluation of the clinical benefit and cost-effectiveness of CPAP is required. The main focus of interest is how CPAP compares with placebo, conservative therapy and dental devices and not how different types of CPAP devices vary in effectiveness. Therefore, different CPAP devices should be treated as one technology. If the data are available, the question of whether there are subgroups of people for whom CPAP is particularly appropriate should be investigated.

Overall aims and objectives of assessment

The aim of this review was to determine the clinical effectiveness, safety, and cost-effectiveness of continuous positive airway pressure (CPAP) devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome (OSAHS) compared with best supportive care, placebo and dental devices.
Chapter 3
Assessment of clinical effectiveness

Methods for reviewing clinical effectiveness

Search strategy
The search terms used to capture the concepts of sleep apnoea and CPAP were arrived at by discussion with reviewers and experts. These search terms were then adapted for each individual database and relevant thesaurus terms used where possible. The search strategies used for each database are included in Appendix 1.

A range of databases and websites were searched to identify existing systematic reviews and guidelines on CPAP for sleep apnoea:

- Cochrane Database of Systematic Reviews (Cochrane Library 2006 issue 3) (www.thecochranelibrary.com)
- Database of Abstracts of Reviews of Effects [Centre for Review and Dissemination’s (CRD) administration version of the database]
- Health Technology Assessment Database (CRD administration version of the database)
- Scottish Intercollegiate Guidelines Network (www.sign.ac.uk)
- National Guideline Clearinghouse (www.guideline.gov/)
- Turning Research into Practice Database (Trip) (www.tripdatabase.com/)
- Health Evidence Bulletins Wales (http://hebw.cf.ac.uk/index.html)
- Clinical Evidence (www.clinicalevidence.com)
- National Library for Health Guidelines Finder (www.library.nhs.uk/guidelinesfinder/).

Further databases were searched to identify primary studies:

- MEDLINE (1996 to November week 3 2006) (OVID)
- MEDLINE In-Process & Other Non-Indexed Citations (28 November 2006) (OVID)
- EMBASE (1980 to 2006 week 47) (OVID)
- Cochrane Central Register of Controlled Trials (Cochrane Library 2006 issue 4) (www.thecochranelibrary.com)
- CINAHL (1982 to November week 3 2006) (OVID)
- Science Citation Index (1900 to 25 November 2006) (Web of Knowledge)
- Zetoc Conferences (1993 to 29 November 2006) (http://zetoc.mimas.ac.uk/)
- SIGLE (1980 to March 2005) (SilverPlatter)
- Index to Theses (1716 to 16 October 2006) (www.theses.com/)
- NHS Economic Evaluation Database (NHS EED) (CRD internal administration system 13 January 2007)
- Health Technology Assessment (HTA) database (CRD internal administration system 13 January 2007)
- EconLit (1969 to October 2006) (SilverPlatter)
- EconPapers (http://econpapers.repec.org/).

The contents pages of the following journals (selected by the review team based on included references from a previous systematic review on this topic) were also hand searched to identify reports that might not have been indexed by the electronic databases. In addition, electronic alerts were set up for each journal so that the contents page could be scanned as the latest edition was published:

- Thorax [2005 vol 60(1) to vol 62(4)]
- Sleep Medicine [2005 vol 6(6) to vol 7(1)]
- European Respiratory Journal [2005 vol 26(5) to vol 29(4)]
- Sleep [2005 vol 28(11) to vol 29(12)]
- Respiratory Medicine [2005 vol 99(11) to vol 101(5)]
- QJM [2005 vol 98(11) to vol 100(3)]
- Journal of Internal Medicine [2005 vol 258(5) to vol 261(4)]
- Journal of Sleep Research [2005 vol 14(4) to vol 16(1)]
- European Journal of Orthodontics [2005 vol 27(6) to vol 29(1)].
The following conference proceedings were also scanned for relevant abstracts. This selection was based on recommendations from the Cochrane Airways Group:

- American Thoracic Society international conferences 2005 and 2006 (www.thoracic.org/)
- British Thoracic Society winter meeting 2006 (2005 winter meeting abstracts are published as part of the journal Thorax and therefore searched electronically) (www.brit-thoracic.org.uk/)

The industry submissions were also searched for any additional unpublished data. No additional studies were identified.

**Inclusion and exclusion criteria**

Titles and abstracts identified from the searches were independently screened for relevance by two reviewers and disagreements were resolved by consensus. The full papers were ordered for all potentially relevant studies. Full papers were screened independently by two reviewers based on the inclusion criteria below. Disagreements were resolved by consensus and, if necessary, a third reviewer was consulted. Studies in any language (published or unpublished or in abstract form only) were included in the review if they met the following criteria.

**Population**

Studies of adults (16 years or older) with a diagnosis of predominantly obstructive sleep apnoea, confirmed by use of an appropriate tool (e.g. a respiratory polysomnographic sleep study, analysed by an appropriately qualified respiratory physician, from which a standard severity criterion such as the API or arterial oxygen desaturation index was derived), were included. Populations with disease of any severity were eligible. Studies of participants with central nervous system (CNS) dysfunction (e.g. stroke or dementia such as Alzheimer’s disease) and heart failure were excluded. Both of these conditions can produce disorders of breathing control that are central in origin (i.e. breathing is interrupted by a lack of effort due to dysfunction in the part of the brain that controls breathing), in addition to OSAHS, making it difficult to determine OSAHS. Because of the complexities of differentiating obstructive from central sleep apnoea and the potential for a mixture of these disorders to complicate the interpretation of outcomes, studies conducted specifically in these patient groups were excluded. However, studies of general population groups that may have included some patients with these co-morbid conditions were included.

**Intervention and comparators**

Studies of fixed CPAP or autotitrating CPAP therapy were eligible for inclusion provided the treatment was of at least 1 week’s duration. For the purposes of this review, fixed and autotitrating CPAP were treated as the same intervention; studies comparing the two technologies were not eligible for inclusion. Relevant comparators were best supportive/usual care (including conservative intervention such as lifestyle advice regarding weight loss, alcohol consumption and sleep hygiene as well as sleep posture advice or treatment), placebo (including placebo pill and sham CPAP) and dental devices. For sham CPAP the subtherapeutic pressure used varies between studies. We included studies in which it was stated sham CPAP was used and did not exclude studies based on the specific subtherapeutic pressure used.

**Outcomes**

The following outcomes were included.

**Primary outcomes**

- Subjective sleepiness as assessed by the ESS
- Objective sleepiness as assessed by the MWT, Osler test, MSLT or equivalent measure.

**Secondary outcomes**

- Blood pressure (mean day and night blood pressure were assessed separately as the mechanisms and patterns of daytime and night-time blood pressure disturbance in OSAHS vary, and the relationship between daytime blood pressure and vascular risk has been more clearly described in other studies)
- Cardiovascular disease (e.g. myocardial infarction, stroke)
- Accidents (e.g. driving, occupational), although it was thought unlikely that such data would be found in randomised controlled trials (RCTs)
- Quality of life, where it was measured using a standardised scale
- Mood, anxiety and depression, where they were measured using a standardised scale
- Simulated driving performance
- Neuropsychological functioning
- AHI/desaturation rate
- Any complications or adverse effects of treatment.
Outcomes such as changes to sleep architecture (e.g. rapid eye movement sleep, slow-wave sleep, sleep efficiency) were not considered.

**Study design**

RCTs using a parallel or crossover design were included. In this field there is no standard practice as to whether a washout period is used in crossover trials and, if so, how long the washout period should be. Because the effect of CPAP in relation to daytime sleepiness is thought to be short-lived, the risk of carryover was not considered to be a serious problem.

**Data extraction**

The authors of the recent systematic review by Giles et al. provided the extracted data from their review to avoid duplication of work. This also included some unpublished data. These data had been independently extracted by two reviewers.

Data from the new studies, as well as any additional data required from the studies previously extracted by Giles et al., were extracted by one reviewer and checked by another. Discrepancies were resolved by discussion and, if necessary, a third reviewer was consulted. Where there were multiple publications from the same study, the main publication for each study was identified and data were extracted from that paper. Where additional relevant outcomes were available in a related paper these were also extracted. For some of the studies cognitive outcomes were reported for only a subset of participants from the main study. These data were extracted. Where only a conference abstract was available, authors were contacted for further data. Where necessary, authors were contacted to clarify whether published studies had any overlapping patients or to obtain missing data such as standard errors from a paired analysis in crossover trials or where data were only available in graphs.

Data were extracted into Review Manager (RevMan) and into a standard form in Microsoft Word. Data extracted included patient characteristics (age, sex, severity of OSAHS, BMI), details of the intervention (fixed or autotitrating CPAP, use of humidifier), comparator (details of placebo, conservative management or dental device), adherence (usually reported as the average number of hours the machine was running at night), length of follow-up, outcomes as identified above and study quality.

Predominantly end point data were reported in the trials, except for blood pressure, for which a mixture of change and end point data were reported. Where both end point and change data were reported, preference was given to end point data for all outcomes except blood pressure, in which case change data were used (provided the variance for the change score was reported). Where only change data were reported, the variance was imputed if necessary. Change scores may be less efficient than end point data in some situations as they have two sources of measurement error (at baseline and follow-up). However, unlike end point values, the use of change scores removes a component of between-person variability. Whether the between-person variation is increased or reduced by using an end point or change score depends on the size of the correlation between baseline and follow-up; therefore, it is important to specify in advance which measure will be used. Use of change from baseline scores in crossover trials may increase the variation. The decision was made in advance to use change data for blood pressure where they were available, as this outcome was being used in the economic model, and change in blood pressure was preferred to end point for use in this model. All outcomes were continuous data and the mean difference (MD) between CPAP and comparator was calculated for each outcome.

Paired data were extracted from crossover trials where available. If the SD or SE from a paired analysis was not reported, the SE was imputed from the t-statistic, the p-value or the CI from a paired analysis. For one crossover study it was necessary to impute the SE for blood pressure: a within-person correlation of 0.5 was used and a within-person correlation of 0.1 and 0.9 for a sensitivity analysis. It is generally recommended that when analysing a crossover trial the method of testing first for a carryover effect and then analysing only the data from the first sequence period as though it were data from a parallel trial should be avoided.

In the studies we included, in a few instances there was evidence of a carryover effect into the second period, but the authors reported only data from the first sequence of the crossover trial and these data were treated as data from a parallel trial. These are not ideal data but, where these were the only data available they were used in the review.

Owing to time limitations and the quantity of cognitive data from crossover trials it was not feasible to impute data for a paired analysis, where these were not reported, for all the cognitive outcomes. Where three or more studies were available for potential pooling, the SE was estimated where data were available as above. For the other cognitive outcome measures the mean end value at follow-up and the SD for the
intervention and control group with the associated p-value were extracted. Where available, the SD or SE from a paired analysis was extracted.

**Quality assessment**

Study quality was assessed on the basis of criteria from CRD Report No. 4 and additional criteria were used to assess crossover trials (see Study quality, below). The criteria assessed were broad in anticipation that a narrative synthesis may have been necessary. Quality was assessed by one reviewer and checked by another. Discrepancies were resolved by discussion and, if necessary, a third reviewer was consulted.

**Data analysis**

Where sufficient data were available, they were pooled in quantitative syntheses using a random-effects model. Studies comparing CPAP with placebo or best supportive/usual care were pooled separately from studies comparing CPAP with dental devices. Where data sets included both study designs, parallel and crossover trials were pooled. The generic inverse variance method in RevMan was used to pooling data sets which included both parallel and crossover designs, or only crossover trials. When only parallel trials were being pooled the weighted mean difference (WMD) method in RevMan was used. To transform the parallel data for entry into the generic inverse variance facility, the SE for the MD was calculated from the 95% CI. This was calculated using the formula SE = (upper confidence limit – lower confidence limit)/3.92. This method assumes a sample size of at least 30; however, given the number of outcomes and studies included in the review it was not considered feasible in the time available to use the t-statistic.

Statistical heterogeneity between trials was assessed using the I² statistic. Five sources of potential clinical and methodological heterogeneity were identified a priori as being of priority: baseline disease severity, baseline daytime sleepiness, study design, type of placebo and study quality. We planned to investigate these for the primary outcomes using subgroup analysis, as clinically important variations in the magnitude of treatment effects are likely in different severity groups. The subgroups specified in advance were as follows:

- **population subgroups**
  - baseline disease severity, as classified using the AHI or the desaturation rate using the mean baseline score for each study: mild (AHI 5–14/hour or oxygen desaturation rate 5–10/hour), moderate (AHI 15–30/hour or oxygen desaturation rate 10–30/hour) and severe (AHI > 30/hour or oxygen desaturation rate > 30/hour)
  - baseline symptom severity, as classified using the mean baseline ESS score for each study: mild (0–9 points), moderate (10–15 points) and severe (16–24 points)
- **comparator subgroups**
  - sham CPAP, oral placebo and best supportive care
- **study design subgroups**
  - parallel and crossover
  - end point data and change from baseline data.

We planned to investigate the influence of study quality on the treatment effect by pooling studies with adequate concealment of allocation separately from those with inadequate or unclear adequacy of concealment. This analysis was limited due to the small number of studies that reported an adequate method of concealing treatment allocation.

The pooling of the primary outcomes and blood pressure were rerun using a fixed-effect model to test the impact of the model of analysis used. The robustness of the findings for these outcomes was also investigated by assessing the impact on the treatment effect of removing each study singly.

Where no new data were identified for specific outcomes subsequent to the review by Giles et al. we reported the analysis based on the data sets from that review, although we report the pooling from a random-effects model, combining crossover and parallel designs, as per our protocol rather than a fixed-effect model and separate analyses by study design, as used by the earlier review.

The risk of publication bias was not formally assessed.

**Results of review of clinical effectiveness**

**Quantity and quality of research available**

The searches identified 6325 potentially relevant references (Figure 1). On the basis of screening titles and abstracts, 235 full papers were ordered for further assessment. Inclusion screening of full papers identified 48 individual relevant studies. Eighteen of these were new studies or provided additional data subsequent to the review by Giles et al. Four were available at the time of the review by
Giles et al., but were classified as additional studies due to the different inclusion criteria used by the two reviews;58–61 two provided additional data as only abstracts had been available at the time of the earlier review;66,67 and 11 had become available since the earlier review had been completed.63–73

Three of the new studies were available in abstract form only and did not provide sufficient data for inclusion in the analysis.69,71,72 Three studies that had been included in the review by Giles et al. were excluded because they focused on participants with CNS dysfunction or heart failure, and these populations were not considered in the current review.74–76 Details of the included studies and their related papers are provided in Appendix 5. For the purpose of simplicity the main papers from individual studies are referred to in the main body of the report although data from more than one paper may have been used.

**Study characteristics**

The characteristics of the included studies are summarised in Table 1. This table focuses on the study characteristics that were used for the subgroup analyses: severity of daytime sleepiness at baseline (ESS), baseline disease severity (AHI), comparator and study design (parallel and crossover). Further details of study characteristics, including baseline data, are reported in Appendix 5.

**Intervention and comparators**

Forty-six of the 48 included studies that used fixed pressure CPAP. The remaining two studies used autotitrating pressure CPAP.67,77 Three studies used humidified CPAP73,78,79 and in two studies the use of a humidifier was optional.80,81 All CPAP interventions were treated as a single class in the analysis.

There were three three-arm trials: CPAP versus oral placebo and dental device;82 CPAP versus conservative/usual care and dental device;70 and CPAP versus sham CPAP and supplemental oxygen.73

CPAP was compared with sham CPAP (18 studies),56,58,62–68,73,77,79,85–88 oral placebo (nine studies);78,82,89–95 conservative/usual care (eight studies);59,69,70,96–100 dental devices (12 studies);70,72,80–82,101–107 and posture-related devices (three studies).60,61,108

Where sham CPAP was used as placebo, the subtherapeutic pressure ranged from 0 to 4 cmH2O. Where reported, the majority of studies (n = 12) used a pressure of 2 cmH2O or less; two used a pressure of between 3 and 4 cmH2O.64,84 In the studies using oral placebo an inactive tablet was used and participants were told that the tablet was intended to improve their airway function. The information provided on usual care/conservative treatment as a comparator was limited, but generally included dietary advice, dietary advice or referral to weight loss programmes, or advice on sleep hygiene and sleep posture.

Where reported, there were two main types of dental devices used in the included studies, one-
piece non-adjustable devices;70,81,103 and two-piece adjustable devices.72,80,82,101,102,105 In four of these studies incremental mandibular advancement was used until symptoms abated or further advancement was uncomfortable. 72,80,82,102 In one study some participants used a one-piece and some used a two-piece device.106

Studies which compared CPAP with some form of device to control sleeping position used a backpack with a soft ball inside to prevent a supine position while sleeping;108 a shoulder–head elevation pillow to maintain an upright position (60˚) while sleeping;60 or a cervicomandibular collar to retain the head in a natural position and to prevent the jaw from opening during sleep.61

Participants

The participants in the included studies were predominantly middle-aged, male and overweight or obese. The mean age in the CPAP and comparison groups at baseline ranged from 44 to 58 years. With the exception of one study,98 the majority of participants in the included studies were male; the proportion of female participants ranged from 0% to 48%. Based on the mean BMI (where reported) ten studies were of an overweight population (BMI 25–30 kg/m²) and 30 were of an obese population (BMI 30.1–40 kg/m²); the highest mean BMI at baseline was 40.1 kg/m².88 Two studies were of patients who were being treated for another primary disease: type 2 diabetes67 and headache symptoms.98 Two studies specifically recruited patients with hypertension.65,68

Table 1 provides details of baseline disease severity for the individual studies. Based on mean baseline daytime sleepiness, as reported by participants using the ESS, the majority of studies were of participants experiencing moderate sleepiness (n = 27); five of the included studies were of participants with severe daytime sleepiness and two were of participants with mild sleepiness. Symptom severity, as defined by the ESS, was not available for 14 studies. Based on disease severity at baseline, defined by AHI [or 4% oxygen desaturation or the respiratory disturbance index (RDI)], the majority of studies (n = 26) investigated a population with severe OSAHS, 15 investigated a population with moderate disease, and three investigated a population with mild disease. One study recruited patients with OSAHS that was mild in the lateral sleep position and severe in the supine position.108 Disease severity, as defined by AHI or equivalent, was not available for three studies.

Study design

All the included studies were RCTs. There were 26 crossover trials, two partial crossover trials (only one group was crossed over in the second sequence) and 20 parallel trials. Only the data from the first sequence before crossover were used from the partial crossover trials.85,86 For one crossover trial the outcome data appeared to be from the first sequence and these data were treated as parallel data.85 For some individual outcomes, only the data from the first sequence of the crossover trials were reported in the papers due to detection of a carryover effect, and these were treated as parallel data in the synthesis. Studies using oral placebo as a comparator were exclusively of crossover design, as were the trials in which the comparator was postural therapy. This was also the dominant study design for trials comparing dental devices with CPAP. Parallel trials were the dominant design used in trials comparing CPAP with sham CPAP or conservative/usual treatment.

Treatment duration varied. The majority of studies were between 4 and 12 weeks’ duration. There were six studies of less than 4 weeks’ duration58,73,79,85,91,108 and four of longer than 12 weeks’ duration.80,81,99,100 Participants were assessed at the end of treatment.

Study quality

The following checklist was used to assess the methodological quality of included studies.

Criteria

1. Was the method used to assign participants to treatment groups or the sequence of treatments really random (e.g. computer generated or random number table)?
2. Was treatment allocation concealed?
3. Were the groups similar at baseline in terms of ESS and AHI?
4. If not, were adjustments made for differences in the treatment groups?
5. Did the analysis include an intention-to-treat (ITT) analysis?
6. Were appropriate methods used to account for missing data in the ITT analysis?
7. What proportion of participants was lost to follow-up for the primary outcomes?
8. Was the study described as blind or double-blind?
9. Who was blinded?
10. Were the participants CPAP naïve?
11. Was an appropriate analysis, using paired data, conducted? (Crossover trials only.)
12. Was there a treatment by period interaction? (Crossover trials only.)
<table>
<thead>
<tr>
<th>Study details</th>
<th>Number randomised (N)</th>
<th>Target population</th>
<th>Disease severity [AHI, mean (SD)]</th>
<th>Severity of sleepiness, [ESS, mean (SD)]</th>
<th>Treatment duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPAP vs sham CPAP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Parallel trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a,bArias et al., 200665</td>
<td>23</td>
<td>AHI ≥ 10 and ESS ≥ 10</td>
<td>Severe, 44.1 (29.3)</td>
<td>NR</td>
<td>12</td>
</tr>
<tr>
<td>Barbé et al., 200183</td>
<td>55</td>
<td>AHI ≥ 30 and no or mild daytime sleepiness</td>
<td>Severe, I 54 (16.2), C57 (20)</td>
<td>Mild, I 7 (2.2), C 7 (2)</td>
<td>6</td>
</tr>
<tr>
<td>Becker et al., 20039</td>
<td>60</td>
<td>AHI ≥ 5 and ESS ≥ 10</td>
<td>Severe, I 62.5 (17.8), C65 (26.7)</td>
<td>Moderate, I 14.4 (2.5), C 14.1 (3.2)</td>
<td>9</td>
</tr>
<tr>
<td>Campos-Rodriguez et al., 200685</td>
<td>72</td>
<td>AHI ≥ 10 and hypertension</td>
<td>Severe, I 58.3 (24.6), C 59.5 (21.7)</td>
<td>Moderate, I 15 (3.9), C 13.6 (3.6)</td>
<td>4</td>
</tr>
<tr>
<td>'Dimsdale et al., 200086</td>
<td>39?</td>
<td>RDI &gt; 15 with or without hypertension</td>
<td>Severe, I RDI 53.6 (SD 23.2), C 41.7 (SD 25.6)</td>
<td>NR</td>
<td>1</td>
</tr>
<tr>
<td>'Hui et al., 200687</td>
<td>45</td>
<td>AHI &gt; 10 with daytime sleepiness or AHI &gt; 10 with or without daytime sleepiness</td>
<td>Severe, I 62.1 (27.4), C 68.1 (25.2)</td>
<td>Severe, I 16.4 (5.6), C 16 (4.8)</td>
<td>2</td>
</tr>
<tr>
<td>Jenkinson et al., 199978</td>
<td>107</td>
<td>Men with &gt; 10 episodes per hour of greater than 4% drop in SaO₂ and ESS ≥ 10</td>
<td>Moderate, I median 32.9 (SE 3.2), C 29.5 (SE 3.1)</td>
<td>Severe, I median 16 (10.7–21.7), C 17 (10–23)</td>
<td>4</td>
</tr>
<tr>
<td>'Norman et al., 200689</td>
<td>46</td>
<td>AHI &gt; 15 with or without hypertension</td>
<td>Severe, I 66.1 (SE 29.1), C 53.9 (29.8)</td>
<td>Moderate, I 12 (5.5), C 12 (6.6)</td>
<td>2</td>
</tr>
<tr>
<td>Pepperell et al., 200290</td>
<td>118</td>
<td>Men with ≥ 10 episodes per hour of greater than 4% drop in SaO₂ and ESS ≥ 10</td>
<td>Severe, I 38 (19.8), dips per hour &gt; 4% SaO₂, C 35.9 (19.6)</td>
<td>Severe, I 16.3 (3.3), C 16 (3.1)</td>
<td>4</td>
</tr>
<tr>
<td>'Spicuzza et al., 200691</td>
<td>25</td>
<td>Moderate to severe OSAHS</td>
<td>Severe, I 55.3 (11.9), C 59.2 (17.3)</td>
<td>NR</td>
<td>4</td>
</tr>
<tr>
<td>'West et al., 200692</td>
<td>42</td>
<td>Men with type 2 diabetes and &gt; 10 episodes per hour of greater than 4% drop in SaO₂ and ESS ≥ 9</td>
<td>Severe, I 33.1 (21.6), dips per hour &gt; 4% SaO₂, C 39.1 (24.8)</td>
<td>Moderate, I 14.7 (3.5), C 13.6 (3.5)</td>
<td>12</td>
</tr>
</tbody>
</table>

*continued*
### TABLE 1 Characteristics of included studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Number randomised (N)</th>
<th>Target population</th>
<th>Disease severity [AH1, mean (SD)]</th>
<th>Severity of sleepiness, [ESS, mean (SD)]</th>
<th>Treatment duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Arias et al., 2005</em>5*6</td>
<td>27</td>
<td>Men with AH1 ≥ 10 and ESS ≥ 10</td>
<td>Severe, 44 (27.5)</td>
<td>NR</td>
<td>12</td>
</tr>
<tr>
<td><em>Coughlin et al., 2007</em>5*2</td>
<td>35</td>
<td>RDI &gt; 15 and ESS ≥ 10 or two other symptoms</td>
<td>Severe, RDI 39.7 (13.8)</td>
<td>Moderate, 13.8 (4.9)</td>
<td>6</td>
</tr>
<tr>
<td><em>Cross et al., 2005, Abstract</em></td>
<td>10</td>
<td>Two major symptoms of OSAHS and &gt; 20 episodes per hour of greater than 4% drop in SaO2</td>
<td>Severe, 63 (26)</td>
<td>NR</td>
<td>6</td>
</tr>
<tr>
<td><em>Marshall et al., 2005</em>7*9</td>
<td>31</td>
<td>AHI 5–30, habitual snoring or nocturnal choking and at least one symptom of daytime sleepiness or ESS ≥ 8</td>
<td>Moderate, 21.6 (7.5)</td>
<td>Moderate, 12.5 (4.3)</td>
<td>3</td>
</tr>
<tr>
<td><em>Robinson et al., 2006</em>8*8</td>
<td>35</td>
<td>Patients with hypertension and &gt; 10 episodes per hour of greater than 4% drop in SaO2 and ESS &lt; 10</td>
<td>Moderate, median 28.1 (IQR 18.0–38.0), dips per hour &gt; 4% SaO2</td>
<td>Mild, Median 5.3 (IQR 3.0–7.0)</td>
<td>4</td>
</tr>
<tr>
<td><strong>CPAP vs oral placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 20028*9</td>
<td>42</td>
<td>AHI 5–30 and symptoms of OSAHS</td>
<td>Mild, 12.9 (6.3)</td>
<td>Moderate, 11.2 (5)</td>
<td>8</td>
</tr>
<tr>
<td>Barnes et al., 20048*2</td>
<td>114</td>
<td>AHI 5–30</td>
<td>Moderate, 21.3 (13.6)</td>
<td>Moderate, 10.7 (6.5)</td>
<td>12</td>
</tr>
<tr>
<td>Engleman et al., 19948*0</td>
<td>35</td>
<td>AHI ≥ 5 and at least two symptoms of OSAHS</td>
<td>Moderate, median 28 (range 7–129)</td>
<td>NR</td>
<td>4</td>
</tr>
<tr>
<td>Engleman et al., 19968*1</td>
<td>16</td>
<td>AHI ≥ 5 and at least two symptoms of OSAHS</td>
<td>Severe, 49 (32.5)</td>
<td>NR</td>
<td>3</td>
</tr>
<tr>
<td>Engleman et al., 19978*1</td>
<td>18</td>
<td>AHI 5–14.9 and at least two symptoms of OSAHS</td>
<td>Mild, 11 (4)</td>
<td>Moderate, 14 (4)</td>
<td>4</td>
</tr>
<tr>
<td>Engleman et al., 19988*3</td>
<td>23</td>
<td>AHI ≥ 15 and at least two symptoms of obstructive sleep apnoea</td>
<td>Severe, 43 (37)</td>
<td>Moderate, 12 (4)</td>
<td>4</td>
</tr>
<tr>
<td>Engleman et al., 19998*8</td>
<td>37</td>
<td>AHI 5–14.9 and at least two symptoms of OSAHS including daytime sleepiness (ESS ≥ 8 or reported sleepiness while driving)</td>
<td>Mild, 10 (3)</td>
<td>Moderate, 13 (3)</td>
<td>4</td>
</tr>
<tr>
<td>Faccenda et al., 20018*4</td>
<td>71</td>
<td>AHI ≥ 15 and at least two symptoms of OSAHS</td>
<td>Severe, median 35 (range 15–129)</td>
<td>Moderate, median 15 (range 6–14)</td>
<td>4</td>
</tr>
<tr>
<td>McArdle et al., 20018*5</td>
<td>23</td>
<td>AHI &gt; 15 and at least two symptoms of OSAHS</td>
<td>Severe, median 40 (IQR 25–65)</td>
<td>Moderate, median 14 (IQR 10–17)</td>
<td>4</td>
</tr>
</tbody>
</table>
### TABLE 1 Characteristics of included studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Number randomised (N)</th>
<th>Target population</th>
<th>Disease severity [AHI, mean (SD)]</th>
<th>Severity of sleepiness, [ESS, mean (SD)]</th>
<th>Treatment duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPAP vs conservative/usual care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parallel trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ballester et al., 1999⁹⁶</td>
<td>105</td>
<td>AHI &gt; 15 and severe clinical symptoms or AHI &gt; 30 and mild to moderate symptoms</td>
<td>Severe, I 55 (22.3), C 58 (18.3)</td>
<td>Moderate, I 12.1 (5.0), C 11.4 (6.1)</td>
<td>12</td>
</tr>
<tr>
<td>Chakravorty et al., 2002²⁷</td>
<td>71</td>
<td>AHI &gt; 15</td>
<td>Severe, I 55 (28.7), C 35 (19.1)</td>
<td>Severe, I 16 (5.6), C 14 (4.2)</td>
<td>12</td>
</tr>
<tr>
<td>&quot;Drager et al., 2006,&quot; Abstract</td>
<td>16</td>
<td>AHI &gt; 30, normotensive</td>
<td>Severe, I 54 (8), C 65 (13)</td>
<td>NR</td>
<td>12</td>
</tr>
<tr>
<td>&quot;Lam et al., 2007&quot;⁷⁰</td>
<td>101</td>
<td>AHI 5–40 or AHI 5–20 along with ESS &gt; 9</td>
<td>Moderate, I 23.8 (11.1), C 19.3 (10.9)</td>
<td>Moderate, I 12 (5.8), C 12 (5.8)</td>
<td>10</td>
</tr>
<tr>
<td>Lim et al., 2005, Abstract</td>
<td>23</td>
<td>Primary headache symptoms and AHI ≥5</td>
<td>NR</td>
<td>NR</td>
<td>4</td>
</tr>
<tr>
<td>Lojander et al., 1996⁹⁹</td>
<td>44</td>
<td>Diagnosis of OSAHS and BMI &lt; 40 kg/m²</td>
<td>Moderate</td>
<td>NR</td>
<td>52</td>
</tr>
<tr>
<td>Monasterio et al., 2001¹⁰⁰</td>
<td>142</td>
<td>AHI 10–30 and absence of severe daytime sleepiness</td>
<td>Moderate, I 20 (6), C 21 (6)</td>
<td>Moderate, I 12.1 (4.9), C 13.2 (4.3)</td>
<td>24</td>
</tr>
<tr>
<td>&quot;Redline et al., 1998&quot;⁵⁹</td>
<td>111</td>
<td>RDI 5–30 and absence of ‘pathological sleepiness’</td>
<td>Moderate, I RDI 14.6 (9.8), C 11.8 (9.6)</td>
<td>Moderate, I 10.4 (4.3), C 10.6 (5.6)</td>
<td>8</td>
</tr>
<tr>
<td><strong>CPAP vs posture-related device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crossover trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jokic et al., 1999¹⁰⁸</td>
<td>14</td>
<td>AHI &lt; 15 in the lateral position and AHI in the supine sleep position at least twice that in the lateral position</td>
<td>Severe, (supine) 63.8 (148.9), mild (lateral) 4.9 (SE 4.1)</td>
<td>Moderate, I 13 (SD 1.3)</td>
<td>2</td>
</tr>
<tr>
<td>&quot;Skinner et al., 2004&quot;⁶⁰</td>
<td>14</td>
<td>AHI 10–60 and daytime symptoms of obstructive sleep apnoea</td>
<td>Moderate, 27 (12)</td>
<td>Moderate, I 11.9 (4.6)</td>
<td>4</td>
</tr>
<tr>
<td>&quot;Skinner et al., 2004&quot;⁶¹</td>
<td>10</td>
<td>AHI 10–60 and mild to moderate OSAHS</td>
<td>Moderate, 29.4 (13.4)</td>
<td>Moderate, I 13.2 (SD 4.9)</td>
<td>4</td>
</tr>
<tr>
<td><strong>CPAP vs dental devices</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parallel trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleetham et al., 2002¹⁰¹</td>
<td>101</td>
<td>AHI &gt; 10</td>
<td>Severe, I 37.6 (22.8), C 38.7 (22.2)</td>
<td>Moderate, I 12.8 (4.1), C 11.1 (4.9)</td>
<td>12</td>
</tr>
<tr>
<td>Hoekema et al., 2006¹⁰¹</td>
<td>103</td>
<td>Adults with a diagnosis of OSAHS</td>
<td>NR</td>
<td>NR</td>
<td>8</td>
</tr>
<tr>
<td>&quot;Lam et al., 2007&quot;⁷⁰</td>
<td>101</td>
<td>AHI 5–40 or AHI 5–20 along with ESS &gt; 9</td>
<td>Moderate, I 23.8 (11.1), C 20.9 (9.9)</td>
<td>Moderate, I 12 (5.8), C 12 (5.8)</td>
<td>10</td>
</tr>
</tbody>
</table>

*continued*
### TABLE 1 Characteristics of included studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Number randomised (N)</th>
<th>Target population</th>
<th>Disease severity [AHI, mean (SD)]</th>
<th>Severity of sleepiness, [ESS, mean (SD)]</th>
<th>Treatment duration (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2004</td>
<td>114</td>
<td>AHI 5–30</td>
<td>Moderate, 21.3 (13.6)</td>
<td>Moderate, 10.7 (6.5)</td>
<td>12</td>
</tr>
<tr>
<td>Cibele et al., 2006</td>
<td>13</td>
<td>AHI ≥20</td>
<td>Severe, 45.5 (SD 28)</td>
<td>Moderate, 10.6 (SD 4)</td>
<td>4</td>
</tr>
<tr>
<td>Ferguson et al., 1996</td>
<td>27</td>
<td>AHI 15–50</td>
<td>Moderate, 24.5 (8.8)</td>
<td>NR</td>
<td>16</td>
</tr>
<tr>
<td>Engleman et al., 2002</td>
<td>51</td>
<td>AHI ≥5 and two or more symptoms of OSAHS, including sleepiness (ESS ≥8 or sleepiness while driving)</td>
<td>Severe, 31 (26)</td>
<td>Moderate, 14 (4)</td>
<td>8</td>
</tr>
<tr>
<td>Ferguson et al., 1997</td>
<td>24</td>
<td>AHI 15–55</td>
<td>Moderate, 26.8 (11.9)</td>
<td>Moderate, I 10.3 (3.1), C 11.0 (3.8)</td>
<td>16</td>
</tr>
<tr>
<td>L’Estrange et al., 1999</td>
<td>15</td>
<td>AHI &gt; 50</td>
<td>Severe, 63.7 (10)</td>
<td>Moderate, 17.2 (3.8)</td>
<td>8</td>
</tr>
<tr>
<td>Olson et al., 2002</td>
<td>24</td>
<td>AHI &gt; 15 and AI &gt; 5 or AHI &gt; 5 and AI &gt; 15</td>
<td>NR</td>
<td>NR</td>
<td>6</td>
</tr>
<tr>
<td>Randerath et al., 2002</td>
<td>20</td>
<td>AHI 5–30 and clinical symptoms of OSAHS</td>
<td>Moderate, 17.5 (7.7)</td>
<td>NR</td>
<td>6</td>
</tr>
<tr>
<td>Tan et al., 2002</td>
<td>24</td>
<td>AHI &lt; 50</td>
<td>Moderate, 22.2 (9.6)</td>
<td>Moderate, 13.4 (4.6)</td>
<td>8</td>
</tr>
</tbody>
</table>

AHI, apnoea–hypopnoea index; AI, Arousal Index; C, Comparator; ESS, Epworth Sleepiness Scale; I, Intervention (CPAP); IQR, interquartile range; NR, not reported; OSAHS, obstructive sleep apnoea–hypopnoea syndrome; RDI, respiratory disturbance index.

- **a** Additional data since the review by Giles et al. 
- **b** Data reported for first arm of crossover only.
- **c** New data due to different inclusion criteria.
- **d** Partial crossover, first arm data extracted only.
- **e** 5th–95th centile.
- **f** unpublished data obtained from the systematic review by Giles et al.

Full details of the quality assessment are presented in Appendix 3. Eighteen of 48 studies reported an adequate method of random sequence generation. The majority of studies did not report, or reported suboptimal methods of allocation concealment, with five studies reporting adequate allocation concealment, defined according to Cochrane criteria. As a consequence of the comparators used, only the 18 studies using sham CPAP were double-blinded; other comparators are visibly different and cannot therefore be double-blinded. Fourteen studies reported that participants were CPAP naïve; of these, 11 studies used sham CPAP as a comparator. It was unclear in the remaining studies using sham CPAP whether participants were CPAP naïve. ITT analysis was defined as all randomised patients included in the analysis within the treatment group to which they were randomised. Although a number of studies described themselves as being ITT, only four studies used ITT analysis according to this criterion. The majority of studies reported loss to follow-up; with the exception of a few studies, this was low (< 20%), with little difference between treatment arms. Of the 26 crossover studies included in the review, 19 reported an appropriate analysis using paired data. Fifteen studies evaluated the possibility of carryover effects, with four studies reporting carryover effects in primary or secondary outcomes.

### Assessment of effectiveness

The primary outcomes of interest for clinical effectiveness were subjective daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS).
and objective sleepiness as assessed by the Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) or Osler test.

**Epworth Sleepiness Scale**

**CPAP versus placebo or conservative/usual care**

Data were available for the ESS from 23 trials (1334 participants). When all the studies were pooled there was a statistically significant benefit with CPAP compared with placebo/usual care for daytime sleepiness as measured by the ESS (MD –2.7, 95% CI –3.5 to –2.0). However, heterogeneity was high ($I^2 = 71\%$) and this treatment effect is unlikely to be generalisable. The heterogeneity was investigated using subgroup analysis.

**Clinical subgroup analyses**

When studies were grouped by severity of daytime sleepiness at baseline (mild, moderate or severe, as defined by the ESS), heterogeneity was reduced. Although there was still evidence of moderate heterogeneity within the subgroups, with the exception of two studies, the direction of the effect was consistently in favour of CPAP (Figure 2). There was a statistically significant improvement

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP $n$</th>
<th>Control $n$</th>
<th>ESS Score (random) 95% CI</th>
<th>Weight %</th>
<th>ESS Score (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (ESS score 0–9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbé, 2001</td>
<td>29</td>
<td>25</td>
<td>–</td>
<td>2.40</td>
<td>0.00 (–2.29 to 2.29)</td>
</tr>
<tr>
<td>Robinson, 2006</td>
<td>32</td>
<td>32</td>
<td>–</td>
<td>6.46</td>
<td>–1.20 (–2.00 to –0.40)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>61</td>
<td>57</td>
<td>–</td>
<td>10.67</td>
<td>–1.07 (–1.82 to –0.31)</td>
</tr>
<tr>
<td>Test for heterogeneity: $\chi^2 = 0.94$, df = 1 ($p = 0.33$), $I^2 = 0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 2.78$ ($p &lt; 0.0006$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Moderate (ESS score 10–15) |         |             |                          |         |                          |
| Ballester, 1999     | 68      | 37          | –                        | 4.35    | –5.00 (–7.19 to –2.81)   |
| Engleman, 1997      | 66      | 37          | –                        | 2.65    | 0.10 (–3.51 to 3.71)     |
| Engleman, 1998      | 51      | 46          | –                        | 3.27    | –6.00 (–9.00 to –3.00)   |
| Redline, 1998       | 13      | 13          | –                        | 5.58    | –1.09 (–2.50 to 0.32)    |
| Engleman, 1999      | 34      | 34          | –                        | 4.50    | –3.00 (–5.09 to –0.91)   |
| Faccenda, 2001      | 68      | 68          | –                        | 5.61    | –2.40 (–3.79 to –1.01)   |
| Monasterio, 2001    | 66      | 59          | –                        | 4.83    | –2.20 (–4.08 to –0.32)   |
| Barnes, 2002        | 28      | 28          | –                        | 3.76    | –0.60 (–3.21 to 2.01)    |
| Becker, 2003        | 16      | 16          | –                        | 3.18    | –3.80 (–6.88 to –0.72)   |
| Barnes, 2004        | 80      | 80          | –                        | 6.04    | –1.00 (–2.11 to 0.11)    |
| Marshall, 2005      | 29      | 29          | –                        | 4.96    | –2.40 (–4.20 to –0.60)   |
| Campos-Rodriguez, 2006 | 34   | 34          | –                        | 5.49    | –1.00 (–2.47 to 0.47)    |
| Hui, 2006           | 23      | 23          | –                        | 3.55    | –1.10 (–3.87 to 1.67)    |
| Lam, 2007           | 34      | 33          | –                        | 3.55    | –3.00 (–5.77 to –0.23)   |
| Coughlin, 2007      | 34      | 34          | –                        | 5.61    | –3.10 (–4.49 to –1.71)   |
| West, 2006          | 19      | 21          | –                        | 3.39    | –4.00 (–6.90 to –1.10)   |
| Subtotal (95% CI)    | 610     | 571         | –                        | 70.33   | –2.33 (–3.04 to –1.62)   |
| Test for heterogeneity: $\chi^2 = 30.53$, df = 15 ($p = 0.01$), $I^2 = 50.99\%$ |
| Test for overall effect: $z = 6.46$ ($p < 0.00001$) |

| Severe (ESS score 16–24) |         |             |                          |         |                          |
| Jenkinson, 1999      | 54      | 53          | –                        | 5.02    | –4.80 (–6.56 to –3.04)   |
| Henke, 2001         | 27      | 18          | –                        | 2.24    | –4.00 (–8.10 to 0.10)    |
| Montserrat, 2001    | 24      | 23          | –                        | 3.91    | –7.94 (–10.44 to –5.44)  |
| Chakravorty, 2002   | 32      | 21          | –                        | 3.18    | –3.00 (–6.08 to 0.08)    |
| Pepperell, 2002     | 53      | 51          | –                        | 4.66    | –4.50 (–6.49 to –2.51)   |
| Subtotal (95% CI)    | 190     | 166         | –                        | 19.01   | –4.99 (–6.51 to –3.47)   |
| Test for heterogeneity: $\chi^2 = 7.45$, df = 4 ($p = 0.11$), $I^2 = 46.3\%$ |
| Test for overall effect: $z = 6.43$ ($p < 0.00001$) |

| Total (95% CI)       | 861     | 794         | –                        | 100.00  | –2.70 (–3.45 to –1.96)   |
| Test for heterogeneity: $\chi^2 = 74.92$, df = 22 ($p < 0.00001$), $I^2 = 70.6\%$ |
| Test for overall effect: $z = 7.12$ ($p < 0.00001$) |

**FIGURE 2** Epworth Sleepiness Scale (CPAP versus placebo/usual care), stratified by severity of sleepiness at baseline (ESS).
in symptoms of daytime sleepiness with CPAP treatment compared with placebo or usual care for all levels of disease severity. The improvement was greatest in trials in which baseline sleepiness was severe (MD –5.0, 95% CI –6.5 to –3.5) and was consecutively smaller with moderate (MD –2.3, 95% CI –3.0 to –1.6) and mild severity (MD –1.1, 95% CI –1.8 to –0.3). The estimate of treatment effect for studies of mild sleepiness at baseline is based on only two studies, one which reported no difference between CPAP and placebo and one which reported a small but statistically significant improvement in favour of CPAP.

When studies were grouped by disease severity (AHI) at baseline there was a statistically significant improvement in daytime sleepiness with CPAP compared with placebo or usual care in trials of severe and moderate disease populations but not mild disease (Figure 3). As with the subgroup analysis based on ESS, the treatment effect was largest in the severe disease population and the treatment effect was consecutively smaller with moderate and mild disease. There was moderate to high statistical heterogeneity in the subgroup analyses of trials of severe ($I^2 = 71\%$) and moderate ($I^2 = 65\%$) disease. Only three trials were available

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP n</th>
<th>Control n</th>
<th>ESS Score (random)</th>
<th>Weight %</th>
<th>ESS Score (random)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>95% CI</td>
<td></td>
<td>95% CI</td>
</tr>
<tr>
<td>Mild (AHI 5–14 events/hour)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1997</td>
<td>16</td>
<td>16</td>
<td></td>
<td>2.65</td>
<td>0.10 (–3.51 to 3.71)</td>
</tr>
<tr>
<td>Engleman, 1999</td>
<td>34</td>
<td>34</td>
<td></td>
<td>4.50</td>
<td>–3.00 (–5.09 to –1.91)</td>
</tr>
<tr>
<td>Barnes, 2002</td>
<td>28</td>
<td>28</td>
<td></td>
<td>3.76</td>
<td>–0.60 (–3.21 to 2.01)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>78</td>
<td>78</td>
<td></td>
<td>10.91</td>
<td>–1.50 (–3.43 to 0.42)</td>
</tr>
<tr>
<td>Test for heterogeneity: $\chi^2 = 3.13$, df = 2 ($p = 0.21$), $I^2 = 36.0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 1.53$ ($p = 0.13$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (AHI 15–30 events/hour)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1998</td>
<td>51</td>
<td>46</td>
<td></td>
<td>5.58</td>
<td>–1.09 (–2.50 to 0.32)</td>
</tr>
<tr>
<td>Jenkinson, 1999</td>
<td>54</td>
<td>53</td>
<td></td>
<td>5.02</td>
<td>–4.80 (–6.56 to –3.04)</td>
</tr>
<tr>
<td>Monasterio, 2001</td>
<td>66</td>
<td>59</td>
<td></td>
<td>4.83</td>
<td>–2.20 (–4.08 to –0.32)</td>
</tr>
<tr>
<td>Barnes, 2004</td>
<td>80</td>
<td>80</td>
<td></td>
<td>6.04</td>
<td>–1.00 (–2.11 to 0.11)</td>
</tr>
<tr>
<td>Marshall, 2005</td>
<td>29</td>
<td>29</td>
<td></td>
<td>4.96</td>
<td>–2.40 (–4.20 to –0.60)</td>
</tr>
<tr>
<td>Lam, 2007</td>
<td>34</td>
<td>33</td>
<td></td>
<td>3.55</td>
<td>–3.00 (–5.77 to –0.23)</td>
</tr>
<tr>
<td>Robinson, 2006</td>
<td>32</td>
<td>32</td>
<td></td>
<td>6.46</td>
<td>–1.20 (–2.00 to –0.40)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>346</td>
<td>332</td>
<td></td>
<td>36.45</td>
<td>–2.04 (–2.99 to –1.09)</td>
</tr>
<tr>
<td>Test for heterogeneity: $\chi^2 = 17.35$, df = 6 ($p = 0.008$), $I^2 = 65.4%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 4.20$ ($p &lt; 0.0001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (AHI &gt; 30 events/hour)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ballester, 1999</td>
<td>68</td>
<td>37</td>
<td></td>
<td>4.35</td>
<td>–5.00 (–7.19 to –2.81)</td>
</tr>
<tr>
<td>Engleman, 1998</td>
<td>10</td>
<td>13</td>
<td></td>
<td>3.27</td>
<td>–6.00 (–9.00 to –3.00)</td>
</tr>
<tr>
<td>Barbe, 2001</td>
<td>29</td>
<td>25</td>
<td></td>
<td>4.20</td>
<td>0.00 (–2.29 to 2.29)</td>
</tr>
<tr>
<td>Faccenda, 2001</td>
<td>68</td>
<td>68</td>
<td></td>
<td>5.61</td>
<td>–2.40 (–3.79 to –1.01)</td>
</tr>
<tr>
<td>Henke, 2001</td>
<td>27</td>
<td>18</td>
<td></td>
<td>2.24</td>
<td>–4.00 (–8.10 to 0.10)</td>
</tr>
<tr>
<td>Montserrat, 2001</td>
<td>24</td>
<td>23</td>
<td></td>
<td>3.91</td>
<td>–7.94 (–10.44 to –5.44)</td>
</tr>
<tr>
<td>Chakravorty, 2002</td>
<td>32</td>
<td>21</td>
<td></td>
<td>3.18</td>
<td>–3.00 (–6.08 to 0.08)</td>
</tr>
<tr>
<td>Pepperell, 2002</td>
<td>53</td>
<td>51</td>
<td></td>
<td>4.66</td>
<td>–4.50 (–6.49 to –2.51)</td>
</tr>
<tr>
<td>Becker, 2003</td>
<td>16</td>
<td>16</td>
<td></td>
<td>3.18</td>
<td>–3.80 (–6.88 to –0.72)</td>
</tr>
<tr>
<td>Campos-Rodriguez, 2006</td>
<td>34</td>
<td>34</td>
<td></td>
<td>5.49</td>
<td>–1.00 (–2.47 to 0.47)</td>
</tr>
<tr>
<td>Hui, 2004</td>
<td>23</td>
<td>23</td>
<td></td>
<td>3.55</td>
<td>–1.10 (–3.87 to 1.67)</td>
</tr>
<tr>
<td>Coughlin, 2007</td>
<td>34</td>
<td>34</td>
<td></td>
<td>5.61</td>
<td>–3.10 (–4.49 to –1.71)</td>
</tr>
<tr>
<td>West, 2006</td>
<td>19</td>
<td>21</td>
<td></td>
<td>3.39</td>
<td>–4.00 (–6.90 to –1.10)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>437</td>
<td>384</td>
<td></td>
<td>52.64</td>
<td>–3.41 (–4.56 to –2.26)</td>
</tr>
<tr>
<td>Test for heterogeneity: $\chi^2 = 41.38$, df = 12 ($p &lt; 0.0001$), $I^2 = 71.0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 5.81$ ($p &lt; 0.00001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>861</td>
<td>794</td>
<td></td>
<td>100.00</td>
<td>–2.70 (–3.45, –1.96)</td>
</tr>
<tr>
<td>Test for heterogeneity: $\chi^2 = 74.92$, df = 22 ($p &lt; 0.00001$), $I^2 = 70.6%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 7.12$ ($p &lt; 0.00001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FIGURE 3 Epworth Sleepiness Scale (CPAP versus placebo/usual care), stratified by disease severity at baseline (AHI or oxygen desaturation dip rate).
for the analysis of mild disease and there was low statistical heterogeneity.

**Other subgroup analyses**

The variation in treatment effect with study design (parallel and crossover trials), type of data (end point and change scores) and comparator (sham CPAP, oral placebo and conservative/usual care) was also investigated. Each subgroup analysis was conducted for the whole data set. There was a statistically significant improvement in symptoms of daytime sleepiness (ESS) with CPAP over the comparator in each of the subgroups investigated and the treatment effects in the subgroups were consistent with each other, i.e. the 95% confidence intervals overlapped (see Appendix 4, Table 41).

Four of the five studies that reported an adequate method of concealment of allocation reported ESS as an outcome.\(^{62,77,87,109}\) When these four studies were pooled, the treatment effect was consistent with the treatment effect from the overall analysis (MD –3.5, 95% CI –4.5 to –2.5). There was no statistical heterogeneity (\(I^2 = 0\%\)).

Further subgroup analyses were conducted on the subset of studies using sham CPAP as a comparator on a post hoc basis. Blinding of participants is particularly useful in reducing bias when subjective outcome measures such as ESS are being used. Participant blinding was possible only in the studies in which a sham CPAP was used as the comparator. Effectively, sham CPAP provides the best placebo. Therefore, further subgroup analysis was conducted on the subset of studies using sham or placebo CPAP. Studies comparing CPAP with sham CPAP were grouped by mean symptom severity at baseline (ESS) and disease severity at baseline (AHI). There was a high degree of statistical heterogeneity (\(I^2 > 75\%\)) in the analyses based on the mean AHI at baseline and the treatment effect is unlikely to be generalisable. When the 12 studies of CPAP versus sham CPAP were grouped based on baseline ESS the findings were similar to the subgroup analysis of symptom severity conducted on the complete data set (CPAP versus sham placebo, sham placebo and usual care) (see Appendix 4, Figure 21). The benefit of CPAP was largest in the trials in which mean baseline sleepiness was severe (MD –5.4, 95% CI –7.0 to –3.7, \(I^2 = 46\%\)) and was consecutively smaller in trials of moderate (MD –2.4, 95% CI –3.4 to –1.4, \(I^2 = 31\%\)) and mild (MD –1.1, 95% CI –1.8 to –0.3, \(I^2 = 0\%\)) daytime sleepiness at baseline. Statistical heterogeneity within subgroups was low to moderate.

**Sensitivity analyses**

The effect of removing individual trials from the meta-analyses in which studies were subgrouped by mean baseline severity of sleepiness was investigated. The removal of individual studies resulted in only minor variations in the size of treatment effect in the severe and moderate subjective sleepiness at baseline subgroups and the difference between CPAP and control remained statistically significant (see Appendix 4, Table 42).

Using a fixed-effect model rather than a random-effects model did not result in any substantive changes to the results (see Appendix 4, Table 41).

**CPAP versus dental devices**

Data were available for the ESS from six trials (\(n = 337\)). All of these trials comprised populations with moderate daytime sleepiness (ESS) at baseline. There was no statistically significant difference in the impact on daytime sleepiness (ESS) between CPAP and dental devices (MD –0.9, 95% CI –2.1 to 0.4) (Figure 4). There was evidence of moderate statistical heterogeneity (\(I^2 = 60\%\)) and the treatment effect ranged from MD –4.0 in favour of CPAP to a small treatment effect in favour of dental devices (MD 0.4).

**Clinical subgroup analyses**

When studies were subgrouped on the basis of baseline disease severity (AHI), the findings were not substantially altered, although this analysis was limited by the small number of studies in the severe disease category and no studies in the mild group. There was no statistically significant difference between CPAP and dental devices in either the severe or moderate disease subgroup (see Appendix 4, Table 43). The treatment effects in the severe and moderate disease severity subgroups were consistent with each other, i.e. the 95% confidence intervals overlapped. The two trials of patients with severe disease were contradictory: one reported a statistically significant mean improvement of 4 points on the ESS (95% CI –6.3 to –1.7) with CPAP compared with dental devices and the other trial reported no statistically significant difference (MD 0.4, 95% CI –1.6 to 2.0).

**Other subgroup analyses**

The findings were similar within the subgroups of crossover and parallel trials, although these analyses were limited by the small number of trials. There was no statistically significant difference between CPAP and dental devices in either the crossover or parallel subgroup (see Appendix 4, Table 43).
Assessment of clinical effectiveness

Sensitivity analyses

The effect of removing individual trials from the meta-analysis of the whole data set was investigated. The removal of individual studies did not substantially alter the findings; the pooled effect size ranged from –0.1 to –1.2 and the effect remained not statistically significant (see Appendix 4, Table 44). The removal of one study that used two different dental devices dramatically reduced the statistical heterogeneity. The use of a fixed-effect model did not substantially alter the findings (see Appendix 4, Table 43).

We conducted a post hoc sensitivity analysis to investigate the impact on the treatment effect of removing studies from the analysis that used a one-piece dental device, which is generally viewed as inferior to a two-piece adjustable device. The findings were not substantially altered, although the effect size moved in favour of dental devices (MD 0.13, 95% CI –0.71 to 0.97). When the two studies that specifically reported using incremental mandibular advancement with a two-piece device were pooled, the findings were not substantially altered (MD 0.11, 95% CI –0.84 to 1.06), although the effect size moved in favour of dental devices.

CPAP versus postural therapy

Data were available for the ESS from three small crossover trials (n = 36), the studies were not pooled for an overall treatment effect because of differences in the comparators used. Symptom severity was moderate in all three trial populations. No statistically significant differences were found between CPAP and postural therapy (consisting of a backpack with a soft ball inside) on the ESS in patients with positional OSAHS (i.e. AHI while sleeping on the back was two or more times the AHI during sleep in the lateral position) (MD –1.5 (95% CI –2.9 to 0.8). Similarly, there was no statistically significant difference between CPAP and a shoulder–head elevation pillow (p = 0.69 for difference in change) or a cervicomandibular support collar (p = 0.22 for difference in change) on the Scottish National Sleep Survey Questionnaire. Only overall baseline ESS scores were reported for the last two studies so change scores and the corresponding mean difference could not be calculated.

Maintenance of Wakefulness Test

CPAP versus placebo or conservative/usual care

Outcome data were available from five studies (n = 287) on the MWT. One of these studies used the Osler test. There was a benefit with CPAP compared with placebo/usual care in the length of time participants could stay awake in a setting conducive to sleep (MD 3.3 minutes, 95% CI 1.3–5.3) and this was statistically significant (Figure 5). Statistical heterogeneity was low (I² = 11%) and the treatment effect was consistently in favour of CPAP being beneficial.

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP n</th>
<th>Dental devices n</th>
<th>ESS score (random)</th>
<th>Weight %</th>
<th>ESS score (random)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (ESS 0–9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferguson, 1997</td>
<td>19</td>
<td>19</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Engleman, 2002</td>
<td>48</td>
<td>48</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Fleetham, 2002</td>
<td>51</td>
<td>50</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Tan, 2002</td>
<td>21</td>
<td>21</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Lam, 2007</td>
<td>34</td>
<td>34</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>253</td>
<td>252</td>
<td>–</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 12.59, df = 5 (p = 0.03), I² = 60.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.32 (p = 0.19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Severe (ESS 16–24)   |        |                  |                    |          |                    |
| Ferguson, 1997       | 19     | 19               | –                  |          | –                  |
| Engleman, 2002       | 48     | 48               | –                  |          | –                  |
| Fleetham, 2002       | 51     | 50               | –                  |          | –                  |
| Tan, 2002            | 21     | 21               | –                  |          | –                  |
| Lam, 2007            | 34     | 34               | –                  |          | –                  |
| Subtotal (95% CI)    | 253    | 252              | –                  |          | –                  |
| Test for heterogeneity: χ² = 12.59, df = 5 (p = 0.03), I² = 60.3% |
| Test for overall effect: z = 1.32 (p = 0.19) |

FIGURE 4 Epworth Sleepiness Scale (CPAP versus dental devices), stratified by severity of sleepiness at baseline (ESS).
Clinical subgroup analyses

The subgroup analysis by severity of daytime sleepiness at baseline (ESS) was limited by only one study being available in the severe symptom severity group and none being available in the mild group. When studies were subgrouped there was a statistically significant improvement with CPAP compared with control in the single severe study (MD 6.5 minutes, 95% CI 2.6–10.4) and the moderate subgroup (MD 2.3 minutes, 95% CI 0.4–4.3) (see Figure 5). The benefit was greatest in the study in which symptoms were severe at baseline. The subgroup analysis by baseline disease severity (AHI) was limited by having only a single study in the mild and severe disease groups. The difference between CPAP and control was not statistically significant for the single studies of mild and severe daytime sleepiness at baseline. The treatment benefit was greatest with moderate disease and the difference between CPAP and control was statistically significant, although this analysis was limited by the small number of studies available (see Appendix 4, Table 45).

Other subgroup analyses

The variation in treatment effect with study design (parallel and crossover trials) was also investigated. In both subgroups there was a statistically significant benefit with CPAP compared with control. The treatment effect from the pooled crossover trials was smaller than that from parallel trials, although the 95% confidence intervals overlapped (see Appendix 4, Table 45).

Sensitivity analyses

The effect of removing individual trials from the meta-analysis was investigated. The statistically significant benefit of CPAP over placebo/usual care remained when individual studies were removed from the pooled analysis although the effect size ranged from 2.3 to 4.4 (see Appendix 4, Table 46). Using a fixed-effect rather than a random-effects model did not lead to any substantive changes to the results (see Appendix 4, Table 45).

CPAP versus dental devices

Data were available from two crossover trials (n = 128) on the MWT (Figure 6). In both studies baseline severity of daytime sleepiness (ESS) was classified as moderate. Neither study showed a statistically significant difference between CPAP and dental devices in the length of time participants could stay awake in a setting conducive to sleep (MD 0.7 minutes, 95% CI −1.6 to 2.9). The studies reported consistent findings.

### Table 45: Maintenance of Wakefulness Test (CPAP versus placebo), stratified by severity of sleepiness at baseline (ESS).

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>Treatment</th>
<th>Control</th>
<th>MWT (min) (random) 95% CI</th>
<th>Weight</th>
<th>MWT (min) (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (ESS score 0–9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (ESS score 10–15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1999</td>
<td>34</td>
<td>34</td>
<td>16.68</td>
<td>1.80 (−2.77 to 6.37)</td>
<td></td>
</tr>
<tr>
<td>Barnes, 2004</td>
<td>80</td>
<td>80</td>
<td>45.11</td>
<td>2.00 (−0.49 to 4.49)</td>
<td></td>
</tr>
<tr>
<td>Marshall, 2005</td>
<td>29</td>
<td>29</td>
<td>10.76</td>
<td>5.20 (−0.60 to 11.00)</td>
<td></td>
</tr>
<tr>
<td>West, 2006</td>
<td>17</td>
<td>20</td>
<td>5.71</td>
<td>1.94 (−6.15 to 10.03)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>160</td>
<td>163</td>
<td>78.27</td>
<td>2.33 (0.35 to 4.32)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 1.07, df = 3 (p = 0.78), I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 2.31 (p = 0.02)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (ESS score 16–24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jenkinson, 1999</td>
<td>54</td>
<td>53</td>
<td>21.73</td>
<td>6.50 (2.57 to 10.43)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>54</td>
<td>53</td>
<td>21.73</td>
<td>6.50 (2.57 to 10.43)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 3.24 (p = 0.001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>214</td>
<td>216</td>
<td>100.00</td>
<td>3.29 (1.32 to 5.25)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 4.51, df = 4 (p = 0.34), I² = 11.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 3.27 (p = 0.001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FIGURE 5 Maintenance of Wakefulness Test (CPAP versus placebo), stratified by severity of sleepiness at baseline (ESS).
**Assessment of clinical effectiveness**

**CPAP versus postural therapy**

Data were available for the MWT from one small crossover trial\(^{108}\) (\(n=13\)). There was no statistically significant difference between CPAP and postural therapy in the length of time participants could stay awake (MD 1.7 minutes, 95% CI \(-1.9\) to 3.3, \(p = 0.32\)).

**Multiple Sleep Latency Test**

**CPAP versus placebo or conservative/usual care**

Outcome data were available from seven trials on the MSLT (\(n=331\)). There was no statistically significant difference between CPAP and placebo/usual care in the length of time it took participants to fall asleep in surroundings conducive to sleep (MD 0.6 minutes, CI \(-0.7\) to 1.9). There was evidence of moderate heterogeneity (\(I^2 = 46\%\)) (Figure 7).

**Clinical subgroup analyses**

The subgroup analysis by severity of daytime sleepiness at baseline (ESS) was limited by only one study being available in the severe and mild symptom severity groups and because one study could not be classified (see Figure 7). There was no statistically significant difference between CPAP and control in the one trial of severe disease severity (MD \(-6.1\), 95% CI \(-27.3\) to 15.1) and the direction of the treatment effect favoured the control group. There was no statistically significant difference between CPAP and control in the moderate subgroup (MD 0.2, 95% CI \(-1.8\) to 2.2) or in the single trial of mild symptom severity (MD 2.0, 95% CI \(-0.8\) to 4.8). When studies were subgrouped by baseline disease severity (AHI) there was a statistically significant benefit with CPAP compared with placebo/usual care for studies of a severe disease population (MD 2.3, 95% CI 0.9–3.7, \(I^2 = 0\%\)) but not for those with mild- or moderate-severity disease (see Appendix 4, Table 47).

**Other subgroup analyses**

The pooled treatment effects estimated by crossover and parallel trials separately were similar; there was no statistically significant difference between CPAP and control in either subgroup (see Appendix 4, Table 47).

**Sensitivity analyses**

The effect of removing individual trials from the meta-analysis was investigated. When the Monasterio et al. trial\(^{100}\) was removed from the pooling, there was a statistically significant benefit in favour of CPAP (MD 1.2, 95% CI 0.0–2.4). Removing the other individual studies from the pooling did not change the overall result and the finding of no statistically significant difference between CPAP and control remained; the effect size ranged from 0 to 0.9 minutes when the individual studies were removed (see Appendix 4, Table 48). Using a fixed-effect rather than a random-effects model did not lead to any substantive changes to the results (see Appendix 4, Table 47).

**CPAP versus dental devices**

No data were available for the MSLT.

**Summary of sleepiness outcomes**

**CPAP compared with control**

The primary outcome of interest in the review was subjective sleepiness. Data were available on the ESS from 23 trials. Overall, CPAP reduced daytime sleepiness by a small amount compared with control; the effect probably varies among different groups of people. The average reduction on the ESS was 2.7 points, but might be anywhere between 2.0 and 3.5 points. There was considerable variation or inconsistency in the treatment effect (statistical heterogeneity); therefore some caution...
is needed in applying this result to all populations. Variation was reduced when studies were grouped based on baseline symptom severity and there was a trend towards a greater treatment effect with greater baseline symptom severity. It is not surprising that there would be less of a difference between CPAP and control in a population that reports only mild sleepiness at baseline.

In a severely symptomatic population the average reduction on the ESS was 5 points, but might be anywhere between 3.5 and 6.6 points; in a moderate symptom severity population the average reduction was 2.3 points, but might be anywhere between 1.6 and 3.0 points; and in mild severity the average reduction was 1.1 points, but might range anywhere between 0.3 and 1.8 points. When studies were subgrouped by disease severity at baseline, as measured by the AHI, there was a broadly similar trend. Although the definitions of disease and symptom severity used were based on current guidelines, these are arbitrary definitions and interpretation of the results for these subgroups needs to be carried out with that in mind.

The benefit with CPAP compared with control was robust across all the methodological subgroup analyses (trial design, type of data, comparator, quality) and sensitivity analyses investigating the influence of individual trials and use of a fixed-effect model.

Objective sleepiness was assessed using the MWT and MSLT. Data from the MWT were available from five trials. The length of time participants could stay awake in surroundings conducive to sleep as measured by the MWT was greater with CPAP compared with control. The average reduction in sleep latency with CPAP than with control was 3.3 minutes, but might be anywhere between 1.3 and 5.3 minutes. There was a trend towards a greater treatment effect with greater symptom severity, although this analysis was

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>Treatment</th>
<th>Control</th>
<th>MSRT (min) (random) 95% CI</th>
<th>Weight %</th>
<th>MSRL (min) (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (ESS score 0–9)</td>
<td>Barbaré, 200183</td>
<td>29</td>
<td>25</td>
<td>13.45</td>
<td>2.00 (−0.77 to 4.77)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td>29</td>
<td>25</td>
<td>13.45</td>
<td>2.00 (−0.77 to 4.77)</td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.42 (p = 0.16)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (ESS score 10–15)</td>
<td>Engleman, 199792</td>
<td>16</td>
<td>16</td>
<td>8.90</td>
<td>0.10 (−3.66 to 3.86)</td>
</tr>
<tr>
<td>Engleman, 199893</td>
<td>23</td>
<td>23</td>
<td>22.50</td>
<td>2.40 (0.79–4.01)</td>
<td></td>
</tr>
<tr>
<td>Monasterio, 2001100</td>
<td>66</td>
<td>59</td>
<td>21.07</td>
<td>−1.00 (−2.76 to 0.76)</td>
<td></td>
</tr>
<tr>
<td>Barnes, 200289</td>
<td>28</td>
<td>28</td>
<td>14.24</td>
<td>−1.12 (−3.76 to 1.52)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>133</td>
<td>126</td>
<td>66.71</td>
<td>0.20 (−1.82 to 2.22)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 9.64, df = 3 (p = 0.02), I² = 68.9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 0.19 (p = 0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (ESS score 16–24)</td>
<td>Chakravorty, 200297</td>
<td>32</td>
<td>21</td>
<td>0.38</td>
<td>−6.10 (−27.26 to 15.06)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>32</td>
<td>21</td>
<td>0.38</td>
<td>−6.10 (−27.26 to 15.06)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 0.57 (p = 0.57)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not reported</td>
<td>Engleman, 199490</td>
<td>32</td>
<td>32</td>
<td>19.47</td>
<td>1.10 (−0.84 to 3.04)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>32</td>
<td>32</td>
<td>19.47</td>
<td>1.10 (−0.84 to 3.04)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.11 (p = 0.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>226</td>
<td>204</td>
<td>100.00</td>
<td>0.64 (−0.67 to 1.94)</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 11.19, df = 6 (p = 0.08), I² = 46.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 0.96 (p = 0.34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 7** Multiple Sleep Latency Test (CPAP versus placebo), stratified by severity of sleepiness at baseline (ESS).
limited by the availability of only one study of a severe symptom severity population and none of a mild population. The benefit with CPAP compared with control was robust across the methodological subgroup analysis (trial design) and sensitivity analyses investigating the influence of individual trials and use of a fixed-effect model. The investigation of methodological factors was limited by the small number of trials available. There was no statistically significant difference between CPAP and control in how quickly participants could fall asleep in surroundings conducive to sleep when seven trials were pooled (MSLT).

CPAP compared with dental devices
Data were available from six trials. In a population with moderate daytime sleepiness at baseline, there was no statistically significant difference between CPAP and dental devices in the impact on daytime sleepiness. The treatment effect probably varies among different groups of people. The average effect was a reduction in sleepiness of less than one ESS point (0.9) with CPAP compared with dental devices, but might be anywhere between an increase in sleepiness of about half a point (0.4) to a decrease in sleepiness of 2.1 points. There was moderate variation in the treatment effect (statistical heterogeneity); therefore some caution needs to be taken in generalising this to all populations. The finding of no statistically significant difference between CPAP and dental devices was robust across subgroup analysis by disease severity (AHI) and trial design and sensitivity analyses investigating the influence of individual trials and use of a fixed-effect model. The investigation of methodological factors was limited by the small number of trials available.

There was no statistically significant difference between CPAP and dental devices in length of time participants could stay awake in surroundings conducive to sleep when measured by the MWT; though this is based on only two studies. No data were available for the MSLT.

Daytime blood pressure
Daytime blood pressure was the primary blood pressure outcome of interest and these data are reported below. A brief summary of the effects of treatment on night-time and 24-hour blood pressure is given below and the full data are reported in Appendix 4.

Fifteen studies reported outcome data for daytime blood pressure (Table 2); 12 used ambulatory blood pressure monitoring (ABPM) over 24 hours, and three used conventional clinic blood pressure monitoring. Data were reported in graphs only for two additional studies, from which it was not possible to obtain an accurate variance estimate. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) were reported. Where daytime blood pressure was reported, four studies reported SBP, DBP and MAP; four reported MAP only, and five reported SBP and DBP but not MAP. The proportion of hypertensive patients ranged from 15% to 100% and, where reported, antihypertensive medication remained unchanged throughout the studies.

CPAP compared with dental devices
Data were available on daytime MAP for six trials (n = 309). There was an improvement in daytime MAP with CPAP compared with placebo/usual care (MD –2.1 mmHg, 95% CI –4.3 to 0.0) and this was statistically significant (Figure 8). There was moderate statistical heterogeneity (I² = 59%).

Clinical subgroup analyses
There was some evidence of a variation in treatment effect with severity of sleepiness at baseline (ESS), but this analysis was limited by the small number of trials (see Figure 8); only one trial each of severe and moderate baseline sleepiness was available. The single trial of severely symptomatic patients showed the largest treatment effect in favour of CPAP (MD –4.2 mmHg, 95% CI –6.4 to –2.0) and the difference between CPAP and control was statistically significant (see Figure 8). The difference between CPAP and control was not statistically significant for the moderate subgroup (MD –3.4 mmHg, 95% CI –7.9 to 1.2); the one trial of mild disease severity also reported no statistically significant difference between CPAP and control (MD 1.1 mmHg, 95% CI –2.9 to 5.1) (see Figure 8). Therefore, the overall treatment effect appears to be dominated by the one trial of severely symptomatic patients. When studies were grouped by disease severity at baseline (AHI) the treatment effect was largest with severe disease and there was a statistically significant difference in favour of CPAP; however, only one trial was available of moderate disease and none of mild disease (see Appendix 4, Table 49).

Other subgroup analyses
Studies were subgrouped based on whether they were crossover or parallel and whether end point or change data were used. This analysis was limited by four of the six trials being parallel trials using change data (see Appendix 4, Table 49). For the subgroup of parallel...
TABLE 2  Summary of blood pressure data reported in included studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Baseline daytime BP [mean (SD)]</th>
<th>% (n) patients hypertensive at baseline</th>
<th>How BP was measured</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ambulatory blood pressure monitoring (ABPM)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Conventional clinic BP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CPAP vs sham CPAP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arias et al., 2005$^{56}$</td>
<td>SBP 127 (9), DBP 79 (5)</td>
<td></td>
<td>✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Arias et al., 2006$^{63}$</td>
<td>SBP 127 (9), DBP 79 (5)</td>
<td></td>
<td>✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Barbé et al., 2001$^{83}$</td>
<td>CPAP: SBP 130 (11), DBP 82 (5); Control: SBP 127 (10), DBP 80 (10)</td>
<td></td>
<td>✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Becker et al., 2003$^{84}$</td>
<td>CPAP: MAP 104 (16), SBP 140 (18), DBP 86 (16); Control: MAP 104 (12), SBP 141 (14), DBP 85 (12)</td>
<td>CPAP: 50% (n = 8); Control: 81% (n = 13); on medication or office BP ≥ 160 and/or 90 mmHg; BP medication unchanged</td>
<td>✓ ✓ ✓ ✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Campos-Rodríguez et al., 2006$^{85}$</td>
<td>CPAP: MAP 101 (11); Control: MAP 99 (10)</td>
<td>100% (&gt; 140/90 mmHg in three independent measurements); BP medication unchanged</td>
<td>✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td><strong>continued</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study details</td>
<td>Baseline daytime BP [mean (SD)]</td>
<td>% (n) patients hypertensive at baseline</td>
<td>How BP was measured</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------</td>
<td>---------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Coughlin et al., 2007&lt;sup&gt;62&lt;/sup&gt;</td>
<td>MAP 98 (11), SBP 128 (9), DBP 84 (9)</td>
<td>79% (n = 27) (resting BP of 140/90 mmHg)</td>
<td>Waking BP measured between 8 a.m. and 11 a.m. in supine position after 5-minute rest; recorded as mean of three measurements taken at 1-minute intervals using automatic oscillometric digital BP monitor (end point data)</td>
</tr>
<tr>
<td>Hui et al., 2006&lt;sup&gt;64&lt;/sup&gt;</td>
<td>MAP 98 (11), SBP 128 (9), DBP 84 (9)</td>
<td>50% (n = 28) (BP &gt; 140/90 on two occasions or using antihypertensive medication; medication unchanged)</td>
<td>24-hour ABPM as outpatients during normal activities; BP measured every 30 minutes for 48 hours and second 24 hours of data used; patients recorded time at which they went to bed and woke up to identify sleep and wake periods (change and end point data)</td>
</tr>
<tr>
<td>Pepperell et al., 2002&lt;sup&gt;87&lt;/sup&gt;</td>
<td>CPAP: MAP 104 (10), Control: MAP 104 (11)</td>
<td>19% (n = 22) taking medication for hypertension</td>
<td>24-hour ABPM measured during normal daily activities (except driving); patients kept diary and pressed event monitor to identify sleep and wake periods (change data)</td>
</tr>
<tr>
<td>Robinson et al., 2006&lt;sup&gt;63&lt;/sup&gt;</td>
<td>CPAP: MAP 106 (14); Control: MAP 109 (13)</td>
<td>100% (BP &gt; 140/90 on 24-hour ABPM or taking hypertensive drugs); medication unchanged</td>
<td>24-hour ABPM measured during normal daily activities (except driving); patients kept diary and pressed event monitor to identify sleep and wake periods (change and end point data)</td>
</tr>
</tbody>
</table>

**Table 2: Summary of blood pressure data reported in included studies**

- **Ambulatory blood pressure monitoring (ABPM)**: Daytime MAP, Daytime SBP, Daytime DBP, Night MAP, Night-time SBP, Night-time DBP, 24-hour MAP, 24-hour SBP, 24-hour DBP, Morning MAP, Evening MAP.
<table>
<thead>
<tr>
<th>Study details</th>
<th>Baseline daytime BP [mean (SD)]</th>
<th>% (n) patients hypertensive at baseline</th>
<th>How BP was measured</th>
<th>Conventional clinic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPAP vs oral placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2002</td>
<td>SBP 132 (11), DBP 84 (8)</td>
<td>25% (n = 7) (24-hour SBP &gt; 140 or DBP &gt; 90)</td>
<td>24-hour ABPM measured every 20 minutes during daytime and every 60 minutes overnight (change data)</td>
<td>✓ ✓ ✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Barnes et al., 2004</td>
<td>NR</td>
<td>15% (n = 14) (SBP &gt; 140 and/or DBP &gt; 90)</td>
<td>24-hour ABPM measured every 20 minutes during daytime and every 60 minutes overnight (end point data)</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>Engleman et al., 1996</td>
<td>NR</td>
<td>38% (n = 5) (SBP &gt; 134 and DBP &gt; 84); medication unchanged</td>
<td>24-hour ABPM measured at 30-minute intervals during which patients conducted normal day-to-day activities in community (end point data)</td>
<td>✓ ✓ ✓ ✓ ✓ ✓</td>
</tr>
<tr>
<td>Faccenda et al., 2001</td>
<td>NR</td>
<td>NR</td>
<td>24-hour ABPM measured every 30 minutes over 48 hours during which patients went about normal daily activities, recorded in a diary; first 24 hours of data discarded (end point data)</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td><strong>CPAP vs conservative/usual care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lam et al., 2007</td>
<td>CPAP: SBP 128 (13), DBP 77 (11); Control: SBP 126 (20), DBP 74 (14)</td>
<td>19% (n = 19); medication unchanged</td>
<td>Evening (8–9 p.m.) and morning (8–9 a.m.; BP recorded during admission to sleep clinic; average of three readings taken at 1-minute intervals used (end point data)</td>
<td>✓ ✓</td>
</tr>
</tbody>
</table>

**continued**
TABLE 2  Summary of blood pressure data reported in included studies

<table>
<thead>
<tr>
<th>Study details</th>
<th>Baseline daytime BP [mean (SD)]</th>
<th>% (n) patients hypertensive at baseline</th>
<th>How BP was measured</th>
<th>Ambulatory blood pressure monitoring (ABPM)</th>
<th>Conventional clinic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Daytime MAP</td>
<td>24-hour MAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Daytime SBP</td>
<td>NR (SBP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Daytime DBP</td>
<td>(DBP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Night MAP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Night-time SBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Night-time DBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24-hour MAP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24-hour SBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24-hour DBP</td>
<td></td>
</tr>
</tbody>
</table>

Monasterio et al., 2001<sup>100</sup>  
CPAP: SBP 126 (17), DBP 81 (12); Control: SBP 132 (17), DBP 84 (11)  
NR  
Office daytime arterial BP recorded (end point data)

CPAP vs dental devices

Barnes et al., 2004<sup>82</sup>  
NR  
See above

Lam et al., 2007<sup>70</sup>  
CPAP: See above; Dental device: SBP 127 (15), DBP 76 (12)  
See above

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; NR, not reported; SBP, systolic blood pressure.
trials using change from baseline data there was a statistically significant improvement with CPAP compared with control. For the other two subgroups consisting of single studies there was no statistically significant difference between groups. The MAP treatment effect ranged from 1.1 mmHg to –3.5 mmHg (see Appendix 4, Table 49).

**Sensitivity analyses** When studies were individually removed from the analysis the treatment effect ranged from –1.4 mmHg to –2.7 mmHg and remained statistically significant in only one instance (see Appendix 4, Table 50). There was no substantial change in the MAP results using a fixed-effect model (see Appendix 4, Table 49).

**Daytime systolic and diastolic blood pressure (using ABPM)**

Data were available on daytime SBP and DBP from seven trials (n = 220). There was no statistically significant difference between CPAP and control for SBP although there was a small decrease in SBP in favour of CPAP (MD –1.1 mmHg, 95% CI –3.4 to 1.2) (Figure 9). There was no evidence of statistical heterogeneity. Similarly, there was no statistically significant difference between CPAP and control for DBP although there was a small decrease in favour of CPAP (MD –1.2 mmHg, 95% CI –2.9 to 0.5); heterogeneity was low (I² = 29%) (Figure 10).

**Clinical subgroup analyses** The mean baseline daytime sleepiness (ESS) was not reported for three trials and in the remaining trials the populations were classified as having symptoms of moderate severity at baseline. Therefore, it was not possible to explore the difference in treatment effect with different symptom severity at baseline for SBP or DBP. With the exception of one trial, in which the population was classified as having disease of mild severity (AHI), the study populations were all classified as having severe disease. When the single mild disease severity

### Table 49

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP n</th>
<th>Control n</th>
<th>Day MAP (random) 95% CI</th>
<th>Weight %</th>
<th>Day MAP (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (ESS score 0–9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robinson, 2006*18</td>
<td>32</td>
<td>32</td>
<td>1.10 (–2.90 to 5.10)</td>
<td>14.98</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>32</td>
<td>32</td>
<td></td>
<td>14.98</td>
<td>1.10 (–2.90 to 5.10)</td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 0.54 (p = 0.59)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (ESS score 10–15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Becker, 2003*39</td>
<td>16</td>
<td>16</td>
<td>11.20 (–19.70 to –2.70)</td>
<td>5.23</td>
<td></td>
</tr>
<tr>
<td>Campos-Rodriguez, 2006*24</td>
<td>34</td>
<td>34</td>
<td>–0.80 (–4.80 to 3.20)</td>
<td>14.98</td>
<td></td>
</tr>
<tr>
<td>Hui, 2006*14</td>
<td>23</td>
<td>23</td>
<td>–2.20 (–6.26 to 1.86)</td>
<td>14.75</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>73</td>
<td>73</td>
<td></td>
<td>34.96</td>
<td>–3.35 (–7.86 to 1.16)</td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 4.74, df = 2 (p = 0.09), I² = 57.8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.46 (p = 0.15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (ESS score 16–24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pepperell, 2002*20</td>
<td>59</td>
<td>59</td>
<td>23.78 (–4.00 to –2.00)</td>
<td>23.78</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>59</td>
<td>59</td>
<td></td>
<td>23.78</td>
<td>–4.20 (–6.40 to –2.00)</td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 3.74 (p = 0.0002)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1996*13</td>
<td>13</td>
<td>13</td>
<td>26.27 (–1.00 to 0.74)</td>
<td>26.27</td>
<td>–1.00 (–2.74 to 0.74)</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>13</td>
<td>13</td>
<td></td>
<td>26.27</td>
<td>–1.00 (–2.74 to 0.74)</td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.12 (p = 0.26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>177</td>
<td>177</td>
<td>100.00 (–2.13 to –4.25)</td>
<td>100.00</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: χ² = 12.27, df = 5 (p = 0.03), I² = 59.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z = 1.96 (p = 0.05)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 8** Daytime mean arterial pressure using ambulatory blood pressure monitoring (CPAP versus placebo/usual care), stratified by severity of sleepiness at baseline (ESS).
(AHI) study was removed from the analyses for SBP and DBP, the difference between CPAP and control remained not statistically significant (see Appendix 4, Tables 51 and 52).

Other subgroup analyses The treatment effects in the crossover and parallel subgroups and the end point data and change data subgroups were consistent with each other, i.e. the 95% confidence intervals overlapped. The SBP treatment effect ranged from 1.2 for parallel trials using end point data to –5.2 for parallel trials using change from baseline data although the difference between CPAP and control was not statistically significant in any of the subgroups (see Appendix 4, Table 51). The DBP treatment effect ranged from 0.5 for parallel trials using end point data to –5.7 for parallel trials using change from baseline data although the difference between CPAP and control was not statistically significant in any of the subgroups (see Appendix 4, Table 52). These analyses are limited by the small number of studies in each of the subgroups.

Sensitivity analyses The finding of no statistically significant difference between CPAP and control for SBP and DBP did not alter when a fixed-effect model was used. For DBP the treatment effect was smaller using a fixed-effect model and there was no substantial change for the SBP results using a fixed-effect model (see Appendix 4, Tables 51 and 52).

The SE for the MD in systolic and diastolic blood pressure for Arias et al. 2005 was imputed based on an estimated within-person correlation of 0.5. The meta-analyses were rerun using an SE based on an assumed within-person correlation of 0.1 and 0.9. For SBP this altered the treatment effect slightly but the finding of no statistically significant

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP n</th>
<th>Control n</th>
<th>Day SBP (random) 95% CI</th>
<th>Weight %</th>
<th>Day SBP (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engleman, 1996</td>
<td>13</td>
<td>13</td>
<td>24.31</td>
<td>100.00</td>
<td>–1.06 (–3.35 to 1.23)</td>
</tr>
<tr>
<td>Barbè, 2001</td>
<td>29</td>
<td>26</td>
<td>10.49</td>
<td>3.00</td>
<td>(–4.07 to 10.07)</td>
</tr>
<tr>
<td>Barnes, 2002</td>
<td>28</td>
<td>28</td>
<td>4.68</td>
<td>–2.90</td>
<td>(–13.48 to 7.68)</td>
</tr>
<tr>
<td>Becker, 2003</td>
<td>16</td>
<td>16</td>
<td>4.90</td>
<td>–10.30</td>
<td>(–20.65 to 0.05)</td>
</tr>
<tr>
<td>Arias, 2005</td>
<td>25</td>
<td>25</td>
<td>30.67</td>
<td>0.00</td>
<td>(–4.14 to 4.14)</td>
</tr>
<tr>
<td>Arias, 2006</td>
<td>10</td>
<td>11</td>
<td>8.82</td>
<td>–1.00</td>
<td>(–8.71 to 6.71)</td>
</tr>
<tr>
<td>Hui, 2006</td>
<td>23</td>
<td>23</td>
<td>16.12</td>
<td>–2.50</td>
<td>(–8.20 to 3.20)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>144</td>
<td>142</td>
<td>100.00</td>
<td>–1.06</td>
<td>(–3.35 to 1.23)</td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2 = 4.94$, df = 6 ($p = 0.55$), $I^2 = 0$

Test for overall effect: $z = 0.91$ ($p = 0.36$)

FIGURE 9 Daytime systolic blood pressure using ambulatory blood pressure monitoring (CPAP versus placebo/usual care).

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>Treatment n</th>
<th>Control n</th>
<th>Daytime DBP (random) 95% CI</th>
<th>Weight %</th>
<th>Daytime DBP (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engleman, 1996</td>
<td>13</td>
<td>13</td>
<td>25.90</td>
<td>100.00</td>
<td>–2.00 (–4.41 to 0.41)</td>
</tr>
<tr>
<td>Barbè, 2001</td>
<td>29</td>
<td>26</td>
<td>11.94</td>
<td>1.00</td>
<td>(–3.38 to 5.38)</td>
</tr>
<tr>
<td>Barnes, 2002</td>
<td>28</td>
<td>28</td>
<td>2.73</td>
<td>–2.60</td>
<td>(–12.75 to 7.55)</td>
</tr>
<tr>
<td>Becker, 2003</td>
<td>16</td>
<td>16</td>
<td>3.93</td>
<td>–11.20</td>
<td>(–19.55 to –2.85)</td>
</tr>
<tr>
<td>Arias, 2005</td>
<td>25</td>
<td>25</td>
<td>28.59</td>
<td>0.00</td>
<td>(–2.18 to 2.18)</td>
</tr>
<tr>
<td>Arias, 2006</td>
<td>10</td>
<td>11</td>
<td>10.65</td>
<td>0.00</td>
<td>(–4.71 to 4.71)</td>
</tr>
<tr>
<td>Hui, 2006</td>
<td>23</td>
<td>23</td>
<td>16.26</td>
<td>–1.80</td>
<td>(–5.35 to 1.75)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>144</td>
<td>142</td>
<td>100.00</td>
<td>–1.20</td>
<td>(–2.92 to 0.52)</td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2 = 8.46$, df = 6 ($p = 0.21$), $I^2 = 29.1$

Test for overall effect: $z = 1.37$ ($p = 0.17$)

FIGURE 10 Daytime diastolic blood pressure using ambulatory blood pressure monitoring (CPAP versus placebo/usual care).
difference between CPAP and control did not change: assuming a within-patient correlation of 0.1 gave an SE of 2.75 for the study and the overall pooled treatment effect was –1.2 mmHg (95% CI –3.7 to 1.2); assuming a correlation of 0.9 gave an SE of 1.18 for the study and the overall pooled estimate was –0.6 mmHg (95% CI –2.4 to 1.1). Similarly, for DBP the treatment effect was slightly altered but the finding of no statistically significant difference between CPAP and control did not change: assuming a correlation of 0.1 gave an SE of 1.48 and the overall treatment effect was –1.3 mmHg (95% CI –3.1 to 0.5); assuming a correlation of 0.9 gave an SE of 0.53 and the overall treatment effect was –1.1 mmHg (95% CI –2.7 to 0.6).

Conventional clinic blood pressure

Three studies (n = 226) used conventional or clinic daytime blood pressure: one study reported waking blood pressure recorded as the mean of three measurements taken at 1-minute intervals between 8 a.m and 11 a.m;62 one study used a similar method to record morning (8–9 a.m.) and evening (8–9 p.m.) blood pressure70 and one provided very little information.100 The populations in all three studies were classified as having moderate daytime sleepiness at baseline. There was an improvement in daytime SBP (MD −6.62mmHg, 95% CI −9.48 to −3.76) and DBP (MD −3.47mmHg, 95% CI −6.27 to −0.68) with CPAP compared with placebo/usual care and these were both statistically significant (Figures 11 and 12). Statistical heterogeneity was low ($I^2 = 0\%$ and 33% for SBP and DBP respectively).

CPAP versus dental devices

No studies were found that reported daytime ABPM. One study reported morning and evening blood pressure in a population with moderate sleepiness and moderate disease severity at baseline (see Table 2).70 This study (a parallel trial, $n = 68$) found no statistically significant difference between CPAP and dental devices in terms of morning SBP (MD −2.9 mmHg, 95% CI −11.0 to 5.2), evening SBP (MD −4.9 mmHg, 95% CI −14.8 to 5.0), morning DBP (MD −1.6 mmHg, 95% CI −7.4 to 4.2) and evening DBP (MD −1.9 mmHg, 95% CI −7.6 to 3.8).

**FIGURE 11** Daytime conventional systolic blood pressure (CPAP versus placebo/usual care).

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP $n$</th>
<th>Control $n$</th>
<th>Day SBP (random) 95% CI</th>
<th>Weight %</th>
<th>Day SBP (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monasterio, 2001100</td>
<td>66</td>
<td>59</td>
<td>−8.00 (−14.70 to −1.30)</td>
<td>18.21</td>
<td></td>
</tr>
<tr>
<td>Lam, 200670</td>
<td>34</td>
<td>33</td>
<td>−3.70 (−12.45 to 5.05)</td>
<td>10.68</td>
<td></td>
</tr>
<tr>
<td>Coughlin, 200762</td>
<td>34</td>
<td>34</td>
<td>−6.70 (−10.09 to −3.31)</td>
<td>71.11</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>134</td>
<td>126</td>
<td>−6.62 (−9.48 to −3.76)</td>
<td>100.00</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2 = 0.59, df = 2 (p = 0.74), I^2 = 0\%$
Test for overall effect: $z = 4.54 (p < 0.00001)$

**FIGURE 12** Daytime conventional diastolic blood pressure (CPAP versus placebo/usual care).

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP $n$</th>
<th>Control $n$</th>
<th>Daytime DBP (random) 95% CI</th>
<th>Weight %</th>
<th>Daytime DBP (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monasterio, 2001100</td>
<td>66</td>
<td>59</td>
<td>−4.00 (−7.70 to 0.30)</td>
<td>36.11</td>
<td></td>
</tr>
<tr>
<td>Lam, 200770</td>
<td>34</td>
<td>33</td>
<td>0.80 (−4.90 to 6.50)</td>
<td>19.31</td>
<td></td>
</tr>
<tr>
<td>Coughlin, 200762</td>
<td>34</td>
<td>34</td>
<td>−4.90 (−8.00 to −1.80)</td>
<td>44.57</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>134</td>
<td>126</td>
<td>−3.47 (−6.27 to −0.68)</td>
<td>100.00</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2 = 3.00, df = 2 (p = 0.22), I^2 = 33.2\%$
Test for overall effect: $z = 2.44 (p < 0.01)$

© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Night-time and 24-hour blood pressure
CPAP versus placebo or conservative/usual care

Data were available on night-time MAP from six trials (\(n = 309\)).\(^{64,65,68,67,91,109}\) Overall, there was an improvement in night-time MAP with CPAP compared with placebo/usual care (MD –3.0 mmHg, 95% CI –4.7 to –1.4) and this was statistically significant. There was no statistical heterogeneity. The pooled treatment effects estimated by crossover and parallel trials and end point and change data separately were similar (see Appendix 4, Figure 23).

Data on SBP and DBP were available from seven trials (\(n = 220\)).\(^{56,63,64,83,89,109,138}\) There was no statistically significant difference between CPAP and control for night-time SBP (MD –2.9 mmHg, 95% CI –5.8 to 0.1) or DBP (MD –1.3 mmHg, 95% CI –3.2 to 0.7) (see Appendix 4, Figures 24 and 25).

Data on 24-hour blood pressure were available in one study that did not report daytime and night-time pressure separately (a crossover trial, \(n = 68\) participants).\(^{94}\) There was a statistically significant benefit with CPAP compared with oral placebo on 24-hour DBP (MD –1.5 mmHg, 95% CI –2.9 to –0.1); there was no statistically significant difference in 24-hour SBP (MD –1.3 mmHg, 95% CI –3.3 to 0.7); or 24-hour MAP (MD –1.0 mmHg, 95% CI –2.6 to 0.6).

CPAP versus dental devices

One study reported 24-hour blood pressure (crossover trial, \(n = 80\)) in a population with moderate symptom severity and moderate disease severity at baseline.\(^{82}\) There was no statistically significant difference between CPAP and dental devices for 24-hour SBP (MD 0.6 mmHg, 95% CI –2.5 to 3.7) or DBP (MD 0.4 mmHg, 95% CI –1.7 to 2.5).

Summary of blood pressure outcomes

Data were available from 15 trials. Studies using 24-hour ABPM were considered separately from those using conventional clinic-based measures. Daytime and night-time blood pressure were assessed separately as the mechanisms and patterns of daytime and night-time blood pressure disturbance in OSAHS vary and the relationship between daytime blood pressure and vascular risk has been more clearly described in the literature.

CPAP versus control

Six trials reported MAP using ABPM. There was a statistically significant reduction in MAP with CPAP compared with control; the size of the effect probably varies among different groups of people. The average reduction in MAP was 2.1 mmHg, but might be anywhere between no reduction and 4.3 mmHg. There was moderate inconsistency in the treatment effect (statistical heterogeneity), but due to the small number of studies it was not possible to adequately investigate sources of this variation. Only one study was available of severely symptomatic patients and the overall treatment effect did seem to be dominated by this trial. There was no substantial change in the MAP results when a fixed-effect model was used as a sensitivity analysis. However, when individual studies were removed from the analysis the treatment effect remained statistically significant in only one instance, indicating a possible lack of statistical power due to the small number of participants.

There was no statistically significant difference between CPAP and control for SBP or DBP (measured using ABPM). The treatment effect probably varies among different groups of people. The average effect for SBP was a decrease of 1.1 mmHg with CPAP, but might be anywhere between a decrease of 3.4 mmHg and an increase of 1.2 mmHg compared with control. The average effect for DBP was a decrease of 1.2 mmHg with CPAP, but might be anywhere between a decrease of 2.9 mmHg and an increase of 0.5 mmHg compared with control. There was no inconsistency in the treatment effect (statistical heterogeneity). It was not possible to investigate whether the treatment effect varied with disease or symptom severity at baseline due to limitations in the data available. When a fixed-effect model was used, the findings were not substantially altered, except that the treatment effect for DBP was smaller. The pooling of three studies reporting conventional clinic blood pressure showed a large and statistically significant improvement in SBP and DBP with CPAP compared with control.

The results for night-time blood pressure were similar to those for daytime blood pressure. There was a statistically significant improvement in night-time MAP (using ABPM) but not SBP and DBP. The magnitude of the effects was broadly similar.

CPAP versus dental devices

Only one study was available that reported daytime blood pressure (morning and evening blood pressure using a conventional clinic method). This trial of a moderate symptom severity and moderate disease severity population found no statistically significant difference between CPAP and dental devices. Another trial that did not report daytime and night-time blood pressure separately reported
Health-related quality of life
The most commonly used quality of life measures were the FOSQ, SF-36 and NHP (Table 3). The majority of studies in which quality of life was assessed were of populations with moderate symptom severity (ESS) at baseline.

CPAP versus placebo or usual care
SF-36
Six studies reported the SF-36 subscales. There were three crossover trials (n = 91), all of moderate baseline symptom severity (ESS) and three parallel trials (n = 215), two of severe symptoms and one moderate. There was no statistically significant benefit with CPAP compared with control on any of the subscales of the SF-36 although for two of the scales (vitality and physical roles) there was a trend towards improvement with CPAP (see Table 4 for the overall effect and Appendix 4, Figure 26, for the forest plots). However, the pooled estimates are likely to have limited generalisability as there was moderate to high heterogeneity in the analyses for most of the subscales and specifically for the vitality and physical role subscales. For these two subscales, the findings encompassed two studies reporting a statistically significant improvement with CPAP and the remaining studies reporting no statistically significant difference between CPAP and control (see Appendix 4, Figure 26).

The treatment effects in the crossover and parallel subgroups were consistent with each other, i.e. the 95% confidence intervals overlapped (see Appendix 4, Figure 26). For bodily pain, general health and physical function there was a statistically significant benefit with CPAP compared with control for the parallel trial subgroup but not the crossover subgroup. This may be driven by two of the parallel trials being of populations with severe baseline symptoms. There was a statistically significant difference between CPAP and control for the physical component summary score but not the mental component summary scores [three trials, one of mild and two of severe symptoms (ESS)] or the total score (one trial, moderate symptom severity) (see Appendix 4, Figure 26).

Functional Outcomes of Sleep Questionnaire (FOSQ)
Four trials reported the FOSQ subscales: three crossover trials (n = 125) of moderate symptom severity at baseline and one parallel trial (n = 47) of severe symptom severity. There was a statistically significant benefit with CPAP compared with control for the activity level and social outcome subscales of the FOSQ (see Table 5 for the overall effect and Appendix 4, Figure 27, for the forest plots).
TABLE 4  SF-36 subscales (CPAP versus placebo/usual care)

<table>
<thead>
<tr>
<th>SF-36 Subscale (six trials)</th>
<th>Mean difference (95% CI)</th>
<th>Statistical heterogeneity (I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bodily pain</td>
<td>4.3 (–0.9 to 9.5)</td>
<td>48%</td>
</tr>
<tr>
<td>Emotional role</td>
<td>–0.4 (–12.3 to 11.5)</td>
<td>72%</td>
</tr>
<tr>
<td>General health</td>
<td>3.2 (–0.4 to 6.7)</td>
<td>0%</td>
</tr>
<tr>
<td>Mental health</td>
<td>2.2 (–2.2 to 6.7)</td>
<td>52%</td>
</tr>
<tr>
<td>Physical function</td>
<td>2.6 (–0.6 to 5.9)</td>
<td>8%</td>
</tr>
<tr>
<td>Physical role</td>
<td>6.9 (–3.8 to 17.5)</td>
<td>63%</td>
</tr>
<tr>
<td>Social function</td>
<td>1.9 (–4.4 to 8.1)</td>
<td>57%</td>
</tr>
<tr>
<td>Vitality</td>
<td>7.3 (–0.3 to 14.9)</td>
<td>77%</td>
</tr>
</tbody>
</table>

Statistical heterogeneity was low for both of these subscales. Statistical heterogeneity was high for general productivity (I² = 70%); there was a statistically significant benefit with CPAP compared with control for the parallel trial of severe symptom severity population but not for the subgroup of crossover, moderate disease trials. For activity level and social outcome the statistically significant benefit with CPAP did not appear to be dominated by the parallel trial of severe symptom severity (see Appendix 4, Figure 27).

Nottingham Health Profile (NHP)

Data from the NHP were reported in six studies, four of which reported NHP Part 2 (all crossover trials, n = 105), three of moderate symptom severity and one unclassified. There was a statistically significant benefit with CPAP compared with placebo/usual care on the NHP Part 2 (MD –1.7, 95% CI –2.9 to –0.5) (see Appendix 4, Figure 28). There was no statistical heterogeneity. Monasterio et al. did not specify which part of the NHP they used but the data presented suggest that it was probably Part 1. There was no statistically significant difference between CPAP and conservative treatment on NHP Part 1 (total score) in this parallel trial of a moderate symptom severity population (MD 0.0, 95% CI –5.8 to 5.8). Ballester et al. reported the six domains from NHP Part 1 but not the total score. There was a statistically significant difference between CPAP and conservative treatment on the energy (p = 0.03) and social isolation (p < 0.005) domains but not the emotional reactions, sleep, physical mobility or pain domains.

Sleep apnoea quality of life index (SAQLI)

Data were available on the SAQLI from two parallel trials, of moderate symptom severity populations. One study (n = 67) reported all the subscales and the overall score and one reported the overall score only (n = 41). There was a statistically significant improvement with CPAP compared with conservative treatment on the daily functioning, emotional and symptoms subscales but not for the social interaction subscale (see Appendix 4, Figure 29). For the total score (A–D subscales) one study showed a significant benefit with CPAP compared with conservative treatment and one showed no significant difference between CPAP and sham treatment.

TABLE 5  FOSQ subscales (CPAP versus placebo/usual care)

<table>
<thead>
<tr>
<th>FOSQ subscale (number of trials)</th>
<th>Mean difference (95% CI)</th>
<th>Statistical heterogeneity (I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity level (n = 4)</td>
<td>0.2 (0.0–0.3)</td>
<td>34%</td>
</tr>
<tr>
<td>General productivity (n = 4)</td>
<td>0.1 (–0.1 to 0.3)</td>
<td>70%</td>
</tr>
<tr>
<td>Intimacy and sexual activity (n = 4)</td>
<td>0.3 (–0.4 to 0.9)</td>
<td>0%</td>
</tr>
<tr>
<td>Social outcome (n = 4)</td>
<td>0.2 (0.0 to 0.4)</td>
<td>0%</td>
</tr>
<tr>
<td>Vigilance (n = 4)</td>
<td>0.2 (–0.1 to 0.5)</td>
<td>76%</td>
</tr>
<tr>
<td>Total score (n = 6)</td>
<td></td>
<td>51%</td>
</tr>
</tbody>
</table>

FOSQ, Functional Outcomes of Sleep Questionnaire.
CPAP (see Appendix 4, Figure 29). When change data from the latter study were used instead of end point data the difference between CPAP and sham CPAP was statistically significant and in favour of CPAP (p = 0.05). There was no baseline imbalance between groups.

**EuroQol and standard gamble utility**
One study was available of a severely symptomatic population (n = 53). There was no difference between CPAP and conservative treatment in quality of life at follow-up, as measured by the EuroQol thermometer (0–100) (MD 2.0, 95% CI –8.1 to 12.1). The EuroQol-derived utility was 0.77 (SD 0.18) for CPAP versus 0.77 (SD 0.09) for conservative treatment. There was a 0.04 utility gain in the CPAP group and no change in the conservative treatment group, although the CPAP group started from a poorer baseline (EuroQol 0.73 versus 0.77 for CPAP and control respectively) and had more severe OSAHS at baseline (AHI 55 versus 35 for CPAP and control respectively).

**CPAP versus dental devices**
Data were available from a small number of studies comparing CPAP with dental devices. Where reported, the studies were all of moderate symptom severity populations at baseline.

**Functional Outcomes of Sleep Questionnaire**
Data from the FOSQ were available from two studies (crossover, n = 128) of populations with moderate symptom severity. When both studies were pooled there was no difference between CPAP and dental devices in terms of quality of life as measured by the FOSQ (MD –0.5, 95% CI –1.4 to 0.5). These two studies had contradictory findings: one showed a statistically significant benefit with CPAP compared with dental devices on both the physical and mental component summary scores. In contrast, when CPAP was compared with dental devices on the bodily pain subscale of SF-36 but not on any of the other subscales (see Appendix 4, Figure 32).

**Sleep apnoea quality of life index**
One study (parallel, n = 68) reported subscale scores for the SAQLI as well as a summed score for A–D and A–E subscales. Unpublished data were available from Giles et al. for two studies for a summed score, although it was unclear whether this was for subscales A–D or A–E, therefore these studies were pooled separately (see Appendix 4, Figure 31). Based on the summed score for the last two studies there was no difference between CPAP and dental devices (see Appendix 4, Figure 32). For the summed score for A–D, CPAP showed a benefit over dental devices in the third study. However, when treatment-related symptoms were included to calculate the total score for A–E for this study, CPAP no longer showed a benefit over dental devices (see Appendix 4, Figure 32).

**SF-36**
One study reported the physical and mental component summary scores for SF-36 (crossover, n = 80), one reported the total score (crossover, n = 80) and one reported the subscale scores (parallel, n = 68). One study (see Appendix 4, Figure 33) reported a benefit with CPAP compared with dental devices on both the physical and mental component summary scores. In contrast, one study reported no difference between CPAP and dental devices on the total score. For one study there was a statistically significant benefit with CPAP compared with dental devices on the bodily pain subscale of SF-36 but not on any of the other subscales (see Appendix 4, Figure 34).

**Golombok Rust Inventory of Sexual Satisfaction (GRISS)**
This outcome was reported in two related papers. The included male participants (n = 38) who were in a heterosexual relationship and had more erectile dysfunction and sexual dissatisfaction than age-matched controls. There was no difference between CPAP and dental devices on any of the subscales at follow-up (see Appendix 4, Figure 35).

**CPAP versus postural therapy**
Data were available from two small crossover trials (n = 23). The studies were not pooled for an overall treatment effect due to differences in the comparators used, i.e. a shoulder–head elevation pillow and a cervicomandibular support collar.

**Functional Outcomes of Sleep Questionnaire**
No statistically significant difference was found when CPAP was compared with either the shoulder–head elevation pillow (p = 0.93 for difference in change) or the cervicomandibular support collar (p = 0.85 for difference in change). Only overall baseline scores were reported so change scores and the corresponding mean difference could not be calculated.

**SF-36**
The physical and mental component summary scores for the SF-36 were reported. There was no statistically significant difference in the impact on the summary physical component score between CPAP and the shoulder–head elevation pillow (p = 0.74 for difference in change) or the
cervicomandibular support collar ($p = 0.18$ for difference in change). Similarly, there was no statistically significant difference in the impact on the summary mental component score between CPAP and the shoulder–head elevation pillow ($p = 0.91$ for difference in change) or the cervicomandibular support collar ($p = 0.19$ for difference in change). Only overall baseline scores were reported so change scores and the corresponding mean difference could not be calculated.

**Summary of HRQoL outcomes**

The majority of studies assessing quality of life were of populations with moderate symptom severity at baseline. A variety of disease-specific and generic measures were used and only those measures reported in two or more studies are summarised here. The findings for quality of life were somewhat contradictory, which may have been related to factors such as different outcome measures used, or differences in the study population or aspects of study design. Exploration of sources of heterogeneity was limited by the small number of trials.

**CPAP versus control**

Six studies reported the SF-36 subscales. There was no statistically significant difference between CPAP and control on any of the SF-36 subscales. There was moderate to high variation or inconsistency in the treatment effect (statistical heterogeneity) for most of the subscales, therefore some caution needs to be taken in generalising these findings to all populations receiving CPAP. Although the treatment effects from the crossover and parallel trial subgroup analysis were consistent with each other, in that their $95\%$ confidence intervals overlapped, for bodily pain, general health and physical function there was a statistically significant benefit with CPAP compared with control for the parallel trials but not for the crossover trials. This may have been driven by two of the parallel trials being of severe symptom populations. In contrast, on the other generic scale, the NHP Part 2, there was a statistically significant benefit with CPAP compared with control based on a pooling of four studies. The treatment effect probably varies among different groups of people. The average effect was a reduction of 1.7 points with CPAP compared with control, but might fall anywhere between 0.5 and 2.9 points. There was no variation or inconsistency (statistical heterogeneity) in the treatment effect.

The findings from the disease-specific measures were also somewhat contradictory, although only a small number of studies were available. On the FOSQ (four trials), a disease-specific measure, there was a statistically significant benefit with CPAP compared with control for the activity level and social outcome subscales but not for general productivity, intimacy and sexual activity, vigilance or total score. Only two studies reported the SAQLI total score; one reported a significant benefit with CPAP compared with control and for one there was no statistically significant difference.

**CPAP versus dental devices**

For the majority of the quality of outcome measures only single studies were available. There was no statistically significant difference between CPAP and dental devices when two studies reporting the FOSQ and two studies reporting the SAQLI were pooled. Three studies reported the SF-36 but all used different scores and the findings were not consistent.

**Psychological outcomes**

There were very few new data available on psychological outcomes following the review by Giles *et al.* One additional publication was available which reported the Profile of Mood State (POMS) from a 1-week study by the Dimsdale group and the Brief Symptom Inventory from a 2-week study by Norman *et al.*

**CPAP versus placebo/usual care**

**General Health Questionnaire-28 (GHQ-28)**

Three studies reported on the GHQ-28 (all crossover, $n = 74$) and these were pooled. There was no statistically significant difference between CPAP and placebo (MD $–1.4$, $95\%$ CI $–4.1$ to $1.4$), although this estimate is of limited value as it was derived from only three studies, with moderate to high statistical heterogeneity ($F = 70\%$) (see Appendix 4, Figure 36).

**Hospital Anxiety and Depression Scale (HADS)**

Five studies reported on the HADS and these were pooled (all crossover, $n = 134$). There was no statistically significant difference between CPAP and placebo for the anxiety (MD $–0.3$, $95\%$ CI $–1.2$ to $0.5$) or the depression (MD $–0.9$, $95\%$ CI $–1.9$ to $0.1$) subscales. There was moderate statistical heterogeneity in both analyses ($F = 45\%$ and $62\%$ respectively) (see Appendix 4, Figures 37 and 38).

**Brief Symptom Inventory (BSI)**

One study reported the BSI global severity index and the BSI depression subscale (parallel, $n = 24$). The standard deviation was estimated for the former but, because data were only presented as a low-scale graph, it was not possible to estimate...
the standard deviation for the depression subscale. There was no statistically significant difference between CPAP and sham CPAP at follow-up for the global symptom index of the BSI (See Appendix 4, Figure 39).

Profile of Mood State (POMS)
One study reported the POMS (parallel, $n = 34$). There was no statistically significant difference between CPAP and placebo on any of the POMS subscales or the total score (see Appendix 4, Figure 40).

University of Wales Institute of Science and Technology Mood Adjective Checklist (UMACL)
Three studies reported the energetic arousal score from the UMACL and these were pooled (all crossover, $n = 73$). There was a statistically significant benefit in favour of CPAP compared with placebo (MD 1.7, 95% CI –0.0 to 3.3) (see Appendix 4, Figure 41). There was no statistical heterogeneity in this analysis.

CPAP versus dental devices
Hospital Anxiety and Depression Scale
One study reported the HADS (crossover, $n = 48$). There was no statistically significant difference between CPAP and dental devices for the anxiety or depression subscales (see Appendix 4, Figures 42 and 43).

Summary of psychological outcomes
CPAP versus control
Data were available for three psychological outcome measures from two or more studies. There was no statistically significant difference between CPAP and control on the GHQ-28 or the HADS. There was a statistically significant benefit in favour of CPAP compared with control on the energetic arousal score from the UMACL. There was no inconsistency (statistical heterogeneity) in the treatment effect.

CPAP versus dental devices
There was no statistically significant difference between CPAP and dental devices in one trial reporting the HADS.

Cognitive outcomes
Eighteen trials used formal testing to measure the effects of CPAP on cognitive function in adults with obstructive sleep apnoea. Ten of the studies used a crossover design, while eight used a parallel group design. Six trials compared CPAP with sham CPAP, six trials with oral placebo, four trials with dental devices, two trials with conservative treatment and one trial with postural therapy. Most of the studies included small sample sizes (range 14–125), with three studies reporting on a subgroup of the original randomised population. Based on mean ESS score at baseline (where reported), the majority of trials were of reported moderate symptom severity populations, two trials were of severely symptomatic populations and one trial studied mild symptom severity. Based on mean baseline AHI, seven study populations were classified as having severe disease, seven as having moderate disease and three as having mild disease.

A total of 28 different cognitive tests were used, examining several areas of cognition (administered as verbal, pen-and-paper or computer-based tasks), making comparisons across trials difficult. The areas of functioning assessed were attention or vigilance, psychomotor function, construction, verbal fluency, IQ decrement, memory and learning (see Table 12). Seventeen tests were used by two trials or fewer; even when tests were used by multiple trials the scales used were not always uniform.

Testing protocols may have a confounding effect on performance; therefore assessment procedures were examined. Some variation between testing protocols existed (see Appendix 4, Table 54). Testing protocol issues include order of test presentation, which is a particular issue with test batteries containing many different types of test, and time of day when fluctuations in performance and levels of alertness can occur in response to circadian rhythms. In addition, performance may be improved by prior exposure to testing stimuli and procedures, which can have a significant beneficial impact on test performance when tests are administered on more than one occasion. Use of stimulants, such as nicotine and caffeine, can also modify cognitive performance, as can mood and depression. Therefore, ideally, testing protocols should employ measures to minimise risks of possible confounding, or account for potential biases in the analysis.

Nine trials administered a familiarisation session prior to baseline assessment and four trials used alternative test forms in subsequent sessions in an attempt to minimise learning effects. Thirteen trials reported the time of day that assessments were conducted (five in the afternoon, two in the morning, and
Six years across the course of the day). Eight trials reported administering tests in a standardised order in an attempt to control the impact of each test in relation to each other across the test session. Four trials assessed for, or attempted to minimise, the effects of stimulants such as caffeine or nicotine, or the effects of alcohol consumption or drug intake. No study specifically looked at the effect of mood in relation to cognitive function, although one trial stated that significant depression was present in 40% of the included participants. Level of baseline function, compared with normative standards, was reported in only one trial. However, a number of papers indicated that many participants demonstrated normal values at baseline, highlighting the possibility of a ceiling effect.

All of these issues could affect the findings of the studies and should be considered when interpreting the results reported below. Owing to time limitations and the quantity of cognitive data from crossover trials it was not feasible to impute data for a paired analysis, where these were not reported, for all the cognitive outcomes. Where three or more studies were available for potential pooling the SE was estimated where appropriate data were available. A narrative synthesis was used where pooling was not feasible. Details of the individual study results are reported in Appendix 4, Table 53. Where end point data were not reported, change scores were used.

**CPAP versus placebo or conservative/usual care**

**Simulated driving task**
Seven studies used a simulated driving task. Daytime sleepiness, based on ESS scores at baseline, varied between study populations; in one study daytime sleepiness was classified as severe, in one it was classified as mild and in four it was classified as moderate.

Six of the seven studies used the SteerClear simulated driving test. SteerClear is a computerised program that attempts to mimic different components of attention involved in driving a car; the program simulates a long and monotonous highway drive that presents a number of obstacles over a period of 30 minutes.

Two studies reported performance in terms of the percentage of obstacles hit and four reported the number of obstacles hit. These were treated separately.

There was no statistically significant difference between CPAP and oral placebo in terms of the percentage of obstacles hit (Figure 15), or in the number of obstacles hit (MD = 5.74, 95% CI -14.75 to 3.27) (Figure 14). There was no statistical significance for trials reporting the number of obstacles hit.

One parallel group trial used a different simulated driving test, based on the work of Land and Horwood. This computerised program presents a white on black image (as in night driving) of the moving edges of the road with an image of the vehicle bonnet at the bottom of the screen. The primary object is to steer the centre of the vehicle as accurately as possible down the middle of the road for 30 minutes. In addition, single digits are displayed at each corner of the screen (digits change randomly at an interval of 8–10 seconds) and the participant is required to identify target digits by pressing a button on either side of the steering wheel. Baseline ESS was classified as moderate in both groups. An improvement in terms of steering performance was found with CPAP compared with sham CPAP, although not all differences were statistically significant: SD of position on road (median difference -0.1, p = 0.08), SD of deterioration (median difference -0.2, p = 0.007), and length of drive (minutes) (median difference -0.3, p = 0.08). This was based on end point data as per the protocol; when difference in change was considered, a significant difference in favour of CPAP was found for SD position on road (p = 0.03) and length of drive (p = 0.02).

**Trail Making Task (TMT)**
The TMT is a task of complex attention given in two parts, A and B. Individuals are asked to draw lines to connect consecutively numbered circles on one work sheet (Part A), and then connect the same number of consecutively numbered and lettered circles on another work sheet, alternating between the two sequences (Part B); time taken to complete the task (seconds) and errors made are typically recorded. The test is sensitive to a range of mental processes including speed of processing and mental flexibility.

Eight studies (five parallel, three crossover, n = 260) reported on TMT Part A and 12 (six crossover, six parallel, n = 406) reported on TMT Part B.

**TMT Part A** The severity of daytime sleepiness was classified as moderate in four studies, and in one study each was classified as mild.
<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP Mean (SD)</th>
<th>Control Mean (SD)</th>
<th>WMD (random) 95% CI</th>
<th>Weight %</th>
<th>WMD (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Steer Clear</td>
<td>29 4.00 (5.39)</td>
<td>25 5.00 (10.00)</td>
<td>36.88 −1.00 (−5.38 to 3.38)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monasterio, 2001</td>
<td>66 8.00 (9.00)</td>
<td>59 8.00 (10.00)</td>
<td>63.12 0.00 (−3.35 to 3.35)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 13** SteerClear (CPAP versus placebo/usual care), percentage of obstacles hit.

<table>
<thead>
<tr>
<th>Study or subcategory</th>
<th>CPAP n</th>
<th>Control n</th>
<th>Cows hit (random) 95% CI</th>
<th>Weight %</th>
<th>Cows hit (random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engleman, 1994</td>
<td>32 28.6 (7.82)</td>
<td>32 27.6 (7.82)</td>
<td>34.55 −5.00 (−20.33 to 10.33)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1997</td>
<td>16 16 (11.51)</td>
<td>16 16 (11.51)</td>
<td>15.95 −0.50 (−23.06 to 22.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1998</td>
<td>23 23 (6.63)</td>
<td>23 23 (6.63)</td>
<td>48.04 −8.00 (−21.00 to 5.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman, 1999</td>
<td>34 34 (38.08)</td>
<td>34 34 (38.08)</td>
<td>1.46 −6.00 (−80.63 to 68.63)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>103 103</td>
<td>103 103</td>
<td>100.00 −5.74 (−14.75 to 3.27)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: $\chi^2 = 0.33$, df = 3 ($p = 0.95$), $I^2 = 0$

Test for overall effect: $z = 1.25$ ($p = 0.21$)

**FIGURE 14** SteerClear (CPAP versus placebo/usual care), number of obstacles hit.

**TABLE 6** Summary of TMT Part A data reported in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2002</td>
<td>28.1 (NR)</td>
<td>27.6 (NR)</td>
<td>0.5</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1994</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1999</td>
<td>26 (11)</td>
<td>29 (11)</td>
<td>−3.0</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbé et al., 2001</td>
<td>47 (NR)</td>
<td>47 (NR)</td>
<td>0</td>
<td>&gt; 0.20</td>
</tr>
<tr>
<td>Dimsdale et al., 2000</td>
<td>27.4 (NR)</td>
<td>27.4 (NR)</td>
<td>0</td>
<td>NR</td>
</tr>
<tr>
<td>Henke et al., 2001</td>
<td>Only available in graph</td>
<td>Only available in graph</td>
<td>0</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Monasterio et al., 2001</td>
<td>49 (19)</td>
<td>49 (20)</td>
<td>0</td>
<td>0.76</td>
</tr>
<tr>
<td>Norman et al., 2006</td>
<td>26.5 (NR)</td>
<td>21.7 (NR)</td>
<td>4.9</td>
<td>0.49 (relates to time × treatment interaction for three treatment groups)</td>
</tr>
</tbody>
</table>

NR, not reported.
and severe; two studies did not report symptom severity. None of the studies showed a significant difference between CPAP and control in the length of time it took to complete TMT Part A (Table 6). None of the studies reported adequate allocation concealment, and it was unclear whether groups were similar at baseline in four of the included studies.

Five trials (three crossover, two parallel) did not report sufficient data to calculate a variance. Therefore, only three of the eight trials reporting TMT Part A were used to generate a pooled estimate of treatment effect and are displayed on the forest plot below (Figure 15). When data from these three parallel group trials (n = 215) were pooled, no statistically significant between-group difference was found (MD 0.0, 95% CI –2.5 to 2.5). There was no statistical heterogeneity (I² = 0%). Given that only a proportion of the available studies could be pooled, caution needs to be taken in interpreting the pooled effect.

**TMT Part B** Where reported, the populations in the majority of trials were classified as having moderate baseline daytime sleepiness, and in one study each as having mild and severe daytime sleepiness. One trial reported a significant difference in favour of CPAP compared with oral placebo in the length of time taken to complete the task; no statistically significant between-group differences were found in the other trials (Table 7). Half of the studies did not report adequate allocation concealment, and it is unclear if the trials had sufficient power to detect a treatment effect.

Seven trials did not report sufficient data or used different scales; therefore, only data from two crossover and three parallel trials were pooled (n = 328) for TMT Part B (Figure 16). There was a statistically significant benefit with CPAP compared with control for time (seconds) taken to complete TMT Part B (MD –9.1, 95% CI –14.9 to –3.1). There was low statistical heterogeneity (I² = 34%). However, as only a proportion of the studies were pooled, the treatment effect may not be generalisable.

**Wechsler Adult Intelligence Scale (WAIS) Digit Symbol Substitution Test (DSST)** Ten studies used the DSST, a test of complex attention (five parallel and five crossover, n = 488). In this test of attention and processing, respondents are given a code table displaying the correspondence between pairs of digits (from 1 to 9) and symbols, and then asked to fill in blank squares with the symbol that is paired to the digit displayed above the square. Six out of the eight studies reporting daytime sleepiness could be classified as moderate and one trial each classified the study population as having mild and severe daytime sleepiness. Two trials found a significant benefit of CPAP compared with control in the number of correct responses, and
### TABLE 7 Summary of TMT Part B data reported in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2002</td>
<td>60.1 (NR)</td>
<td>65.2 (NR)</td>
<td>-5.1</td>
<td>Not significant (p-value not reported)</td>
</tr>
<tr>
<td>Barnes et al., 2004</td>
<td>73.3 (29.5)</td>
<td>74.2 (32.2)</td>
<td>-0.9</td>
<td>Not significant (p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1994</td>
<td>66 (28.3)</td>
<td>76 (28.3)</td>
<td>-10</td>
<td>0.02</td>
</tr>
<tr>
<td>Engleman et al., 1997</td>
<td>64.1 (22)</td>
<td>77.7 (36.8)</td>
<td>-13.6</td>
<td>0.02</td>
</tr>
<tr>
<td>Engleman et al., 1998</td>
<td>69 (32)</td>
<td>68 (32)</td>
<td>1.0</td>
<td>Not significant (p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1999</td>
<td>63 (33)</td>
<td>65 (27)</td>
<td>-2</td>
<td>Not significant (p-value not reported)</td>
</tr>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbé et al., 2001</td>
<td>96 (32.3)</td>
<td>110 (50)</td>
<td>-14.0</td>
<td>0.10</td>
</tr>
<tr>
<td>Dimsdale et al., 2000</td>
<td>71.2 (31.8)</td>
<td>87 (34.8)</td>
<td>-15.8</td>
<td>Not significant (p-value not reported)</td>
</tr>
<tr>
<td>Henke et al., 2001</td>
<td>Only available in graph</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lojander et al., 1999</td>
<td>130, median</td>
<td>75, median</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Monasterio et al., 2001</td>
<td>106 (42)</td>
<td>100 (39)</td>
<td>6.0</td>
<td>0.15 (difference in change based on median values)</td>
</tr>
</tbody>
</table>

NR, not reported.

### FIGURE 16 Trail Making Task Part B (CPAP versus placebo/usual care), stratified by type of data.
one trial found a significant difference in change from baseline in favour of placebo;\textsuperscript{89} no significant between-group differences were found in the other trials (Table 8). None of the trials reported adequate allocation concealment.

Four studies did not provide sufficient data to calculate a variance and one trial used a different scale; therefore, only five trials (three crossover and two parallel, \( n = 170 \)) were pooled (Figure 17).\textsuperscript{78,83,90,93,117} no statistically significant benefit with CPAP was found compared with control in terms of the number of correct responses (MD 0.2, 95% CI –0.6 to 1.0). There was no statistical heterogeneity (\( I^2 = 0\% \)).

**Paced Auditory Serial Addition Task (PASAT)**

Seven studies used the PASAT test of vigilance.\textsuperscript{78,82,83,90,92,93,100} In this computerised task, a series of digits are presented at a set rate and the respondent is asked to add the numbers in pairs, such that each number is added to the one that immediately precedes it. Presentation rates range from 1 to 4 seconds. Different formats have been developed, for example the PASAT 1.2 and the PASAT 2.4, which are thought to be more difficult than the standard PASAT 1 and PASAT 2. One study reported outcomes for the PASAT 1.2,\textsuperscript{82} six studies for the PASAT 2,\textsuperscript{78,83,90,92,93,100} and two studies for the PASAT 2.4,\textsuperscript{82} two studies for the PASAT 3,\textsuperscript{85,100} and two studies for the PASAT 4.\textsuperscript{83,90}

Daytime sleepiness was reported for six trial populations; five populations were classified as moderate\textsuperscript{78,90,92,93,100} and one trial as mild.\textsuperscript{83} One crossover trial\textsuperscript{78} found a significant benefit in favour of CPAP in the number of correct responses made; no statistically significant between-group differences were found in any of the other trials (Table 9). None of the studies reported adequate allocation concealment, and one study reported a significant treatment by period interaction for the PASAT 2\textsuperscript{90} indicating a potential carryover effect of treatment.

Data from three or more trials were available for PASAT 1 and PASAT 2. Of the three studies reporting PASAT 1, two studies\textsuperscript{82,83} did not provide sufficient data to calculate a variance for pooling, and, of the six studies reporting the PASAT 2, two studies did not provide sufficient data to calculate a variance.\textsuperscript{90,92} Two crossover and two parallel trials were therefore pooled (\( n = 234 \)) for PASAT 2 (Figure 18). No statistically significant benefit was found with CPAP compared with control for number of correct responses made (MD 2.30, 95% CI 0.24–4.37); statistical heterogeneity was low (\( I^2 = 25\% \)).

---

**TABLE 8** Summary of Wechsler Adult Intelligence Digit Symbol Substitution Test data reported in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>( p )-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2002\textsuperscript{49}</td>
<td>47.3 (NR)</td>
<td>48 (NR)</td>
<td>–0.7</td>
<td>0.07 (difference in change)</td>
</tr>
<tr>
<td>Barnes et al., 2004\textsuperscript{82}</td>
<td>47.3 (3.6)</td>
<td>46.8 (3.6)</td>
<td>0.5</td>
<td>Not significant (( p )-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1994\textsuperscript{90}</td>
<td>52 (11.3)</td>
<td>51 (11.3)</td>
<td>1</td>
<td>0.05</td>
</tr>
<tr>
<td>Engleman et al., 1998\textsuperscript{93}</td>
<td>52 (13)</td>
<td>52 (14)</td>
<td>0</td>
<td>Not significant (( p )-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1999\textsuperscript{78}</td>
<td>59 (12)</td>
<td>57 (14)</td>
<td>2</td>
<td>0.0004</td>
</tr>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbe et al., 2001\textsuperscript{83}</td>
<td>43 (16.2)</td>
<td>47 (20)</td>
<td>–4</td>
<td>( &gt; 0.20 ) (difference in change)</td>
</tr>
<tr>
<td>Dimsdale et al., 2000\textsuperscript{10,117}</td>
<td>53.2 (11.2)</td>
<td>53.5 (12)</td>
<td>–0.3</td>
<td>Not significant (( p )-value not reported)</td>
</tr>
<tr>
<td>Henke et al., 2001\textsuperscript{85}</td>
<td>Only available in graph</td>
<td></td>
<td></td>
<td>A binary variable of improved or not improved was assessed; not significant (( p )-value not reported)</td>
</tr>
<tr>
<td>Monasterio et al., 2001\textsuperscript{100}</td>
<td>9 (3) scaled score</td>
<td>9 (2)</td>
<td>0</td>
<td>0.97 (difference in change, based on median values)</td>
</tr>
<tr>
<td>Norman et al., 2006\textsuperscript{13,341}</td>
<td>73.8 (NR)</td>
<td>68.7 (NR)</td>
<td>5.1</td>
<td>0.26 (based on time ( \times ) treatment interaction for three-armed trial)</td>
</tr>
</tbody>
</table>

NR, not reported.
FIGURE 17 Wechsler Adult Intelligence Digit Symbol Substitution Test (CPAP versus placebo/usual care), stratified by type of data.

TABLE 9 Summary of PASAT data reported in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2004</td>
<td>PASAT 1: 2.9 (0.9)</td>
<td>3.4 (0.9)</td>
<td>-0.5</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td></td>
<td>PASAT 2: 3.8 (1.8)</td>
<td>3.7 (0.9)</td>
<td>0.1</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1994</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1997</td>
<td>PASAT 2: 37.8 (13.2)</td>
<td>35.3 (11.2)</td>
<td>2.5</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1998</td>
<td>PASAT 2: 37 (11)</td>
<td>35 (11)</td>
<td>2</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td>Engleman et al., 1999</td>
<td>PASAT 2: 40 (11)</td>
<td>36 (14)</td>
<td>4</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbé et al., 2001</td>
<td>PASAT 1: 15 (5.4)</td>
<td>15 (5)</td>
<td>0</td>
<td>&gt; 0.20 (difference in change)</td>
</tr>
<tr>
<td></td>
<td>PASAT 2: 16 (5.4)</td>
<td>15 (5)</td>
<td>1</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>PASAT 3: 12 (5.4)</td>
<td>12 (5)</td>
<td>0</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>PASAT 4: 5 (5.4)</td>
<td>5 (5)</td>
<td>0</td>
<td>&gt; 0.20</td>
</tr>
<tr>
<td>Monasterio et al., 2001</td>
<td>PASAT 1: 5 (4)</td>
<td>5 (3)</td>
<td>0</td>
<td>0.32 (based on data for median values)</td>
</tr>
<tr>
<td></td>
<td>PASAT 2: 12 (4)</td>
<td>12 (4)</td>
<td>0</td>
<td>0.12</td>
</tr>
<tr>
<td></td>
<td>PASAT 3: 15 (4)</td>
<td>15 (4)</td>
<td>0</td>
<td>0.20</td>
</tr>
<tr>
<td></td>
<td>PASAT 4: 14 (4)</td>
<td>16 (4)</td>
<td>-2</td>
<td>0.20</td>
</tr>
</tbody>
</table>

PASAT, Paced Auditory Serial Addition Task.
Assessment of clinical effectiveness

FIGURE 18 Paced Auditory Serial Addition Task (PASAT) 2 (second presentation rate) (CPAP versus placebo/usual care), stratified by type of data.

Verbal fluency

Nine trials assessed verbal fluency; there are a variety of verbal fluency tests in use and each is designed to measure the speed and flexibility of verbal thought processes. Six trials used the Controlled Oral Word Association Test (COWAT).82,85,89,90,92,93 The remaining trials did not specify the test used.58,73,100 Insufficient reported data, and uncertainty as to whether instruments were measuring the same thing, meant that these studies were not pooled (Table 10).

One small crossover study \( (n = 28) \)89 reported a significant improvement in the number of correct words in the CPAP group compared with the oral placebo group. However, an order effect was found; individuals receiving placebo in the first treatment period had no significant change with either treatment. No significant differences between treatment groups were found in the remaining studies.

Digit Vigilance Test (DVT)

Two parallel group trials used the DVT, which is a measure of sustained attention and psychomotor speed, using a rapid visual tracking task (Table 11).117,541 Only one trial reported baseline ESS, 541 which was classified as moderate; both trials reported severe AHI scores. Time by treatment interactions showed a significant improvement specific to CPAP for time taken to complete the task, but not errors made, in a 2-week study \( (n = 31) \) comparing CPAP with supplemental oxygen and placebo.541 A 1-week study \( (n = 36) \) found a significant difference between CPAP and sham CPAP in the number of errors made;117 however, after controlling for pre-treatment differences, no significant difference between groups was found. A summary of the results is presented in Table 11.

Other cognitive tests

A number of additional cognitive tests were also used by individual studies, including Stroop colour and word test, psychomotor vigilance, brief visuospatial memory and a concentration endurance test; however, no statistically significant between-group differences were found. It was unclear whether most of these studies were appropriately powered to detect an effect. In addition, few trials reported adequate allocation concealment, baseline comparisons were not always reported and intention-to-treat analysis was seldom conducted. Results for these studies are presented in Appendix 4, Table 53.
### TABLE 10 Summary of data for verbal fluency tests reported in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crossover</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2002⁸⁹</td>
<td>38.7 (NR)</td>
<td>36 (NR)</td>
<td>2.7</td>
<td>0.02 (difference in change)</td>
</tr>
<tr>
<td></td>
<td>COWAT: no. correct</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnes et al., 2004⁸²</td>
<td>46.5 (10.7)</td>
<td>46.3 (8.9)</td>
<td>0.2</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>COWAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman et al., 1994⁹⁰</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td></td>
<td>COWAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman et al., 1997⁹²</td>
<td>38.5 (14.0)</td>
<td>39.2 (12.4)</td>
<td>–0.7</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td></td>
<td>COWAT: no. correct</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engleman et al., 1998⁹³</td>
<td>41 (12)</td>
<td>42 (11)</td>
<td>–1</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td></td>
<td>COWAT: no. correct</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimsdale et al., 2000⁵⁸,¹¹⁷</td>
<td>44.5 (12.1)</td>
<td>37.3 (12.8)</td>
<td>7.2</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>No. correct</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henke et al., 2001⁸⁵</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Not significant (precise p-value not reported)</td>
</tr>
<tr>
<td></td>
<td>COWAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monasterio et al., 2001¹⁰⁰</td>
<td>69 (27)</td>
<td>70 (29)</td>
<td>–1</td>
<td>0.53 (based on data for median values)</td>
</tr>
<tr>
<td></td>
<td>Percentile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norman et al., 2006⁷³,³⁴¹</td>
<td>40.9 (NR)</td>
<td>45.5 (NR)</td>
<td>–4</td>
<td>0.15 (relates to time × treatment interaction from a three-arm trial)</td>
</tr>
<tr>
<td></td>
<td>Total score</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

COWAT, Controlled Oral Word Association Test; NR, not reported.

### TABLE 11 Summary of Digit Vigilance Test data reported in the included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>CPAP [mean (SD)]</th>
<th>Control [mean (SD)]</th>
<th>MD</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parallel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimsdale et al., 2000⁵⁸,¹¹⁷</td>
<td>Time: 6.9 (1.3)</td>
<td>Time: 6.6 (1.6)</td>
<td>0.3</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Errors: 10.1 (11.6)</td>
<td>Errors: 12.3 (12.4)</td>
<td>–2.2</td>
<td>0.49</td>
</tr>
<tr>
<td>Norman et al., 2006⁷³,³⁴¹</td>
<td>Time: 312.3 (NR)</td>
<td>Time: 303.1 (NR)</td>
<td>9.2</td>
<td>0.02 (relates to time × treatment interaction from a three-arm trial)</td>
</tr>
<tr>
<td></td>
<td>Errors: 7.2 (NR)</td>
<td>Errors: 10.6 (NR)</td>
<td>–3.4</td>
<td>0.08 (relates to time × treatment interaction from a three-arm trial)</td>
</tr>
</tbody>
</table>

NR, not reported.
### TABLE 12  List of cognitive tests reported by individual studies

<table>
<thead>
<tr>
<th>Cognitive test</th>
<th>Barbé et al., 2001&lt;sup&gt;a1&lt;/sup&gt;</th>
<th>Barnes et al., 2002&lt;sup&gt;a2&lt;/sup&gt;</th>
<th>Barnes et al., 2004&lt;sup&gt;a3&lt;/sup&gt;</th>
<th>Cibele et al., 2006&lt;sup&gt;a4&lt;/sup&gt;</th>
<th>Dimsdale et al., 2000&lt;sup&gt;a5&lt;/sup&gt;</th>
<th>Engleman et al., 1994&lt;sup&gt;a6&lt;/sup&gt;</th>
<th>Engleman et al., 1997&lt;sup&gt;a7&lt;/sup&gt;</th>
<th>Engleman et al., 1998&lt;sup&gt;a8&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tests of attention</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CET</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DO</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVT</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RT (8-C)</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroop</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>TMT</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>PASAT</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>BW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>SteerClear</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other driving tests</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tests of verbal fluency</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COWAT</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>VFT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Tests of memory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>CT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HVL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WMS</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>WPMR</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tests of motor performance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tests of construction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copying</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurocognitive test batteries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WAIS</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
<td>✓ (s)</td>
</tr>
<tr>
<td>IQ decrement</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

BVM, brief verbal memory test; BVRT, Benton Visual Retention Test; BW, Bourdon–Wiersma test; CET, Continuous Endurance Test; CFD, clock-face drawing task; CFT, complex figure test; COWAT, Controlled Oral Word Association Test; CT, Consonant Triagram; DO, Digit Ordering; DVT, Digit Vigilance Test; FTT, finger tapping test; HVL, Hopkins Verbal Learning test; IQ, intelligence quotient; MDT, memory distractor task; PASAT, Paced Auditory Serial Addition Task; PP, Purdue Pegboard test; PVT, Psychomotor Vigilance Test; RT-8C, Eight Choice Reaction Time Test; s, subscales used; TMT, Trail Making Task; VFT, verbal fluency test; WAIS: Wechsler Adult Intelligence Scale; WMS, Wechsler Memory Scale; WPMR, word paired memory recall.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tests of attention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CET</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DO</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RT (8-C)</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVIP</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroop</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TMT</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASAT</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SteerClear</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other driving tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tests of verbal fluency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COWAT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tests of memory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVRT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HVL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WMS (s)</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WPMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tests of motor performance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PP</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tests of construction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFD</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copying</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFT</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b,c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurocognitive test batteries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WAIS (s)</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a  Borkowski’s Controlled Oral Word Association Test.

b  Medical College of Georgia Complex Figure Recall Test.

c  Results presented in graph format only.

d  Related paper ref. 117.

e  Related paper ref. 114.

f  Related paper ref. 118.

g  Related paper ref. 341.

© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
the cognitive tests assessed (see Appendix 4, Table 53). None of these trials reported appropriate allocation concealment, and only one trial reported adequate randomisation methods and used intention-to-treat analysis.

**CPAP versus postural therapy**
Data were available for one small crossover study \( (n = 14) \). No statistically significant between-group differences were found on any of the cognitive tests administered (see Appendix 4, Table 53). It is unclear whether performance differences at baseline existed, or whether the study was appropriately powered to detect an effect.

**Apnoea–hypopnoea index**

**CPAP versus placebo/usual care**
Nine studies reported the AHI at follow-up.\(^6^6,7^0,7^3,8^2,8^5,8^7,9^7,1^0^0,1^0^9\) There was high statistical heterogeneity \( (I^2 = 97\%) \) and any pooled effect is likely to be meaningless. All the studies reported a statistically significant reduction in the AHI with CPAP compared with placebo/usual care and the effect size ranged from \( -9.2 \) (95% CI \(-18.3\) to \(-0.1\)) to \(-60.0 \) (95% CI \(-72.1\) to \(-47.5\)) (see Appendix 4, Figure 44).

**CPAP versus dental devices**
Nine studies reported the AHI at follow-up.\(^7^0,8^0–8^2,1^0^3,1^0^5–1^0^7,1^1^9\) There was a statistically significant reduction in AHI in favour of CPAP compared with dental devices (MD \(-8.4\), 95% CI \(-10.5\) to \(-6.3\)) (see Appendix 4, Figure 45). Statistical heterogeneity was low to moderate \( (I^2 = 40\%) \).

**CPAP versus postural therapy**
Data were available for the AHI from three small crossover trials \( (n = 36) \).\(^6^6,6^1,1^0^8\) There was a statistically significant benefit with CPAP on the AHI compared with postural therapy (shoulder–head elevation pillow, MD \( 15.5 \), \( p = 0.008\); cervicomandibular support collar, MD in change \( 16.8 \), \( p = 0.001\); backpack with soft ball inside, MD \( 6.1 \), 95% CI \( 2.0\)–\(10.2\), \( p = 0.007\)).

**Adverse effects**
Reporting of adverse effects was patchy across studies. Reported adverse effects with CPAP were related mainly to discomfort with the equipment (e.g. machine noise, a feeling of pressure and mask discomfort), dry mouth and stuffy or runny nose (Table 13). Reported adverse effects with use of dental devices were related mainly to excess salivation, tooth discomfort and temporomandibular joint discomfort.

**CPAP versus postural therapy**
Data were available from two trials \( (n = 23) \).\(^6^6,6^1\) No statistically significant difference in the overall number of self-reported adverse events was found when CPAP was compared with a shoulder–head elevation pillow (MD \(-0.8\), \( p = 0.16\)). However, there were significantly fewer self-reported adverse events with a cervicomandibular support collar than with CPAP (MD in change \( 4.2\), \( p = 0.01\)). Type of adverse event and indication of perceived severity were not reported in either study.

**Patient preference**
New data were not found regarding patient preference for CPAP compared with dental devices. Giles et al. highlighted the difficulties in interpreting the data they found: preferences can be measured only when participants receive both treatment options (i.e. in crossover trials), leading to possible order effects.\(^5^0\) It was not considered appropriate to pool the data.\(^5^0\) Based on two studies \( (n = 15) \) of patients who had a successful outcome with both treatments there was a preference for CPAP. When all patients were considered (four studies, \( n = 164\)), in one study participants showed a statistically significant preference for dental devices over CPAP, but there was no statistically significant difference in the other studies and they did not show a consistent direction for preference.\(^5^0\) Participants were more likely to withdraw while using dental devices than with CPAP [odds ratio (OR) \( 0.46\), 95% CI \( 0.25\)–\(0.84\)] (see Appendix 4, Figure 46).
### TABLE 13 Adverse effects

<table>
<thead>
<tr>
<th>Effect</th>
<th>Study</th>
<th>CPAP (n/N)</th>
<th>Control (n/N)</th>
<th>Dental device (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mask discomfort or other problems with mask/headgear</td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>8/34</td>
<td>0/34</td>
<td>–</td>
</tr>
<tr>
<td>Machine noise</td>
<td>Lojander et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>2/13</td>
<td>0/20</td>
<td>–</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>8/34</td>
<td>–</td>
<td>0/34</td>
</tr>
<tr>
<td></td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>8/34</td>
<td>0/34</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>16/48</td>
<td>–</td>
<td>12/48</td>
</tr>
<tr>
<td></td>
<td>Lojander et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>1/13</td>
<td>0/20</td>
<td>–</td>
</tr>
<tr>
<td>Difficulty falling asleep with prescribed pressure</td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>1/34</td>
<td>0/34</td>
<td>–</td>
</tr>
<tr>
<td>Feeling of pressure</td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>11/34</td>
<td>–</td>
<td>0/34</td>
</tr>
<tr>
<td>Pressure (on face)</td>
<td>Randerath et al., 2002&lt;sup&gt;85&lt;/sup&gt;</td>
<td>8/19</td>
<td>–</td>
<td>2/19</td>
</tr>
<tr>
<td>Pressure (in mouth)</td>
<td>Randerath et al., 2002&lt;sup&gt;85&lt;/sup&gt;</td>
<td>0/19</td>
<td>–</td>
<td>2/19</td>
</tr>
<tr>
<td>Early awakening</td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>1/34</td>
<td>0/34</td>
<td>–</td>
</tr>
<tr>
<td>Residual sleepiness</td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>0/34</td>
<td>3/34</td>
<td>–</td>
</tr>
<tr>
<td>Dry throat/nose/mouth</td>
<td>Engleman et al., 1999&lt;sup&gt;78&lt;/sup&gt;</td>
<td>4/34</td>
<td>0/34</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>5/48</td>
<td>–</td>
<td>0/48</td>
</tr>
<tr>
<td></td>
<td>Lojander et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>2/13</td>
<td>0/20</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>16/34</td>
<td>–</td>
<td>11/34</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>Lojander et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>7/13</td>
<td>0/20</td>
<td>–</td>
</tr>
<tr>
<td>Skin irritation or abrasion</td>
<td>Redline et al., 1998&lt;sup&gt;89&lt;/sup&gt;</td>
<td>2/51</td>
<td>0/46</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>7/34</td>
<td>–</td>
<td>0/34</td>
</tr>
<tr>
<td>Minor nosebleeds (related to nasal spray)</td>
<td>Redline et al., 1998&lt;sup&gt;89&lt;/sup&gt;</td>
<td>1/51</td>
<td>2/46</td>
<td>–</td>
</tr>
<tr>
<td>Use of antibiotics during intervention period</td>
<td>Redline et al., 1998&lt;sup&gt;89&lt;/sup&gt;</td>
<td>7/51</td>
<td>2/46</td>
<td>–</td>
</tr>
<tr>
<td>Excess salivation</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>0/48</td>
<td>–</td>
<td>9/48</td>
</tr>
<tr>
<td></td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>0/34</td>
<td>–</td>
<td>19/34</td>
</tr>
<tr>
<td>Tooth discomfort</td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>0/34</td>
<td>–</td>
<td>11/34</td>
</tr>
<tr>
<td>Tooth damage</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>0/48</td>
<td>–</td>
<td>3/48</td>
</tr>
<tr>
<td>Temporomandibular joint discomfort</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>0/48</td>
<td>–</td>
<td>33/48</td>
</tr>
<tr>
<td></td>
<td>Lam et al., 2007&lt;sup&gt;80&lt;/sup&gt;</td>
<td>0/34</td>
<td>–</td>
<td>13/34</td>
</tr>
<tr>
<td></td>
<td>Randerath et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>0/19</td>
<td>–</td>
<td>8/19</td>
</tr>
<tr>
<td>Removal of appliance during sleep</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>7/48</td>
<td>–</td>
<td>19/48</td>
</tr>
<tr>
<td>Leakage</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>11/48</td>
<td>–</td>
<td>0/48</td>
</tr>
<tr>
<td>Stuffy nose</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>8/48</td>
<td>–</td>
<td>0/48</td>
</tr>
<tr>
<td>Inconvenience</td>
<td>Engleman et al., 2002&lt;sup&gt;83&lt;/sup&gt;</td>
<td>6/48</td>
<td>–</td>
<td>0/48</td>
</tr>
<tr>
<td>Side-effect severity</td>
<td>Ferguson et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>11/25</td>
<td>–</td>
<td>10/21</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1997&lt;sup&gt;80&lt;/sup&gt;</td>
<td>10/20</td>
<td>–</td>
<td>7/20</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>1/25</td>
<td>–</td>
<td>9/21</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1997&lt;sup&gt;80&lt;/sup&gt;</td>
<td>4/20</td>
<td>–</td>
<td>9/20</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>5/25</td>
<td>–</td>
<td>5/21</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1997&lt;sup&gt;80&lt;/sup&gt;</td>
<td>3/20</td>
<td>–</td>
<td>4/20</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1996&lt;sup&gt;81&lt;/sup&gt;</td>
<td>4/25</td>
<td>–</td>
<td>1/21</td>
</tr>
<tr>
<td></td>
<td>Ferguson et al., 1997&lt;sup&gt;80&lt;/sup&gt;</td>
<td>3/20</td>
<td>–</td>
<td>1/20</td>
</tr>
</tbody>
</table>
Chapter 4
Assessment of cost-effectiveness evidence

The examination of the cost-effectiveness of continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea–hypopnoea syndrome (OSAHS) comprises:

1. A systematic review of existing evidence on the cost-effectiveness of CPAP, against relevant comparators, including dental devices and conservative management. The review includes the manufacturer ResMed’s submission\(^\text{120}\) to the National Institute for Health and Clinical Excellence (NICE).

2. Employment of this systematic review to inform the development of an economic model to evaluate the cost-effectiveness of CPAP for the treatment of OSAHS.

Systematic review of existing cost-effectiveness evidence

Cost-effectiveness review methods

A systematic review of cost-effectiveness studies was undertaken to compare CPAP with other interventions routinely used for the treatment of OSAHS in the National Health Service (NHS). The review comprised manufacturer submissions to NICE and relevant, published cost-effectiveness analyses. To obtain the latter, papers obtained from the clinical effectiveness review (see Chapter 3) were scanned to check whether they included cost-effectiveness data. In addition, several economic databases were searched for cost-effectiveness studies as listed below (for full details see Appendix 1, Cost-effectiveness searches).

- MEDLINE and in process MEDLINE and other non-indexed citations (1950–Jan 10 2007) (OVID)
- EMBASE (1980–2007 week 1) (OVID)
- Cochrane Central Register of Controlled Trials (Cochrane Library 2006, issue 4) (www.thecochranelibrary.com)
- NHS Economic Evaluation Database (NHS EED) (CRD internal administration system 13/1/07)
- HTA database (CRD internal administration system 13/1/07)
- EconLit (1969–2006/10) (SilverPlatter)
- EconPapers (http://econpapers.repec.org/).

A broad range of studies was considered in the assessment of cost-effectiveness, including economic evaluations conducted alongside trials, modelling studies and analyses of administrative databases. Studies were included in the cost-effectiveness review if they considered the costs and outcomes associated with two or more interventions in the treatment of OSAHS. Therefore, studies based on cost–consequence analysis, cost–utility analysis, cost-effectiveness analysis, cost minimisation analysis and cost–benefit analysis were eligible for inclusion.

Data were extracted using a data extraction form that was developed for use in previous technology assessment reviews. The quality of the cost-effectiveness studies was assessed based on a checklist developed by Drummond et al. (2005)\(^\text{121}\) and which reflects the criteria for economic evaluation detailed in the methodological guidance developed by NICE (www.nice.org.uk) (see Appendix 6 for economic evaluation data extraction table and Table 40 for economic evaluation quality assessment table).

Cost-effectiveness review results

The above searches identified four full economic evaluations for inclusion in the cost-effectiveness review of published studies,\(^\text{14,122,123,124}\) One manufacturer (ResMed) submitted a full cost-effectiveness study to NICE.\(^\text{120}\) Two manufacturers, Fisher Paykel Ltd\(^\text{125}\) and Respironics (UK) Ltd,\(^\text{126}\) submitted a partial economic evaluation. Full economic evaluations, including ResMed’s submission and the four published economic evaluations (i.e. Ayas et al.\(^\text{122}\), Mar et al.\(^\text{123}\), the Trent Report by Chilcott et al.\(^\text{44}\) and Tousignant et al.\(^\text{124}\)), are reviewed next and reported in Table 40. These are followed by an overall summary of the cost-effectiveness evidence base.
Review of manufacturers’ submissions
ResMed model

Overview
ResMed performed a cost–utility analysis comparing CPAP using fixed pressure and CPAP using autotitrated pressure with a ‘do nothing’ alternative for the treatment of patients with severe OSAHS.\textsuperscript{120} The hypothetical patient population depicted by the model consisted of 55-year-old patients with severe OSAHS as defined by an AHI > 30 and daytime sleepiness represented by a score of 12 on the ESS. The analysis was undertaken from the NHS and PSS perspective.

ResMed produced a cohort-based Markov model with a 14-year time horizon and each Markov cycle lasted a year.\textsuperscript{120} Patients enter the model following an initial outpatient visit or a diagnostic sleep study test. Treatment begins 8.4 months after whichever visit takes place first. For each year in the model patients can remain event free in the severe OSAHS state, or can have a non-fatal or fatal stroke, a cardiovascular event (CVE), e.g. myocardial infarction or a road traffic accident (RTA), as illustrated in Figure 19. In each subsequent year patients who have had a non-fatal CVE or an RTA can have a stroke, CVE or RTA. However, patients who have a stroke can no longer drive and, therefore, are not at subsequent risk of an RTA.

The primary measure of cost-effectiveness was incremental cost per quality-adjusted life-year (QALY) gained, and the secondary measure was cost per life-year gained. The QALY estimate incorporated the impact on health-related quality of life (HRQoL) of stroke, CVE and RTA. Effectiveness estimates and utilities were drawn from the HRQoL published literature and government statistics, and based on the authors’ assumptions. Data on patient management and resource use were obtained from 19 clinicians throughout the UK who had relevant clinical experience. Unit cost data on CPAP treatment, and resource use associated with CVEs and RTAs, were obtained from list prices, the published literature and government statistics. The authors undertook several univariate sensitivity analyses and probabilistic sensitivity analysis to test the robustness of findings.

Summary of effectiveness data
For the base-case analysis, utility values for treated and untreated OSAHS were obtained from Mar et al.\textsuperscript{123} In this study, a survey of 51 OSAHS patients who attended a sleep clinic in Spain was undertaken before the initiation of CPAP and 5 months after initiation of CPAP in order to generate ‘do nothing’ and nasal CPAP (nCPAP) utility values, respectively. The EQ-5D instrument
(EuroQoL Group\textsuperscript{127}) was used to describe patient health states and completed data for 46 patients were obtained. These were then elicited using the time trade-off technique and valued based on UK societal preferences (Dolan \textit{et al.}\textsuperscript{128}). No information was obtained on the HRQoL of OSAHS patients with stroke and coronary heart disease (CHD). To estimate these utilities, the authors assumed quality adjustment factors of 0.8 and 0.9 in relation to standard OSAS patient utilities (Table 14, based on Torrance \textit{et al.}\textsuperscript{129}) To estimate utility associated with a non-fatal RTA, ResMed took the average utility for OSAHS and a non-fatal CVE in treated and untreated patients.

The annual incidence rates of fatal and non-fatal cardiovascular and cerebrovascular events in patients with severe OSAHS (AHI > 30) were calculated for CPAP-treated and untreated patients using the results of a long-term observational study by Marin \textit{et al.}\textsuperscript{130} The untreated patients comprised those who had refused CPAP treatment on initial referral to the sleep clinic. The baseline characteristics of these patients may differ compared with the treated patients for reasons other than chance, thus undermining the internal validity of the study results. Results were extrapolated from years 12–14. No method of extrapolation was reported. The authors justified the use of a 14-year time horizon because 14 is divisible by seven: the estimated NHS shelf-life of CPAP according to the authors. ResMed used the Marin \textit{et al.}\textsuperscript{130} study to estimate the ratio of CHD and stroke in patients with untreated severe OSAHS as 1.185 and 1.353 respectively compared with treated OSAHS. Therefore, they estimated the ratio of developing CHD to stroke as 1 : 1.13. Based on the same data, ResMed estimated the ratio of CHD to stroke in treated patients as 1 : 1. Thus, treatment with CPAP was assumed to reduce the incidence of CHD and stroke, and to reduce the proportion of total CHD and stroke events. Using these estimates, ResMed calculated the annual risk of CVE and stroke.

To estimate the risk of an RTA, ResMed took the average risk increase of an RTA in patients with OSAHS based on two studies. One study assessed RTAs in patients with OSAHS before and after treatment with CPAP (George \textit{et al.}\textsuperscript{131}) Patients were followed-up for at least 3 years. The other study (Mazza \textit{et al.}\textsuperscript{132}) measured driving ability in OSAHS patients before and after CPAP treatment using a ‘road safety platform’ (i.e. a stretch of road to test driving ability). The risk of an RTA was estimated as 2.6 times greater than the risk among controls, whereas the risk among treated patients was assumed to be equivalent to that among controls. Using data from the Department of Transport\textsuperscript{133} and assuming that all OSAHS patients were drivers of a licensed motor vehicle, ResMed estimated that the risk of an RTA among the control group and treated OSAHS patients was 0.009 per year and 0.023 per year for untreated OSAHS patients.

ResMed reviewed the published literature to obtain data on compliance among OSAHS patients with fixed CPAP. Compliance was defined as the percentage of patients with OSAHS of all severity levels who have not discontinued using their CPAP device. ResMed estimated that 79\% of patients would continue to use CPAP after the first year of treatment, based on the results of four studies that followed patient compliance for at least 1 year.\textsuperscript{39,40,134,135} It took the average compliance across the studies, the follow-up time for which varied between 2 and 7 years. For patients who continued their use of the device for at least 1 year, it was assumed that there would be no further loss to compliance, based on expert clinical opinion. For autotitrating CPAP it was estimated.

The annual incidence rates of fatal and non-fatal cardiovascular and cerebrovascular events in patients with severe OSAHS (AHI > 30) were calculated for CPAP-treated and untreated patients using the results of a long-term observational study by Marin \textit{et al.}\textsuperscript{130} The untreated patients comprised those who had refused CPAP treatment on initial referral to the sleep clinic. The baseline characteristics of these patients may differ compared with the treated patients for reasons other than chance, thus undermining the internal validity of the study results. Results were extrapolated from years 12–14. No method of extrapolation was reported. The authors justified the use of a 14-year time horizon because 14 is divisible by seven: the estimated NHS shelf-life of CPAP according to the authors. ResMed used the Marin \textit{et al.}\textsuperscript{130} study to estimate the ratio of CHD and stroke in patients with untreated severe OSAHS as 1.185 and 1.353 respectively compared with treated OSAHS. Therefore, they estimated the ratio of developing CHD to stroke as 1 : 1.13. Based on the same data, ResMed estimated the ratio of CHD to stroke in treated patients as 1 : 1. Thus, treatment with CPAP was assumed to reduce the incidence of CHD and stroke, and to reduce the proportion of total CHD and stroke events. Using these estimates, ResMed calculated the annual risk of CVE and stroke.

To estimate the risk of an RTA, ResMed took the average risk increase of an RTA in patients with OSAHS based on two studies. One study assessed RTAs in patients with OSAHS before and after treatment with CPAP (George \textit{et al.}\textsuperscript{131}) Patients were followed-up for at least 3 years. The other study (Mazza \textit{et al.}\textsuperscript{132}) measured driving ability in OSAHS patients before and after CPAP treatment using a ‘road safety platform’ (i.e. a stretch of road to test driving ability). The risk of an RTA was estimated as 2.6 times greater than the risk among controls, whereas the risk among treated patients was assumed to be equivalent to that among controls. Using data from the Department of Transport\textsuperscript{133} and assuming that all OSAHS patients were drivers of a licensed motor vehicle, ResMed estimated that the risk of an RTA among the control group and treated OSAHS patients was 0.009 per year and 0.023 per year for untreated OSAHS patients.

ResMed reviewed the published literature to obtain data on compliance among OSAHS patients with fixed CPAP. Compliance was defined as the percentage of patients with OSAHS of all severity levels who have not discontinued using their CPAP device. ResMed estimated that 79\% of patients would continue to use CPAP after the first year of treatment, based on the results of four studies that followed patient compliance for at least 1 year.\textsuperscript{39,40,134,135} It took the average compliance across the studies, the follow-up time for which varied between 2 and 7 years. For patients who continued their use of the device for at least 1 year, it was assumed that there would be no further loss to compliance, based on expert clinical opinion. For autotitrating CPAP it was estimated.

<table>
<thead>
<tr>
<th>Health state</th>
<th>Utility values</th>
<th>Untreated OSAS patients</th>
<th>nCPAP OSAS patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSAS</td>
<td>0.738</td>
<td>0.811</td>
<td></td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>0.590</td>
<td>0.649</td>
<td></td>
</tr>
<tr>
<td>Non-fatal CHD</td>
<td>0.664</td>
<td>0.730</td>
<td></td>
</tr>
<tr>
<td>Non-fatal RTA</td>
<td>0.701</td>
<td>0.771</td>
<td></td>
</tr>
</tbody>
</table>

CHD, coronary heart disease; nCPAP, nasal continuous positive airway pressure; OSAS, obstructive sleep apnoea syndrome; RTA, road traffic accident.

© 2009 Queen's Printer and Controller of HMSO. All rights reserved.
Assessment of cost-effectiveness

that compliance would be 84%. The increase in compliance with autotitrating CPAP compared with fixed CPAP was based on expert opinion.

Summary of resource utilisation and cost data

The opinion of 19 clinical experts was sought in order to estimate the health-care resource use associated with the management of OSAHS in the UK. Resource use and unit costs were reported separately and these are detailed in Tables 15 and 16 respectively. Unit costs were reported in 2005 prices and were based on list prices, ResMed estimates, the published literature and government statistics. Costs were calculated by multiplying the resource use by the relevant unit costs (Table 17). Confidence intervals were calculated based on the resource use estimates provided by clinical experts.

Examination of the electronic model submitted by ResMed revealed a number of modelling errors that may have affected the ability of the model to provide an accurate estimate of mean costs and QALYs. The beta distributions used to characterise the uncertainty around transition probabilities and utilities were mis-specified. The alpha and beta parameters were correctly estimated from the mean and SD, but the scale parameter was set equal to the mean, effectively truncating the distributions at the mean. This meant that for the probabilistic analysis the mean and SD of every transition probability was lower than indicated by the source data. In addition, a number of other distributions were truncated; for example, the relative risk of an RTA was modelled as a normal distribution with mean = 2.6, SD = 0.26, and truncated at a lower limit of 2.4 and an upper limit of 2.9. The reason for the truncation is unclear, and it effectively reduces the uncertainty around the model input parameters. The uncertainties around resource use and cost data were characterised using normal distributions, which allow negative values to be drawn for simulations in the probabilistic analysis.

The numbers of CHD and stroke events were calculated as a proportion of the number of patients alive in the first year of the model for every cycle rather than as a proportion of those patients at risk at a given time point. This led to an overestimate of the number of events, as patients who die as the model progresses are not removed from the pool of those at risk.

**TABLE 15** ResMed estimates of health-care resource use

<table>
<thead>
<tr>
<th>Resource use</th>
<th>Probability (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of having an initial outpatient visit before a diagnostic sleep</td>
<td>0.31 (0.11–0.51)</td>
</tr>
<tr>
<td>study</td>
<td></td>
</tr>
<tr>
<td>Probability of one outpatient visit after a diagnostic sleep study</td>
<td>0.69 (0.49–0.89)</td>
</tr>
<tr>
<td>Probability of having a home sleep study</td>
<td>0.75 (0.59–0.90)</td>
</tr>
<tr>
<td>Probability of having a home titration study</td>
<td>0.99 (0.97–1.00)</td>
</tr>
<tr>
<td>Probability of having a titration study in hospital</td>
<td>0.04 (0.00–0.05)</td>
</tr>
<tr>
<td>Probability of using CPAP (fixed) for titration</td>
<td>0.19 (0.01–0.36)</td>
</tr>
<tr>
<td>Probability of using CPAP (auto) for titration</td>
<td>0.81 (0.64–0.99)</td>
</tr>
<tr>
<td>Probability of seeing a consultant during the titration phase</td>
<td>0.40 (0.05–0.52)</td>
</tr>
<tr>
<td>Probability of seeing a specialist nurse during the titration phase</td>
<td>1.00 (0.53–1.00)</td>
</tr>
<tr>
<td>Probability of seeing a technician during the titration phase</td>
<td>0.48 (0.10–0.93)</td>
</tr>
<tr>
<td>Probability of having a humidifier</td>
<td>0.38 (0.22–0.50)</td>
</tr>
<tr>
<td>Probability of switching from fixed to autotitrating CPAP in the second</td>
<td>0.06 (0.04–0.07)</td>
</tr>
<tr>
<td>year</td>
<td></td>
</tr>
<tr>
<td>Probability of switching from fixed to autotitrating CPAP in subsequent</td>
<td>0.01 (0.00–0.02)</td>
</tr>
<tr>
<td>years</td>
<td></td>
</tr>
<tr>
<td>Probability of a non-compliant patient returning his or her machine</td>
<td>0.75 (0.50–1.00)</td>
</tr>
<tr>
<td>Probability of having a follow-up visit within 3 months of starting CPAP</td>
<td>0.75 (0.50–1.00)</td>
</tr>
<tr>
<td>Probability of having a follow-up visit within 4–6 months of starting</td>
<td>0.75 (0.75–1.00)</td>
</tr>
<tr>
<td>CPAP</td>
<td></td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a</td>
<td>0.13 (0.00–0.27)</td>
</tr>
<tr>
<td>consultant</td>
<td></td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a specialist</td>
<td>0.61 (0.33–0.79)</td>
</tr>
<tr>
<td>nurse</td>
<td></td>
</tr>
<tr>
<td>Probability of annual follow-up visits after starting CPAP with a</td>
<td>0.26 (0.09–0.54)</td>
</tr>
<tr>
<td>technician</td>
<td></td>
</tr>
<tr>
<td>Probability of a dead patient’s machine being returned</td>
<td>0.90 (0.75–1.00)</td>
</tr>
</tbody>
</table>
### TABLE 16 ResMed unit costs

<table>
<thead>
<tr>
<th>Resource</th>
<th>Cost</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarction episode</td>
<td>£1694.51</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Home-based cardiac rehabilitation for the first year</td>
<td>£3702.49</td>
<td>Taylor et al., 2006&lt;sup&gt;138&lt;/sup&gt;</td>
</tr>
<tr>
<td>following a myocardial infarction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke episode</td>
<td>£1667.23</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Annual cost of stroke rehabilitation</td>
<td>£10,140</td>
<td>Department of Health, 2005&lt;sup&gt;139&lt;/sup&gt;</td>
</tr>
<tr>
<td>Initial outpatient visit with specialist</td>
<td>£115.00</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Follow-up outpatient visit with specialist</td>
<td>£108.00</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Initial sleep study</td>
<td>£115.35</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Follow-up sleep study</td>
<td>£107.87</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Specialist nurse visit (30-minute appointment)</td>
<td>£34.00</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Technician visit (30-minute appointment)</td>
<td>£9.50</td>
<td>Department of Health, 2005&lt;sup&gt;137&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fatal car accident</td>
<td>£5688.23</td>
<td>Department of Transport, 2004&lt;sup&gt;133&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serious/slight car accident</td>
<td>£12,019.89</td>
<td>Department of Transport, 2004&lt;sup&gt;133&lt;/sup&gt;</td>
</tr>
<tr>
<td>CPAP S8 Escape</td>
<td>£280.00</td>
<td>ResMed&lt;sup&gt;121&lt;/sup&gt;</td>
</tr>
<tr>
<td>APAP S8 AutoSet Spirit</td>
<td>£410.00</td>
<td>ResMed&lt;sup&gt;121&lt;/sup&gt;</td>
</tr>
<tr>
<td>HumidAire H3i (Humidifier)</td>
<td>£150.00</td>
<td>ResMed&lt;sup&gt;121&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ultra Mirage II Nasal (Mask)</td>
<td>£80.00</td>
<td>ResMed&lt;sup&gt;121&lt;/sup&gt;</td>
</tr>
<tr>
<td>Miscellaneous spare parts for CPAP</td>
<td>£100.00</td>
<td>Estimate</td>
</tr>
<tr>
<td>Cost of using CPAP (auto) for dose titration</td>
<td>£2.51</td>
<td>Estimate</td>
</tr>
<tr>
<td>Cost of using CPAP (fixed) for dose titration</td>
<td>£1.71</td>
<td>Estimate</td>
</tr>
<tr>
<td>Nightly cost of using Embletta X10 for a diagnostic sleep study</td>
<td>£6.69</td>
<td>Estimate</td>
</tr>
</tbody>
</table>

APAP, autotitrating positive airway pressure.

NB The nightly cost of using an Embletta X10 (portable diagnostic device) is based on an acquisition cost of £6690, a shelf-life of 5 years and the device being used four nights a week for 50 weeks a year.

The proportion of males in the hypothetical patient population was modelled with uncertainty. Risks that differed according to gender, such as mortality risks, were averaged according to the proportion of males and females at the start of the model. Averaging over heterogeneous subgroups in this manner can produce misleading results. For example, as the risk of death is greater among men, the proportion of men in the hypothetical patient population would be expected to fall over time. By not reflecting this in the model the number of deaths will be overestimated.

A number of other minor errors were also found. The lack of internal validity indicates that the model results should be interpreted with caution.

**Summary of cost-effectiveness**

The expected outcomes associated with severe OSAHS at 14 years from commencement of treatment with CPAP compared with no treatment are provided in Table 18. Based on the Markov model, differences in health gain between patients receiving CPAP and patients who are untreated becomes apparent after 2–3 years of treatment.

The primary cost driver in patients with severe OSAHS was managing stroke [i.e. 68% of the total cost for the no treatment group, 48% for the CPAP (fixed) and 45% for CPAP (auto) groups]. The secondary cost driver in untreated patients was the cost associated with managing RTAs (i.e. 23% of the total cost for the no treatment group), whereas in CPAP-treated patients it was the cost associated with the device itself [i.e. 22% for the CPAP (fixed) and 26% for CPAP (auto) groups].

Key results of the cost-effectiveness model are shown in Table 19. The incremental cost-effectiveness ratio (ICER) was based on deterministic analysis and over 14 years it was estimated that CPAP dominates no treatment (i.e.
TABLE 17 ResMed annual cost associated with CPAP

<table>
<thead>
<tr>
<th></th>
<th>CPAP (fixed)</th>
<th>CPAP (auto)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial outpatient visit</td>
<td>£35.65</td>
<td>£35.65</td>
</tr>
<tr>
<td>Diagnostic sleep study at home</td>
<td>£5.02</td>
<td>£5.02</td>
</tr>
<tr>
<td>Diagnostic sleep study at hospital</td>
<td>£115.35</td>
<td>£115.35</td>
</tr>
<tr>
<td>Follow-up outpatient visit after sleep study</td>
<td>£74.52</td>
<td>£74.52</td>
</tr>
<tr>
<td>Dose titration study (home)</td>
<td>£2.34</td>
<td>–</td>
</tr>
<tr>
<td>Dose titration study (inpatient)</td>
<td>£4.31</td>
<td>–</td>
</tr>
<tr>
<td>Consultant visit during titration phase</td>
<td>£43.20</td>
<td>–</td>
</tr>
<tr>
<td>Specialist nurse visit during titration phase</td>
<td>£38.08</td>
<td>–</td>
</tr>
<tr>
<td>Technician visit during titration phase</td>
<td>£90.25</td>
<td>–</td>
</tr>
<tr>
<td>CPAP machine</td>
<td>£280.00</td>
<td>£410.00</td>
</tr>
<tr>
<td>Mask</td>
<td>£80.00</td>
<td>£80.00</td>
</tr>
<tr>
<td>Humidifier</td>
<td>£57.00</td>
<td>£57.00</td>
</tr>
<tr>
<td>Sundries</td>
<td>£100.00</td>
<td>£100.00</td>
</tr>
<tr>
<td>Follow-up visit within 3 months of starting CPAP</td>
<td>£81.00</td>
<td>£81.00</td>
</tr>
<tr>
<td>Follow-up visit within 4–6 months of starting CPAP</td>
<td>£81.00</td>
<td>£81.00</td>
</tr>
<tr>
<td><strong>Year 1 total</strong></td>
<td>£1087.72</td>
<td>£1039.54</td>
</tr>
<tr>
<td><strong>Years 2–7 and 9–14</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up outpatient visit</td>
<td>£37.25</td>
<td>£37.25</td>
</tr>
<tr>
<td>Replacement mask</td>
<td>£80.00</td>
<td>£80.00</td>
</tr>
<tr>
<td>Sundries</td>
<td>£100.00</td>
<td>£100.00</td>
</tr>
<tr>
<td><strong>Total for each year (2–7 and 9–14)</strong></td>
<td>£217.25</td>
<td>£217.25</td>
</tr>
<tr>
<td><strong>Year 8</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up outpatient visit</td>
<td>£37.25</td>
<td>£37.25</td>
</tr>
<tr>
<td>Replacement CPAP machine</td>
<td>£280.00</td>
<td>£410.00</td>
</tr>
<tr>
<td>Replacement mask</td>
<td>£80.00</td>
<td>£80.00</td>
</tr>
<tr>
<td>Replacement humidifier</td>
<td>£57.00</td>
<td>£57.00</td>
</tr>
<tr>
<td>Sundries</td>
<td>£100.00</td>
<td>£100.00</td>
</tr>
<tr>
<td><strong>Year 8 total</strong></td>
<td>£554.25</td>
<td>£684.25</td>
</tr>
</tbody>
</table>

TABLE 18 ResMed probabilities of expected outcomes after 14 years

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No treatment</th>
<th>CPAP (fixed)</th>
<th>CPAP (auto)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVE</td>
<td>0.57 (0.55–0.66)</td>
<td>0.74 (0.69–0.80)</td>
<td>0.78 (0.73–0.81)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.35 (0.20–0.53)</td>
<td>0.16 (0.08–0.26)</td>
<td>0.14 (0.07–0.25)</td>
</tr>
<tr>
<td>RTA</td>
<td>0.39 (0.23–0.60)</td>
<td>0.17 (0.08–0.29)</td>
<td>0.15 (0.07–0.28)</td>
</tr>
<tr>
<td>Event-free survival</td>
<td>0.30 (0.15–0.47)</td>
<td>0.63 (0.52–0.73)</td>
<td>0.68 (0.56–0.74)</td>
</tr>
<tr>
<td>QALYs</td>
<td>7.22 (6.85–7.62)</td>
<td>8.19 (7.79–8.69)</td>
<td>8.32 (7.97–8.81)</td>
</tr>
</tbody>
</table>

CVE, cardiovascular event; QALYs, quality-adjusted life-years; RTA, road traffic accident.
CPAP was associated with lower costs and higher effects than no treatment). However, at 1 year, the cost per QALY for CPAP is expected to exceed £20,000. After 2 years the expected cost per QALY gained is £10,000 or less, and after 11 years CPAP is the dominant treatment. CPAP (fixed) was compared with no treatment and CPAP (auto) was compared with no treatment. Based on this indirect analysis, the authors found that CPAP (auto) dominated CPAP (fixed).

Several univariate sensitivity analyses were undertaken and demonstrated that the cost-effectiveness of CPAP was robust to changes in some input values. However, the model was sensitive to the following parameters: time to start of treatment, compliance rate with CPAP, risk of having a cardiovascular event or a cerebrovascular event, risk of having an RTA, utility for treated and untreated OSAHS, cost of managing a non-fatal RTA and cost of managing stroke rehabilitation.

The results of the univariate sensitivity analyses are reported in Table 20. No rationale was provided for the ranges over which input values were varied.

### TABLE 19 Key ResMed model results at end of 14 years

<table>
<thead>
<tr>
<th>Model result</th>
<th>CPAP (fixed)</th>
<th>CPAP (auto)</th>
<th>No treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base case</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per QALY gained compared with no treatment</td>
<td>£1620</td>
<td>£1845</td>
<td>–</td>
</tr>
<tr>
<td>95% CI –£4123 to £259</td>
<td>95% CI –£3936 to £37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per life-year gained compared with no treatment</td>
<td>–£9215</td>
<td>–£9845</td>
<td>–</td>
</tr>
<tr>
<td>95% CI –£19,824–£22,224</td>
<td>95% CI –£18,530 to £218</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per event-free life-year gained</td>
<td>–£4813</td>
<td>–£5441</td>
<td>–</td>
</tr>
<tr>
<td>95% CI –£10,195 to £1158</td>
<td>95% CI –£10,005 to £135</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per QALY gained compared with no treatment when clinical outcomes relating to cardiovascular and cerebrovascular events are excluded</td>
<td>£2311</td>
<td>£2173</td>
<td>–</td>
</tr>
<tr>
<td>95% CI £483–£3254</td>
<td>95% CI £460–£2912</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost per QALY gained compared with no treatment when clinical outcomes relating to cardiovascular and cerebrovascular events and RTAs are excluded</td>
<td>£4551</td>
<td>£4219</td>
<td>–</td>
</tr>
<tr>
<td>95% CI £2259–£6597</td>
<td>95% C £2124–£5799</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected alive</td>
<td>74%</td>
<td>78%</td>
<td>57%</td>
</tr>
<tr>
<td>Increased probability of survival compared with no treatment</td>
<td>26%</td>
<td>32%</td>
<td>–</td>
</tr>
<tr>
<td>Expected event-free survival</td>
<td>63%</td>
<td>68%</td>
<td>30%</td>
</tr>
<tr>
<td>Increased probability of event-free survival compared with no treatment</td>
<td>100%</td>
<td>113%</td>
<td>–</td>
</tr>
<tr>
<td>Reduction in relative risk of having a CVE compared with no treatment</td>
<td>55%</td>
<td>60%</td>
<td>–</td>
</tr>
<tr>
<td>Reduction in relative risk of having a stroke compared with no treatment</td>
<td>57%</td>
<td>63%</td>
<td>–</td>
</tr>
<tr>
<td>Reduction in relative risk of having an RTA compared with no treatment</td>
<td>36%</td>
<td>41%</td>
<td>–</td>
</tr>
<tr>
<td>Expected cost (NHS perspective) per patient</td>
<td>£9086</td>
<td>£8622</td>
<td>£10,645</td>
</tr>
<tr>
<td>95% CI £6851–£11,117</td>
<td>95% CI £6712–£10,947</td>
<td>95% CI £7912–£14,177</td>
<td></td>
</tr>
<tr>
<td>Reduction in NHS management costs compared with no treatment</td>
<td>15% (£1559)</td>
<td>19% (£2,023)</td>
<td>–</td>
</tr>
</tbody>
</table>

CVE, cardiovascular event; QALY, quality-adjusted life-year; RTA, road traffic accident.
Cost-effectiveness acceptability curves (CEACs) were presented for CPAP (auto) and CPAP (fixed). Each was assessed in a pair-wise comparison against a ‘do nothing’ alternative. The CEAC showed that CPAP (auto) has a marginally higher probability of being cost-effective compared with a ‘do nothing’ option than CPAP (fixed) compared with a ‘do nothing’ option at a willingness to pay threshold of less than £5000 per QALY in all simulations.

Comments on methodology

Use of observational data

ResMed used the results of a before and after study (Mar et al., 2003) to examine the impact of no treatment compared with CPAP on HRQoL associated with sleepiness. There are numerous weaknesses associated with before and after data which might undermine results. A number of factors may bias and confound the results, for example a placebo effect, a Hawthorne effect, regression to the mean and/or co-intervention. As Chapter 3 demonstrates, a considerable RCT-based literature exists which compares the efficacy and effectiveness of CPAP compared with other therapies in the treatment of OSAHS. The study by Mar et al. did not report the change in ESS or any other measure in the utility study that would have allowed comparison with the results of the systematic review of trial evidence in Chapter 3.

Choice of comparators

ResMed did not include the full range of comparators that are discussed in Chapter 3. For patients with diagnosed severe OSAHS it is not clear that a ‘do nothing’ option represents routine clinical practice. Incremental cost-effectiveness analysis examines the relative cost-effectiveness of treatment options. It is possible that by comparing CPAP with a ‘do nothing’ alternative, the comparative benefit of CPAP is increased, compared, for example, with dental devices. ResMed briefly describes the recent systematic review by Giles et al. This review suggests that symptoms post treatment did not show a significant difference between CPAP and dental devices. However, Giles et al. also suggest that additional data are required.

Time horizon

ResMed modelled cost-effectiveness results over a 14-year time horizon. However, OSAHS is a chronic condition; therefore, given the NICE guidelines, it is appropriate to model the results for a lifetime horizon. ResMed used a 14-year time horizon for analytical convenience. It was assumed that the device life of CPAP was 7 years and a 14-year time horizon is a multiple of seven. The device life of CPAP was not tested in the univariate sensitivity analysis. However, it was found that results were sensitive to the second most important cost driver in CPAP-treated patients: the cost associated with the device itself [i.e. 22% for CPAP (fixed) and 26% for CPAP (auto)]. Ayas et al. and Mar et al. assumed the device life of CPAP to be 5 years. The shorter the device life, the greater the cost associated with the relevant treatment.

Errors in the model

There were shortcomings in the internal validity of the electronic model that may have led to inaccurate estimates of costs and QALYs.

Review of other NICE submissions (2007)

Fisher Pakyel Ltd and Respironics Ltd submitted partial economic evaluations that are not summarised here as they did not contain a full cost-effectiveness analysis.

Review of published economic evaluations

Review of Ayas et al.

Overview

Ayas et al. performed a cost-utility analysis comparing CPAP with a ‘do nothing’ alternative for the treatment of patients with moderate to severe OSAHS. The base-case analysis was patients aged between 25 and 54 years who were newly diagnosed with moderate to severe OSAHS, classified as having an AHI ≥15 events per hour. The analysis was undertaken from the US third-party payer perspective and the societal perspective.

The authors developed a Markov model with a 5-year time horizon. Each Markov cycle lasted 1 year. The primary outcome measure used in the analysis was incremental cost per QALY. The QALY estimate for CPAP incorporated the expected gains in HRQoL due to a reduction in RTAs. Effectiveness, utility and resource use estimates were obtained from the published literature and administrative databases. A number of univariate sensitivity analyses were undertaken. In addition, the authors undertook a probabilistic sensitivity analysis.

Summary of effectiveness data

For the base-case analysis, QALY estimates were obtained using utilities valued based on the standard gamble, in patients with OSAHS, pre and post CPAP therapy (Chakravorty et al.). Therefore, patient preferences rather than societal preferences were used for the valuations. Overall, a weighted average of the findings was obtained for patients
### TABLE 20 ResMed model results of deterministic sensitivity analysis at end of 14 years

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Base-case value</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time to start of treatment: range 4.8 months to 12.0 months</strong></td>
<td>8.400</td>
<td>Relative cost–utility changes marginally but CPAP (fixed) and CPAP (auto) remain dominant vs no treatment</td>
</tr>
<tr>
<td>Compliance rate with CPAP (fixed): range 0.5–1.0</td>
<td>0.790</td>
<td>Relative cost–utility of CPAP (fixed): range £703 to −£2543; at a compliance rate &lt; 0.6 CPAP (fixed) is no longer dominant treatment; relative cost–utility of CPAP (auto) remains unchanged</td>
</tr>
<tr>
<td>Compliance rate with CPAP (auto): range 0.7–1.0</td>
<td>0.790</td>
<td>Relative cost–utility of CPAP (auto): range −£1,574 to −£2564; relative cost–utility of CPAP (fixed) remains unchanged</td>
</tr>
<tr>
<td>Risk of CVEs among treated and untreated patients: range 50% below to 75% above the base-case value</td>
<td>1.000</td>
<td>As risk increases, relative cost–utility of CPAP (fixed) ranges from £24 to −£2843, CPAP (auto) ranges from −£218 to −£2999; if risk falls to 60% below the base-case value, CPAP (fixed) ceases to be dominant</td>
</tr>
<tr>
<td>Ratio of CVEs to stroke among untreated OSAHS patients: range 1:4 to 1:0</td>
<td>0.47 : 0.53</td>
<td>As the ratio increases, the relative cost–utility of CPAP (fixed) ranges from −£404 to −£3534 and of CPAP (auto) ranges from −£870 to £3374</td>
</tr>
<tr>
<td>Risk of untreated OSAHS patients having an RTA: range 1.0–5.0 above background rate</td>
<td>2.600</td>
<td>As risk increases, relative cost–utility of CPAP (fixed) ranges from −£498 to −£3107 and of CPAP (auto) ranges from −£812 to £3244</td>
</tr>
<tr>
<td>Utility for untreated OSAHS: range 0.5–0.9</td>
<td>0.738</td>
<td>If utility falls below 0.68 CPAP ceases to be most cost-effective alternative, assuming treated OSAHS unchanged</td>
</tr>
<tr>
<td>Utility for treated OSAHS: range 0.5–0.9</td>
<td>0.811</td>
<td>If utility rises above 0.89 CPAP ceases to be most cost-effective alternative, assuming untreated OSAHS unchanged</td>
</tr>
<tr>
<td>Utility of non-fatal stroke in untreated OSAHS patients: range 0.5–0.9</td>
<td>0.590</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1532 to −£2020 and of CPAP (auto) ranges from −£1751 to −£2262</td>
</tr>
<tr>
<td>Utility of non-fatal stroke in treated OSAHS patients: range 0.5–0.9</td>
<td>0.649</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1694 to −£1510 and of CPAP (auto) ranges from −£1914 to £1739</td>
</tr>
<tr>
<td>Utility of non-fatal CVE in untreated OSAHS patients: range 0.5–0.9</td>
<td>0.664</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1565 to −£1708 and of CPAP (auto) ranges from −£1787 to £1936</td>
</tr>
<tr>
<td>Utility of non-fatal cardiovascular event in treated OSAHS patients: range 0.5–0.9</td>
<td>0.730</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1646 to −£1602 and of CPAP (auto) ranges from −£1858 to £1835</td>
</tr>
<tr>
<td>Utility of non-fatal RTA in untreated OSAHS patients: range 0.5–0.9</td>
<td>0.701</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1573 to −£1901 and of CPAP (auto) ranges from −£1792 to £1901</td>
</tr>
<tr>
<td>Utility of non-fatal RTA in treated OSAHS patients: range 0.5–0.9</td>
<td>0.771</td>
<td>As utility increases, relative cost–utility of CPAP (fixed) ranges from −£1649 to −£1607 and of CPAP (auto) ranges from −£1876 to £1831</td>
</tr>
<tr>
<td>NHS cost of cardiac rehabilitation in the first year following a non-fatal CVE: range £1851–£7404</td>
<td>£3702</td>
<td>As cost increases, relative cost–utility of CPAP (fixed) ranges from −£1445 to −£1970 and of CPAP (auto) ranges from −£1677 to −£2180</td>
</tr>
<tr>
<td>Annual NHS cost of stroke rehabilitation following non-fatal stroke: range £5070–£20,280</td>
<td>£10,140</td>
<td>As cost increases, relative cost–utility of CPAP (fixed) ranges from −£287 to −£4286 and of CPAP (auto) ranges from −£456 to £4623</td>
</tr>
<tr>
<td>NHS cost of managing a non-fatal RTA: range £6000–£22,000</td>
<td>£12,020</td>
<td>As cost increases, relative cost–utility of CPAP (fixed) ranges from −£1113 to −£2461 and of CPAP (auto) ranges from −£1384 to −£2609</td>
</tr>
</tbody>
</table>

**continued**
Assessment of cost-effectiveness

TABLE 20 | ResMed model results of deterministic sensitivity analysis at end of 14 years

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Base-case value</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Model results that are not sensitive to input values</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per cent of OSAHS patients who are male: range 0.5–1.0</td>
<td>0.700</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Probability of having a home diagnostic sleep study: range 0.5–1.0</td>
<td>0.750</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Probability of having a home titration study: range 0.5–1.0</td>
<td>0.990</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Probability of switching (fixed) to (auto) CPAP in the 2nd year: range 0.0–0.1</td>
<td>0.060</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Probability of a clinician visit within 3 months of starting treatment: range 0.5–1.0</td>
<td>0.750</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Probability of an annual visit with a consultant: range 0.0–0.5</td>
<td>0.130</td>
<td>Relative effect unchanged; relative cost–utility of CPAP (fixed) and CPAP (auto) changes marginally</td>
</tr>
<tr>
<td>Probability of an annual visit with a specialist nurse: range 0.4–1.0</td>
<td>0.610</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Initial NHS cost of managing a CVE: range £1000–£2500</td>
<td>£1695</td>
<td>Relative effect unchanged; relative cost–utility of CPAP (fixed) and CPAP (auto) changes marginally</td>
</tr>
<tr>
<td>Initial NHS cost of managing an episode of stroke: range £1000–£2500</td>
<td>£1667</td>
<td>Relative effect unchanged; relative cost–utility of CPAP (fixed) and CPAP (auto) changes marginally</td>
</tr>
<tr>
<td>NHS cost of managing a fatal RTA: range £2000–£8000</td>
<td>£5688</td>
<td>Relative effect unchanged</td>
</tr>
<tr>
<td>Annual discount: rate 0–6%</td>
<td>3.5%</td>
<td>Relative effect unchanged; relative cost–utility of CPAP (fixed) and CPAP (auto) changes marginally</td>
</tr>
</tbody>
</table>

CVE, cardiovascular event; OSAHS, obstructive sleep apnoea–hypopnoea syndrome; RTA, road traffic accident.

TABLE 20 | ResMed model results of deterministic sensitivity analysis at end of 14 years

by age group and sex. These were adjusted for the impact of CPAP on RTAs and the impact of death due to natural causes, as explained below.

Estimates of effect were calculated based on the proportion of patients in one of six patient groups (i.e. ages 25–34, 35–44, 45–54 by sex), reflecting the distribution found in a sample of 99 patients with OSAHS: a distribution comparable to that in the United States. The probabilities of RTAs were stratified by the relevant patient groups. An RTA could either result in a fatality or property damage only or be injury related. The injury-related RTAs were stratified into one of five levels on the Maximum Abbreviated Injury Scale (MAIS), with scores ranging from one (minimal injury) to five (most severely injured). Of the patients having an RTA, the severity of injury was estimated as 85.6%, 10.5%, 3.3%, 0.4% and 0.2% for severity levels 1–5. RTA survivors in level 5 MAIS state were assumed to be unable to drive again and therefore were confined to a tunnel state in the model.

The effect of CPAP on RTAs was based on a random-effects meta-analysis of eight observational studies in which actual RTAs were observed in patients pre and post initiation of CPAP (Table 21). It excluded driving simulator studies. A pooled reduction in RTA risk and an improvement in HRQoL due to CPAP were calculated by a random-effects meta-analysis using the inverse variance of the logarithm of the odds ratio. It was assumed that the RTA crash rate in OSAHS patients who received CPAP equalled that in the general population. The RTA rates in OSAHS patients who were not receiving CPAP were obtained taking the general population RTA rates and dividing these by the proportionate reduction in RTAs associated with CPAP therapy.

Based on one study (Chakravorty et al.97) it was assumed that the average utility in patients receiving CPAP was 0.55, an increase in utility of 0.23 compared with baseline (no CPAP). The utilities were valued using the standard gamble. Quality weights for the five MAIS injury levels were obtained using the Functional Capacity Index (FCI), which used rating scale preferences from patients who had functional limitations exceeding
1 year. The FCI weights were applied using similar methods to those of Graham et al.\textsuperscript{143}

The transition probability of death was estimated by applying the yearly, sex-specific probability of an RTA death to the rate of death due to natural causes, based on US life tables.

**Summary of resource utilisation and cost data**

The base-case analysis included third-party payer, direct medical costs only. For the first year, the total cost of CPAP was calculated using the US Medicare fee schedule. For year 2 and year 5, ongoing annual CPAP cost components were included. The costs included those of the device and the time of medical and emergency specialists. For the first 15 months, rental fees were applied based on Medicare guidelines. Following this, patients incurred a rental fee. The CPAP machine was assumed to have a device life of 5 years.

For the analysis undertaken from a societal perspective, productivity losses associated with RTAs were also included, e.g., losses in household and market productivity, and associated workplace costs were calculated using the human capital approach. Non-medical costs including legal costs and insurance administration costs were also included. Societal costs of RTAs were stratified by level of severity using the MAIS scale and were based on national data. Lifetime costs of RTA outcomes and costs were based on public sources. In addition, it was assumed that all RTA costs were uniformly distributed over a future of 40 years for all patient groups. Unit costs were reported separately from resource use. Costs were reported for the year 2003. A discount rate of 3\% was applied to the costs and effects for the base-case analysis.

Patient compliance with CPAP was included in the analysis. A compliance rate of 70\% was assumed, based on findings in one article (McArdle et al.\textsuperscript{39}) It was assumed that non-compliant patients incurred rental costs for the device and the cost of a single visit to their doctor over a 3-month period but did not benefit from the device over the period.

<table>
<thead>
<tr>
<th>Source</th>
<th>Country</th>
<th>Number of patients</th>
<th>Mean AHI</th>
<th>Mean age</th>
<th>Definition of crash</th>
<th>Rates of RTA</th>
</tr>
</thead>
<tbody>
<tr>
<td>George, 2001\textsuperscript{131}</td>
<td>Canada</td>
<td>210</td>
<td>54</td>
<td>52</td>
<td>From provincial insurance database</td>
<td>CPAP</td>
</tr>
<tr>
<td>Findley et al., 1988\textsuperscript{137}</td>
<td>US</td>
<td>50</td>
<td>37</td>
<td>56</td>
<td>State DMV (injury or property damage &gt; $500)</td>
<td>0.06 per year</td>
</tr>
<tr>
<td>Krieger et al., 1997\textsuperscript{136}</td>
<td>France</td>
<td>547</td>
<td>59.8</td>
<td>56.6</td>
<td>Self-report</td>
<td>0 per year</td>
</tr>
<tr>
<td>Engleman et al., 1996\textsuperscript{138}</td>
<td>Scotland</td>
<td>215</td>
<td>47</td>
<td>53</td>
<td>Self-report (major incidents)</td>
<td>0.0256 per year</td>
</tr>
<tr>
<td>Horstmann et al., 2000\textsuperscript{139}</td>
<td>Switzerland</td>
<td>85</td>
<td>NA</td>
<td>NA</td>
<td>Self-report</td>
<td>0.001 per 16,000 km driven</td>
</tr>
<tr>
<td>Suratt and Findley, 1992\textsuperscript{140}</td>
<td>US</td>
<td>22</td>
<td>NA</td>
<td>NA</td>
<td>NS</td>
<td>2.7 per 1,000,000 km driven</td>
</tr>
<tr>
<td>Cassel et al., 1996\textsuperscript{144}</td>
<td>Germany</td>
<td>59</td>
<td>38.9</td>
<td>49</td>
<td>Self-report</td>
<td>0.023 per year</td>
</tr>
<tr>
<td>Yamamoto et al., 2000\textsuperscript{145}</td>
<td>Japan</td>
<td>39</td>
<td>55.7</td>
<td>48</td>
<td>Self-report</td>
<td>0.14 per 100,000 km driven</td>
</tr>
</tbody>
</table>

AHI, apnoea–hypopnoea index; DMV, Department of Motor Vehicles; RTA, road traffic accident.
Summary of cost-effectiveness

From a third-party payer perspective, CPAP was more costly and more effective than no CPAP and the ICER was $3354 per QALY (95% CI $1062 per QALY to $9715 per QALY). From the societal perspective CPAP was also found to be more costly and more effective and had an ICER of $314 (95% CI cost saving to $6114). Based on the probabilistic sensitivity analysis, if the value of society’s willingness to pay for a QALY is $50,000, 100% of the 1000 Monte Carlo simulations favoured the cost-effectiveness of CPAP from the third-party payer and the societal perspective. From the societal perspective, 42% of the ICERs from the simulations indicated that CPAP was dominant, i.e. it was associated with lower costs and greater effects than was no treatment.

Based on the univariate sensitivity analyses, ICER estimates were shown to be robust to many assumptions associated with the parameter estimates chosen. The analytical perspective had a substantial influence on the ICER, resulting in a more than 10-fold higher ICER when comparing the third-party payer perspective with the societal perspective. The type of utility estimate used also had considerable influence on the ICER. When EQ-5D utility estimates were used in place of standard gamble estimates, the ICER estimate increased more than fivefold.

Comments on Ayas et al.122

A single study (Chakravorty et al.97) was used to measure the treatment effect of CPAP on sleepiness and hence HRQoL. This treatment effect was obtained from one arm of an RCT, with the pre-CPAP utility estimate used for the no treatment arm and the 3-month post-CPAP utility estimate used for the CPAP arm. As revealed by the systematic review (see Chapter 3), a considerable number of other data are available on the treatment effect of CPAP. Since only one arm of an RCT was used, in effect the data were subject to the same limitations associated with the before and after study design as mentioned in the discussion of the ResMed submission. It is worth noting that the mean change in ESS in the study arm used to inform the utility estimates was –8, which is considerably greater than the reduction with CPAP indicated by the weight of evidence incorporated in the systematic review in Chapter 3.

The impact of CPAP on RTAs was based on eight before and after studies, pre and post CPAP. Another influence that might undermine the results derived from this study design is referral bias. Patients may have been referred for suspected sleep-disordered breathing because they were involved in an RTA, thereby falsely inflating rates prior to using CPAP. The authors undertook a sensitivity analysis, using the odds ratio of the lower end of the confidence interval, which gave an ICER of around $3530 per QALY. The utility values were adjusted for various MAIS injury levels using the FCI. FCI weights represent rating scale preferences, whereas the NICE guidance focuses on choice-based measures of valuation.

For the base-case analysis, patient preferences were used to estimate utilities, based on the standard gamble technique. NICE methods guidance focuses on the use of societal preferences to inform healthcare decision-making. However, it is worth noting that the authors applied EQ-5D estimates based on societal preferences in a sensitivity analysis.123,144 The resultant CPAP ICER was within ranges typically considered to be cost-effective.

CPAP is a chronic condition; therefore, it would have been appropriate to extrapolate results over the life course.

Review of Mar et al.123

Overview

Mar et al.123 performed a cost–utility analysis comparing nCPAP with a ‘do nothing’ alternative for the treatment of patients with OSAHS. The base case was defined as a 50-year-old male patient with moderate to severe OSAHS, classified as having an AHI ≥30 per hour and an ESS > 10. The analysis was undertaken from the Spanish healthcare system perspective.

The authors developed a semi-Markov (time-varying) model with a time horizon of 5 years and over the lifetime. Each Markov cycle lasted 1 year. The primary outcome measure used in the analysis was incremental cost per QALY. The QALY estimate for nCPAP incorporated the expected gains in HRQoL due to a reduction in stroke and CHD as well as the impact of these events on mortality and RTAs. At the end of each cycle patients could be in an OSAS state, have a non-fatal stroke or non-fatal CHD or die. During the cycle, patients could experience a temporary event: a stroke, CHD or an RTA. Cost estimates were also adjusted for the reduced risk of these three events. Effectiveness, utility and resource use estimates were obtained from the published literature and administrative databases. A number of univariate sensitivity analyses were undertaken. In addition, the authors undertook a probabilistic sensitivity analysis.
Summary of effectiveness data

The effect of CPAP on stroke, CHD, RTAs and HRQoL was incorporated in a series of steps. To model the reduced risk of stroke and CHD due to nCPAP compared with no CPAP, it was assumed that use of nCPAP returned blood pressure to its pre-OSAHS levels, as a consequence of the reduction in AHI by nCPAP. Based on an assessment of CVE risk, it was assumed that OSAHS patients with an AHI of greater than 30 had an increase in diastolic arterial pressure of 3.6 mmHg. It was estimated that increases in blood pressure were linearly correlated with the natural logarithm of the risk of stroke and CHD, based on MacMahon et al. Therefore, applying this to the 3.6 mmHg increase in diastolic pressure, the natural logarithms of the risk could be obtained, thus estimating the relative risks of stroke and CHD. It was assumed that relative risk of these events remained constant at a given blood pressure and that absolute risk was best estimated by applying this relative risk to the baseline absolute risk for patient and age and sex using rates tables.

Mortality rates for stroke, CHD, RTAs and all causes by age and sex were based on an administrative database from the Basque country, Spain. The transition probabilities from OSAHS to death were based on the mortality rates of all causes, excluding stroke, CHD and RTAs. Age- and sex-specific mortality rates for the general population were multiplied by the corresponding relative risks to calculate the corrected rate for nCPAP and no CPAP groups (Table 22).

Utility values were obtained as described in Summary of effectiveness review for the ResMed submission (see pp. 54–5).

Summary of resource utilisation and cost data

The cost analysis was undertaken from the healthcare perspective. The following direct costs were considered: costs of investigation, diagnosis and treatment of OSAHS and costs attributable to CVE morbidity, costs associated with in-home technical maintenance and medical follow-up. The nCPAP was assumed to have a device life of 5 years. Data relating to the last 5000 patients who had suspected OSAHS and who attended a sleep clinic (in the Basque country) were used to estimate the cost of diagnosis and the proportion of patients abandoning treatment during the first year. It was assumed that no benefits of treatment accrued to these patients.

Costs were reported for the year 2000 and were converted from Spanish pesetas to euros. A discount rate of 3% was applied to the costs and effects for the base-case analysis.

Summary of cost-effectiveness

The base-case analysis found that CPAP was more costly and more effective than no CPAP. The ICER for CPAP was €7861 per QALY over a 5-year time horizon and €4938 per QALY for the lifetime horizon.

Based on the univariate and multivariate sensitivity analyses, ICER estimates were robust to many assumptions associated with the parameter estimates chosen and remained in the region of €5000–€10,000. The only case where the ICER was found to exceed €20,000 per QALY was for a worst-case scenario analysis in which the authors used the lower limit of the CI obtained from the patient preference utility survey and a 5-year time horizon. As anticipated, the authors found that the cost-effectiveness ratio increases as the cost of nCPAP increases. For example, the authors assessed the impact of an increase in diagnostic costs on cost-effectiveness and the impact of two different types of diagnostic protocol on the ICER. As well as this, they presented disaggregated incremental effectiveness data (for CVE risk, RTAs and utility effect) and disaggregated incremental cost information for a 50-year-old male using nCPAP for both a 5-year and a lifespan time horizon. They

<table>
<thead>
<tr>
<th>Probabilities (relative risks)</th>
<th>Untreated OSAS patients</th>
<th>nCPAP OSAS patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD</td>
<td>1.185</td>
<td>1.0</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.353</td>
<td>1.0</td>
</tr>
<tr>
<td>Car accident</td>
<td>8.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Death after stroke</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Death after CHD</td>
<td>1.1</td>
<td>1.1</td>
</tr>
</tbody>
</table>

CHD, coronary heart disease; OSAS, obstructive sleep apnoea syndrome.
found that the results were very sensitive to the time horizon specified. Over the lifespan of the patient, improvements in quality of life accounted for 84% of the incremental effectiveness of nCPAP. The purchase and maintenance costs of nCPAP accounted for 86% of the overall incremental costs. When the time horizon was reduced to 5 years, these costs amounted to 98% and 61% of the overall incremental costs respectively.

Overall, therefore, the authors suggested that nCPAP is cost-effective in patients with an AHI ≥30 and who also exhibit symptoms of daytime sleepiness. The authors suggested that the improvement in HRQoL, associated with nCPAP is the main force behind its clinical effectiveness, as measured in QALYs, being seven times greater than that of reduced CVE mortality, which in turn is seven times greater than that of decreased numbers of RTAs. The authors suggested that the remaining uncertainties about the impact of nCPAP on long-term mortality have relatively little impact on the clinical and economic efficiency of treatment.

Comments on Mar et al.123
Data from a single survey, conducted as part of the study, were used to measure the treatment effect (in the form of change in sleepiness in terms of utilities) of CPAP versus no CPAP. As mentioned in the comments on the Ayas et al.122 study, a large number of other data were available but were not used to inform this estimate, and the data were based on a before and after design, which represents a weak source of evidence of effectiveness.

No account in the model was taken of the impact of an RTA on morbidity/utility or costs. It is not clear that the mortality rates for RTAs (or stroke or CHD) were related to OSAHS. Probabilistic sensitivity analysis was not undertaken.

Review of the Chilcott et al. Trent Report44
Overview
The Trent Report, written by Chilcott et al.,44 provided the foundation for the work undertaken by Mar et al.123 A cost–utility analysis was undertaken which compared nCPAP with a ‘do nothing’ alternative for the treatment of patients with OSAS. Summary results were reported comparing nCPAP and dental devices. The authors undertook the analysis based on a review of the literature and using clinical opinion. The analysis was undertaken from the UK health-care system perspective. The primary outcome measure used in the analysis was incremental cost per QALY. Cost estimates were also adjusted for the reduced risk of these three events. Effectiveness, utility, resource use estimates and costs were obtained from the published literature, administrative databases and clinical expert opinion. Several univariate sensitivity analyses were undertaken.

Summary of effectiveness data
No relevant utility data were available; therefore, an indirect approach was undertaken to estimate utilities. No data were reported on any change in ESS associated with treatment. The authors used SF-36 data generated by the Sleep Disorders Unit at the Royal Hallamshire Hospital in Sheffield. This involved a cohort study in which patients who were referred to the Unit for suspected OSAHS completed the SF-36 questionnaire before and after initiation of treatment, as reported in a conference abstract (Waterhouse et al.146,147). Given that the data were not randomised, the authors attempted to validate them by comparing the results with data presented in Jenkinson et al.27 They found that the before and after results were broadly similar for all SF-36 dimensions in the two studies. However, the population from the Waterhouse et al.147 study appeared to have a lower initial baseline health status. The 1998 Brazier algorithm (Brazier et al.149) (and another algorithm: no further details) was applied to the Waterhouse results to derive a preference-based single index measure of health. The QALY results at 1 year are reported in Table 23.

Summary of resource utilisation and cost data
The cost analysis was undertaken from the health-care perspective. As for the Mar et al.123 analysis, the Trent Report considered the costs of investigation, diagnosis and treatment of OSAHS and maintenance and medical follow-up costs. In contrast to Mar et al.,123 any costs attributable to CVE morbidity were not included in the analysis. The report did not mention the financial year of the cost data. The device life of nCPAP was estimated to be 5 years. A discount rate of 6% was applied to the costs and a discount rate of 1.5% was applied to effects for the base-case analysis.

Summary of cost-effectiveness
The results of the base-case analysis are reported in Table 24. The results were extrapolated on a time horizon of up to 5 years, assuming that the benefits accrued in the trial period were maintained.

Several univariate sensitivity analyses were undertaken, comprising impact of the analytical time horizon; costs of investigation for nCPAP;
long-term costs of maintenance, follow-up and other health-care resource usage; long-term impact of gross annual health-care costs; potential impact of improved mortality from use of nCPAP treatment; impact of uncertainty in morbidity benefits from nCPAP therapy; and discount rate. All estimates of cost-effectiveness over 1 year were < £16,000 per QALY gained.

The authors suggested that the cost-effectiveness of dental devices compared with no treatment was likely to be similar or worse than the cost-effectiveness of nCPAP therapy compared with no treatment. The costs of nCPAP and dental devices were similar. Based on two studies, they found small differences in clinical effectiveness and costs when comparing nCPAP with dental devices. The implied differences in costs and outcomes, and the considerable level of uncertainty associated with both, suggested to the authors that the incremental cost-effectiveness of nCPAP over dental advancement devices was likely to be highly uncertain.

**Comments on the Trent Report**

Data used to estimate effectiveness were short term and based on observational data (Waterhouse et al., 2 weeks’ duration; Jenkinson et al., 4 weeks’ duration). No account was taken of the potential impact of nCPAP on the risk of CVE or RTAs in terms of costs or effects. The analysis was deterministic.

### Review of Tousignant et al.

**Overview**

Tousignant et al. performed a cost–utility analysis retrospectively comparing the impact on HRQoL of pre-treatment with treatment using nCPAP. In this way nCPAP was compared with a ‘do nothing’ option in 19 patients with moderate to severe OSAHS. The study took place at a sleep clinic in Montreal, Canada.

**Summary of effectiveness data**

Patients attending a hospital sleep clinic (mean age 57 years, SD 10) and who had been receiving nCPAP treatment for an average of 9 months completed a standard gamble exercise. The health states valued were receiving treatment with nCPAP, pre-treatment, full health and immediate death. To assess the reliability of the results, patients completed the exercise on two occasions 2–3 weeks apart. The mean utility score for the pre-treatment health state was 0.63 (± 0.29) and the mean utility score for the nCPAP treatment health state was 0.87 (± 0.17). The intraclass correlation coefficients for the retest data were above 0.7 for both the treatment health state and pre-treatment health states. Patient life expectancy was estimated using Canadian life tables. The difference in utility pre and post treatment was multiplied by the life-years to calculate QALYs.

**Summary of resource utilisation and cost data**

The perspective of the cost analysis was not stated but appears to be the health-care system

---

**TABLE 23  Gain in QALYs at 1 year in the Chilcott et al. Trent Report**

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>Lower 95% CI</th>
<th>Upper 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All study participants</td>
<td>0.10</td>
<td>0.07</td>
<td>0.12</td>
</tr>
<tr>
<td>Participants offered long-term nCPAP treatment</td>
<td>0.12</td>
<td>0.09</td>
<td>0.16</td>
</tr>
</tbody>
</table>

nCPAP, nasal continuous positive airway pressure; QALY, quality-adjusted life-year.

**TABLE 24  Baseline cost per QALY gained in the Chilcott et al. Trent Report**

<table>
<thead>
<tr>
<th>Time horizon</th>
<th>Cost per QALY gained</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month</td>
<td>£99,000</td>
</tr>
<tr>
<td>1 year</td>
<td>£8300</td>
</tr>
<tr>
<td>2 years</td>
<td>£5200</td>
</tr>
<tr>
<td>5 years</td>
<td>£3200</td>
</tr>
</tbody>
</table>

QALY, quality-adjusted life-year.
Assessment of cost-effectiveness

perspective. Costs included the cost of supplies and the rental and maintenance costs of the nCPAP device and associated devices (e.g. tubing and masks). It was estimated that the yearly cost of treating a patient in Quebec was CAN$2,348 (price year not given). Costs also included the cost of one overnight sleep study at the outset of treatment at CAN$500, which included physician fees, technician salaries, supplies and amortisation of capital costs over 7 years. Alternatively, an ongoing cost of treatment per patient per year was estimated at CAN$800.

Summary of cost-effectiveness
Based on the use of the different cost estimates (above) a high estimate of CAN$9,792 per QALY gained by nCPAP was calculated as well as a low estimate of CAN$3,397 per QALY gained. Three patients had particularly large treatment effects. The authors explored the impact of excluding the three patients on the cost–utility ratio. Without the three patients, based on the high cost estimate, the cost–utility ratio increased to CAN$18,637 per QALY.

Comments on Tousignant et al.124
As all the patients were currently receiving nCPAP therapy, their valuation of the pre-treatment health state was done retrospectively. Given this, it is difficult to ascertain the extent to which the difference in pre-treatment and treatment utility scores is a real difference reflecting the impact of nCPAP treatment and the extent to which it reflects some sort of measurement error due to bias in recall. In addition, the results may be unreliable due to the weaknesses associated with observational data. It appears that costs (and effects) were not discounted to present values. For the most part, resource use estimates were reported separately from costs. Only the impact of treatment effects over the short term was considered. The analysis was deterministic.

Discussion of manufacturers’ submissions and published cost-effectiveness studies
Of the studies reviewed, none compared all therapies identified in the NICE scope, i.e. none compared CPAP with dental devices and conservative management. The NICE Reference Case states that costs included in the economic evaluation should be based on the NHS and PSS perspective. Only two studies (ResMed120 and Chilcott et al.,14) examined the treatment of OSAHS in the UK NHS context, the others focusing on the US,122 Spanish123 and Canadian124 health-care systems.

The existing cost-effectiveness studies had several limitations that need to be addressed in order to assess the value for money of these technologies. The key limitations were:

- The cost-effectiveness studies did not use the full range of clinical trial evidence for estimating the impact of treatment on daytime sleepiness, blood pressure, HRQoL and other relevant outcomes.
- There was a lack of trial-based evidence to compare the utility associated with different treatments for OSAHS.
- There were limited data (in terms of quantity and quality) on the long-term impact of OSAHS on HRQoL, CVE, RTAs and other outcomes.
- None of the evaluations examined all the comparators relevant to this review.

In an attempt to make full use of all of the available evidence on therapies for the treatment of OSAHS and in order to overcome some of the limitations noted above, a new cost-effectiveness model was developed.

York economic model
The objective of the York economic assessment was to assess the cost-effectiveness of CPAP by developing a clinically and economically appropriate decision model structured to characterise OSAHS and the impact of the different therapies. Several sources of evidence were used to inform the analysis. The model was developed using the methodological guidance for the NICE Reference Case (www.nice.org) as reported in Table 25. The development of the model was informed by research in the published literature including the clinical effectiveness systematic review reported in Chapter 3, published cost-effectiveness analyses, previously performed economic models and the advice of clinical experts participating in this technology assessment review. The methods used for decision modelling are based on those described in Briggs et al.150

The new economic evaluation, undertaken by a team in York (and termed the York economic model from now on), is described in two parts. First, the methods used to perform the economic analysis are described; these comprise the structure of the model, the parameter estimates including a brief summary of the literature searches undertaken to inform the model, and the assumptions underlying the base-case analysis.
Second, the results of the base-case analysis are presented and the role of parameter uncertainty is investigated by means of a probabilistic sensitivity analysis.

**Methods of York economic model**

**Overview**

A cost–utility analysis was undertaken that compared CPAP with use of dental devices and conservative management, using comparators relevant to the NHS. The scope developed by NICE indicated that CPAP devices should be treated as a single class of intervention, and this was reflected in the modelling. However, in the secondary analysis, various adjuncts to CPAP, e.g. the use of a humidifier, were examined to assess their impact on the costs associated with CPAP. The costs and QALYs associated with CPAP, dental devices and conservative management were compared over a lifetime time horizon as OSAHS is a chronic condition. The cost of the resource use associated with each intervention was estimated from the NHS and PSS perspective for England and Wales. Costs relating to the financial year 2005 were reported.

The health effects of OSAHS, and the impacts of alternative treatments, were expressed in terms of QALYs. Given the dearth of HRQoL data expressed in terms of utility in the randomised trials (see Chapter 3), it was necessary to estimate the relationships between clinical end points and QALYs using other data. Three clinical end points were related to QALYs. The first was difference in ESS between treatments; ESS was taken as the main measure of sleepiness given that it was reported in most trials, and in many it was the primary end point (see Chapter 3). The second clinical end point was differential treatment effect on blood pressure, which was reported in trials, and was related to CVE risks and hence to QALYs in the model. The third end point was differences in the risk of RTAs, which was based on non-randomised evidence and was related to QALYs in the model.

HRQoL in terms of utilities was expressed on the basis of generic HRQoL instruments, the EQ-5D and the SF-6D (a preference-based single-index measure for health, based on SF-36 and SF-12, allowing QALYs to be obtained for use in cost–utility analysis), and valued using the public preferences associated with those instruments. An annual discount rate of 3.5% was applied to costs and benefits to discount them to present values. The assumed target patient population is adults (16 years or older) with a diagnosis of OSAHS confirmed by use of an appropriate tool (e.g. the AHI or arterial oxygen desaturation index and the ESS). The model was run separately by age and

---

**TABLE 25** Summary of NICE Reference Case

<table>
<thead>
<tr>
<th>Element of health technology assessment</th>
<th>Reference case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defining the decision problem</td>
<td>Scope developed by the Institute</td>
</tr>
<tr>
<td>Comparator</td>
<td>Alternative therapies routinely used in the NHS</td>
</tr>
<tr>
<td>Perspective on costs</td>
<td>NHS and PSS</td>
</tr>
<tr>
<td>Perspective on outcomes</td>
<td>All health effects on individuals</td>
</tr>
<tr>
<td>Types of economic evaluation</td>
<td>Cost-effectiveness analysis</td>
</tr>
<tr>
<td>Synthesis of evidence on outcomes</td>
<td>Based on a systematic review</td>
</tr>
<tr>
<td>Measure of health benefits</td>
<td>QALYs</td>
</tr>
<tr>
<td>Description of health states for calculation of QALYs</td>
<td>Health states described using a standardised and validated generic instrument</td>
</tr>
<tr>
<td>Methods of preference elicitation for health state valuation</td>
<td>Choice-based method, e.g. time trade-off, standard gamble (not rating scale)</td>
</tr>
<tr>
<td>Source of preference data</td>
<td>Representative sample of the public</td>
</tr>
<tr>
<td>Discount rate</td>
<td>Annual rate of 3.5% on both costs and health effects</td>
</tr>
<tr>
<td>Equity provision</td>
<td>An additional QALY has the same weight regardless of the other characteristics of the individuals receiving the health benefit</td>
</tr>
</tbody>
</table>

NICE, National Institute for Health and Clinical Excellence; PSS, Personal Social Services; QALYs, quality-adjusted life-years.
sex, given the availability of age- and sex-specific mortality data and CVE risks. The base-case analysis is based on a male aged 50, as the average age of patients in the RCTs was around 50 [at baseline the mean age range was 44–58 years (see Chapter 3)] and the majority of participants in the included RCT studies were male.

The following analyses were undertaken to explore the robustness of the findings in the York economic model.

**Base-case analysis**

- The base-case analysis compared the costs and QALYs of CPAP versus dental devices versus conservative management in a male aged 50 years.
- Subgroup analyses were undertaken by gender, OSAHS severity (as measured by ESS) and other relevant baseline patient characteristics.

**Secondary analysis**

- Scenario analyses undertaken to explore the impact on cost-effectiveness of:
  - excluding the impact of treatment on CVE
  - excluding the impact of treatment on RTAs
  - excluding the impact of treatment on both CVE and RTAs
  - change in ESS linked to SF-6D utility score rather than EQ-5D
  - relative risk reduction for CVE based on DBP and MacMahon et al.\(^{145}\)
  - autotitrating positive airway pressure (APAP) machine with 5-year life span and humidifier
  - treatment effects from bivariate random-effects meta-analysis (BRMA) (APBM only)
  - treatment effects from BRMA (APBM and office measurements).
- Subgroup analyses
  - for a cohort aged (35 and 65).
- Other relevant modelling assumptions.
- Uncertainty and value of information analysis.

The York economic model is fully probabilistic and the results from the model are presented probabilistically to reflect the implications of parameter uncertainty on decision uncertainty.

To inform research priorities, the expected value of perfect information (EVPI) was calculated for the decision problem.\(^{150}\) This represents the value of obtaining perfect information on all the model parameters to eliminate the decision uncertainty (given acceptance of the model structure and evidence base). The EVPI can be compared with the potential costs of additional research to indicate whether there is value in further research to reduce the decision uncertainty.

**Structure of the York economic model**

A Markov state transition cohort model was developed in Microsoft\textsuperscript{®} Excel 2002 and the Bayesian evidence synthesis was undertaken using WinBUGS 1.4 (the WinBUGS code is reported in Appendix 8). The structure of the model is shown in Figure 20. The model characterises the patient’s prognosis over his or her lifetime in terms of four health states: (1) OSAHS; (2) OSAHS post coronary heart disease (CHD); (3) OSAHS post stroke; and (4) death. Yearly cycles were chosen for the current model. The model records the ESS score of the hypothetical patient cohort and any change in ESS associated with treatment. As described in Chapter 3, the evidence suggests that interventions for OSAHS might have a beneficial effect on sleepiness, which may in turn affect the risk of RTAs. The trial data also describe the effect of treatment on blood pressure, which may in turn affect the incidence of CHD and stroke. Therefore, these events are included in the model. Based on the model structure, patients can remain in the initial OSAHS state until death. Alternatively, they could experience CHD, and those that survive move to an OSAHS post-CHD state that incorporates the increased mortality and morbidity associated with having had a first CHD event. They could then remain in this state until death, experience an RTA or have a stroke that may render them disabled.

Alternatively, they could experience a stroke from the initial OSAHS health state. Patients who survive a stroke enter an OSAHS post-stroke health state which incorporates the increased mortality and morbidity associated with having had a first stroke. Patients who are not disabled remain at risk of an RTA. In contrast, if they become disabled post stroke, it is assumed that they are no longer able to drive and therefore incur no further risk of a driving accident. Once in the OSAHS post-stroke health state it is assumed that they will remain in this health state until death, which could happen directly or following an RTA. The model does not record CHD events separately following a stroke.

Patients in the initial OSAHS state might at some point have an RTA which could be fatal or non-fatal. In the latter case they would return to the OSAHS state.
Parameter estimates for inclusion in the York economic model

This section reports the methods used to estimate parameters for the base-case analysis and secondary analyses. It describes the approach used to estimate the utility, resource use and costs associated with CPAP, dental devices and conservative management in the treatment of OSAHS.

The evidence used to populate the parameters of the economic model comprises the RCT data reviewed in Chapter 3 as well as relevant evidence from non-randomised trials, modelling studies, analyses of administrative databases and expert clinical opinion. In addition, individual patient data from three trials were obtained from the clinical experts on this technology assessment (RJOD/JS).

Several searches were undertaken to populate specific parameters of the economic model. Searches in MEDLINE were conducted to identify data to inform three elements of the model: (1) HRQoL studies, utilities and QALYs; (2) literature linking CVE, particularly stroke and CHD, to OSAHS; and (3) literature linking RTAs to OSAHS. The search strategies are presented in Appendix 1, Cost-effectiveness searches.

Utility estimation for inclusion in the York economic model

As reviewed in Chapter 3, the evidence base on the effectiveness of CPAP in OSAHS consists of a number of randomised trials of varying designs (crossover and parallel), which display heterogeneity in their inclusion criteria and which report a considerable range of outcome measures covering sleepiness, HRQoL and blood pressure. Analysis was required to link the short-term outcome measures of clinical effectiveness to a preference-based measure of HRQoL in terms of utilities. The randomised trial data provided evidence on what can be viewed as intermediary outcomes in terms of sleepiness and blood pressure, but did not measure either treatment effects in terms of a reduction in the number of CVEs or a reduction in the risk of RTAs. Therefore, a model was required to link the available clinical data to long-term outcomes, HRQoL and costs in order to estimate the long-term cost-effectiveness of treatment with CPAP.
Valuing clinical effectiveness in terms of utility

The NICE Reference Case indicates that the measure of health outcome used in the cost-effectiveness analysis should be QALYs calculated with utility values derived from a validated generic, preference-based measure of HRQoL. The systematic review reported in Chapter 3 highlighted the measures used to describe the efficacy of treatments for OSAHS in RCTs, among which the ESS was the most frequently reported \( (n = 27 \text{ trials}) \). Utility values and quality-adjusted survival were infrequently reported \( (n = 1 \text{ trial comparing CPAP to placebo}) \) (Chakravorty et al.\(^9^7\)). Therefore, an additional literature search was undertaken, and this identified four other papers that contained potentially relevant HRQoL/utility data for inclusion in the model.

Table 26 reports key information on the four studies (see Appendix 7 for more details). Jenkinson et al.\(^{152}\) and Chakrovarty et al.\(^{97}\) also reported pre- and post-ESS scores. The former reported a pre-treatment ESS of 14 (SD 5) and a post-treatment score of 8.2 (SD 4.8). In a CPAP treatment arm, Chakrovarty et al.\(^{97}\) reported a pre-treatment ESS of 16 (SD 6) and a post-treatment score of 8 (SD 6). In the lifestyle arm, Chakrovarty et al.\(^{97}\) reported a pre-treatment ESS of 14 (SD 4) and a post-treatment score of 11 (SD 5). Note that none of the studies reporting utility data assessed the use of dental devices.

In order to use the trial data and to allow a comparison between CPAP and dental devices, there was a need to link the data on clinical efficacy, in the form of the disease-specific ESS, to utility. Data on mean difference in ESS were available for 23 studies comparing CPAP with placebo and six studies comparing CPAP with dental devices. To achieve the link between change in ESS and change in utility, three sets of individual patient data were obtained, two that measured ESS and SF-36 profile in the same patients\(^8^7,^{151}\) and one that measured ESS, SF-36 profile and EQ-5D in the same patients.\(^{144}\) The SF-36 data were used to calculate utility values based on the SF-6D, using an algorithm developed by Brazier et al.\(^{153}\) based on UK public preferences. The EQ-5D data were used to calculate utility based on general UK

### Table 26 Summary of studies reporting utility data

<table>
<thead>
<tr>
<th>Authors</th>
<th>Method</th>
<th>Study design</th>
<th>Utility values [mean (SD)]</th>
<th>Source of values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tousignant et al., 1994(^{124})</td>
<td>SG</td>
<td>Retrospective before and after study. Patients did SG exercise twice (2–3 weeks apart) to assess reliability. Health states valued were: receiving nCPAP treatment and pre-treatment</td>
<td>Pre-treatment health state = 0.63 (0.29); nCPAP treatment health state = 0.87 (0.17)</td>
<td>Patients attending hospital sleep clinic who had been receiving nCPAP (for around 9 months) ( (n = 19) )</td>
</tr>
<tr>
<td>Jenkinson et al., 1997(^{152})</td>
<td>EQ-5D</td>
<td>Before and after study. Patients completed EQ-5D before commencing treatment with nCPAP and 5 weeks later</td>
<td>Baseline EQ-5D index = 0.79 (0.21); post-treatment EQ-5D index = 0.84 (0.25)</td>
<td>Patients attending sleep clinic for nCPAP therapy ( (n = 108) )</td>
</tr>
<tr>
<td>Chakravorty et al., 2002(^{97})</td>
<td>EQ-5D, SG</td>
<td>RCT comparing 3 months’ treatment with CPAP with lifestyle management. EQ-5D and SG were completed before randomisation and at 3 months. In SG patients were asked whether they would choose their current state of health or treatment with two potential outcomes: complete cure or failure leading to a worst health state/death</td>
<td>CPAP group: SG pre-treatment = 0.32 (0.17); SG post-treatment = 0.55 (0.26); EQ-5D index pre-treatment = 0.73 (0.18); EQ-5D index post-treatment = 0.77 (0.18)</td>
<td>Patients referred to hospital sleep clinic ( (n = 71) )</td>
</tr>
<tr>
<td>Mar et al., 2003(^{123})</td>
<td>EQ-5D</td>
<td>Before and after study. Patients completed EQ-5D pre-treatment and after using nCPAP for 3 months</td>
<td>Baseline EQ-5D index = 0.74; post-treatment EQ-5D index = 0.81</td>
<td>Patients referred to sleep unit ( (n = 46) )</td>
</tr>
</tbody>
</table>

EQ-5D, EuroQol-5 Dimensions; nCPAP, nasal continuous positive airway pressure; SG, standard gamble.
population tariff values. The three data sets were then used to develop prediction models to estimate the relationship between ESS and (1) utility values based on SF-6D and (2) utility scores based on EQ-5D.

A simple linear regression model was fitted to predict absolute utility scores from absolute ESS, controlling for baseline utility and baseline ESS. A larger number of observations were available with the SF-6D in comparison with the EQ-5D and, where multiple observations were available on the same patient, analyses were adjusted to reflect the dependence between repeated observations on the same individual. All variables were treated as continuous data, and baseline scores were centred prior to estimation. The use of ordinary least squares (OLS) regression relies on the assumption that the error terms are normally distributed. Assessment of the residuals estimated in both regressions revealed that this assumption appeared reasonable for utility scores based on the SF-6D (Figure 21). However, typically, EQ-5D scores do not follow a normal distribution, and as expected the EQ-5D scores in the data set formed a distribution skewed to the left, with a large number of observations clustered at a score of 1. Figure 21 shows that the residuals from the regression of EQ-5D scores on ESS deviate somewhat from a normal distribution. Although OLS regression methods have been found to perform well when predicting EQ-5D scores, a generalised linear model was also fitted to the data to ascertain whether an alternative error distribution such as a gamma might produce a better fit. However, this model did not improve the fit on the basis of the Akaike Information Criterion and so the results from the OLS model were used for both the EQ-5D and the SF-6D.

The results of the regression analyses are shown in Tables 27 and 28. The models indicate that an increase of 1 point in ESS is associated with a fall in utility of 0.01 and this is true for both the SF-6D and EQ-5D instruments, the results of which were remarkably similar. A test was performed to see if there was evidence for a change in relationship between different levels of baseline ESS (i.e. a change in the slope of the regression line for particular cut-off values of ESS) but there was no evidence to support such a subgroup effect.

The Cholesky decomposition of the covariance matrix from the regressions was employed to characterise the uncertainty around the estimated coefficients and to reflect the correlation between coefficients in the probabilistic sensitivity analysis. The baseline utility for the hypothetical patient population was predicted from the specified baseline ESS score. Changes in ESS associated with treatment were converted to changes in utility.

![FIGURE 21 Standardised normal plot of residuals for use in York economic model.](image-url)
Assessment of cost-effectiveness

### TABLE 27 Predicting utility scores from ESS for use in York economic model

<table>
<thead>
<tr>
<th>Utility</th>
<th>Coefficient</th>
<th>SE</th>
<th>p-Value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OLS model for utility based on SF-6D</strong> (n = 294)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESS</td>
<td>-0.0095213</td>
<td>0.0013849</td>
<td>0.000</td>
<td>-0.0122512 –0.0067915</td>
</tr>
<tr>
<td>Baseline ESS</td>
<td>0.0050331</td>
<td>0.0011942</td>
<td>0.000</td>
<td>0.0026791 0.0073871</td>
</tr>
<tr>
<td>Baseline utility</td>
<td>0.5588972</td>
<td>0.0534972</td>
<td>0.000</td>
<td>0.4534455 0.6643489</td>
</tr>
<tr>
<td>Constant</td>
<td>0.8067555</td>
<td>0.0115013</td>
<td>0.000</td>
<td>0.7840845 0.8294265</td>
</tr>
<tr>
<td><strong>OLS model for utility based on EQ-5D</strong> (n = 94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESS</td>
<td>-0.0096984</td>
<td>0.003947</td>
<td>0.016</td>
<td>-0.0175364 –0.0018604</td>
</tr>
<tr>
<td>Baseline ESS</td>
<td>0.0029526</td>
<td>0.0033693</td>
<td>0.383</td>
<td>-0.0037382 0.0096435</td>
</tr>
<tr>
<td>Baseline utility</td>
<td>0.6287684</td>
<td>0.1346153</td>
<td>0.000</td>
<td>0.3614492 0.8960877</td>
</tr>
<tr>
<td>Constant</td>
<td>0.8925207</td>
<td>0.0286109</td>
<td>0.000</td>
<td>0.8357052 0.9493363</td>
</tr>
</tbody>
</table>

ESS, Epworth Sleepiness Scale; OLS, ordinary least squares; SF-6D, a preference-based single-index measure for health, based on SF-36 and SF-12, allowing QALYs to be obtained for use in cost-utility analysis.

(utility increments) using the predicted relationship between ESS and utility.

The utility decrements associated with stroke, CHD and age were based on the regression analysis reported by Sullivan et al. and are reported in Table 28. Utility decrements and increments can be applied to the baseline utility of the hypothetical cohort to reflect the utility associated with being in any health state in the model. The EQ-5D scores used in the analysis by Sullivan et al. were calculated using US community preferences. However, equivalent decrements were not available based on UK community preferences. The uncertainty around the utility decrements was characterised using a normal distribution, as the utility decrements are described by the coefficients from a regression analysis. The standard errors are small enough that there is no risk of unsuitable values being selected in the probabilistic analysis.

The utility associated with experiencing an RTA was based on EQ-5D measures from the Health Outcomes Data Repository (HODaR). HODaR recorded EQ-5D data for individuals 6 weeks after their inpatient episode (at Cardiff Hospital, UK) for injuries sustained from an RTA. Data were extracted for all patients who had a traffic accident as a motorcycle rider, an occupant of a three-wheeled motor vehicle, a car occupant or an occupant of a pick-up truck or a van. Results were found for 56 patients. A gamma distribution was used to characterise

### TABLE 28 Utility scores for use in the York economic model

<table>
<thead>
<tr>
<th>Utility</th>
<th>Mean</th>
<th>SD</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSAHS untreated (baseline)</td>
<td>Baseline ESS $\times (-0.01 + 0.89)^a$</td>
<td></td>
<td>Estimated from prediction equation (see Table 27)</td>
</tr>
<tr>
<td>OSAHS treated with CPAP (change from baseline)</td>
<td>MD_ESS$_{CPAP CM} \times -0.01$</td>
<td></td>
<td>Estimated from prediction equation (see Table 27)</td>
</tr>
<tr>
<td>OSAHS treated with dental devices (change from baseline)</td>
<td>MD_ESS$_{DD CM} \times -0.01$</td>
<td></td>
<td>Estimated from prediction equation (see Table 27)</td>
</tr>
<tr>
<td>Stroke (absolute decrement)</td>
<td>-0.0524</td>
<td>0.0002</td>
<td>Sullivan and Ghushchyan, 2006$^{155}$</td>
</tr>
<tr>
<td>CHD (absolute decrement)</td>
<td>-0.0635</td>
<td>0.0001</td>
<td>Sullivan and Ghushchyan, 2006$^{155}$</td>
</tr>
<tr>
<td>RTA (absolute utility)</td>
<td>0.62</td>
<td>0.27</td>
<td>Currie et al., 2005$^{156}$</td>
</tr>
<tr>
<td>Age decrement (per year)</td>
<td>-0.0007</td>
<td>0</td>
<td>Sullivan and Ghushchyan, 2006$^{155}$</td>
</tr>
</tbody>
</table>

CM, conservative management; CHD, coronary heart disease; DD, dental device; ESS, Epworth Sleepiness Scale; MD_ESS, mean difference in ESS; OSAHS, obstructive sleep apnoea–hypopnoea syndrome; RTA, road traffic accident.

$^a$ When using equation based on EQ-5D.
the uncertainty around the utility decrements associated with clinical events.

For the base-case analysis the effect of treatment on ESS was derived by pooling all of the available trial data to obtain an overall effect. However, in Chapter 3 it was noted that there was a high level of heterogeneity in this overall analysis that was reduced when trials were grouped by baseline severity of OSAHS. The treatment effects estimated by pooling trials grouped according to average baseline ESS (mild, moderate or severe) were applied in three separate analyses (see Chapter 3, Figure 2). These analyses cannot be interpreted as subgroup analyses reflecting differential treatment effects according to OSAHS severity as they are based on a study-level covariate in the form of average baseline ESS. In order to conduct a true subgroup analysis, trial data would have to be available that estimated the relationship at the patient level between baseline ESS and change in ESS with treatment.

**Linking reduction in blood pressure to cardiovascular events**

As noted above, the randomised trials provided information on the effect of CPAP on blood pressure but, for the economic model, the implications of this treatment effect for clinical events need to be estimated. The Framingham risk equations provide a link between risk factors such as blood pressure and the incidence of fatal and non-fatal CVEs. Published risk equations predict the risk of CHD and stroke over a range of 4–12 years as a function of either SBP or DBP. Anderson et al. state that, of the two alternative measures, SBP was the best predictor of stroke, and therefore this was selected as the measure of blood pressure to be included in the economic model. We did not identify corresponding risk equations that incorporated MAP. The risk equations were estimated separately for men and women using the baseline characteristics of the hypothetical patient population shown in Table 29, which were determined from the RCT data where possible and based on plausible assumptions otherwise. It was also possible to incorporate the increased baseline risk associated with high BMI using the relative risk published by Mora et al. However, as none of the relevant comparators demonstrated efficacy in terms of weight loss and reducing BMI, this was not included in the analysis.

It was assumed that the only risk factor affected by use of CPAP was blood pressure. The Framingham risk equations are based on Weibull models, and so the predicted risk is non-linear with respect to each risk factor. To determine whether the use of the mean change in blood pressure would bias the results, a check was performed on a set of individual patient data that reported change in blood pressure. The risk of CHD and stroke was predicted for each patient individually, and the mean of the individual predicted risks was compared with the risk based on the mean change in blood pressure for the whole group. The risks were found to be identical to two decimal places, and so it was felt that, although the equations are non-linear, the use of the mean change would not bias the model results.

In order to estimate the probability of CHD and stroke events per model cycle, a piece-wise exponential was assumed. The equations were used

| TABLE 29 Hypothetical baseline patient characteristics for use in the risk equations of the York economic model |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age 50          | SBP 130         | Smoking (0 = no; 1 = yes) 1 | Total cholesterol (mg/dl) 224 | HDL-cholesterol (mg/dl) 43 |
| Diabetes (0 = no; 1 = yes) 1 | ECG-LVH (0 = no; 1 = yes) 0 | Ten-year probability of stroke event 3.4% (male); 3.7% (female) | Ten-year probability of death from CVD 3.8% (male); 3.6% (female) |
| Ten-year probability of death from CVD 19.7% (male); 19.2% (female) | Ten-year probability of death from CHD 3.9% (male); 3.7% (female) |

CHD, coronary heart disease; CVD, cardiovascular disease; ECG-LVH, electrocardiographic left ventricular hypertrophy; HDL, high-density lipoprotein; SBP, systolic blood pressure.
to predict the 4-year probability of an event every 4 years given the current age of the hypothetical patient cohort and starting from year 0. For the intervening years it was assumed that survival followed an exponential distribution, and so each 4-year probability was converted into a constant yearly probability to be applied over the relevant 4-year interval. When multiple equations from the Framingham set are used they should be applied in random order to take into account competing risks. However, in a cohort model structure the risk equations must be applied in the same order across the entire cohort for any given model cycle. This is relevant to patients in the initial state of the model who may experience either CHD or a stroke event. Rather than specify an order in which to apply the equations, the probability of any event was calculated by summing the hazards and then the proportion of events that were CHD or stroke events was calculated.

The relative risk reduction for CVE implied by the difference in SBP with CPAP compared with usual care is estimated to be relatively low using the Framingham risk equations (RR = 0.96 for CHD and RR = 0.94 for stroke given a mean reduction in DBP of 1.20 mmHg).

**Evidence synthesis on change in ESS and SBP**

The model incorporates data on the effectiveness of treatments for OSAHS in terms of change in ESS and change in SBP. The use of a BRMA allows the incorporation of the between- and within-study correlation in the treatment effect in these two end points. The between-study correlation is estimated in the meta-analysis on the basis of those studies that report both outcomes. However, none of the studies provided an estimate of the within-study correlation between the mean change in ESS and the mean change in SBP. As it was felt that these treatment effects might be correlated, a set of patient-level data were obtained from which an informative prior distribution for the within-study correlation could be estimated. Note that the assumption in the BRMA is that treatment effects on different outcomes may be correlated, and not that measures of ESS and blood pressure might themselves be correlated. The meta-analysis was performed in WinBUGS, and the code and data appear in Appendix 8.

The results of the BRMA are shown in Table 30. The estimate for the mean change in ESS is similar to that reported in Chapter 3. This is not surprising given the relatively small number of data points that inform this estimate. However, the estimate for the mean change in blood pressure differs somewhat from that reported in Chapter 3. This is because the BRMA in essence imputes the missing SBP for the 19 studies that did not report that end point on the basis of the observed between-study correlation. Only four trials reported both ESS and daytime SBP based on ABPM. This provides limited data to inform the estimation of the parameters of the BRMA relating to between-study correlation. For this reason the mean changes estimated in separate univariate meta-analyses in Chapter 3 were applied in the base-case analysis, and these were used regardless of whether the differences were statistically significant. The estimates from the BRMA were applied in a sensitivity analysis. Three additional trials reported both ESS and daytime SBP based on office measurements. While the absolute SBP recorded by ABPM may be expected to differ from that recorded by an office-
based measure, it could be argued that the changes in SBP may be comparable. If this assumption is acceptable, then a BRMA could be estimated based on seven trials that report both outcome measures, as shown in Table 30.

No trials reported change in daytime SBP based on ABPM for the comparison of CPAP with dental devices. For the base-case analysis, it was assumed that the ratio of the treatment effects on daytime SBP for CPAP and dental devices compared with placebo would be equal to the ratio of the observed treatment effects on ESS. The mean differences in ESS for CPAP versus conservative management (MD_ESS_{CPAP,CM}) and for CPAP versus dental devices (MD_ESS_{CPAP,DD}) were reported in Chapter 3. The mean difference in ESS for dental devices versus conservative management (MD_ESS_{DD,CM}) was calculated from this information using standard methods for an indirect comparison (MD_ESS_{DD,CM} = MD_ESS_{CPAP,CM} – MD_ESS_{CPAP,DD}) (Bucher et al.161). The mean difference in SBP for dental devices compared with conservative management was therefore calculated as MD_SBP_{DD,CM} = MD_SBP_{CPAP,CM} \times (MD_ESS_{DD,CM}/MD_ESS_{CPAP,CM}).

Where parameters were estimated in WinBUGS, the output from 10,000 Monte Carlo iterations was used directly to characterise the uncertainty around the estimated treatment effects and to incorporate the correlation between outcomes. The uncertainty around treatment effects estimated in the meta-analysis reported in Chapter 3 was characterised using a normal distribution.

### Estimating the treatment effect of interventions on RTAs

To estimate the impact of CPAP on RTAs, the meta-analysis of before and after studies undertaken by Ayas et al.122 was updated (see Table 21). Only one additional study was found (Barbé et al.162). Because this study reported a relative risk rather than an odds ratio (as in the Ayas et al. paper122), the data reported on events and non-events were used to (re)calculate an odds ratio. The log odds ratios were then pooled by means of inverse variance weighting. The separate and pooled odds ratios are reported in Table 31. Note that, although the relative risk reduction of experiencing an RTA with CPAP treatment is high, the absolute baseline risk is very low.

The literature search did not identify any studies that assessed the impact of treatment with dental devices on RTAs. For the base-case analysis an adjusted odds ratio for dental devices compared with conservative management was estimated by applying the ratio of the treatment effects on ESS for CPAP and dental devices versus conservative management to the odds ratio for RTAs for CPAP versus conservative management.

It was assumed that patients left disabled following a first stroke event would no longer be at risk of an RTA. For the base-case analysis the proportion of first strokes that were disabling was estimated to be 30.9% based on the Second European Stroke Prevention Study (ESPS-2).163 Note that the base-case analysis applies to patients who hold a driving

<table>
<thead>
<tr>
<th>Measure</th>
<th>ESS [MD (SD)]</th>
<th>SBP [MD (SD)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRMA incorporating trials that report SBP based on ABPM</td>
<td>–2.65 (0.43)</td>
<td>–1.64 (1.72)</td>
</tr>
<tr>
<td>BRMA incorporating trials that report SBP based on ABPM or office measures</td>
<td>–2.62 (0.43)</td>
<td>–3.69 (1.55)</td>
</tr>
</tbody>
</table>

ABPM, ambulatory blood pressure monitoring; BRMA, bivariate random-effects meta-analysis; ESS, Epworth Sleepiness Scale; SBP, systolic blood pressure.

### Table 31  Meta-analysis to calculate the RTA rates with CPAP compared with those without CPAP

<table>
<thead>
<tr>
<th>Source</th>
<th>Odds ratio</th>
<th>Variance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ayas et al., 2006122 (based on eight studies)</td>
<td>0.15</td>
<td>0.00094</td>
</tr>
<tr>
<td>Barbé et al., 2007162 (single study)</td>
<td>0.33</td>
<td>0.02075</td>
</tr>
<tr>
<td>Pooled data Ayas et al., 2006122 and Barbé et al., 2007162</td>
<td>0.17</td>
<td>0.00098</td>
</tr>
</tbody>
</table>

RTA, road traffic accident.

© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Assessment of cost-effectiveness

In summary, Table 32 shows the treatment effects used to populate the York economic model.

Compliance
The long-term compliance with CPAP will have implications for the estimated effectiveness in the target population. The majority of the trial data were based on less than 12 weeks’ follow-up. Given this, long-term compliance with CPAP was estimated on the basis of observational data provided by McArdle et al.39 This study reported compliance over 6 years in a cohort of Scottish patients with a median age of 50 and an average ESS score at baseline of 12. The results indicated that 84% of patients continued to use CPAP 1 year after initiation of treatment, and that compliance was steady after a period of 4 years, with 68% of patients continuing treatment. The percentage of patients compliant at 2 and 3 years after treatment initiation was read from the survival curve (74% and 73% respectively) and these data were then used to model the rate of discontinuation from years 1 to 4 in the model. Patients discontinuing treatment were assumed to return immediately to the levels of ESS, SBP and utility associated with no treatment. In the base-case analysis it was assumed that 90% of patients who discontinued treatment with CPAP would return their machine. Equivalent data were not available for dental devices, and so in the base-case analysis it was assumed that compliance with dental devices was equivalent to that for CPAP.

Mortality rates
Table 33 reports the parameters associated with CHD, stroke and RTAs.

The mortality rate for individuals who have not experienced CHD or stroke (by age and sex) was taken from the UK life tables of the Government Actuary Department (www.gad.gov.uk). For each age band, the all-cause hazard was reduced by the proportion of people dying of cardiovascular disease (CVD) or ischaemic heart disease (IHD) causes to get the hazard of death for non-CVD or non-IHD causes using methods developed by Chiang.168 For patients who experienced CHD or stroke, an elevated mortality rate was used based on relative risks from the literature. For patients who experienced CHD and stroke, relative risks of death of 3.2165 and 2.3,164 respectively, were employed. These relative risks were applied to the non-cardiovascular/ischaemic heart disease mortality rates in the UK population (by age and sex).

Resource use and cost estimation for the York economic model
The costs of the three interventions for OSAHS included the initial costs of the interventions as well as the ongoing costs of care associated with the interventions. The costs included the cost of the devices, staff time and overheads associated with providing the interventions and the cost of other NHS health care and PSS related to OSAHS. Costs were reported in prices relating to 2005 and any

### TABLE 32 Treatment effects used to populate the York economic model

<table>
<thead>
<tr>
<th></th>
<th>CPAP vs CM (mean (SD))</th>
<th>CPAP vs DD (mean (SD))</th>
<th>DD vs CM (mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESS (mean difference)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>−2.7 (0.38)</td>
<td>−0.85 (0.64)</td>
<td>−1.85b</td>
</tr>
<tr>
<td>Mild baseline severity (ESS)</td>
<td>−1.07 (0.39)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Moderate</td>
<td>−2.33 (0.36)</td>
<td>−0.85 (0.64)</td>
<td>−1.48b</td>
</tr>
<tr>
<td>Severe</td>
<td>−4.99 (0.76)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Blood pressure (mean difference)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP</td>
<td>−1.06 (1.17)</td>
<td>NA</td>
<td>−0.73b</td>
</tr>
<tr>
<td>DBP</td>
<td>−1.20 (0.88)</td>
<td>NA</td>
<td>−0.82b</td>
</tr>
<tr>
<td>RTA (odds ratio)b</td>
<td>0.17 (0.001)</td>
<td>NA</td>
<td>0.25</td>
</tr>
</tbody>
</table>

CM, conservative management; DBP, diastolic blood pressure; DD, dental device; ESS, Epworth Sleepiness Scale; NA, not applicable; RTA, road traffic accident; SBP, systolic blood pressure.

a Base-case analysis.
b Derived parameter.
The review of the published cost-effectiveness studies identified limited information on resource use associated with CPAP treatment. Only one study related to the UK setting.\textsuperscript{44} This study included the costs of investigation and diagnosis for OSAHS and nCPAP. In contrast, the York model includes adults who have already been diagnosed with OSAHS and therefore does not incorporate this cost. The current study attempts to take into account the impact of treatment in terms of the utilisation of other health-care resources comprising any health-care use due to stroke, CHD and RTAs. None of the existing published cost-effectiveness studies included the full range of relevant costs and none compared dental devices with CPAP for OSAHS in the UK.

The costs of CPAP, dental devices and conservative management used in the York economic model are shown in Table 34.\textsuperscript{165} The majority of CPAP costs and resource use were obtained from the ResMed submission, which was informed by a survey of 19 clinical experts. Other relevant data were obtained from published studies and from correspondence with clinical experts. It was assumed that the CPAP machine has a device life of 7 years (which was the device life used by ResMed and confirmed by a clinical expert) and that a dental device lasts for 2 years (based on clinical opinion). The costs of the devices were expressed as equivalent annual costs\textsuperscript{121} using the public sector discount rate of 3.5%.

No published NHS cost of dental devices for the treatment of OSAHS was found; therefore, to fulfil the scope of the review, the cost was estimated based on clinical opinion. It was assumed that the dentist provided a Thornton Adjustable Positioner (TAP), a device that is commonly used for the treatment of OSAHS in the UK. Under the new NHS Dental Contract a course of treatment is classified into a treatment band. It is appropriate to classify TAP provision as Band 3 as such treatment requires laboratory work (www.ic.nhs.uk/). Twelve units of dental activity (UDAs) are applied to Band 3.\textsuperscript{167} The national average reimbursement rate for a UDA is not known. The value of UDAs varies because of a number of factors, including the contract values negotiated locally by primary care trusts (PCTs), differences in the treatment patterns, treatment needs in different areas and the degree to which PCTs may have set broader service objectives for contractors that cannot be measured by units of dental activity (Department of Health, personal communication). Therefore, the value of a UDA was obtained from published material (Bath.

<p>| TABLE 33 | Parameters associated with CHD, stroke, RTAs and death from other causes used in the York economic model\textsuperscript{a} |
|--------------|---------------------------------|--------------------------|-------------------|</p>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>95% CI</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative risk of death following CHD</td>
<td>3.2</td>
<td>2.67–3.83</td>
<td>Rosengren et al., 1998\textsuperscript{165}</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative risk of death following stroke</td>
<td>2.3</td>
<td>2.0–2.7</td>
<td>Dennis et al., 1993\textsuperscript{144}</td>
</tr>
<tr>
<td>RTAs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rate of non-fatal RTAs for male licence holders</td>
<td>0.0089</td>
<td>b</td>
<td>Department of Transport, 2004\textsuperscript{133}</td>
</tr>
<tr>
<td>Rate of non-fatal RTA for female licence holders</td>
<td>0.0082</td>
<td>b</td>
<td>Department of Transport, 2004\textsuperscript{133}</td>
</tr>
<tr>
<td>Rate of fatal RTA for male licence holders</td>
<td>0.00014</td>
<td>b</td>
<td>Department of Transport, 2004\textsuperscript{133}</td>
</tr>
<tr>
<td>Rate of fatal RTA for female licence holders</td>
<td>0.000060</td>
<td>b</td>
<td>Department of Transport, 2004\textsuperscript{133}</td>
</tr>
</tbody>
</table>

CHD, coronary heart disease; RTAs, road traffic accidents.

\textsuperscript{a} The following risks are not detailed in the table as they were estimated as age and sex dependent from national life tables (other cause mortality) or from the Framingham risk equation (risk of fatal and non-fatal stroke and fatal and non-fatal CHD).

\textsuperscript{b} Estimates based on population (rather than sample) data, therefore no uncertainty expressed.
### TABLE 34 Costs and resource use associated with treatments for OSAHS included in the York economic model

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Costs (2006)</th>
<th>Probability [mean (SD)]</th>
<th>Number</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPAP and APAP initial costs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outpatient visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unit cost of outpatient (consultant) visit</td>
<td>£107.87</td>
<td></td>
<td></td>
<td>NHS reference costs 2006</td>
</tr>
<tr>
<td>Probability of having a follow-up outpatient visit</td>
<td></td>
<td>0.69 (0.3)</td>
<td></td>
<td>ResMed survey of clinicians</td>
</tr>
<tr>
<td>Total cost of follow-up outpatient visit</td>
<td>£74.52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Home titration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probability of home titration</td>
<td></td>
<td>0.99 (0.01)</td>
<td></td>
<td>ResMed survey of clinicians</td>
</tr>
<tr>
<td>Probability of using APAP</td>
<td></td>
<td>0.81 (0.19)</td>
<td></td>
<td>ResMed survey of clinicians</td>
</tr>
<tr>
<td>APAP machine</td>
<td>£410</td>
<td></td>
<td></td>
<td>ResMed</td>
</tr>
<tr>
<td>Probability of using CPAP</td>
<td></td>
<td>0.19</td>
<td></td>
<td>ResMed survey of clinicians</td>
</tr>
<tr>
<td>CPAP machine</td>
<td>£280</td>
<td></td>
<td></td>
<td>ResMed</td>
</tr>
<tr>
<td>Number of times CPAP/APAP used for dose titration</td>
<td></td>
<td>163</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost of home titration</td>
<td>£2.34</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inpatient titration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probability of inpatient titration</td>
<td></td>
<td>0.01</td>
<td></td>
<td>Assume if not home titration must be inpatient titration (1–0.99)</td>
</tr>
<tr>
<td>Unit cost of sleep study follow up</td>
<td>£107.87</td>
<td></td>
<td></td>
<td>NHS reference costs 2006</td>
</tr>
<tr>
<td>Total cost of inpatient titration</td>
<td>£1.08</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Titration by specialist nurse</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probability of seeing a specialist nurse for titration</td>
<td></td>
<td>1</td>
<td></td>
<td>Assumption</td>
</tr>
<tr>
<td>Unit cost of 30-minute appointment with specialist nurse</td>
<td></td>
<td>£34</td>
<td></td>
<td>NHS reference costs 2006</td>
</tr>
<tr>
<td>Total cost of titration by specialist nurse</td>
<td>£34</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Titration by consultant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probability of seeing a consultant for titration</td>
<td></td>
<td>0.4</td>
<td></td>
<td>ResMed survey of clinicians</td>
</tr>
<tr>
<td>Total cost of titration by consultant</td>
<td>£43.10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost of 30-minute appointment with technician</td>
<td></td>
<td>£9.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total initial costs (first year)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPAP</td>
<td>£164.64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APAPa</td>
<td>£108</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CPAP ongoing costs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest rate</td>
<td></td>
<td>3.5%</td>
<td></td>
<td>NICE methods guidance</td>
</tr>
<tr>
<td>Estimated device life of CPAP</td>
<td></td>
<td>7 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual equivalent cost of CPAP device</td>
<td>£44.24</td>
<td></td>
<td></td>
<td>280/annuity factor</td>
</tr>
<tr>
<td>Annual equivalent cost of CPAP mask</td>
<td>£80</td>
<td></td>
<td></td>
<td>ResMed</td>
</tr>
<tr>
<td>Annual sundries</td>
<td>£15</td>
<td></td>
<td></td>
<td>Clinical opinion</td>
</tr>
<tr>
<td>Annual follow-up</td>
<td>£79</td>
<td></td>
<td></td>
<td>Clinical expert referring to NHS tariff</td>
</tr>
</tbody>
</table>
TABLE 34 Costs and resource use associated with treatments for OSAHS included in the York economic model

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Costs (2006)</th>
<th>Probability [mean (SD)]</th>
<th>Number</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CPAP ongoing costs (yearly)</td>
<td>£218.24</td>
<td>£44.24 + £80 + £15 + £79</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APAP ongoing costs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APAP machine</td>
<td>£410</td>
<td>ResMed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humidifier</td>
<td>£150</td>
<td>ResMed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated device life of APAP and humidifier</td>
<td>5 years</td>
<td>ResMed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual equivalent cost of APAP with humidifier</td>
<td>£100</td>
<td>560/annuity factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual sundries</td>
<td>£100</td>
<td>ResMed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual equivalent cost of CPAP mask</td>
<td>£80</td>
<td>ResMed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual follow-up</td>
<td>£79</td>
<td>Clinical expert referring to NHS tariff</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total APAP ongoing costs (yearly)</td>
<td>£359</td>
<td>£100 + £100 + £80 + £79</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dental device costs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated device life of dental device</td>
<td>2 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHS cost of dental device and its provision</td>
<td>£250.92</td>
<td>12 units of dental activity × 20.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total dental device costs (yearly)</td>
<td>£128.82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dental device ongoing costs (yearly)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance of dental device</td>
<td>£19.47</td>
<td>Edwards et al., 1999,168</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conservative management cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One-off consultation with a GP</td>
<td>£21</td>
<td>Curtis and Netten, 2006166</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APAP, autotitrating positive airway pressure; OSAHS, obstructive sleep apnoea–hypopnoea syndrome.

a Applied in sensitivity analysis.

NB Some figures are approximate as reported to limited number of decimal places.

TABLE 35 Mean costs associated with CHD, stroke and RTAs used in the York economic model

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean cost</th>
<th>SD</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHD and stroke</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of fatal CVE</td>
<td>£3021</td>
<td>367</td>
<td>Briggs et al., 2007148</td>
</tr>
<tr>
<td>Acute cost of CHD</td>
<td>£9997</td>
<td>428</td>
<td>Briggs et al., 2007148</td>
</tr>
<tr>
<td>Ongoing cost of CHD</td>
<td>£751</td>
<td>117</td>
<td>Briggs et al., 2007148</td>
</tr>
<tr>
<td>Acute cost of stroke</td>
<td>£9067</td>
<td>294</td>
<td>Bravo et al., 2007149</td>
</tr>
<tr>
<td>Ongoing cost of stroke</td>
<td>£2392</td>
<td>282</td>
<td>Bravo et al., 2007149</td>
</tr>
<tr>
<td><strong>RTA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of RTA (all injuries)</td>
<td>£2700</td>
<td>1643</td>
<td>Department of Transport, 2004133</td>
</tr>
<tr>
<td>Cost of fatal RTA</td>
<td>£5450</td>
<td>1643</td>
<td>Department of Transport, 2004133</td>
</tr>
</tbody>
</table>

CHD, coronary heart disease; CVE, cardiovascular event; RTA, road traffic accident.
Assessment of cost-effectiveness

Table 36: Base-case results from York economic model comparing costs and QALYs of conservative management, dental devices and CPAP in males aged 50

<table>
<thead>
<tr>
<th></th>
<th>Conservative management</th>
<th>Dental device</th>
<th>CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment costs</td>
<td>£21</td>
<td>£1726</td>
<td>£2465</td>
</tr>
<tr>
<td>RTA costs</td>
<td>£2201</td>
<td>£1138</td>
<td>£904</td>
</tr>
<tr>
<td>CVE costs</td>
<td>£5918</td>
<td>£5932</td>
<td>£5931</td>
</tr>
<tr>
<td>Total costs</td>
<td>£8140</td>
<td>£8797</td>
<td>£9301</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>11.93</td>
<td>12.26</td>
<td>12.39</td>
</tr>
<tr>
<td>ICER</td>
<td></td>
<td>£2000</td>
<td>£3899</td>
</tr>
</tbody>
</table>

Probability of being cost-effective for threshold

- £10,000 per QALY: 0.01, 0.32, 0.66
- £20,000 per QALY: 0.00, 0.20, 0.80
- £30,000 per QALY: 0.00, 0.17, 0.83

CVE, cardiovascular event; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RTA, road traffic accident.

The cost of non-compliance was determined by the proportion of CPAP machines not returned (10%) and the cost of dental devices no longer used. The data were entered probabilistically based on estimates of the service and resource use data obtained from ResMed’s survey of clinicians. The uncertainty around the probability distributions was characterised by beta distributions.

On the basis of clinical advice, conservative management was estimated as the cost of a one-off GP consultation during which the patient may receive advice on posture, dietary habits and lifestyle. A unit cost of a GP appointment was obtained from the Personal Social Services Research Unit (PSSRU) costs of health and social care report.

The unit costs associated with stroke, CHD and RTAs are reported in Table 35. Published references were used to estimate these parameters. The uncertainty around the costs was characterised by gamma distributions, where mean costs and SD were presented, and by normal distributions, where the costs were based on coefficients from a regression analysis. The Department of Transport information regarding the costs of RTAs was presented as point estimates. In order to characterise the uncertainty around these estimates it was assumed that the SD would be equal to that reported by HODaR (Currie et al., 156) for the hospital cost associated with non-fatal RTAs (mean £2437, SD £1643).

Results of York economic model

Base-case analysis

The base-case analysis is based on a hypothetical cohort of men aged 50 with the baseline cardiovascular risk factors described in Table 36. In this cohort CPAP was associated with both higher costs and higher QALYs in comparison with treatment with dental devices or conservative management. The incremental cost-effectiveness of CPAP compared with dental devices is estimated to be £4000 per QALY. CPAP might therefore be considered cost-effective at a cost-effectiveness threshold per QALY of £20,000.

Similar results were obtained for a hypothetical cohort of women aged 50, as shown in Table 37.

For the base-case analysis the effect of CPAP on ESS was derived by pooling all of the available trial data to obtain an overall effect. The treatment effects estimated by pooling trials, grouped according to average baseline ESS (mild, moderate or severe), were applied in three separate analyses.
TABLE 37 Results from York economic model comparing costs and QALYs of conservative management, dental devices and CPAP in females aged 50

<table>
<thead>
<tr>
<th></th>
<th>Conservative management</th>
<th>Dental device</th>
<th>CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment costs</td>
<td>£21</td>
<td>£1824</td>
<td>£2608</td>
</tr>
<tr>
<td>RTA costs</td>
<td>£2139</td>
<td>£1108</td>
<td>£878</td>
</tr>
<tr>
<td>CVE costs</td>
<td>£5840</td>
<td>£5829</td>
<td>£5820</td>
</tr>
<tr>
<td>Total costs</td>
<td>£7999</td>
<td>£8762</td>
<td>£9306</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>12.71</td>
<td>13.02</td>
<td>13.15</td>
</tr>
<tr>
<td>ICER</td>
<td>£2342</td>
<td>£4335</td>
<td></td>
</tr>
</tbody>
</table>

Probability of being cost-effective for threshold

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Probability of cost-effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>£10,000 per QALY</td>
<td>0.02</td>
</tr>
<tr>
<td>£20,000 per QALY</td>
<td>0.01</td>
</tr>
<tr>
<td>£30,000 per QALY</td>
<td>0.00</td>
</tr>
</tbody>
</table>

and the results are shown in Table 38. Note that the trials comparing CPAP with dental devices all had a mean baseline ESS that would classify them as moderate OSAHS. Because it was not possible to estimate the differential effect of baseline severity of OSAHS on CVD and RTA risks, these risks have not been included in the results in Table 38 (i.e. these cost-effectiveness results by severity include only treatment effects on ESS). It can be seen that cost-effectiveness varies according to severity, with CPAP most cost-effective (lower ICER) in severely affected patients. However, CPAP has an ICER below a cost-effectiveness threshold of £20,000 for moderate and severe levels using baseline ESS score. The ICER in a subgroup with mild disease was estimated to be £20,585.

Secondary analysis

There are a number of uncertainties over several of the modelling assumptions, and results are shown as a set of subgroup and scenario analyses in Table 39. In each case the variable or assumption altered from the base-case analysis is indicated in the title of the scenario analysis, and all other variables and assumptions were left unchanged. It can be seen that, although ICERs for CPAP vary according to the different assumptions, they consistently fall below a threshold of £20,000 per QALY. The greatest effect on the CPAP ICER comes from applying the highest feasible acquisition cost for the treatment by including the costs of an APAP machine and a humidifier.

Value of information analysis

The base case per episode EVPI was estimated to be £183 (male) and £202 (female) for a cost-effectiveness threshold of £20,000 per QALY. Assuming a lifetime for the technology of 5 years and incidence of OSAHS of 0.1% in the UK population aged between 16 and 65 (39 million) gives an effective population of 0.18 million (http://www.statistics.gov.uk/cci/nugget.asp?ID=949). This corresponds to a population EVPI of £35 million (male). When CVE and RTA events were excluded from the model, the population EVPI rises to approximately £51 million (based on per episode EVPI of £277 in men).
TABLE 38 Results from the York economic model for subgroups grouped according to baseline severity of OSAHS as measured by ESS

<table>
<thead>
<tr>
<th></th>
<th>Conservative management</th>
<th>Dental device</th>
<th>CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild OSAHS, male aged 50 (mean baseline ESS = 7)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost</td>
<td>£21</td>
<td>NA</td>
<td>£2726</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>14.56</td>
<td>NA</td>
<td>14.69</td>
</tr>
<tr>
<td>ICER</td>
<td></td>
<td></td>
<td>£20,585</td>
</tr>
<tr>
<td>Probability of being cost-effective for threshold</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>£10,000 per QALY</td>
<td>0.95</td>
<td>NA</td>
<td>0.05</td>
</tr>
<tr>
<td>£20,000 per QALY</td>
<td>0.57</td>
<td>NA</td>
<td>0.43</td>
</tr>
<tr>
<td>£30,000 per QALY</td>
<td>0.32</td>
<td>NA</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Moderate OSAHS, male aged 50 (mean baseline ESS = 13)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost</td>
<td>£21</td>
<td>£1906</td>
<td>£2726</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>13.51</td>
<td>13.70</td>
<td>13.80</td>
</tr>
<tr>
<td>ICER</td>
<td></td>
<td>ED</td>
<td>£9391</td>
</tr>
<tr>
<td>Probability of being cost-effective for threshold</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>£10,000 per QALY</td>
<td>0.40</td>
<td>0.24</td>
<td>0.36</td>
</tr>
<tr>
<td>£20,000 per QALY</td>
<td>0.09</td>
<td>0.21</td>
<td>0.70</td>
</tr>
<tr>
<td>£30,000 per QALY</td>
<td>0.04</td>
<td>0.18</td>
<td>0.78</td>
</tr>
<tr>
<td><strong>Severe OSAHS, male aged 5 (mean baseline ESS = 16)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cost</td>
<td>£21</td>
<td>NA</td>
<td>£2726</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>13.01</td>
<td>NA</td>
<td>13.62</td>
</tr>
<tr>
<td>ICER</td>
<td></td>
<td></td>
<td>£4413</td>
</tr>
<tr>
<td>Probability of being cost-effective for threshold</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>£10,000 per QALY</td>
<td>0.05</td>
<td>NA</td>
<td>0.95</td>
</tr>
<tr>
<td>£20,000 per QALY</td>
<td>0.02</td>
<td>NA</td>
<td>0.98</td>
</tr>
<tr>
<td>£30,000 per QALY</td>
<td>0.01</td>
<td>NA</td>
<td>0.99</td>
</tr>
</tbody>
</table>

ED, extended dominance; ESS, Epworth Sleepiness Scale; ICER, incremental cost-effectiveness ratio; NA, not applicable; OSAHS, obstructive sleep apnoea–apnoea syndrome; QALY, quality-adjusted life-year.

a All of the trials comparing CPAP with dental devices were classified as moderate OSAHS based on average baseline ESS.

NB Only differential treatment effects on ESS are included.
### TABLE 39 | Results from the York economic model for a range of scenario and subgroup analyses

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th></th>
<th>Female</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CM</td>
<td>DD</td>
<td>CPAP</td>
<td>CM</td>
<td>DD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subgroup analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort aged 35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8521</td>
<td>£9356</td>
<td>£10,034</td>
<td>£8177</td>
<td>£9155</td>
</tr>
<tr>
<td>QALY</td>
<td>15.55</td>
<td>15.99</td>
<td>16.15</td>
<td>16.21</td>
<td>16.60</td>
</tr>
<tr>
<td>ICER</td>
<td>£1894</td>
<td>£4143</td>
<td></td>
<td>£2477</td>
<td>£4454</td>
</tr>
<tr>
<td>Cohort aged 65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£5969</td>
<td>£6398</td>
<td>£6728</td>
<td>£5159</td>
<td>£5709</td>
</tr>
<tr>
<td>QALY</td>
<td>7.95</td>
<td>8.17</td>
<td>8.26</td>
<td>8.89</td>
<td>9.12</td>
</tr>
<tr>
<td>ICER</td>
<td>£1866</td>
<td>£2960</td>
<td></td>
<td>£2426</td>
<td>£3944</td>
</tr>
<tr>
<td><strong>Scenario analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in ESS linked to SF-6D utility score rather than EQ-5D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8129</td>
<td>£8781</td>
<td>£9295</td>
<td>£8003</td>
<td>£8761</td>
</tr>
<tr>
<td>QALY</td>
<td>10.66</td>
<td>10.95</td>
<td>11.06</td>
<td>11.35</td>
<td>11.62</td>
</tr>
<tr>
<td>ICER</td>
<td>£2258</td>
<td>£4451</td>
<td></td>
<td>£2748</td>
<td>£4669</td>
</tr>
<tr>
<td>Relative risk reduction for CVE based on DBP and MacMahon et al., 1990</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8133</td>
<td>£8734</td>
<td>£9207</td>
<td>£7949</td>
<td>£8656</td>
</tr>
<tr>
<td>QALY</td>
<td>11.92</td>
<td>12.28</td>
<td>12.42</td>
<td>12.70</td>
<td>13.04</td>
</tr>
<tr>
<td>ICER</td>
<td>£1678</td>
<td>£3330</td>
<td></td>
<td>£2040</td>
<td>£3756</td>
</tr>
<tr>
<td>Exclude CVE events from model</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£2488</td>
<td>£3171</td>
<td>£3736</td>
<td>£2389</td>
<td>£3252</td>
</tr>
<tr>
<td>ICER</td>
<td>£1896</td>
<td>£4184</td>
<td></td>
<td>£2557</td>
<td>£4732</td>
</tr>
<tr>
<td>Exclude CVE and RTA events from model</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£21</td>
<td>£1906</td>
<td>£2726</td>
<td>£21</td>
<td>£2038</td>
</tr>
<tr>
<td>ICER</td>
<td>ED</td>
<td>£8098</td>
<td>ED</td>
<td>ED</td>
<td>ED</td>
</tr>
<tr>
<td>APAP machine with 5-year life span and humidifier</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8150</td>
<td>£8816</td>
<td>£10,939</td>
<td>£7979</td>
<td>£8741</td>
</tr>
<tr>
<td>QALY</td>
<td>11.92</td>
<td>12.25</td>
<td>12.38</td>
<td>12.70</td>
<td>13.01</td>
</tr>
<tr>
<td>ICER</td>
<td>£2017</td>
<td>£16,362</td>
<td>£2408</td>
<td>£18,356</td>
<td></td>
</tr>
<tr>
<td>Treatment effects from BRMA (APBM only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8132</td>
<td>£8799</td>
<td>£9283</td>
<td>£7973</td>
<td>£8737</td>
</tr>
<tr>
<td>QALY</td>
<td>11.93</td>
<td>12.26</td>
<td>12.40</td>
<td>12.69</td>
<td>13.01</td>
</tr>
<tr>
<td>ICER</td>
<td>£2003</td>
<td>£3678</td>
<td></td>
<td>£2412</td>
<td>£4093</td>
</tr>
<tr>
<td>Treatment effects from BRMA (APBM and office measurements)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>£8139</td>
<td>£8771</td>
<td>£9237</td>
<td>£7989</td>
<td>£8728</td>
</tr>
<tr>
<td>QALY</td>
<td>11.92</td>
<td>12.27</td>
<td>12.42</td>
<td>12.70</td>
<td>13.04</td>
</tr>
<tr>
<td>ICER</td>
<td>£1787</td>
<td>£3097</td>
<td></td>
<td>£2170</td>
<td>£3249</td>
</tr>
</tbody>
</table>

APBM, ambulatory blood pressure monitoring; BRMA, bivariate random-effects meta-analysis; CM, conservative management; CVE, cardiovascular event; DBP, diastolic blood pressure; DD, dental device; ED, extended dominance; ESS, Epworth Sleepiness Scale; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RTA, road traffic accident.
## TABLE 40  Economic evaluation quality assessment

<table>
<thead>
<tr>
<th>Cost-effectiveness</th>
<th>Ayas et al., 2006(^\text{122})</th>
<th>Mar et al., 2003(^\text{123})</th>
<th>ResMed, 2007(^\text{120})</th>
<th>Chilcott et al., 2000(^\text{44})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study question</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Were costs and effects examined?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Were alternatives compared?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Are viewpoint/s clearly stated?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Selection of alternatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All relevant alternatives were compared</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>For the alternatives compared are all clearly described?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>The rationale for choosing the alternative programmes compared is stated</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Form of evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The choice of form of economic evaluation is justified in relation to questions addressed</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>If a cost minimisation analysis is chosen, have equivalent outcomes been adequately demonstrated?</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Effectiveness data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The sources of effectiveness estimates used are stated</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Effectiveness data are from RCTs or review of RCTs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Potential biases are identified</td>
<td>✓</td>
<td>✓</td>
<td>X</td>
<td>✓</td>
</tr>
<tr>
<td>Details of method of synthesis or meta-analysis of estimates are given</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Costs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All the important and relevant resource use is included</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>All the important and relevant resource use is measured accurately</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Appropriate unit costs are estimated</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Unit costs are reported separately from resource use data</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>If productivity costs are included, are they treated separately from other costs?</td>
<td>✓</td>
<td>NA</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>The year and country to which unit costs apply are stated with appropriate adjustments for inflation and/or currency conversion</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Benefit measurement and valuation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The primary outcome measure for the economic evaluation is clearly stated</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Methods to value health states and other benefits are stated</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Details of the individuals from whom valuations were obtained are given</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
### TABLE 40 Economic evaluation quality assessment

<table>
<thead>
<tr>
<th>Cost-effectiveness</th>
<th>Ayas et al., 2006(^{122})</th>
<th>Mar et al., 2003(^{123})</th>
<th>ResMed, 2007(^{20})</th>
<th>Chilcott et al., 2000(^{44})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Decision modelling</strong></td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td>Details of any model used are given</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td>The choice of model used and the key input parameters on which it is based are adequately detailed and justified</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td>All model outputs are described adequately</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td><strong>Discounting</strong></td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>X</td>
</tr>
<tr>
<td>Discount rates are used for both costs and benefits</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>X</td>
</tr>
<tr>
<td>Do discount rates accord with current NHS guidance?</td>
<td>X X ✓</td>
<td>X ✓ ✓</td>
<td>X ✓ ✓</td>
<td>X</td>
</tr>
<tr>
<td>Allowance for uncertainty: stochastic analysis of patient-level data</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA</td>
</tr>
<tr>
<td>Details of statistical tests and confidence intervals are given for stochastic data</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA</td>
</tr>
<tr>
<td>Uncertainty around cost-effectiveness estimates are expressed</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA</td>
</tr>
<tr>
<td>Sensitivity analysis is used to assess uncertainty in non-stochastic variables and analytic methods</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA NA NA NA</td>
<td>NA</td>
</tr>
<tr>
<td>Allowance for uncertainty: stochastic analysis of decision models</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td>Are all appropriate input parameters included with uncertainty?</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td>Is second-order uncertainty (uncertainty in means) included rather than first-order uncertainty (uncertainty between patients)?</td>
<td>✓ X ✓</td>
<td>✓ X ✓</td>
<td>✓ X ✓</td>
<td>NU</td>
</tr>
<tr>
<td>Are the probability distributions adequately detailed and appropriate?</td>
<td>✓ X X</td>
<td>✓ X X</td>
<td>✓ X X</td>
<td>NU</td>
</tr>
<tr>
<td>Sensitivity analysis is used to assess uncertainty in non-stochastic variables (e.g. unit costs) and analytic decisions (e.g. methods to handle missing data)</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>NU</td>
</tr>
<tr>
<td><strong>Deterministic analysis</strong></td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>The approach to sensitivity analysis is given</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>The choice of variables for sensitivity analysis is justified</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>The ranges over which the variables are varied are stated</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>Presentation of results</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>Incremental analysis is reported using appropriate decision rules</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>Major outcomes are presented in a disaggregated as well as an aggregated form</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
<td>✓ ✓ ✓</td>
</tr>
<tr>
<td>They are applicable to the UK setting</td>
<td>X X ✓</td>
<td>X X ✓</td>
<td>X X ✓</td>
<td>X X ✓</td>
</tr>
</tbody>
</table>

✓, yes; X, no; NA, not applicable; NU, not undertaken.
Chapter 5

Assessment of factors relevant to the NHS and other parties

It is unlikely that the implementation of CPAP as a treatment for OSAHS would have training requirements for clinicians that have major resource implications for the NHS. Consultant-level respiratory physicians are currently required to have completed a basic sleep apnoea training programme. Appropriate diagnosis is important and may have additional cost implications. The trials included in this technology assessment mainly used thorough diagnostic assessment (encompassing recordings of multiple physiological signals during sleep) to establish a diagnosis of OSAHS, and the findings of this review are applicable to a population where there has been an adequate diagnostic assessment. Trained staff and structured induction programmes are another feature of specialist units. The detailed consideration of what would constitute an appropriate diagnostic assessment and the associated cost implications were outside the remit of this technology appraisal.

In practice, dental devices are unlikely to be provided under NHS dental care, and in regions where they may be available under the NHS waiting times for treatment may need consideration. The cost-effectiveness model in this appraisal (the York model) considered NHS costs and PSS costs; incorporating private costs of dental care would reduce the cost-effectiveness of dental devices.
Chapter 6
Discussion

Statement of principal findings
Clinical effectiveness

The clinical effectiveness and safety of CPAP compared with best supportive care, placebo and dental devices for the treatment of OSAHS was investigated using systematic review and meta-analyses. The majority of studies in the review included participants with moderate daytime symptom severity (ESS) at baseline, who were male and overweight or obese. Several studies excluded patients who reported sleepiness while driving; this may indirectly have led to most studies having a mean baseline symptom severity that was classified as moderate. When disease at baseline was classified based on the AHI, most included studies were classified as being of severe disease populations.

The mean age of participants in the included studies ranged from 44 to 58 years and the duration of follow-up in most studies was between 4 and 12 weeks. We excluded studies that were restricted to patients with serious co-morbid conditions such as heart failure or Alzheimer’s disease; therefore, the findings may not be generalisable to those groups. Although 48 relevant studies were identified, the outcomes investigated varied and data for some outcomes were available from only a small number of studies. In general, there was inconsistency (statistical heterogeneity) in the treatment effect within groups of studies with the same comparators. Heterogeneity for the primary outcome of subjective sleepiness (as measured by the ESS) was reduced when studies were subgrouped based on mean severity of daytime symptoms at baseline, but not when subgrouping was based on the mean number of episodes of airway obstruction at night (AHI). This was possibly because ESS and AHI are not strongly correlated. It was considered appropriate to focus on the stratification of studies by symptom severity rather than the number of episodes of airway obstruction at night as the treatment of OSAHS is targeted mainly at controlling its symptoms and consequences, e.g. hypertension, rather than correcting the breathing disturbance itself. Any variation in the treatment effect discussed below is in relation to disease severity based on severity of daytime symptoms at baseline, as measured by the ESS.

There was clear evidence of a benefit with CPAP compared with placebo, conservative treatment/best supportive care, on two of the three primary outcomes, one assessing subjective symptoms of daytime sleepiness (ESS) and one objective measure of sleepiness (MWT). The benefit with CPAP on daytime sleepiness was robust across all the methodological subgroup analyses and sensitivity analyses. There was consistent evidence that the treatment effect increased with symptom severity at baseline. The evidence for any benefit with CPAP was less clear on the secondary outcome measures, although there was some evidence of a beneficial impact on quality of life and daytime MAP. The identified studies comparing CPAP with dental devices were in populations with symptoms of moderate severity. There was no statistically significant difference between CPAP and dental devices on any of the measures investigated. However, only a small number of studies was available and there was some inconsistency in the findings, making it difficult to draw firm conclusions. Despite obesity being an important aetiological factor for adult OSAHS, there were no studies directly comparing CPAP with weight loss interventions; where a weight loss programme was used, both the intervention and comparator group received this.

There was a lack of evidence on long-term outcomes such as stroke and cardiac events (with changes in event rates in the economic model being inferred from blood pressure changes rather than being measured directly), and a lack of direct evidence on RTAs and accidents in the workplace.

Daytime sleepiness

The primary outcome of interest for the clinical treatment of OSAHS is the control of excessive daytime sleepiness, for its symptomatic benefits and the consequences for tasks that require vigilance and the resistance of sleep onset, e.g. driving and employment performance. In this review, sleepiness was quantified as subjective daytime sleepiness as measured by the ESS and
objective sleepiness as measured by the MWT and MSLT. These objective and subjective measures of sleepiness were used as primary outcomes, as the daytime consequences of OSAHS are the primary concern for patients. There was evidence that CPAP was more effective than placebo or conservative treatment/usual care in reducing symptoms of daytime sleepiness as measured by the ESS and MWT but not the MSLT. There was no statistically significant difference between CPAP and dental devices or CPAP and postural therapy on any of the three primary outcomes in a population classified as having moderate symptom severity at baseline.

The random-effects model that we used for the statistical pooling assumes that the effect of treatment differs in different populations, but that these effects cluster around a mean. The estimated MD for daytime sleepiness in the overall pooling was 2.7 points on the ESS, but might be anywhere between 2.0 and 3.5. However, this probably has limited generalisability, due to high statistical heterogeneity or inconsistency in the treatment effect. Heterogeneity was reduced when estimates were generated for studies subgrouped by mean baseline symptom severity. The benefit with CPAP was greatest in the group of trials of severe symptoms (MD −5.0 points, 95% CI −6.5 to −3.5), and was smaller with moderate (MD −2.3 points, 95% CI −3.0 to −1.6) and mild symptoms (MD −1.1 points, 95% CI −1.8 to −0.3). These were all statistically significant. It is not surprising to find a smaller benefit in the studies of populations that only had mild sleepiness prior to treatment. The estimate for mild disease was based on only two trials; therefore, this finding may not be robust. Although there was still moderate statistical heterogeneity in the subgroups, the direction of the treatment effect was consistently in favour of CPAP, with the exception of two studies.

There was a statistically significant benefit with CPAP compared with placebo/usual care on the ability to stay awake in a setting conducive to sleep (MWT). It is not possible to make a firm conclusion about whether the benefit with CPAP varied by disease severity as there were no trials of mild symptom severity and only one of severe. There was a benefit with CPAP in the single trial of a severe symptom severity population, which was apparently greater than that in the group of trials of moderate disease symptoms. There was no statistically significant difference between CPAP and control in the length of time it took participants to fall asleep in a setting conducive to sleep (MSLT), for any level of disease severity. This finding may have limited generalisability due to the evidence of inconsistency in the treatment effect which could not be adequately investigated. Again, only single trials were available of mild and severe symptomatic populations, making it impossible to draw firm conclusions about whether there may be a variation in the treatment effect in populations with different disease severity.

It is not surprising that the findings from the MSLT and MWT do not correspond, as, although the two tests appear to measure the same thing, time to onset of sleep, low correlations have been found between the two tests, implying that there is not a simple single dimension of sleepiness.170 It has been suggested that the MSLT measures underlying arousal as well as propensity to sleep. American Academy of Sleep Medicine practice parameters state that use of MSLT is not routinely indicated for the diagnosis of OSAHS or for assessment of response to treatment.171 The ESS and MWT may be more clinically meaningful in that they measure the ability to resist sleep. This has potentially more applicability to real-life situations, in which the ability to resist sleep while driving or carrying out a daily activity is important, than does the length of time it takes a person to fall asleep, when instructed to do so, as measured by the MSLT.

There was no statistically significant difference between CPAP and dental devices amongst a population with moderate symptom severity at baseline (where reported). The treatment effect is likely to differ in different groups of people, based on the random-effects model used. The average effect was a reduction in sleepiness of less than 1 point (0.9) in favour of CPAP compared with dental devices, but might be anywhere between an increase in sleepiness of 0.4 points with CPAP and a decrease in sleepiness of 2.1 points. However, it is unclear how generalisable this is within a moderate disease population as there was evidence of moderate inconsistency (heterogeneity) in the treatment effect. The effectiveness of CPAP compared with dental devices in severe and mild severity populations could not be estimated due to a lack of studies investigating these populations. Overall it is difficult to draw firm, clinically useful conclusions from the studies comparing CPAP with dental devices and postural therapy. Assessment of the comparative clinical effectiveness of CPAP and dental devices or postural therapy is limited by the number and consistency of available data and by the spectrum of patients studied. The studies of postural therapy, in particular, were very small.
trials and there was only one trial on each type of postural therapy.

**Blood pressure**
The studies assessing blood pressure had diverse populations; the proportion of hypertensive patients ranged from 15% to 100%. Day and night blood pressure were considered separately as the mechanisms and patterns of daytime and nighttime blood pressure disturbance in OSAHS vary. Priority was given to daytime measures as the relationship between daytime blood pressure and vascular risk has been more clearly established and was more useful for the economic model. Based on studies using ABPM, there was a statistically significant benefit with CPAP compared with placebo/usual care in daytime MAP. Based on the random-effects pooling used, the size of the effect probably varies among different groups of people: the average reduction in daytime MAP was 2.1 mmHg, but might be anywhere between no reduction and 4.3 mmHg. When SBP and DBP were considered separately, the differences between CPAP and control were not statistically significant although there was a small decrease in both measures in favour of CPAP (MD −1.1 mmHg, 95% CI −3.4 to 1.2, and MD −1.2 mmHg, 95% CI −2.9 to 0.5, respectively). It should be noted that not all the trials in the analysis of MAP were the same as those in the SBP and DBP analyses. Therefore, the lack of a statistically significant effect for SBP and DBP may be due to differences in the study populations or methods.

The overall treatment effect for MAP did not appear to be robust. When individual studies were removed from the pooling the treatment effect remained statistically significant in only one instance. The analyses for all three blood pressure measures were based on a small number of trials and participants, and blood pressure was not always the primary outcome in the studies. Therefore, the risk of the analyses being underpowered to detect an effect is an important consideration. The subgroup analysis exploring variation in treatment effect with symptom severity was limited by the small number of trials available. The pooling of a small group of studies using conventional clinic blood pressure measurement showed a large and statistically significant improvement in SBP and DBP with CPAP compared with control. Given the evidence that a person’s actual blood pressure is more accurately reflected by the repeated measurements of ABPM than by conventional clinic measures, the results of the studies using ABPM probably provide a more generalisable estimate of the effect of treatment on blood pressure. However, there is always the possibility that there are important differences between these studies other than the method of blood pressure measurement.

**Health-related quality of life (HRQoL)**
There was evidence of a beneficial impact on HRQoL although the findings were somewhat inconsistent. This may have been related to a number of factors including the different types of quality of life outcome measures used, the small number of trials available or aspects of study design. It was not possible to explore these factors due to the small number of trials available. In general, the available data sets were too small to allow meaningful investigation of potential sources of heterogeneity. The included studies reporting these outcomes were of moderate and severely symptomatic populations; it is unclear whether similar benefits would be experienced by a mild disease population.

The most commonly reported quality of life measures were the FOSQ, the NHP and the SF-36, although the number of trials available for any single quality of life measure was small. Only one trial was identified that used a utility-based measure to inform the cost-effectiveness model. The majority of the trials were of moderate symptom severity populations (based on ESS). There was a statistically significant benefit with CPAP compared with placebo/usual care on the activity level and social outcome dimensions of the FOSQ (a condition-specific measure) when three trials of moderate disease and one of severe disease were pooled; and on the NHP (Part 2) in a moderate disease severity population. There was no statistically significant difference between CPAP and control on the SF-36 subscales. However, there was high inconsistency (statistical heterogeneity) for the emotional role and vitality subscales, limiting the reliability of these findings. It is therefore not appropriate to draw general conclusions from these analyses. When parallel and crossover trials were pooled separately, there was a benefit with CPAP compared with control on the SF-36 bodily pain, general health and physical function subscales in the parallel trial subgroup; this may have been driven by two trials of severely symptomatic populations.

Quality of life data regarding CPAP compared with dental devices (all moderate symptom severity) were inconsistent: on the FOSQ one study showed a statistically significant benefit with CPAP compared with dental devices and one found no
difference; there was no statistically significant benefit on the SAQLI with CPAP; and on the SF-36 one study reported a statistically significant benefit with CPAP compared with dental devices on the physical and mental component subscales, one reported a statistically significant benefit on the bodily pain subscale with CPAP and there was no statistically significant difference on the total score in one study. There was no statistically significant difference between CPAP and postural therapy in any quality of life measure studied.

Psychological and cognitive outcomes
Assessment of the effects of CPAP on psychological outcomes was limited by the small number of trials investigating these outcomes. Subgroup analysis by baseline symptom severity was not feasible. The most commonly used scales were the General Health Questionnaire-28 (GHQ-28), Hospital Anxiety and Depression Scale (HADS) and University of Wales Mood Adjective Checklist (UMACL). There was no statistically significant benefit with CPAP compared with placebo/usual care on the GHQ-28 or HADS. However, there was evidence of inconsistency in the treatment effect (statistical heterogeneity) which could not be explored, making any firm conclusions difficult. On the UMACL there was a statistically significant benefit with CPAP compared with placebo. There was no statistically significant difference between CPAP and dental devices in a single trial using HADS.

Despite the substantial number of trials investigating cognitive outcomes, interpretation was difficult due to the wide range of tests used, non-uniform use of the same scales, variation in testing protocols and the difficulty in assessing the risk of a ceiling effect due to lack of information on how baseline performance compared with normative performance. The findings were contradictory from trials for individual cognitive tests, with some showing a benefit with CPAP and others not.

Cost-effectiveness
Published evidence and company submissions
Only one manufacturer submitted a full economic evaluation of CPAP – ResMed. This analysis used decision modelling and evidence drawn from a range of sources to estimate the costs and QALYs associated with CPAP versus a ‘do nothing’ option. The company’s estimated cost-effectiveness over 14 years was that CPAP dominated no treatment (i.e. CPAP was associated with higher QALYs and lower costs), although this varied over shorter time horizons. Comparing CPAP (auto) and CPAP (fixed), the analysis suggested that the former dominated the latter. There are a number of methodological weaknesses associated with the ResMed analysis including the following:

- The results of a before and after study were used to examine the impact of no treatment compared with CPAP on HRQoL (in terms of utilities) associated with sleepiness. There are numerous limitations to this type of study in estimating treatment effects. Furthermore the approach effectively ignores the considerable RCT-based literature examining the efficacy and effectiveness of CPAP compared with other therapies.
- ResMed did not include the full range of comparators and, at least for patients diagnosed with moderate/severe OSAHS, it is not clear that a ‘do nothing’ option represents typical clinical practice.
- ResMed modelled cost-effectiveness results over a 14-year time horizon. However, OSAHS is a chronic condition; therefore, it is appropriate to model the results for a lifetime horizon.
- There were shortcomings in the internal validity of the electronic model that may have led to inaccurate estimates of costs and QALYs.

Four published full economic evaluations of CPAP were identified and reviewed. Although they varied in terms of their detailed methods, there was moderate consistency in the estimates of cost-effectiveness with CPAP; estimates of the incremental cost per QALY gained with CPAP against no therapy ranged from about £1500 to £3000. These studies had several limitations including:

- the failure to use a full range of clinical trial evidence for estimating the impact of treatment on daytime sleepiness, blood pressure, HRQoL and other relevant outcomes
- a lack of evidence to compare the utility associated with different treatments for OSAHS
- limited evidence (in terms of quantity and quality) on the long-term impact of OSAHS on HRQoL, CVEs and RTAs
- the fact that none of the evaluations examined all the comparators relevant to this review.
York economic model

As a result of the limitations of existing cost-effectiveness studies of CPAP, a new model was developed. Its key features (compared with earlier models) were that it compared CPAP with relevant alternative treatment options (taken as conservative management and dental devices); it based the main estimate of effectiveness on the RCT evidence on sleepiness symptoms (based on the ESS), which were ‘mapped’ to utilities using individual patient data from a subset of studies; and it used trial evidence on changes in blood pressure following intervention to estimate differences in the rates of CVEs over time.

The York model found that, on average, CPAP was associated with higher costs and benefits compared with dental devices or conservative management. The incremental cost per QALY gained with CPAP, compared with dental devices, using base-case assumptions and an assumed age of 50 years, was £3899 for men and £4335 for women; the probability of CPAP being more cost-effective than dental devices and conservative management at a threshold of £20,000 per QALY was 0.78 and 0.80 for men and women respectively.

The York model is the first to compare CPAP with dental devices. It was noted earlier that differences between dental devices and CPAP in the effect on the ESS were not statistically significant. However, those differences were incorporated into the cost-effectiveness analysis and the uncertainty in these, as well as all other, parameters are reflected in the expressed decision uncertainty. The systematic review detailed in Chapter 3 included only trials in which CPAP was a comparator. As a consequence, trials comparing dental devices with placebo will not have been identified. Hence, the comparison between dental devices and conservative management is not based on the full range of available data. However, a recent systematic review of dental devices by Hoekema et al. identified few additional dental device versus placebo studies.123 Clinically, the treatment effect on the ESS from CPAP, relative to conservative therapy, was greater in patients with greater baseline severity of OSAHS. When this was reflected in the cost-effectiveness analysis by looking at the cost-effectiveness of CPAP in separate severity groups, the ICER (probability of being cost-effective at a threshold of £20,000 per QALY) varied between £20,585 (0.43) and £4413 (0.98) in patients with mild and severe disease respectively. In mild and severe disease, it was only possible to compare the cost-effectiveness of CPAP with conservative management given the absence of trials of dental devices in those patients. Furthermore, given the lack of evidence on the relative treatment effects of the alternative therapies on blood pressure and RTAs by baseline OSAHS severity, these estimates do not factor in differential effects on CVEs or RTAs, so are likely to be an underestimate.

A series of other subgroup and scenario analyses found that the ICER of CPAP was consistently below £20,000 per QALY gained (when there is no distinction between baseline severity of disease). Typically the cost-effectiveness of interventions was lower (i.e. the ICER was higher) in women than in men; this may be due to the fact that women have a lower baseline risk of CVD and RTAs, giving less potential for QALY gains. They also typically have a longer life expectancy, resulting in higher treatment costs compared with no treatment. CPAP remained cost-effective when the age of the hypothetical cohort was increased or decreased by 15 years. Although the target population for this appraisal is patients aged 16 or older, the clinical trials typically included older patients and so the results may not be generalisable to a younger cohort. As mentioned previously, the generalisability to cohorts older than the patient population included in the trials may be compromised by the presence of additional co-morbidity in older people.

The greatest contribution to QALY gain was found to be the gain in utility associated with a reduction in ESS score with CPAP. The next most important factor in differentiating between the alternative treatments in terms of QALY gain was the rate of RTAs. The inclusion of CVEs reduced quality-adjusted survival by similar amounts for all three alternatives. A similar pattern was observed for costs, with the greatest difference between alternatives contributed by the cost of the device and associated care, followed by RTA costs and finally CVE costs.

The cost of the CPAP device is higher than the cost of dental devices or conservative management. However, the NHS and PSS costs of RTAs were lower with CPAP than with those relating to dental devices and conservative management as fewer events occur. The costs of CVD differed little between the alternative treatment strategies. A consequence of the reduced risk of fatal RTAs or fatal CVEs with CPAP was that more patients remained alive and at risk of a non-fatal CVE, partially offsetting any savings from a reduced
Discussion

risk of events overall. Omitting the impact of CVD had little effect on the study results. Even when incorporating the larger relative risk reduction for CVEs implied by the MacMahon et al. study, the reduction in blood pressure associated with CPAP contributed little to the estimation of its cost-effectiveness. When the impact of CVD and RTAs was omitted, the incremental cost of CPAP compared with usual care increased, but the ICER remained low at £8098. Note that the results of this analysis are relevant for patients who do not drive.

The per episode EVPI was high, indicating that the cost of decision uncertainty may be high. Reliable data relating to incidence of OSAHS were not found; therefore, the mortality rate of men aged 55 was used as an approximation (0.1%) in order to calculate the population EVPI, assuming a lifetime for the technology of 5 years. This indicated that the upper boundary for the value of further research was between £33 million and £50 million. Further investigation may be warranted to identify those parameters that contribute most to the decision uncertainty. Including the prevalent patient population in those able to benefit from additional research would increase the EVPI considerably. The indication is that the value of information gained from further research may well exceed the costs of undertaking that research.

Based on the regression analysis to predict utility scores, the EQ-5D and SF-6D utility models indicated that an increase of 1 point in ESS was associated with a decline in utility of 0.01. A crude comparison of the ESS and utility data from Chakravorty et al. indicates that, for a 1-point drop in ESS, an increase in utility of 0.005 was found based on the EQ-5D valuations and 0.03 based on the standard gamble valuations. The 0.23 improvement in utility post treatment, on the basis of a before and after analysis of standard gamble valuations, has been used in a previous economic evaluation by Ayas et al. without an attempt to link in the available clinical evidence. The crude comparison of ESS and utility data from Jenkinson et al. indicated that, for a 1-point drop in ESS, an increase in utility was found of 0.009 based on the EQ-5D valuations. Therefore, our analysis seems to be in line with previously published estimates.

Hypothetically, the sensitivity of EQ-5D scores to changes in sleepiness could be limited as the instrument does not contain a question specifically directed at sleepiness or energy and wakefulness. However, the EQ-5D instrument could still capture the health effects of sleepiness, e.g. in terms of its effects on usual activities or anxiety and depression. This analysis suggests that this concern may be unfounded, as employing the utility scores calculated from SF-6D, which does include a question about energy and vitality, produced strikingly similar results in the set of individual patient-level data available.

The York model considered NHS and PSS costs and, therefore, omitted any private costs of health care. In practice, however, according to our clinical experts, dental devices are infrequently provided under NHS dental care. Private costs of dental devices were estimated at an initial cost of over £600 which, if included in the analysis, would reduce the cost-effectiveness of dental devices.

Strengths and limitations of the assessment

Clinical effectiveness

While there is clear and robust evidence of a benefit with CPAP compared with placebo/usual care in relation to daytime sleepiness, the finding of a variation in the treatment effect with disease severity needs to be interpreted with some caution. The factors of interest investigated (except for one post hoc analysis) were specified in advance and the number of factors investigated was kept as small as possible. In addition, the findings from the subgroup analyses make clinical sense. However, the subgroup analyses are based on summary data and the comparisons are therefore observational and are not based on randomised comparisons as in a trial or an individual patient data analysis. Therefore, the trend of a treatment effect by disease severity should not be considered definitive. In addition, although the cut-off points used to define disease (AHI) and symptom severity (ESS) are based on those used clinically, these are arbitrary cut-off points. The subgroup analyses for other outcomes were limited by the small number of studies available. However, because disease and symptom severity are thought to be clinically important factors in the response to treatment we have tried to make clear the clinical populations to which the findings refer.

The subgroup analyses also do not account for any potential confounding between the factors investigated; for example, studies using a sham CPAP comparator were less likely to be crossover trials. Where the treatment effect varied between crossover and parallel trials, this may not have been due to the study design but may have been related
to the comparator used. There were other factors that may have had an influence on the treatment effect that it was not feasible to investigate, due to the limitations of the available data, such as study duration and the subtherapeutic pressure used for sham CPAP.

The findings for the primary outcome of subjective sleepiness were robust when only studies with adequate concealment of allocation were considered. However, the investigation of the impact of study quality (as defined by adequacy of concealment of allocation) on the findings was limited by the fact that only five studies reported that an adequate method had been used. It was also possible to investigate whether the findings where robust, for the ESS as an outcome measure, when only the studies using sham CPAP as a comparator were considered. Participant blinding was possible only in the studies in which CPAP was used as the comparator; effectively it provides the best placebo in this field. When only studies using a sham CPAP comparator were subgrouped by baseline symptom severity (ESS) the findings were similar to those using the complete data set subgrouped by baseline symptom severity (ESS), i.e. there was a statistically significant benefit with CPAP compared with sham CPAP for each of the three subgroups, and the treatment effect was largest for the severe symptom subgroup and was consecutively smaller for the moderate and mild groups. Only a small subset of studies included all the randomised patients in the analysis; therefore, as a group of studies there is a risk that the size of the treatment effect may have been slightly overestimated. It was not possible to investigate the impact of this; however, loss to follow-up was reasonably low in the majority of studies.

The benefit with CPAP compared with control on the ESS and MWT is consistent with previous systematic reviews.48,50 A previous subgroup analysis reported a more pronounced effect of CPAP in participants with moderate and severe symptoms at baseline, although this was apparent in parallel trials only.50 A systematic review published just as the current review was completed reported 24-hour mean blood pressure, using ABPM, as a primary outcome.174 A small but statistically significant decrease in 24-hour MAP of 1.7 mmHg was reported (MD –1.7 mmHg, 95% CI –2.7 to –0.7). There was a statistically significant decrease in daytime MAP of a similar magnitude to the current review (–1.8 mmHg, 95% CI –3.0 to –0.2) compared with 2.1 mmHg (MD –2.1, 95% CI –4.3 to 0.0) in the current review. Unlike the current review, there was a significant benefit with CPAP compared with placebo for SBP [–2.3 mmHg, (95% CI –4.3 to –0.2)] and DBP [–2.9 mmHg, (95% CI –4.4 to –0.4)]. The recently published review used estimates for MAP from SBP and DBP where MAP was not reported and included data from two studies from which we could not get accurate estimates from the graphs and were not able to obtain the data from the authors. The additional power in the analysis may have been important in deriving a statistically significant benefit on SBP and DBP.

**Cost-effectiveness**

The York model is the first cost-effectiveness study to seek to reflect the implications for long-term costs and QALYs of a broad range of trial evidence on sleepiness and to compare all relevant treatment options in the NHS. It explores a range of scenarios and quantifies decision uncertainty and the EVPI. The analysis suggests that CPAP is cost-effective compared with dental devices and conservative management, assuming a cost-effectiveness threshold of £20,000, with one exception, i.e. the ICER in a subgroup with mild disease in terms of baseline ESS score was estimated to be £20,585.

This is consistent with previously published economic evaluations. However, the York model additionally provided an estimate of the value of further research, which indicated that the cost of the uncertainty associated with the model parameters was high. The EVPI was calculated based only on the incident patient population and does not incorporate uncertainty in model structure, modelling assumptions and data quality. Given this, it may underestimate the cost of the decision uncertainty. When interpreting the results of the York model some caveats must be borne in mind:

- The translation of health benefits in terms of ESS to utility scores was based on simple regression models derived from just three sets of patient-level data.
- The patient-level data on which the regression models were based came from predominantly patients receiving CPAP. To address this problem, future trials would ideally incorporate generic instruments to provide a direct measure of preference-based HRQoL.

© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
• The effect of CPAP treatment on reducing RTAs was derived from observational studies. While it would not seem feasible to conduct an RCT to measure such a rare effect, it would be preferable to have been able to link this information in some way to the information obtained in the systematic review.
• While some trials report the impact of CPAP on blood pressure, this outcome is infrequently reported, and the trials are too short in length to directly measure impact on CVEs, and so estimated changes in CVE rates are inferred from other published risk equations.

Uncertainties

• The effectiveness (and hence cost-effectiveness) of using CPAP to treat mild disease remains uncertain due to a paucity of research; the treatment effect for daytime sleepiness in the current review is based on only two studies.
• The relative treatment benefits with CPAP according to symptom severity are based on summary data and cannot be viewed as definitive.
• The patients studied in most trials tend to be middle-aged and predominantly male. It is unclear whether therapeutic benefits are similar in other groups, in particular the elderly, in whom cognitive impairment and cerebrovascular disease are more prevalent and the OSAHS may be complicated.
• There is evidence of a benefit with CPAP on MAP although this finding was not robust, possibly due to an underpowered analysis. In addition, it remains unclear in what patient groups this benefit might be expected to be found in terms of disease severity and blood pressure status at baseline.
• The evidence of a fall in MAP implies a reduction in cardiovascular risk, but this has not been directly studied and the magnitude of the risk for end-organ cardiovascular damage is therefore uncertain.
• Dental devices may be a treatment option in moderate disease. However, there was inconsistency in the treatment effect comparing CPAP and dental devices, possibly due to the variety of dental devices investigated. It remains unclear precisely what type of devices may be effective and in which populations with OSAHS. The effectiveness of dental devices compared with CPAP in mild and severe disease populations is unclear.
• Only two outcome measures from the clinical trial data (effect of treatment on ESS and SBP) were incorporated in the economic model. Potentially some of the other measures reported in the trials could impact on HRQoL independently of ESS and this is not reflected in the current model. In particular, the model does not differentiate between conservative management, dental devices and CPAP in terms of the disutility associated with undesirable side effects from treatments themselves, which may be expected to differ between the technologies.
• The estimates of cost-effectiveness of CPAP by baseline severity in OSAHS should be considered with caution. Although there was clear heterogeneity in ESS treatment effects in the overall meta-analysis in Chapter 3, it was only possible to group trials by severity using average study-level data. Furthermore, because it was not possible to estimate treatment effects on blood pressure or RTAs by baseline OSAHS severity, these effects have been removed entirely from this analysis.

Other relevant factors

The trials included in this technology assessment mainly used thorough diagnostic assessment to establish a diagnosis of OSAHS and the findings of this review are applicable to a population in which there has been an adequate diagnostic assessment. In view of the diagnostic complexity of sleep apnoea, adequate diagnostic assessment should include a multichannel sleep study reported by an appropriately trained physician (such as a consultant respiratory physician). The detailed consideration of what would constitute an appropriate multichannel sleep study and the associated cost implications were outside the remit of this technology appraisal.

CPAP does not deal with one of the key underlying causes of the disease, which is obesity. It was not possible to assess the relative benefits of CPAP over weight loss interventions due to a lack of appropriate data. The main focus of the current review was CPAP for the treatment of OSAHS, but a recent systematic review comparing lifestyle interventions with placebo found no relevant studies and identified a need for research addressing obesity.30
Chapter 7

Conclusions

Implications for service provision

• CPAP is an effective treatment for OSAHS compared with best supportive care and placebo in populations with moderate to severe symptoms and there may be benefits where the disease is mild. In populations with moderate to severe symptoms there is robust evidence of improvement in symptoms of daytime sleepiness.
• There is evidence of benefit in blood pressure and quality of life with CPAP, although some uncertainty remains about these outcomes.
• Dental devices may be a treatment option in moderate disease but some uncertainty remains.
• On average, CPAP was associated with higher costs and higher benefits than were dental devices or conservative management. The probability of CPAP being more cost-effective than dental devices or conservative management was high for a cost-effectiveness threshold of £20,000 per QALY gained.

Suggested research priorities

• There is uncertainty about the effectiveness of CPAP for populations with OSAHS with mild daytime sleepiness and further investigation of the effectiveness of CPAP for this population is required.
• Although dental devices are not as cost-effective as CPAP, they do provide an alternative treatment option for patients who cannot tolerate CPAP. The trial evidence comparing dental devices with CPAP was not extensive and had some limitations; therefore, further trials may be useful. Given the heterogeneity of devices in use, the research should identify the most effective type and address whether there are specific patient groups that do or do not benefit.
• Further investigation of the effect of CPAP on hypertension and which populations might be expected to benefit in terms of OSAHS disease severity and normotensive and hypertensive patients would be beneficial.
• Currently changes in cardiovascular events have to be inferred from changes in blood pressure; therefore, clinical trials that are adequately powered to identify changes in CVEs would be beneficial.
• The populations studied in current trials are mostly male and middle-aged. Clinical trials to define treatment effects at the extremes of age (particularly in the elderly, in whom cardiovascular co-morbidity complicates assessment) and in women would be beneficial.
• More comprehensive data are required on side effects, and this information should be systematically obtained and reported in any future research.
Acknowledgements

Thanks to Professor John Stradling for providing clinical expertise and interpretation of evidence used in the assessment and to Dr Mark Ter-Berg and Adrian Zacher for information on resource use associated with dental devices.

Thanks to the following authors of clinical effectiveness trials who responded to queries or provided data: Aarnoud Hoekema, John Wilding, Melanie Cross, Joel Dimsdale, David Hui, Francisco García Río and Sophie West. Thanks also to TJ Lasserson and colleagues for providing data from their Cochrane review.

Contribution of authors

Catriona McDaid (Research Fellow) was involved in the clinical effectiveness part of the review, writing the protocol, study selection, data extraction, quality assessment, data analysis and report writing. Susan Griffin (Research Fellow) was involved in the cost-effectiveness section, study selection, development of the economic model and report writing. Helen Weatherly (Research Fellow) was involved in the cost-effectiveness section, study selection, development of the economic model and report writing. Kate Durée (Research Fellow) was involved in the clinical effectiveness section including writing the protocol, study selection, data extraction, quality assessment, data analysis and report writing. Mariëlle van der Burgt (Visiting Researcher) was involved in the cost-effectiveness section, study selection, development of the economic model and report writing. Sue van Hout (Research Fellow) contributed to the quality of life section for the background and summarised the studies reporting utility data which were used to inform the economics section. Jo Akers (Information Officer) devised the search strategy, carried out the literature searches and wrote the search methodology sections of the report. Robert Davies (Reader in Respiratory Medicine) provided technical and clinical advice and commented on drafts of the report. Mark Sculpher provided input at all stages of the review, commented on drafts of the report and took overall responsibility for the economic section. Marie Westwood (Reviews Manager) provided input at all stages of the review, commented on drafts of the report and took overall responsibility for the review.
References


References


References


107. Olson LG, Ambrogetti A, Trevillian Z. A randomised crossover comparison of nasal CPAP and a mandibular advancement splint in mild
obstructive sleep apnea. 2002 [unpublished data reproduced in Cochrane Review CD001106].


References


155. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. The effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes [personal communication].


sleep-disordered breathing on neurocognitive functions pre- and posttreatment with CPAP. Sleep 2006;29:A208–9.


207. Chasens ER, Weaver TE, Maislin G, Dinges D, Pack A. Sleepiness and adherence to CPAP treatment in adults with OSA. Sleep 2003;26:A256.


References


References

nasal continuous positive airway pressure (NCPAP) on simulated steering in obstructive sleep apnoea (OSA). *Am J Respir Crit Care Med* 1999;159:A429.


348. Tan YK, L’Estrange PR, Grant HR, Smith C, Simonds AK, Spiro SG. Subjective assessment of continuous positive airway pressure (CPAP) and a mandibular advancement splint (MAS) in a randomised crossover study of patients with mild or moderate obstructive sleep apnoea (OSA). *Thorax* 1998;53:A4.
Volume 1, 1997

No. 1
Home parenteral nutrition: a systematic review.
By Richards DM, Deeks JJ, Sheldon TA, Shaffer JL.

No. 2
Diagnosis, management and screening of early localised prostate cancer.
A review by Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.

No. 3
The diagnosis, management, treatment and costs of prostate cancer in England and Wales.
A review by Chamberlain J, Melia J, Moss S, Brown J.

No. 4
Screening for fragile X syndrome.
A review by Murray J, Cuckle H, Taylor G, Hewison J.

No. 5
A review of near patient testing in primary care.

No. 6
Systematic review of outpatient services for chronic pain control.
By McQuay HJ, Moore RA, Eccleston C, Morley S, de C Williams AC.

No. 7
Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

No. 8
Preschool vision screening.
A review by Snowden SK, Stewart-Brown SL.

No. 9
Implications of socio-cultural contexts for the ethics of clinical trials.
A review by Ashcroft RE, Chadwick DW, Clark SRL, Edwards RHT, Frith L, Hutton JL.

No. 10
A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment.
By Davis A, Bamford J, Wilson I, Ramkalawan T, Forsaw M, Wright S.

No. 11
Newborn screening for inborn errors of metabolism: a systematic review.

No. 12
Routine preoperative testing: a systematic review of the evidence.
By Munro J, Booth A, Nicholl J.

No. 13
Systematic review of the effectiveness of laxatives in the elderly.
By Petticrew M, Watt I, Sheldon T.

No. 14
When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.
A review by Mowatt G, Bower DJ, Brehmer NA, Cairns JA, Grant AM, McKee L.

Volume 2, 1998

No. 1
Antenatal screening for Down’s syndrome.
A review by Wald NJ, Kennard A, Hackshaw A, McGuire A.

No. 2
Screening for ovarian cancer: a systematic review.
By Bell R, Petticrew M, Luengo S, Sheldon TA.

No. 3
Consensus development methods, and their use in clinical guideline development.

No. 4
A cost-utility analysis of interferon beta for multiple sclerosis.

No. 5
Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews.
By MacLeod A, Grant A, Donaldson C, Khan I, Campbell M, Daly C, et al.

No. 6
Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model.

No. 7
Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials.
By Song F, Glenny AM.

No. 8
Bone marrow and peripheral blood stem cell transplantation for malignancy.
A review by Johnson PWM, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA.

No. 9
Screening for speech and language delay: a systematic review of the literature.
By Law J, Boyle J, Harris F, Harkness A, Nye C.

No. 10
By Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ.

No. 11
Detection, adherence and control of hypertension for the prevention of stroke: a systematic review.
By Ebrahim S.

No. 12
Pacemaker therapy and blood transfusions: a systematic review.
By McQuay HJ, Moore RA.

No. 13
Choosing between randomised and nonrandomised studies: a systematic review.
By Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C.

No. 14
Evaluating patient-based outcome measures for use in clinical trials.
A review by Fitzpatrick R, Davey C, Buxton MJ, Jones DR.
No. 15 Ethical issues in the design and conduct of randomised controlled trials.
   A review by Edwards SJL, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J.

No. 16 Qualitative research methods in health technology assessment: a review of the literature.
   By Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P.

No. 17 The costs and benefits of paramedic skills in pre-hospital trauma care.
   By Nicholl J, Hughes S, Dixon S, Turner J, Yates D.

No. 18 Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.

No. 19 Systematic reviews of trials and other studies.
   By Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.

No. 20 Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different protheses.

Volume 3, 1999

No. 1 Informed decision making: an annotated bibliography and systematic review.

No. 2 Handling uncertainty when performing economic evaluation of healthcare interventions.
   A review by Briggs AH, Gray AM.

No. 3 The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.

No. 4 A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability. Annex: Antenatal HIV testing – assessment of a routine voluntary approach.

No. 5 Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review.
   By Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PG.

No. 6 Assessing the costs of healthcare technologies in clinical trials.
   A review by Johnston K, Buxton MJ, Jones DR, Fitzpatrick R.

No. 7 Cooperatives and their primary care emergency centres: organisation and impact.
   By Hallam L, Henthorne K.

No. 8 Screening for cystic fibrosis.
   A review by Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J.

No. 9 A review of the use of health status measures in economic evaluation.
   By Brazier J, Deverill M, Green C, Harper R, Booth A.

No. 10 Methods for the analysis of quality-of-life and survival data in health technology assessment.
   A review by Billingham LJ, Abrams KR, Jones DR.

No. 11 Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.
   By Zeuner D, Akes AE, Karbon J, Brown J, Dezateux C, Anionwu EN.

No. 12 Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

No. 13 'Early warning systems' for identifying new healthcare technologies.
   By Robert G, Stevens A, Gabbay J.

No. 14 A systematic review of the role of human papillomavirus testing within a cervical screening programme.

No. 15 Near patient testing in diabetes clinics: appraising the costs and outcomes.
   By Grieve R, Beech R, Vincent J, Mazurkiewicz J.

No. 16 Positron emission tomography: establishing priorities for health technology assessment.
   A review by Robert G, Milne R.

No. 17 (Pt 1) The debridement of chronic wounds: a systematic review.
   By Bradley M, Cullum N, Sheldon T.

No. 17 (Pt 2) Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic wounds.
   By Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D.

No. 18 A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease.

No. 19 What role for statins? A review and economic model.

No. 20 Factors that limit the quality, number and progress of randomised controlled trials.
   A review by Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiatu S, et al.

No. 21 Antimicrobial prophylaxis in total hip replacement: a systematic review.
   By Glenny AM, Song F.

No. 22 Health promoting schools and health promotion in schools: two systematic reviews.
   By Lister-Sharp D, Chapman S, Stewart-Brown S, Sowden A.

No. 23 Economic evaluation of a primary care-based education programme for patients with osteoarthritis of the knee.
Volume 4, 2000

No. 1

The estimation of marginal time preference in a UK-wide sample (TEMPUS) project.

By Cairns JA, van der Pol MM.  

No. 2

Geriatric rehabilitation following fractures in older people: a systematic review.


No. 3

Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.

By Davies SC, Cronin E, Gill M, Greengross F, Hickman M, Normand C.  

No. 4

Community provision of hearing aids and related audiology services.

By Reeves DJ, Alborz A, Hickson FS, Bamford JM.  

No. 5

False-negative results in screening programmes: systematic review of impact and implications.

By Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K.  

No. 6

Costs and benefits of community postnatal support workers: a randomised controlled trial.

By Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A.  

No. 7

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.


No. 8

An introduction to statistical methods for health technology assessment.

By White SJ, Ashby D, Brown PJ.  

No. 9

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

By Clegg A, Bryant J, Milne R.  

No. 10

Publication and related biases.

By Song F, Eastwood AJ, Gilbody S, Daley L, Sutton AJ.  

No. 11

Cost and outcome implications of the organisation of vascular services.

By Michals J, Brazier J, Palfreyman S, Shackley P, Slack R.  

No. 12

Monitoring blood glucose control in diabetes mellitus: a systematic review.

By Coster S, Guilford MC, Seed PT, Powrie JK, Swaminathan R.  

No. 13

The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature.


No. 14

The determinants of screening uptake and interventions for increasing uptake: a systematic review.


No. 15

The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth.

A rapid review by Song F, O’Meara S, Wilson E, Golder S, Kleijnen J.  

No. 16


No. 17

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.

By Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.  

No. 18

Liquid-based cytology in cervical screening: a rapid and systematic review.

By Payne N, Chikott J, McGoogan E.  

No. 19

Randomised controlled trial of non-directive counselling, cognitive–behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.


No. 20

Routine referral for radiography of patients presenting with low back pain: is patients’ outcome influenced by GPs’ referral for plain radiography?

By Kerry S, Hilton S, Patel S, Dundas D, Rink E, Lord J.  

No. 21

Systematic review of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.

By O’Meara S, Cullum N, Majid M, Sheldon T.  

No. 22

Using routine data to complement and enhance the results of randomised controlled trials.

By Lewsey JD, Leyland AH, Murray GD, Boddy FA.  

No. 23

Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.

By Meads C, Cummings C, Jolly K, Stevens A, Burls A, Hyde C.  

No. 24

Outcome measures for adult critical care: a systematic review.

By Hayes JA, Black NA, Jenkinson C, Young JD, Rowan KM, Daly K, et al.  

No. 25

A systematic review to evaluate the effectiveness of interventions to promote the initiation of breastfeeding.

By Fairbank L, O’Meara S, Rentfrew MJ, Woolridge M, Sowden AJ, Lister-Sharp D.  

No. 26

Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.

By Parkes J, Bryant J, Milne R.  

No. 27

Treatments for fatigue in multiple sclerosis: a rapid and systematic review.

By Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.  

No. 28

Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.


No. 29

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.

By Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW.  

No. 30

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.

By McDonagh MS, Bachmann LM, Gold S, Kleijnen J, ter Riet G.
No. 31
A randomised controlled trial of prehospital intravenous fluid replacement therapy in serious trauma.
By Turner J, Nicholl J, Webber L, Cox H, Dixon S, Yates D.

No. 32
Intrathecal pumps for giving opioids in chronic pain: a systematic review.
By Williams JE, Louw G, Towler G.

No. 33
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
By Shepherd J, Waugh N, Hewitson P.

No. 34
A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies.
By MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AMS.

No. 35
Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.
By Berry E, Kelly S, Hutton J, Lindsay HSJ, Blaxill JM, Evans JA, et al.

No. 36
A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression.
By Simpson S, Corney R, Fitzgerald P, Beecham J.

No. 37
Systematic review of treatments for atopic eczema.
By Hoare C, Li Wan Po A, Williams H.

No. 38
Bayesian methods in health technology assessment: a review.
By Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR.

No. 39
The management of dyspepsia: a systematic review.

No. 40
A systematic review of treatments for severe psoriasis.
By Griffiths CEM, Clark CM, Chalmers RG, Li Wan Po A, Williams HC.

Volume 5, 2001

No. 1
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic review.

No. 2
The clinical effectiveness and cost-effectiveness of rihuzole for motor neurone disease: a rapid and systematic review.

No. 3
Equity and the economic evaluation of healthcare.
By Sassi F, Archard L, Le Grand J.

No. 4
Quality-of-life measures in chronic diseases of childhood.
By Eiser C, Morse R.

No. 5
Eliciting public preferences for healthcare: a systematic review of techniques.

No. 6
General health status measures for people with cognitive impairment: learning disability and acquired brain injury.
By Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J.

No. 7
An assessment of screening strategies for fragile X syndrome in the UK.
By Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G.

No. 8
Issues in methodological research: perspectives from researchers and commissioners.

No. 9
Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy.
By Cullum N, Nelson EA, Fleming K, Sheldon T.

No. 10
Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review.

No. 11
Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review.
By Jobanputra P, Parry D, Fry-Smith A, Burls A.

No. 12
Statistical assessment of the learning curves of health technologies.
By Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT.

No. 13
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
By Dinnes J, Cave C, Huang S, Major K, Milne R.

No. 14
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.
By Lewis R, Whiting P, ter Riet G, O’Meara S, Glanville J.

No. 15
Home treatment for mental health problems: a systematic review.
By Eccles M, Mason J.

No. 16
The role of specialist nurses in multiple sclerosis: a rapid and systematic review.
By De Broe S, Christopher F, Waugh N.

No. 17
How to develop cost-conscious guidelines.
By Dinnes L, Veitch J, Mather L.

No. 18
By O’Meara S, Riemsma R, Shurratt L, Mather L, ter Riet G.

No. 19
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
By Chilcott J, Wight J, Lloyd Jones M, Tappenden P.

No. 20
Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and preregistration house officers in preoperative assessment in elective general surgery.
No. 21  Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) Acute day hospital versus admission; (2) Vocational rehabilitation; (3) Day hospital versus outpatient care.

No. 22  The measurement and monitoring of surgical adverse events.
   By Bruce J, Russell EM, Mollison J, Krukowski ZH.

No. 23  Action research: a systematic review and guidance for assessment.
   By Waterman H, Tillen D, Dickson R, de Koning K.

No. 24  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.

No. 25  A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatine and raltitrexed for the treatment of advanced colorectal cancer.
   By Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M.

No. 26  Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

No. 27  The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint.

No. 28  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
   By Forbes C, Shirran L, Bagnall A-M, Duffy S, ter Riet G.

No. 29  Superseded by a report published in a later volume.

No. 30  The role of radiography in primary care patients with low back pain of at least 6 weeks duration: a randomised (unblinded) controlled trial.
   By Kendrick D, Fielding K, Bentley E, Miller P, Kerkslake R, Pringle M.

No. 31  Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients.

No. 32  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
   By Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

No. 33  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
   By Brooks ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G.

No. 34  Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes.
   By David AS, Adams C.

No. 35  A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.

No. 36  Cost analysis of child health surveillance.
   By Sanderson D, Wright D, Acton C, Duree D.

Volume 6, 2002

No. 1  A study of the methods used to select review criteria for clinical audit.
   By Hearshaw H, Harker R, Cheater F, Baker R, Grimshaw J.

No. 2  Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.

No. 3  Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin’s lymphoma: a systematic review and economic evaluation.

No. 4  A systematic review of discharge arrangements for older people.

No. 5  The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.
   By Peters J, Stevenson M, Beverley C, Lim J, Smith S.

No. 6  The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
   By O’Meara S, Riemsma R, Shirran L, Mathier L, ter Riet G.

No. 7  The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review.

No. 8  Promoting physical activity in South Asian Muslim women through ‘exercise on prescription’.
   By Carroll B, Ali N, Azam N.

No. 9  Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.

No. 10  A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.
   By Richards RG, Sampson FC, Beard SM, Tappenden P.

No. 11  Screening for gestational diabetes: a systematic review and economic evaluation.
   By Scott DA, Loveman E, McIntyre L, Waugh N.

No. 12  The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation.

No. 13  The clinical effectiveness of trastuzumab for breast cancer: a systematic review.

No. 14  The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
No. 15 A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease.
  By Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC.

No. 16 The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
  By Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al.

No. 17 A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
  By Cummins C, Connock M, Fry-Smith A, Burl A.

No. 18 Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.

  By Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, et al.

No. 20 Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial.
  By Zer mansky AG, Petty DR, Raynor DK, Lowe CJ, Freem entle N, Vail A.

No. 21 The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
  By Jobanputra P, Barton P, Bryan S, Burl A.

No. 22 A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.
  By Kalten haler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J.

No. 23 A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.
  By Forbes C, Wilby J, Richardson G, Sculpter M, Mather L, Reim sma R.

No. 24 A systematic review of the effectiveness of interventions based on a stages-of-change approach to promote individual behaviour change.

No. 25 A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.

No. 26 A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS.

No. 27 A randomised controlled crossover trial of nurse practitioner versus doctor-patient care in a bronchiectasis clinic.

No. 28 Clinical effectiveness and cost–consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.
  By Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C.

No. 29 Treatment of established osteoporosis: a systematic review and cost-utility analysis.
  By Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M.

No. 30 Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial.

No. 31 Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice.

No. 32 The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature.

No. 33 The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
  By Garside R, Round A, Dalziel K, Stein K, Royle R.

No. 34 A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.

No. 35 A systematic review of the costs and effectiveness of different models of paediatric home care.

Volume 7, 2003

No. 1 How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.
  By Egger M, Juni P, Bartlett C, Holenstein F, Sterne J.

No. 2 Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure.

No. 3 Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease.
  By Clark W, Raftery J, Barton P, Song F, Fry-Smith A, Burl A.

No. 4 A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus negative.

No. 5 Systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma.

No. 6 The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.
No. 7
The clinical effectiveness and cost-effectiveness of routine dental checks: a systematic review and economic evaluation.

No. 8
A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia.

No. 9
Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.
By Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C.

No. 10
Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities.

No. 11
First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
By Wald NJ, Rodreck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM.

No. 12
The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation.
By Calvert N, Hind D, McWilliams RG, Thomas SM, Beverley C, Davidson A.

No. 13
A systematic review of atypical antipsychotics in schizophrenia.
By Bagnall A-M, Jones L, Richmond G, Duffy S, Riemsma R.

No. 14
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.
By Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et al.

No. 15
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.

No. 16
Screening for fragile X syndrome: a literature review and modelling.
By Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A.

No. 17
Systematic review of endoscopic sinus surgery for nasal polyps.
By Dalziel K, Stein K, Round A, Garside R, Royle P.

No. 18
Towards efficient guidelines: how to monitor guideline use in primary care.
By Hutchinson A, McIntosh A, Cox S, Gilbert C.

No. 19
Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review.
By Bagnall A-M, Jones L, Richardson G, Duffy S, Riemsma R.

No. 20
Prioritisation of health technology assessment. The PATHS model: methods and case studies.
By Townsend J, Buxton M, Harper G.

No. 21

No. 22
By Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N.

No. 23
The role of modelling in prioritising and planning clinical trials.
By Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P.

No. 24
Cost–benefit evaluation of routine influenza immunisation in people 65–74 years of age.
By Allsup S, Gosney M, Haycox A, Regan M.

No. 25
The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.
By Wight J, Chilcott J, Holmes M, Brewer N.

No. 26
Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment.
By Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT.

No. 27
Evaluating non-randomised intervention studies.

No. 28
A randomised controlled trial to assess the impact of a package comprising a patient-oriented, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease.

No. 29
The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review.
By Dinnes J, Loveman E, McIntyre L, Waugh N.

No. 30
The value of digital imaging in diabetic retinopathy.

No. 31
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.
By Law M, Wald N, Morris J.

No. 32
Clinical and cost-effectiveness of capcitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
By Ward S, Kaltenthaler E, Cowan J, Brewer N.

No. 33
By Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

No. 34
Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system.
By Royle P, Waugh N.
No. 35  Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

No. 36  A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.
By Boland A, Haycox A, Bagust A, Fitzsimmons L.

No. 37  Redesigning postnatal care: a randomised controlled trial of protocol-based midwifery-led care focused on individual women’s physical and psychological health needs.

No. 38  Estimating implied rates of discount in healthcare decision-making.
By West RR, McNabb R, Thompson AGH, Sheldon TA, Grimley Evans J.

By Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, et al.

No. 40  Treatments for spasticity and pain in multiple sclerosis: a systematic review.
By Beard S, Humm A, Wrigt J.

No. 41  The inclusion of reports of randomised trials published in languages other than English in systematic reviews.
By Moher D, Pham B, Lawson ML, Klassen TP.

No. 42  The impact of screening on future health-promoting behaviours and health beliefs: a systematic review.

Volume 8, 2004

No. 1  What is the best imaging strategy for acute stroke?
By Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercok PAG, Dennis MS, et al.

No. 2  Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care.
By Mant J, McManus RJ, Oakes RAJ, Delaney BC, Barton PM, Deeks JJ, et al.

No. 3  The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling.
By Garside R, Stein K, Wyat K, Round A, Price A.

No. 4  A systematic review of the role of bisphosphonates in metastatic disease.

No. 5  Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
By Jones L, Hawkin N, Westwood M, Wright K, Richardson G, Riensma R.

No. 6  Effectiveness and efficiency of guideline dissemination and implementation strategies.

No. 7  Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.
By Bryant J, Clegg AJ, Siddhu MK, Brodin H, Royle P, Davidson P.

No. 8  Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.
By Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M.

No. 9  Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
By Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.

No. 10  A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.

No. 11  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

By Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S.

By Czoski-Murray C, Warren E, Chilcott J, Beverley C, Pyllakoi MA, Cowan J.

No. 14  Routine examination of the newborn: the EMREN study. Evaluation of an extension of the midwife role including a randomised controlled trial of appropriately trained midwives and paediatric senior house officers.

No. 15  Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach.

No. 16  A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery.

No. 17  Does early magnetic resonance imaging influence management or improve outcome in patients referred to secondary care with low back pain? A pragmatic randomised controlled trial.
By Gilbert FJ, Grant AM, Gillan MGC, Vale L, Scott NW, Campbell MK, et al.

No. 18  The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
By Clark W, Johanputtra P, Barton P, Burls A.
No. 19  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

No. 20  Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

No. 21  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

No. 22  Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus.
   By Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A.

No. 23  Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients.
   By Dretzke J, Sandercock J, Bayliss S, Burls A.

No. 24  Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

No. 25  Development and validation of methods for assessing the quality of diagnostic accuracy studies.
   By Whiting P, Rutjes AWS, Dinnes J, Reitsma JB, Bossuyt PMM, Kleijnen J.

No. 26  EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy.

No. 27  Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis.
   By Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C.

   By Dalziel K, Round A, Stein K, Garside R, Price A.

No. 29  VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers.
   By Iglesias C, Nelson EA, Callum NA, Torgerson DJ, on behalf of the VenUS Team.

No. 30  Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction.

No. 31  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
   By Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S.

No. 32  The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas.

No. 33  Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.
   By Green JM, Hewison J, Bekker HL, Bryant, Cuckle HS.

No. 34  Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status.

No. 35  Coronary artery stents: a rapid systematic review and economic evaluation.

No. 36  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

No. 37  Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: a systematic review and economic evaluation.
   By Knight C, Hind D, Brewer N, Abbott V.

No. 38  Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
   By Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al.

No. 39  Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
   By Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

No. 40  Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
   By Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al.

No. 41  Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.
   By Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, et al.

No. 42  Involving South Asian patients in clinical trials.
   By Hussain-Gambles M, Leese B, Atkin K, Brown J, Mason S, Tovey P.

No. 43  Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
   By Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

No. 44  Identification and assessment of ongoing trials in health technology assessment reviews.

No. 45  Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
   By Warren E, Weatherley-Jones E, Chilcott J, Beverley C.
No. 46
Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis.

No. 47
Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
By Green C, Colquitt JL, Kirby J, Davidson P, Payne E.

No. 48
Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis.

No. 49
Generalisability in economic evaluation studies in healthcare: a review and case studies.

No. 50
Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations.

Volume 9, 2005

No. 1
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.

No. 2
Do the findings of case series studies vary significantly according to methodological characteristics?
By Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L.

No. 3
Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.

No. 4
Randomised evaluation of alternative electro Surgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia.
By Fowler C, McAllister W, Plail R, Karim O, Yang Q.

No. 5
A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer.
By Shenefine J, McNamee P, Steen N, Bond J, Griffin SM.

No. 6
Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography.

No. 7
Issues in data monitoring and interim analysis of trials.
By Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Derbyshire JH, et al.

No. 8
Lay public’s understanding of equipoise and randomisation in randomised controlled trials.

No. 9
Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.
By Greenhalgh J, Knight C, Hind D, Beverley C, Walters S.

No. 10
Measurement of health-related quality of life for people with dementia: development of a new instrument (DEM QOL) and an evaluation of current methodology.

No. 11
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

No. 12
Clinical effectiveness and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

No. 13
Clinical effectiveness, tolerability and cost-effectiveness of newer antidepressants for depressive illness: a systematic review and economic evaluation.

No. 14
A randomised controlled trial to compare the cost-effectiveness of tricylic antidepressants, selective serotonin reuptake inhibitors and loperamide.

No. 15
Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK.
By Willis BH, Barton E, Pearlman P, Bryan S, Hyde C.

No. 16
Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.

No. 17
Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation.

No. 18
A randomised controlled comparison of alternative strategies in stroke care.
By Kaufa L, Evans A, Perez I, Knupp M, Schiff C, Donaldson N.

No. 19
The investigation and analysis of critical incidents and adverse events in healthcare.
By Woloshynowych M, Rogers S, Taylor-Adams S, Vincent C.

No. 20
Potential use of routine databases in health technology assessment.
By Rafferty J, Roderick P, Stevens A.

No. 21

No. 22
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
By Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J.
No. 23
A systematic review to examine the impact of psycho-educational interventions on health outcomes and costs in adults and children with difficult asthma.

No. 24
An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.

No. 25
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

No. 26
Indirect comparisons of competing interventions.

No. 27
Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

No. 28
Outcomes of electrically stimulated gracilis neosaphenectomy surgery.
By Tillin T, Chambers M, Feldman R.

No. 29
The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for the management of atopic eczema: a systematic review and economic evaluation.

No. 30
Systematic review on urine albumin testing for early detection of diabetic complications.

No. 31
Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis.
By Cochrane T, Davey RC, Matthes Edwards SM.

No. 32
Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.

No. 33
Cost-effectiveness and safety of epidural steroids in the management of sciatica.
By Price C, Arden N, Cogan L, Rogers P.

No. 34
The British Rheumatoid Outcome Study Group (BROOSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
By Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL.

No. 35
Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials.

No. 36
The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review.
By Bryant J, Brodin H, Loveman E, Payne E, Clegg A.

No. 37
A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study.

No. 38
The causes and effects of socio-demographic exclusions from clinical trials.

No. 39
Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis.

No. 40
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

No. 41
Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty.
By King JF, Grant A, Masson M, Scott NW, Forbes JE.

No. 42
Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

No. 43
The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation.
By Castelnuovo E, Stein K, Pitt M, Garside R, Payne E.

No. 44
Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.

No. 45
The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.

No. 46
The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma.
By Kwartz AJ, Henson DB, Harper RA, Spencer AF, McLeod D.

No. 47
Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation.
No. 48 Systematic review of effectiveness of different treatments for childhood retinoblastoma.  

No. 49 Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.  

No. 50 The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children.  

Volume 10, 2006

No. 1 The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease.  

No. 2 FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke.  
By Dennis M, Lewis S, Cranwick G, Forbes J.

No. 3 The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.  

No. 4 A systematic review of the effectiveness and cost-effectiveness of neuromaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery.  

No. 5 Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.  
By Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR.

No. 6 Systematic review and evaluation of methods of assessing urinary incontinence.  

No. 7 The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.  

No. 8 Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.  
By Garside R, Pitt M, Somervile M, Stein K, Price A, Gilbert N.

No. 9 Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.  

No. 10 Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients.  
By Szczepura A, Westmoreland D, Vinogradova Y, Fox J, Clark M.

No. 11 Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.  

No. 12 A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers.  

No. 13 Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).  

No. 14 The cost-effectiveness of screening for oral cancer in primary care.  
By Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M, et al.


No. 17 Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.  
By Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, et al.

No. 18 Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.  

No. 19 Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.  

No. 20 A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1.  

No. 21 Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.  
By Wright M, Grieve R, Roberts J, Main J, Thomas HC, on behalf of the UK Mild Hepatitis C Trial Investigators.

No. 22 Pressure relieving support surfaces: a randomised evaluation.  
No. 23
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamethasone and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

No. 24
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review.

No. 25
Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model.

No. 26
A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use.

No. 27
A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

No. 28
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
By Shepherd J, Jones J, Takeda A, Davidson P, Price A.

No. 29
By Harvey S, Stevens K, Harrison D, Young D, Brampton W, McCabe C, et al.

No. 30
Accurate, practical and cost-effective assessment of carotid stenosis in the UK.
By Wardlaw JM, Chappell FM, Stevenson M, De Nigris E, Thomas S, Gillard J, et al.

No. 31
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

No. 32
The cost-effectiveness of testing for hepatitis C in former injecting drug users.

No. 33
Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation.

No. 34
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

No. 35
Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation.

No. 36
Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model.

No. 37
Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.
By O’Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A.

No. 38

No. 39
The effectiveness and cost-effectiveness of computed tomography screening for coronary artery disease: systematic review.
By Waugh N, Black C, Walker S, McIntyre L, Cummins E, Hillis G.

No. 40
What are the clinical outcome and cost-effectiveness of endoscopy undertaken by nurses when compared with doctors? A Multi-Institution Nurse Endoscopy Trial (MINuET).

No. 41
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
By Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

No. 42
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

No. 43
Telemedicine in dermatology: a randomised controlled trial.
By Bows IR, Collins K, Walters SJ, McDonagh AJG.

No. 44
By Davies L, Brown TJ, Haynes S, Payne K, Elliot RA, McColm H.

No. 45
Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

No. 46
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

No. 47
Systematic reviews of clinical decision tools for acute abdominal pain.

No. 48
Evaluation of the ventricular assist device programme in the UK.
No. 49

No. 50
Ammiocentesis results: investigation of anxiety. The ARIA trial.

Volume 11, 2007

No. 1
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.

No. 2
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

No. 3
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection.

No. 4
The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
By Stevenson M, Davis S, Lloyd-Jones M, Beverley C.

No. 5
A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines.

No. 6
Naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

No. 7
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.
By Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M.

No. 8
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection.

No. 9
Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

No. 10
Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only.

No. 11
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
By Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

No. 12
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
By Tappenden P, Jones R, Paisley S, Carroll C.

No. 13
A systematic review and economic evaluation of epoetin alfa, epoetin beta and darboepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment.

No. 14
A systematic review and economic evaluation of statins for the prevention of coronary events.

No. 15
A systematic review of the effectiveness and cost-effectiveness of different models of community-based respite care for frail older people and their carers.

No. 16
Additional therapy for young children with spastic cerebral palsy: a randomised controlled trial.
By Weindling AM, Cunningham CC, Glenn SM, Edwards RT, Reeves DJ.

No. 17
Screening for type 2 diabetes: literature review and economic modelling.

No. 18
The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

No. 19
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
By Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ.

No. 20
A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease.

No. 21
The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review.
By Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS.

No. 22
A systematic review of the routine monitoring of growth in children of primary school age to identify growth-related conditions.

No. 23
Systematic review of the effectiveness of preventing and treating Staphylococcus aureus carriage in reducing peritoneal catheter-related infections.
No. 24
The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis.

No. 25
A randomised controlled trial and economic evaluation of direct versus indirect and individual versus group modes of speech and language therapy for children with primary language impairment.
By Boyle J, McCartney E, Forbes J, O’Hare A.

No. 26
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
By Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

No. 27
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
By Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

No. 28
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

No. 29
Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses.

No. 30
Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review.

No. 31
A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial.

No. 32
Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen.

No. 33
The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation.
By Black C, Cummins E, Royle P, Philip S, Waugh N.

No. 34
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

No. 35
The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Homebased compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence.

No. 36
A systematic review of the clinical, public health and cost-effectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food.

No. 37
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.

No. 38
Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anti-coagulation therapy: a systematic review and economic modelling.

No. 39
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

No. 40
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
By Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

No. 41
The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation.

No. 42
Acceptability, benefit and costs of early screening for hearing disability: a study of potential screening tests and models.
By Davis A, Smith P, Ferguson M, Stephens D, Gianopoulos I.

No. 43
Contamination in trials of educational interventions.

No. 44
Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
By Facey K, Bradbury I, Laking G, Payne E.

No. 45
The effectiveness and cost-effectiveness of carbustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

No. 46
Drug-eluting stents: a systematic review and economic evaluation.

No. 47
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

No. 48
Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study.
By Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, et al.
No. 49  
Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial.  
The CECaT trial.  

No. 50  
evaluation of diagnostic tests when there is no gold standard. A review of methods.  
By Rutjes AWS, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PMM.

No. 51  
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.  

No. 52  
A review and critique of modelling in prioritising and designing screening programmes.  

No. 53  
An assessment of the impact of the NHS Health Technology Assessment Programme.  
By Hanney S, Buxton M, Green C, Coulson D, Raftery J.

Volume 12, 2008

No. 1  
A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.  

No. 2  
‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.  
By Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.

No. 3  
A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management.  

No. 4  
By Charlesworth G, Shepstone L, Wilson E, Thalanany M, Mugford M, Boland F.

No. 5  
A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study.  

No. 6  
Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling.  

No. 7  
The use of economic evaluations in NHS decision-making: a review and empirical investigation.  
By Williams I, McIver S, Moore D, Bryan S.

No. 8  
Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation.  

No. 9  
The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review.  
By Loveman E, Frampton GK, Clegg AJ.

No. 10  
Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study.  
By Raftery J, Bryant J, Powell J, Kerr C, Hawker S.

No. 11  
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.  

No. 12  
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.  

No. 13  
Stepped treatment of older adults on laxatives. The STOOLL trial.  

No. 14  
A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.  

No. 15  
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.  
By Hind D, Tappenden P, Tumur I, Eggington E, Sutcliffe P, Ryan A.

No. 16  
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.  

No. 17  
Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease.  

No. 18  
Structural neuroimaging in psychosis: a systematic review and economic evaluation.  

No. 19  
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta, agonists for the treatment of chronic asthma in adults and children aged 12 years and over.  
No. 20
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.

No. 21
Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

No. 22
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study.

No. 23
A prospective randomised comparison of minor surgery in primary and secondary care. The MiSTIC trial.

No. 24
A review and critical appraisal of measures of therapist–patient interactions in mental health settings.

No. 25
The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4–5 years: a systematic review and economic evaluation.
By Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J.

No. 26
A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.

No. 27
A preliminary model-based assessment of the cost–utility of a screening programme for early age-related macular degeneration.

No. 28
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
By Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

No. 29
Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product categories.

No. 30
A systematic review of repetitive functional task practice with modelling of resource use, costs and effectiveness.

No. 31
The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The reflux trial.

No. 32
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
By Takeda A, Loveman E, Harris P, Hartwell D, Welch K.

No. 33
Performance of screening tests for child physical abuse in accident and emergency departments.
By Woodman J, Pitt M, Wentz R, Taylor R, Hodes D, Gilbert RE.

No. 34
Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.

No. 35
Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement.

No. 36
Immunophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
By Wang D, Cummins C, Bayliss S, Sandercok J, Burls A.

Volume 13, 2009

No. 1
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

No. 2
Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis.
By Simpson EL, Stevenson MD, Rawdin A, Papaioannou D.

No. 3
Surgical procedures and non-surgical devices for the management of non-apnoic snoring: a systematic review of clinical effects and associated treatment costs.
By Main C, Liu Z, Welch K, Weiner G, Jones SQ, Stein K.
## Health Technology Assessment Programme

**Director,**  
**Professor Tom Walley,**  
Director, NIHR HTA  
Programme, Professor of Clinical Pharmacology, University of Liverpool

**Deputy Director,**  
**Professor Jon Nicholl,**  
Director, Medical Care Research Unit, University of Sheffield

### Prioritisation Strategy Group

<table>
<thead>
<tr>
<th>Members</th>
</tr>
</thead>
</table>
| **Chair,**  
Professor Tom Walley,  
Director, NIHR HTA  
Programme, Professor of Clinical Pharmacology, University of Liverpool  
Dr Bob Coates,  
Consultant Advisor, NCCHTA |
| **Deputy Chair,**  
Professor Jon Nicholl,  
Director, Medical Care Research Unit, University of Sheffield  
Dr Andrew Cook,  
Consultant Advisor, NCCHTA |
| **Chair,**  
Professor Tom Walley,  
Director, NIHR HTA  
Programme, Professor of Clinical Pharmacology, University of Liverpool  
Dr Bob Coates,  
Consultant Advisor, NCCHTA |
| **Deputy Chair,**  
Professor Jon Nicholl,  
Director, Medical Care Research Unit, University of Sheffield  
Dr Andrew Cook,  
Consultant Advisor, NCCHTA |
| **Chair,**  
Professor Tom Walley,  
Director, NIHR HTA  
Programme, Professor of Clinical Pharmacology, University of Liverpool  
Dr Bob Coates,  
Consultant Advisor, NCCHTA |
| **Deputy Chair,**  
Professor Jon Nicholl,  
Director, Medical Care Research Unit, University of Sheffield  
Dr Andrew Cook,  
Consultant Advisor, NCCHTA |

### HTA Commissioning Board

<table>
<thead>
<tr>
<th>Members</th>
</tr>
</thead>
</table>
| **Programme Director,**  
Professor Deborah Ashby,  
Professor of Medical Statistics, Queen Mary, University of London  
Professor John Cairns,  
Professor of Health Economics, London School of Hygiene and Tropical Medicine  
Professor Peter Croft,  
Director of Primary Care Sciences Research Centre, Keele University  
Professor Nicky Cullum,  
Director of Centre for Evidence-Based Nursing, University of York  
Professor Jenny Donovan,  
Professor of Social Medicine, University of Bristol  
Professor Steve Halligan,  
Professor of Gastrointestinal Radiology, University College Hospital, London  
Professor Paul Glasziou,  
Professor of Evidence-Based Medicine, University of Oxford  
Dr Nick Hicks,  
Director of NHS Support, NCCHTA  
Professor Robin E Ferner,  
Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham  
Professor Paul Glasziou,  
Professor of Evidence-Based Medicine, University of Oxford  
Dr Nick Hicks,  
Director of NHS Support, NCCHTA  
Professor Robin E Ferner,  
Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham |
| **Professor Freddie Hamdy,**  
Professor of Urology, University of Sheffield  
Professor Allan House,  
Professor of Liaison Psychiatry, University of Leeds  
Dr Martin J Landray,  
Reader in Epidemiology, Honorary Consultant Physician, Clinical Trial Service Unit, University of Oxford  
Professor Stuart Logan,  
Director of Health & Social Care Research, The Peninsula Medical School, Universities of Exeter and Plymouth  
Dr Rafael Perera,  
Lecturer in Medical Statistics, Department of Primary Health Care, University of Oxford  
Professor Ian Roberts,  
Professor of Epidemiology & Public Health, London School of Hygiene and Tropical Medicine  
Professor Mark Sculpher,  
Professor of Health Economics, University of York  
Professor Helen Smith,  
Professor of Primary Care, University of Brighton  
Professor Kate Thomas,  
Professor of Complementary & Alternative Medicine Research, University of Leeds  
Professor David John Torgerson,  
Director of York Trials Unit, University of York  
Professor Hywel Williams,  
Professor of Dermato-Epidemiology, University of Nottingham |

### Observers

<table>
<thead>
<tr>
<th>Observers</th>
</tr>
</thead>
</table>
| Ms Kay Pattison,  
Section Head, NHS R&D Programmes, Research and Development Directorate, Department of Health  
Ms Lynn Kertridge,  
Chief Executive Officer, NETSCC and NCCHTA |
| Dr Morven Roberts,  
Clinical Trials Manager, Medical Research Council  
Dr Ruairidh Mihne,  
Director of Strategy and Development, NETSCC |
| Ms Kay Pattison,  
Section Head, NHS R&D Programme, Department of Health  
Ms Pamela Young,  
Specialist Programme Manager, NCCHTA  
Ms Kay Pattison,  
Section Head, NHS R&D Programme, Department of Health  
Ms Pamela Young,  
Specialist Programme Manager, NCCHTA |

© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Current and past membership details of all HTA Programme ‘committees’ are available from the HTA website (www.hta.ac.uk).

---

**Diagnostic Technologies & Screening Panel**

**Members**

**Chair,**
**Professor Paul Glasziou,**
Professor of Evidence-Based Medicine, University of Oxford

**Deputy Chair,**
**Dr David Elliman,**
Consultant Paediatrician and Honorary Senior Lecturer, Great Ormond Street Hospital, London

- Professor Judith E Adams, Consultant Radiologist, Manchester Royal Infirmary, Central Manchester & Manchester Children’s University Hospitals NHS Trust, and Professor of Diagnostic Radiology, Imaging Science and Biomedical Engineering, Cancer & Imaging Sciences, University of Manchester
- Ms Jane Bates, Consultant Ultrasound Practitioner, Ultrasound Department, Leeds Teaching Hospital NHS Trust

- Dr Stephanie Dancer, Consultant Microbiologist, Hairmyres Hospital, East Kilbride
- Professor Glyn Ebryn, Primary Medical Care Research Group, Swansea Clinical School, University of Wales
- Dr Ron Gray, Consultant Clinical Epidemiologist, Department of Public Health, University of Oxford
- Professor Paul D Griffiths, Professor of Radiology, University of Sheffield
- Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford
- Dr Susanne M Ludgate, Medical Director, Medicines & Healthcare Products Regulatory Agency, London

**Observers**

- Dr Tim Elliott, Team Leader, Cancer Screening, Department of Health
- Dr Catherine Moody, Programme Manager, Neuroscience and Mental Health Board
- Dr Ursula Wells, Principal Research Officer, Department of Health

---

**Pharmaceuticals Panel**

**Members**

**Chair,**
**Professor Robin Ferner,**
Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham

**Deputy Chair,**
**Professor Imti Choonara,**
Professor in Child Health, University of Nottingham

- Mrs Nicola Carey, Senior Research Fellow, School of Health and Social Care, The University of Reading
- Mr John Chapman, Service User Representative

- Dr Peter Elton, Director of Public Health, Bury Primary Care Trust
- Dr Ben Goldacre, Research Fellow, Division of Psychological Medicine and Psychiatry, King’s College London
- Mrs Barbara Greggains, Service User Representative
- Dr Bill Gutteridge, Medical Adviser, London Strategic Health Authority
- Dr Dyfrig Hughes, Reader in Pharmacoeconomics and Deputy Director, Centre for Economics and Policy in Health, IMSSCaR, Bangor University
- Professor Jonathan Ledermann, Professor of Medical Oncology and Director of the Cancer Research UK and University College London Cancer Trials Centre
- Dr Yoon K Loke, Senior Lecturer in Clinical Pharmacology, University of East Anglia
- Professor Femi Oyebode, Consultant Psychiatrist and Head of Department, University of Birmingham
- Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician and Gynaecologist, The Rosie Hospital, University of Cambridge
- Dr Martin Shelly, General Practitioner, Leeds, and Associate Director, NHS Clinical Governance Support Team, Leicester
- Dr Gillian Shepherd, Director, Health and Clinical Excellence, Merck Serono Ltd
- Mrs Katrina Sinister, Assistant Director New Medicines, National Prescribing Centre, Liverpool
- Mr David Symes, Service User Representative
- Dr Lesley Wise, Unit Manager, Pharmacoepidemiology Research Unit, VRMM, Medicines & Healthcare Products Regulatory Agency

**Observers**

- Ms Kay Pattison, Section Head, NHS R&D Programme, Department of Health
- Mr Simon Reeve, Head of Clinical and Cost-Effectiveness, Medicines, Pharmacy and Industry Group, Department of Health
- Dr Heike Weber, Programme Manager, Medical Research Council
- Dr Ursula Wells, Principal Research Officer, Department of Health

---
Therapeutic Procedures Panel

Members

Chair,
Dr John C Pounsford,
Consultant Physician, North Bristol NHS Trust

Deputy Chair,
Professor Scott Weich,
Professor of Psychiatry, Division of Health in the Community, University of Warwick, Coventry

Professor Jane Barlow,
Professor of Public Health in the Early Years, Health Sciences Research Institute, Warwick Medical School, Coventry

Ms Maree Barnett,
Acting Branch Head of Vascular Programme, Department of Health

Mrs Val Carlill,
Service User Representative

Mrs Anthea De Barton-Watson,
Service User Representative

Mr Mark Emberton,
Senior Lecturer in Oncological Urology, Institute of Urology, University College Hospital, London

Professor Steve Goodacre,
Professor of Emergency Medicine, University of Sheffield

Professor Christopher Griffiths,
Professor of Primary Care, Barts and The London School of Medicine and Dentistry

Mr Paul Hilton,
Consultant Gynaecologist and Urogaenecologist, Royal Victoria Infirmary, Newcastle upon Tyne

Professor Nicholas James,
Professor of Clinical Oncology, University of Birmingham, and Consultant in Clinical Oncology, Queen Elizabeth Hospital

Dr Peter Martin,
Consultant Neurologist, Addenbrooke’s Hospital, Cambridge

Dr Kate Radford,
Senior Lecturer (Research), Clinical Practice Research Unit, University of Central Lancashire, Preston

Mr Jim Reece
Service User Representative

Dr Karen Roberts,
Nurse Consultant, Dunston Hill Hospital Cottages

Observers

Dr Phillip Leech,
Principal Medical Officer for Primary Care, Department of Health

Ms Kay Pattison,
Section Head, NHS R&D Programme, Department of Health

Dr Morven Roberts,
Clinical Trials Manager, Medical Research Council

Professor Tom Walley,
Director, NIHR HTA Programme, Professor of Clinical Pharmacology, University of Liverpool

Dr Ursula Wells,
Principal Research Officer, Department of Health

Disease Prevention Panel

Members

Chair,
Dr Edmund Jessop,
Medical Adviser, National Specialist, National Commissioning Group (NCG), London

Deputy Chair,
Dr David Pencheon,
Director, NHS Sustainable Development Unit, Cambridge

Dr Elizabeth Fellow-Smith,
Medical Director, West London Mental Health Trust, Middlesx

Ms Jeanett Martin,
Director of Nursing, BarnDoc Limited, Lewisham Primary Care Trust

Dr John Jackson,
General Practitioner, Parkway Medical Centre, Newcastle upon Tyne

Professor Mike Kelly,
Director, Centre for Public Health Excellence, NICE, London

Dr Chris McCall,
General Practitioner, The Hadleigh Practice, Corfe Mullen, Dorset

Dr Julie Mytton,
Locum Consultant in Public Health Medicine, Bristol Primary Care Trust

Miss Nicky Mullanry,
Service User Representative

Professor Ian Roberts,
Professor of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine

Professor Ken Stein,
Senior Clinical Lecturer in Public Health, University of Exeter

Dr Julie Mytton,
Locum Consultant in Public Health Medicine, Bristol Primary Care Trust

Miss Nicky Mullanry,
Service User Representative

Professor Ian Roberts,
Professor of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine

Professor Ken Stein,
Senior Clinical Lecturer in Public Health, University of Exeter

Dr Karen Roberts,
Nurse Consultant, Dunston Hill Hospital Cottages

Observers

Ms Christine McGuire,
Research & Development, Department of Health

Dr Caroline Stone,
Programme Manager, Medical Research Council

Ms Christine McGuire,
Research & Development, Department of Health

Dr Caroline Stone,
Programme Manager, Medical Research Council

© 2009 Queen's Printer and Controller of HMSO. All rights reserved.
Members

Professor Douglas Altman, Professor of Statistics in Medicine, Centre for Statistics in Medicine, University of Oxford
Professor John Bond, Professor of Social Gerontology & Health Services Research, University of Newcastle upon Tyne
Professor Andrew Bradbury, Professor of Vascular Surgery, Solihull Hospital, Birmingham
Mr Shaun Brogan, Chief Executive, Ridgeway Primary Care Group, Aylesbury
Mrs Stella Burnside OBE, Chief Executive, Regulation and Improvement Authority, Belfast
Ms Tracy Burn, Project Manager, World Confederation for Physical Therapy, London
Professor Iain T Cameron, Professor of Obstetrics and Gynaecology and Head of the School of Medicine, University of Southampton
Dr Christine Clark, Medical Writer and Consultant Pharmacist, Rossendale
Professor Collette Clifford, Professor of Nursing and Head of Research, The Medical School, University of Birmingham
Professor Barry Cookson, Director, Laboratory of Hospital Infection, Public Health Laboratory Service, London
Dr Carl Counsell, Clinical Senior Lecturer in Neurology, University of Aberdeen
Professor Howard Cuckle, Professor of Reproductive Epidemiology, Department of Paediatrics, Obstetrics & Gynaecology, University of Leeds
Dr Katherine Darton, Information Unit, MIND – The Mental Health Charity, London
Professor Carol Dezateux, Professor of Paediatric Epidemiology, Institute of Child Health, London
Mr John Dunning, Consultant Cardiothoracic Surgeon, Papworth Hospital NHS Trust, Cambridge
Mr Jonathan Earnshaw, Consultant Vascular Surgeon, Gloucestershire Royal Hospital, Gloucester
Professor Martin Eccles, Professor of Clinical Effectiveness, Centre for Health Services Research, University of Newcastle upon Tyne
Professor Pam Enderby, Dean of Faculty of Medicine, Institute of General Practice and Primary Care, University of Sheffield
Professor Gene Feder, Professor of Primary Care Research & Development, Centre for Health Sciences, Barts and The London School of Medicine and Dentistry
Mr Leonard R Fenwick, Chief Executive, Freeman Hospital, Newcastle upon Tyne
Mrs Gillian Fletcher, Antenatal Teacher and Tutor and President, National Childbirth Trust, Henfield
Professor Jayne Franklyn, Professor of Medicine, University of Birmingham
Mr Tam Fry, Honorary Chairman, Child Growth Foundation, London
Professor Fiona Gilbert, Consultant Radiologist and NCRN Member, University of Aberdeen
Professor Paul Gregg, Professor of Orthopaedic Surgical Science, South Tees Hospital NHS Trust
Bec Hanley, Co-director, TwoCan Associates, West Sussex
Dr Marvann L Hardy, Senior Lecturer, University of Bradford
Mrs Sharon Hart, Healthcare Management Consultant, Reading
Professor Robert E Hawkins, CRC Professor and Director of Medical Oncology, Christie CRC Research Centre, Christie Hospital NHS Trust, Manchester
Professor Richard Hobbs, Head of Department of Primary Care & General Practice, University of Birmingham
Professor Alan Horwich, Dean and Section Chairman, The Institute of Cancer Research, London
Professor Allen Hutchinson, Director of Public Health and Deputy Dean of SCoHARR, University of Sheffield
Professor Peter Jones, Professor of Psychiatry, University of Cambridge, Cambridge
Professor Stan Kave, Cancer Research UK Professor of Medical Oncology, Royal Marsden Hospital and Institute of Cancer Research, Surrey
Dr Duncan Keeley, General Practitioner (Dr Burch & Pmrs), The Health Centre, Thame
Dr Donna Lamping, Research Degrees Programme Director and Reader in Psychology, Health Services Research Unit, London School of Hygiene and Tropical Medicine, London
Mr George Levy, Chief Executive, Motor Neurone Disease Association, Northampton
Professor James Lindesay, Professor of Psychiatry for the Elderly, University of Leicester
Professor Julian Little, Professor of Human Genome Epidemiology, University of Ottawa
Professor Alister McGuire, Professor of Health Economics, London School of Economics
Professor Rajan Madhok, Medical Director and Director of Public Health, Directorate of Clinical Strategy & Public Health, North & East Yorkshire & Northern Lincolnshire Health Authority, York
Professor Alexander Markham, Director, Molecular Medicine Unit, St James’s University Hospital, Leeds
Dr Peter Moore, Freelance Science Writer, Ashhead
Dr Andrew Mortimore, Public Health Director, Southampton City Primary Care Trust
Dr Sue Moss, Associate Director, Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton
Professor Miranda Mugford, Professor of Health Economics and Group Co-ordinator, University of East Anglia
Professor Jim Neison, Head of School of Reproductive & Developmental Medicine and Professor of Obstetrics and Gynaecology, University of Liverpool
Mrs Julietta Patnick, National Co-ordinator, NHS Cancer Screening Programmes, Sheffield
Professor Robert Peveler, Professor of Liaison Psychiatry, Royal South Hants Hospital, Southampton
Professor Chris Price, Director of Clinical Research, Bayer Diagnostics Europe, Stoke Poges
Professor William Rosenberg, Professor of Hepatology and Consultant Physician, University of Southampton
Professor Peter Sandercocck, Professor of Medical Neurology, Department of Clinical Neurosciences, University of Edinburgh
Dr Susan Schonfield, Consultant in Public Health, Hillingdon Primary Care Trust, Middlesex
Dr Eamonn Sheridan, Consultant in Clinical Genetics, St James’s University Hospital, Leeds
Dr Margaret Somerville, Director of Public Health Learning, Peninsula Medical School, University of Plymouth
Professor Sarah Stewart-Brown, Professor of Public Health, Division of Health in the Community, University of Warwick, Coventry
Professor Ala Szczepura, Professor of Health Service Research, Centre for Health Services Studies, University of Warwick, Coventry
Mrs Joan Webster, Consumer Member, Southern Derbyshire Community Health Council
Professor Martin Whittle, Clinical Co-ordinator, National Co-ordinating Centre for Women’s and Children’s Health, Lymington
This version of the monograph does not include the appendices. This is to save download time from the HTA website.

The printed version also excludes the appendices.

View/download the appendices
Feedback

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

We look forward to hearing from you.